


ADVANCED THERAPIES IN WOUND MANAGEMENT

CELLS AND TISSUE-
BASED THERAPIES,
PHYSICAL AND BIO-
PHYSICAL THERAPIES,
SMART AND IT-BASED
TECHNOLOGIES



HEALTH ECONOMICS AND
REGULATORY ISSUES

Alberto Piaggese,¹ MD, Prof, Director, EWMA Scientific Recorder (Editor)
Severin Lächli,² MD, Chief of Dermatosurgery and Woundcare, EWMA Immediate Past President (Co-editor)
Franco Bassetto,³ MD, Prof, Head of Department
Thomas Biedermann,⁴ PhD
Alexandra Marques,⁵ PhD
Bijan Najafi,⁶ PhD, MSc, Professor of Surgery, Director of Clinical Research
Ilaria Palla,⁷ MA, MBA
Carlotta Scarpa,³ MD, PhD
Diane Seimetz,⁸ Founding Partner
Isotta Triulzi,⁷ PharmD
Professor Giuseppe Turchetti,⁷ Prof, PhD, Fulbright Scholar
Annegret Vaggelas,⁸ PhD, Consultant

1. Diabetic Foot Section of the Pisa University Hospital, Department of Endocrinology and Metabolism, University of Pisa, Lungarno Pacinotti 43, 56126 Pisa, Italy

2. Department of Dermatology, University Hospital, Zurich, Rämistrasse 100, 8091 Zürich, Switzerland

3. Clinic of Plastic and Reconstructive Surgery, University of Padova, Via Giustiniani, 35100 Padova

4. Tissue Biology Research Unit, Department of Surgery, University Children's Hospital Zurich, August Forel-Strasse 7, 8008 Zürich, Switzerland

5. University of Minho, 3B's Research Group in Biomaterials, Biodegradables and Biomimetics, Avepark - Parque de Ciência e Tecnologia, Zona Industrial da Gandra, 4805-017 Barco GMR, Portugal

6. Division of Vascular Surgery and Endovascular Therapy, Director of Interdisciplinary Consortium on Advanced Motion Performance (iCAMP), Michael E. DeBakey Department of Surgery, Baylor College of Medicine, One Baylor Plaza, MS: BCM390, Houston, TX 77030-3411, US

7. Institute of Management, Sant'Anna School of Advanced Studies, Piazza Martiri della Libertà, 33, 56127 Pisa, Italy

8. Biopharma Excellence, c/o Munich Technology Center, Agnes-Pockels-Bogen 1, 80992 Munich, Germany

Editorial support and coordination: Julie Bjerregaard, EWMA Secretariat, jb@ewma.org

Corresponding author: Alberto Piaggese, piaggese@immr.med.unipi.it

The document is supported by an unrestricted grant from: Aurealis Pharma, MiMedx, Organogenesis, Klox Technologies, Reaplix, Urgo

This article should be referenced as: Piaggese A, Lächli S, Bassetto F et al. EWMA document: advanced therapies in wound management: cell and tissue based therapies, physical and bio-physical therapies smart and IT based technologies J Wound Care, 2018; 27(6), Suppl 6

©EWMA 2018

All rights reserved. No reproduction, transmission or copying of this publication is allowed without written permission. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanical, electronic, photocopying, recording, or otherwise, without the prior written permission of the European Wound Management Association (EWMA) or in accordance with the relevant copyright legislation.

Although the editor, MA Healthcare Ltd. and EWMA have taken great care to ensure accuracy, neither MA Healthcare Ltd. nor EWMA will be liable for any errors of omission or inaccuracies in this publication.

Published on behalf of EWMA by MA Healthcare Ltd.

Editor: Rachel Webb

Sub Editor Lindsey Stewart

Designer: Lindsey Kitley

Managing Director: Anthony Kerr

Published by: MA Healthcare Ltd, St Jude's Church, Dulwich Road, London, SE24 0PB, UK

Tel: +44 (0)20 7738 5454 Email: anthony.kerr@markallengroup.com Web: www.markallengroup.com

Contents

Abbreviations and definitions	5
Introduction	6
Background and aims	6
Definition of advanced therapies	6
Method	7
Structure of the document	8
Materials/dressings	9
Introduction	9
Films	12
Foams	14
Hydrocolloids	17
Hydrogels	20
Alginates	21
Acellular matrices	22
Future perspectives	28
Cell- and tissue-based therapies	30
Cell therapies	30
<i>The ideal stem cells</i>	30
<i>The stem cells and other therapeutically active cells</i>	31
<i>Bone marrow stem cells</i>	31
<i>Keratinocytes and fibroblasts</i>	32
<i>Adipose derived stem cells (ADSCs)</i>	32
<i>Other cells</i>	33
<i>Platelets</i>	33
<i>Leukocytes</i>	33
<i>Monocytes</i>	33
<i>Epithelial stem cells collected from a hair follicle</i>	33
<i>The application modes of cell therapies</i>	34
<i>Scaffolds</i>	34
<i>Carrier systems</i>	34
<i>Possible uses of cell therapies</i>	34
Autologous blood-derived products for wound care	34
<i>Clinical evidence for platelet-derived products in wound care</i>	37
<i>Other cell therapies/advanced cell therapies</i>	37
<i>The use of safe food-grade lactic acid bacteria</i>	37
Placental-based allografts	38
Cultured tissue-based therapies	40
<i>Tissue-based therapies for in vitro application</i>	40
<i>Tissue-based therapies for in vivo application</i>	41
<i>History of tissue-based therapies</i>	42
<i>Epidermal substitutes (CEAs)</i>	43
<i>Dermal substitutes</i>	45
<i>Dermo-epidermal substitutes</i>	47
Future outlook	48
<i>Melanocytes, vessels, genetic manipulation</i>	48
<i>Automation</i>	50
<i>Algorithm for the use of cell therapies</i>	53
Physical therapies	54
Introduction	54
Shock waves	54
Electromagnetic fields (EMF)	57

Photobiomodulation (PBM)	64
Nanotechnologies (NT)	68
Smart technologies in wound management	74
Introduction	74
Wearables and applications to smartly manage chronic ulcers	77
Wearable device designed to stimulate wound healing and/or reduce risk of DFU	78
Wearable wound therapy using nanotechnology	80
Modern wound dressing	80
Wearables to monitor risks factors associated with poor wound healing or infection	80
Wearables to personalise wound care management	81
Mobile health (m-health) to manage non-healing wounds	82
Telemedicine/tele-monitoring in wound management	83
Telemedicine for wound care: patient acceptability and providers' perceptions of benefits	84
Does telemedicine improve wound care and wound outcomes?	85
Does telemedicine optimise wound care delivery and the quality of care?	86
Does telemedicine reduce the cost of wound care?	87
Is telemedicine as reliable as the in-person visit for purpose of wound care?	88
'Internet of things' and remote management of wounds	89
Conclusions	91
The economic scenario	93
Health economics of advanced technologies	94
Economic impact of cell/tissue therapy	95
Economic impact of materials	98
Economic impact of physical therapies	104
Economic impact of smart technologies	108
Conclusions	108
Regulatory issues: what needs to be considered for an integrated strategy	110
Development of advanced therapy medicinal products for wound management—a challenging field	110
Relevant legislation overview	110
Where do we stand with ATMPs in wound management?	112
How to best address challenges during ATMP development for wound management?	113
Points to consider at the R&D stage	113
Points to consider for manufacturing	113
Non-clinical challenges	114
Clinical challenges	114
What regulatory tools should be considered for setting up an integrated development and regulatory strategy?	114
Outlook and conclusion	116
The wish list – for a better future	117
Contributions from EWMA	119
References	120

Abbreviations and definitions

- ADM: Artificial dermal matrix
- ADSC: Adipose derived stem cell
- ALU: Arterial leg ulcers
- APFP: The autologous leucocyte and platelet-rich fibrin patch
- ATMP: advanced therapy medicinal product
- AM: Adrenomedullin
- ISBF: the International Society for Biofabrication
- DF: Diabetic foot
- DFU: Diabetic foot ulcer
- dHSCAM: dehydrated human amnion-chorion membrane
- EMF: Electromagnetic fields
- ESWT: Extracorporeal shock waves therapy
- EWMA: European Wound Management Association
- FDA: Food and Drug Administration
- GTMP: gene therapy medicinal products
- LST: Local standard treatment
- MVTR: Moisture vapour transmission rate
- NOSF: Nano-oligosaccharide factor
- NT: Nanotechnologies
- PEG: Poly-ethilen glycole
- PBM: Photo bio-modulation
- PEMF: Pulsatile electro-magnetic fields
- PTU: Post traumatic ulceration
- PU: Pressure ulcer
- RCT: Randomised controlled trial
- SSD: Silver sulfadiazine
- sCTMP: somatic cell therapy medicinal products
- STSG: Split-thickness skin graft
- TLC: Tissue lipid-colloidale
- TEP: Tissue-engineered products
- TMR: Therapeutic magnetic resonance
- VLU: Venous leg ulcer

Advanced therapy medicinal product: A term used by regulators that describes a class of medicines for human use that are based on genes, tissues or cells

Advanced therapies: For the purpose of this document, advanced therapies have been defined as therapies based on novel principles and technologies, or in reference to a novel application of consolidated principles and technologies, including either a singular mechanism of action or a strategy with different levels of action, given that some evidence has been produced in a measurable and comparable way by the manufacturers/developers.

'Internet of things' (IoT): The network of physical devices, vehicles, home appliances and other items embedded with electronics, software, sensors, actuators and connectivity, which enables these objects to connect and exchange data. Each thing is uniquely identifiable through its embedded computing system but is able to interoperate within the existing Internet infrastructure.

Introduction

Background and aims

With this document, the European Wound Management Association (EWMA) aims to investigate the barriers and possibilities of advanced therapies in next-generation wound management, including technologies based on cellular therapies, tissue engineering and tissue substitutes, which are all associated with the clinical discipline of regenerative medicine. The document also describes new treatments based on physical therapies and the potential of sensors, software and internet technologies. EWMA wishes to be on the forefront of the development of new, sustainable, cost-effective advanced therapies and to examine further how these measures may support the continuous improvement of wound management with regard to patients' quality of life, while also providing a more effective and efficient approach to wound management.

The objectives of this document are to:

- Review and discuss clinical experiences and the scientific evidence where it is available;
- Provide an objective and exhaustive overview of the available therapies and their potential roles in clinical practice, and make recommendations for the implementation of these therapies in the different areas of wound management;
- Analyse and debate cost-effectiveness issues related to the included therapies; and

- Discuss the regulatory framework for advanced therapies in Europe, providing a point of referral for future discussions and negotiations with health-care providers and payers.

Due to the general lack of scientific documentation for many of these emerging therapies, this document is based on the available literature and experts' opinions. It includes an evaluation of the potentials for future use in clinical practice and a call for research in recommended areas.

Definition of advanced therapies

The group of authors responsible for this document agreed on the following definition for the term 'advanced therapies'. It has been adopted as a basis for selecting relevant technologies for inclusion in this publication.

The therapies related to chronic wound management can be defined as 'advanced' when they are based on novel principles and technologies or when they refer to a novel application of consolidated principles and technologies, including either a singular mechanism of action or a strategy with different levels of action, given that some evidence has been produced in a measurable and comparable way by the manufacturers/developers. For the sake of this document, advanced therapies will be grouped according to their nature into four different categories: materials, cell and tissue engineering, physical and biophysical, and sensors and IT-related measures.

Method

To define relevant literature, the search strategy presented in Table 1 was conducted. A literature search was performed in Pubmed and Embase for each topic included in the document. The search covered the period of 2007–2017. The authors responsible for the included topics were asked to evaluate the search results and select relevant literature based on the agreed upon definition of

advanced therapies defined for this document. Additional literature is included by the authors if relevant in order to describe theory and concepts behind each identified technology. This additional literature may fall outside the time period covered in the search.

The literature was evaluated with reference to the GRADE methodology.¹ Tables providing an

Table 1. Search strategy

Search by titles and abstracts
1. Wound management (and related words with OR)
2. NOT Trauma OR emergency OR heart surgery OR neurosurgery
Combined with the following search terms in separate searches:
Cells
3. AND cells (OR stem cells, skin cells, staminal cells, mesenchymal cells, adipose cells, adipose-derived cells, blood cells, stromal cells, platelets, leucocytes, fibroblasts, monocytes, keratinocytes, endothelial cells)
Materials
3. AND materials OR dressings, biomaterials/bio-materials, matrices, de-cellularised matrices, acellular matrices, dermal substitutes, delivery systems, carriers, scaffolds, hydrogel, foam, hydrocolloids, films, hydrofibers
Tissues
3 AND engineered tissue OR living tissues, skin equivalents, skin substitutes, composite tissues, bilayered tissues, skin analogues, cryopreserved tissues, bank tissues
Physical therapies
3. AND physical therapy OR light, electric, magnetic, shock waves, negative pressure, irrigation, oxygen, pressure, HBOT OR exercise OR exergame OR balance training
Sensors
3. AND Sensors OR software, internet technology, communication technology, temperature sensors, pressure sensors, PH sensors, oxygen sensors, telemedicine, wearable, internet of things, telehealth, smart insoles, smart socks, smart shoes, smart mat
Health economy
3. AND (ALL of the above sections/search strings with OR in between)
4. AND health economics, costs, cost-effectiveness, cost-utility, cost-benefit, budget impact, economic resources, economic analysis, eco-nomic implications, cost of illness

overview of the evaluation of evidence supporting the technologies are inserted after each document section with descriptions.

Structure of the document

This document is organised into six different sections. Four of them deal with the different types of advanced therapies and are, in order of position in the document, dedicated to: materials, cells and tissues, physical means, and smart technologies. Each of these sections include:

1. A text describing and summarising the current status and possible evolutions within the field;
2. Tables outlining available relevant studies (indicating number of subjects, main findings, etc)
3. A table outlining the available evidence and the strength of recommendations for using the different therapies with the related indications.

The document also includes two sections dedicated to the economic and regulatory aspects of advanced therapies in wound management. The aim of these sections is to provide a different

perspective on this complex and fast-evolving field that bridges the gap between the technologies and their inception in the real world of wound healing.

The document is concluded with a 'wish list'; a separate and concise section including ten points that highlight crucial aspects that should be addressed with regard to supporting proper evaluation and potential implementation of relevant advanced therapies in wound management. This final section is included as a potential tool for addressing future issues and controversies in this challenging and promising field. This tool targets health professionals as well as administrators, decision makers and regulators. The list is followed by a paragraph in which EWMA examines the potential role of a European clinical and scientific association with regard to supporting the realisation of the promises that advanced therapies make to wound healing.

The authors hope that reading this document will not only be interesting for scientists and clinicians but also helpful for other stakeholders in the field of wound management by supporting better care for patients with wounds.

Materials/dressings

Introduction

Historically, wounds have been managed with plasters soaked in oil, grease, wine and vinegar after cleansing with astringents or antimicrobial substances, such as honey and resin.² The discovery of the antibiotics late in the 19th, beginning of the 20th century, marked a revolution in the medical field and the beginning of the development of modern wound dressings.³ Up to the mid-1900's, it was confidently believed that wounds should be kept uncovered to dry in order to promote faster healing, but this paradigm was contradicted in the 1980's with the clinical acceptance of new dressings that supported a moist wound environment.^{4,5}

Although traditional dressings, which are made of woven and non-woven cotton, rayon, polyester fibres, confer some protection against bacterial infection, they are in general directed for cleaning dry wounds or for use as a secondary dressings.⁴ This is because their use in exuding wound situations, even those with slight drainage, are associated with maceration of healthy tissues and adhesion to the wound, which can result in painful removal and delayed healing due to additional trauma to the wound bed.⁶ Thus, a new method has risen with the introduction of technologically advanced wound dressings, such as films, foams, hydrocolloids (including hydrofibres), hydrogels, alginates and acellular matrices that are designed to be in contact with the wounds, to act as primary dressing in order to promote healing.

Importantly, the expected enhanced outcome due to the use of advanced wound dressings for healing

does not occur if the wound has devitalised tissue, which obstructs granulation of the wound bed and epithelialisation. Autolytic/enzymatic debridement abilities relying on the self-activation of endogenous enzymes for slough degradation to allow for the exposure of well-perfused healthy tissue has been associated with these dressings.⁷ However, since autolytic debridement is not as efficient as surgical debridement, it cannot replace surgical debridement.⁸ The large number of advanced wound dressings have been divided into different categories, potentially associated with their performance and certain shared features. However, within each group, the various dressings are not identical. In fact, current advanced wound dressings can be successively categorised considering properties that range from general features, such as permeability, absorption and fluid-handling capacity, to more specific features associated with each of the classes and with each of the dressings within that class (Table 2). Hydrocolloids are occlusive dressings that maintain contact of the fluid with the wound during the healing process in a unique way. As with all of the other classes of dressings, they provide a moist environment. Nowadays, this moist environment for healing is well-accepted as advantageous for wound healing.⁹ In contrast, hydrocolloids, semi-permeable films and foam dressings permit gases and water-vapour exchange but maintain a barrier against bacteria infiltration mainly due to a layer of acrylic adhesive. While the use of a secondary dressing is hereby avoided, depending on the adhesive strength of the dressing, its use might be contraindicated for patients with friable

Table 2. Wound dressing types and features

General features				
Moist wound bed	Permeability	Absorption capacity	Fluid-handling capacity	Average time in the wound
Yes	Occlusive <ul style="list-style-type: none"> • Complete barrier features • Unable to manage wound fluid since they do not release water vapour 	Excellent (form a gel when wet)	Light to moderate	3–7 days
Yes	Semi-permeable <ul style="list-style-type: none"> • Permit gases and water vapour exchange but prevent bacteria infiltration • Adhesive acrylic layer might induce periwound lesions 	Little to none	Absent to moderate	up to 7 days
		Excellent	Moderate to heavy	up to 3–4 days
	Permeable <ul style="list-style-type: none"> • Require secondary dressing 	Little to none	Absent to moderate	1 day
		Excellent (form a gel when wet)	Moderate to heavy	up to 7 days
		N/A	N/A	Unchanged or reapplied up to healing

Type of Dressings	Specific features	Limitations
Hydrocolloids (including hydrofibers)	<ul style="list-style-type: none"> The hydrophilicity of the polymer influences the absorption capacity Formulations with alginate have increased absorption ability Polyurethane-based formulations provide thermal insulation Confer a highly hypoxic wound environment Hydrofibres are the most mechanically stable. 	<ul style="list-style-type: none"> Residues can be left in the wound upon dressing removal due to mechanical weakness Tissue maceration possible if the fluid overcomes the absorption-handling capacity Contraindicated in heavily exuding and infected wounds Odour can be mistaken for infection.
Films	<ul style="list-style-type: none"> MVTR varies with properties of the polymer; such as the pore size, density and thickness of the membrane Composition determines transparency Fluid-handling capacity increases when combined with non/low-adherent absorbent pad. 	<ul style="list-style-type: none"> Contraindicated in infected wounds; Contraindicated in wounds with friable periwound skin Can adhere to the wound in the absence of fluids.
Foams	<p>Varied compositions (different types of polyurethanes, silicone, polyvinyl alcohol etc) determine:</p> <ul style="list-style-type: none"> Surface hydrophilicity: fluid-handling capacity; atraumatic removal Design of the foams: time in the wound Insulation Physical properties determine soft character-cushioning If sufficiently hydrophobic, can entrap bacteria. 	<ul style="list-style-type: none"> Possible undesirable drying effect on inadequately exudative wounds Can adhere to the wound in the absence of fluids.
Hydrogels	<ul style="list-style-type: none"> Hydrogel sheets are more stable than amorphous (hydro)gels and are insoluble in water Cross-linking degree determines fluid absorption and amount of moist provided to the wound Provide temporary cooling effect. 	<ul style="list-style-type: none"> Limited absorption ability, thus is indicated for situations where drainage is of secondary concern Over-hydration can cause periwound maceration
Alginates	<ul style="list-style-type: none"> The relative composition in mannuronic and guluronic acid units influences absorption capabilities High content in mannuronic acid leads to reduced mechanical stability Haemostatic due to ion exchanging properties. 	<ul style="list-style-type: none"> Might leave residual debris if exudate is not sufficient Require moisture to ensure atraumatic removal, thus are contraindicated in wounds with little to no exudate
Acellular Matrices	<ul style="list-style-type: none"> Artificial acellular matrices potentially have an improved mechanical stability in relation to natural ones Collagen is often the main component but the additional components affect 3D structure properties and degradation Porosity and pore size of the 3D structure influence cell infiltration One-way or two-way approach have different vascularisation and re-epithelialisation outcomes. 	<ul style="list-style-type: none"> Risk of disease transmission The presence of any material that can cause inflammatory/allergic responses.

skin in order to avoid skin tension and periwound lesions.¹⁰ The use of a secondary dressing is required for permeable dressings such as hydrogels, alginates and most of the acellular matrices.

Independently of this classification in terms of permeability, the dressing's absorption capacity varies from little to none (films and hydrogels) to excellent (foams, hydrocolloids, and alginates). This absorption capacity can be directly translated into wound exudate-handling capability, respectively ranging from absent to moderate for moderate to heavy exudate.⁶ An exception must be highlighted for hydrocolloids, which, although being able to absorb a high amount of fluid, cannot manage it on a higher level since it is unable to release water vapour through the occlusive layer. This duality is often linked with tissue maceration and can be balanced by a cost-effective increase in the number of changes of the dressing.¹⁰ In contrast, if there is too little wound fluid, films and foams can adhere to the wound surface, which can result in a painful and traumatic removal of the dressing.¹⁰ This is prevented by the use of hydrocolloids, hydrogels and alginates that, upon contact with fluids, form a gel, which provides a wet and low-adherence interface with the wound bed.⁶

Acellular matrices (collagen dressings), although permeable and capable of providing a moist environment, can be considered another type of dressing primarily because they are primed for intrinsic wound healing and tissue regeneration. These dressings are prepared from allogeneic or xenogeneic tissue from which viable cells are removed. Thus, the risk of disease transmission and the presence of material that can cause inflammatory/allergic responses is not totally absent. Moreover, awareness regarding the religious, cultural and social context of the patients should be raised due to potential objections to the use of animal products.¹¹

These common general features represent a challenge for health professionals in the selection of an appropriate dressing for a particular wound. Thus, the choice has to rely on the specific properties of each dressing and the knowledge that these will influence the healing process in different ways. In the following sections, the rationale and expectations regarding the mechanism of action of each type of dressings and the achieved level of clinical evidence will be discussed in order to provide comprehensive information that will allow for a better understanding of which type of dressing can/should be used for different wounds. Importantly, no considerations will be made regarding non-debrided wounds in order to only focus on the healing process itself, which can only happen after a proper preparation of the wound bed.

Films

The first reported use of a film dressing occurred in 1945, when cellophane was used to treat burns.¹² Film dressings are thin membranes of synthetic polymers, originally nylon-based, that evolved to become stronger and more resistant to stretching and to shrinking as compared with the polyurethane ones, which were mostly backed by an adhesive layer for fixation. The moisture vapour transmission rates (MVTR) among the different polyurethane dressings varies with the properties of the polymer, such as the pore size, density and thickness of the membrane,¹³ which allows for a tailoring of their fluid-handling capacity and, therefore, can assist in avoiding excessive wound moisture and tissue maceration.¹⁴ Additionally, adhesive films can include the use of a non/low-adherent absorbent pad that is capable of managing a larger, but still light, amount of exudate, which might be sufficient for exudate management.¹⁴ The material of the film also determines if the dressing is transparent. This is an advantage with regard to monitoring the wound without disturbing the healing process.¹²

One proposed mechanism listed as a beneficial effect of semi-permeable film dressings is the accumulation of healing mediators within the wound fluid. This type of dressing is directly in contact with the wound bed, which leads to faster re-epithelialisation, increased healing rates and restoration of the skin barrier.¹⁵ Scientific evidence has shown that the fluid obtained from acute wounds covered with a film dressing can stimulate *in vitro* keratinocytes proliferation,¹⁶ which has recently been associated with an enhanced synthesis of laminin 5.¹⁷ This is a major component of the anchoring filaments in epithelial cells, by playing a role in their adhesion and migration. Although there were speculations that the enhanced keratinocytes proliferation was caused by augmented inflammatory cytokines and growth factors, such as TGF- α , TGF- β 1 and TNF- α , their presence in the wound fluid were not confirmed. Several works have identified some of these molecules and others in wound fluids obtained under different clinical conditions but not from wounds covered with film dressings.^{18–20} Accelerated epithelialisation in this setting was also associated with the presence of a gelatinous co-agulum containing fibrin (ogen) and fibronectin onto which keratinocytes could migrate.²¹ However, a subsequent work showed that keratinocytes do not interact with fibrinogen because they lack the α V β 3 receptor.²² Thus, the exact mechanism behind re-epithelialisation is not yet known. Interestingly, acute wound fluids were shown to elevate, in a healing time-dependent manner, the levels of plasminogen activators both in fibroblasts and in keratinocytes cultured *in vitro*.²³ These are mediators of an enzymatic cascade involved in the control of fibrin degradation, matrix turnover and cell invasion, which are indicative of a highly proteolytic wound environment. Although enhanced collagen synthesis, possibly associated with increased proteases activity, has been attributed to healing with a film dressing, this

proteolytic activity is known to vary based on the type of wound.^{24–26}

Fluids recovered from skin graft wounds covered with film dressings also revealed chemotactic properties towards endothelial cells *in vitro* and angiogenic properties in an *in vivo* assay.²⁷ This was potentially due to the action of FGF-2 although the detected levels were comparable to normal serum. This analysis reflects the early wound environment (24 hours post-wounding), which suggests a rapid pro-angiogenic stimulus in acute wounds that are dressed with films. Nonetheless, a parallel analysis of fluids derived from burn injuries showed a much less immediate angiogenic activity, which suggests that the overall environment of burns seems to be generally non-angiogenic.

When these observations are evaluated together, wound fluid components seem to be a key factor of the healing cascade, but the sparse clinical results obtained so far about the environment of the different wounds is a major limitation for a better understanding of their pathophysiology.

Films are mostly used to dress superficial wounds with minimal to moderate exudates, such as surgical wounds and split-thickness skin graft donor sites. The suitability of film dressings to cover light to moderately exuding acute and chronic wounds by providing a moist environment without compromising periwound skin, even at a lower changing frequency, was also demonstrated.²⁸ Randomised controlled trials (RCTs) compared film dressings with traditional^{29,30} and other advanced film dressings^{31–33} to manage split-thickness skin graft donor sites. When films were compared with paraffin gauze, one of the trials showed no significant differences in terms of the healing rate, which was up to 14 days,²⁹ but in the most recent study,³⁰ the film groups showed significantly shorter healing times of less than 12 days as compared with the gauze group, which had an average healing

time of 14.76 days. Film dressings caused less pain and discomfort than paraffin gauze and were also easier to remove^{29,30} (Table 3).

RCTs with other advanced dressings confirmed no significant differences in terms of the healing rate^{32,33} except for hydrocolloids³² and alginate³¹ dressings. Pain scores were also lower but not significantly different when films were used.^{31–33} In a large trial of 289 patients randomised (of whom 288 were analysed) who had either alginate (45 patients), film (49 patients), gauze (50 patients), hydrocolloid (49 patients), hydrofibre (47 patients) or silicone (48 patients) dressings, patients who had a film dressing were the least satisfied with their overall scar quality.³² Overall, there is no clinical evidence that supports an improved healing of split-thickness skin graft donor sites with film dressings.

A recent systematic review analysed the clinical evidence on the effectiveness of semi-permeable dressings, films and foams, to treat radiation-induced skin reactions related to radiation therapy in cancer patients with a focus on pain, discomfort, itchiness, burning and the overall effect on their daily life activities. From the 181 RCTs conducted between 2010 and 2015, six concluded that semi-permeable dressings are beneficial in the management of skin toxicity related to radiation therapy.⁴⁰

Foams

The concept of foam was first introduced in the 1970s. Silastic foams were prepared in the clinic by mixing two components, the polymer and a catalyst, which reacted in situ releasing heat and expanding to form a more solid structure that conforms to the shape of a cavity. Then, this concept evolved in to a dressing composed of an absorbent, hydrophilic layer in contact with the wound that would expand when moist, and a hydrophobic outer layer that reduced

water vapour loss and acted as a barrier against bacteria.⁴¹ Foam dressings are nowadays associated with multi-layered dressings composed of a hydroconductive, wound-contacting portion that allows wound fluid passage. This is backed by a hydrophobic, highly absorbent, porous structure that draws the fluid into the air spaces and uniformly retains it away from the wound bed. Foam dressings are often combined with a semi-permeable, adhesive, outermost layer, that provides a barrier against bacteria infiltration and an interface for controlling water vapour loss.⁶ Although mainly made of polyurethane, foam dressings have varied compositions, such as different types of polyurethanes, silicone, polyvinyl alcohol etc, which determine the surface hydrophilicity of the foams and consequently their capacity for handling wound fluids.^{42,43} Therefore, this results in differences in the design, as well as the number and type of layers of each one of the available foam dressings⁴⁴ and, potentially, the time that they can safely be left on a wound. The composition of the polyurethane foams also influence their thermal insulation properties,⁴³ which is one of their most advertise features and highly relevant considering that healing players, like cells and enzymes, act optimally at physiological temperature, and temperature drops can cause vasoconstriction.

Due to their physical soft character, foam dressings offer additionally cushioning. Due to the hydrophilic and non-adherent character of the layer that is in contact with the wound, they also provide moisture and can be removed with a minimal amount of pain.⁶ However, this hydrophilic feature might cause desiccation in wounds with eschar or wounds that are not draining due to the absence of fluid to absorb. If the absorbent layer of the foam dressings is sufficiently hydrophobic, they should have enough capacity to entrap bacteria before they reach the wounds.¹⁰

Table 3. Randomised controlled trials evaluating wound dressings' efficiency for the treatment of split-thickness skin graft (STSG) donor site

Author/ year	Type of material	No. of patients	Compared conditions	Follow up (days)	Results
Kazanavicius et al. ³⁴ 2017	Film	98	Polyurethane-based foam vs polyamide-based film vs cotton gauze dressing (control)	21	Similar mean healing time Higher proportion of healed wounds for polyamide-based film (66.7% by postoperative day 9)
Läuchli et al. ³³ 2013		38	Polyurethane-based film vs calcium alginate	Until re-epithelialisation was achieved	Similar time to epithelialisation
Terrill ³¹ 2007		40	Polyurethane-based film vs calcium sodium alginate (control)	30 days	Higher proportion of complete healed wounds (79% vs 16%) Faster mean healing time (14 vs 21 days)
Kaiser et al. ³³ 2013	Alginate	30	Calcium alginate vs polyurethane-based film vs gauze (control)	Day 1 postoperative; Day 5-7 postoperative; and after full epithelialisation of the donor site, approx. 14-21 days after surgery	Similar full epithelialisation time (median: 16 days); higher than the control (median: 14 days)
Brenner et al. ³⁵ 2015	Foam	57 (children)	Polyurethane-based foam vs carboxy-methylcellulose based hydrocolloid vs calcium sodium alginate	until re-epithelialisation was reached	Higher median time for healing: 9.5 days (foam) vs 8 days (hydrocolloid) vs 7.5 days (alginate)
Higgins et al. ³⁶ 2012		36	Polyurethane-based foam vs calcium sodium alginate	14	Similar time for wound re-epithelialisation.
Karlsson et al. ³⁷ 2014	Hydrocolloid	67	Carboxymethyl cellulose-based hydrocolloid vs polyurethane foam vs natural acellular xenograft	21	Faster re-epithelialisation in hydrocolloid and acellular dressing vs polyurethane foam
Brolmann et al. ³⁸ 2013		289	Alginate vs film vs gauze vs polysaccharide hydrocolloid vs carboxymethyl cellulose-based hydrocolloid vs silicone foam	28 (adverse events and scarring after 84 days)	Significantly shorter re-epithelialisation time of polysaccharide hydrocolloid (compared with any other dressings)
Dornseifer et al. ³⁹ 2011		50	Carboxymethyl cellulose-based hydrocolloid vs polyurethane film (control)	10	Lower re-epithelialisation (54.5% vs 86.4%)

While the moist environment provided by film dressings depends on its ability to keep the wound fluid directly in contact with the wound bed, the hydrophilic layer of the dressing is the layer playing that role in wounds dressed with foams. Wound exudate is kept away from the wound bed, and the interchange between the absorbent and the non-adherent layer (many of the dressings imply that fluid is kept away

from the wound) will determine the availability of healing mediators at the wound bed. Foam dressing materials are not inert materials and are not only in contact with the cellular players in the wounds, but they can also react with the biochemical mediators through several chemical interactions that also vary with the chemistry of the materials.¹⁴ These, together with the diffusion properties of the hydrophilic layer, greatly

influence the diffusivity of the molecules, such as nutrients, electrolytes, cytokines and growth factors, and proteases, that can move into and from the dressing, respectively, and from and to the wound bed. Additionally, as wound fluid content varies along with the healing time as well as the type of wound, the dressing changing time is another critical factor when studying the mechanism of action of foam dressings. The studies aiming to unravel the mechanisms that can support foam dressings benefits in wound healing are typically *in vitro* studies. These studies hardly considered these aspects and instead, mainly focus on the material's capacity to bind and inhibit proteases.⁴⁵⁻⁴⁷ Other studies have used animal models to look at the effect of foam dressings over the wound bed by analysing the formation of granulation tissues,⁴⁸ the synthesis of ECM components, such as hyaluronan,⁴⁹ and the level of cytokines⁵⁰ in the wound exudate. However, they do not include any considerations regarding an effect of the composition of the foam on the obtained results. This demonstrates that the specific mode of action of foam dressings is poorly studied.

Features of foam dressings, such as improved wound management, reduced tissue maceration, non-adherence to the wound, and atraumatic application and removal of foam dressings, are unquestionable.⁵¹ Its use in a large range of applications has been reported. However, the performance of the different foam dressings in relation to other advanced dressings for a particular type of wound has yet to be clearly documented. As described for films, sufficient clinical evidence regarding improved healing with foam dressings for split-thickness skin graft donor sites^{32,35,36} and radiation-induced skin reactions related to radiation therapy⁴⁰ has yet to be provided. Foam dressings, when compared with traditional gauze dressings, do reduce the healing time for acute wounds.⁵² However, further research to provide

level A evidence is still needed (Table 3). The main feature of foam dressings is their fluid-handling ability with improved periwound tissue quality. This has been clinically demonstrated in acute (surgical and trauma) and chronic (pressure ulcers (PU), diabetic foot ulcers (DFU), leg ulcers, fungating tumours) wounds although there have been a low number of patients considered in each category.^{42,53} A RCT of 118 patients using two different foam dressings showed completely different abilities of management, ranging from excellent to poor, for the exudate of lower leg ulcers.⁵⁴

A recent systematic review with meta-analysis of 12 RCTs, selected from 4117 publications, showed no statistically significant differences between foam and other advanced wound dressings with regard to achieving complete DFU healing.⁵⁵ This conclusion is backed by another systematic review which included 157 participants, a meta-analysis of two studies. Foam dressings do not promote the healing of DFUs compared with gauze (RR: 2.03; 95% CI: 0.91 to 4.55), and healing was not significantly different than what was observed for alginate dressings (RR: 1.50; 95% CI: 0.92 to 2.44). Moreover, no statistically significant difference in the number of wounds healed was observed when comparing foam and hydrocolloid dressings.⁵⁶ Another systematic review that evaluated 15 eligible studies, foam dressings were shown to increase healing in comparison to basic wound contact materials but not when compared with other advanced wound dressings.⁵⁷ Despite these observations, all included studies were small and/or had limited follow-up times with a high risk of bias. Therefore, there is still no clinical evidence available regarding the use of foam dressings to heal DFUs.

The same review with a meta-analysis of RCTs for DFUs, selected 19 trials that used foam dressing for VLUs, confirmed equivalent dressing efficacies in terms of their ability to promote complete ulcer

healing.⁵⁵ Another systematic review that included twelve RCTs (1023 participants) reported an absence of difference in the healing outcomes between two types of foam dressings based on three separate trials. Additionally, healing in the foam group was not statistically different from the healing observed when using paraffin gauze in two trials and film in one trial and in the proportion of ulcers healed at twelve to sixteen weeks (RR :1.00; 95% CI: 0.81 to 1.22).⁵⁸ Nonetheless, the generated evidence is of low quality, and the analysed trials did not have an overall low risk. Thus, nothing suggests that foams are more effective in the healing of VLU when compared to other dressings (Table 4).

Recently, a RCT comparing the efficiency of a foam and a film in the outpatient treatment of partial thickness burns in paediatric and adult patients showed similar time to re-epithelialisation (12 days; $p=0.75$), but improved overall scar quality in the tissue dressed with the film (Film: 2; Foam: 4.5; $p<0.001$).⁷³ Despite this, no further clinical evidence has been reported.

Hydrocolloids

The term 'hydrocolloid' was devised in the 1960s at the time of the development of mucoadhesives and then introduced to practitioners to the use of a hydrocolloid dressings as an occlusive choice, which is virtually impermeable to water vapour and air. These can be described as dressings in which a hydrophilic adhesive mass that contains a dispersion of carboxymethylcellulose, polyvinyl alcohol, gelatine or pectin, which jellifies upon contact with the wound fluids that is then combined/applied to a flexible occlusive film and/or foam. Respectively, this provides the barrier and the mechanical protection described for these types of dressings.⁶ Hydrocolloids are capable of providing moisture to the wound since they form a gel after contact with the wound fluid.⁷⁴ However, the type of polymer and its hydrophilic characteristics used and its crosslinking degree,

which determines mechanical properties, influences the absorption capacity for the dressings (the higher the crosslinking, the lower the fluid uptake) and potentially their performance.⁷⁵ Some formulations contain an alginate to increase absorption capabilities. Additionally, because waterproof backing is often made of polyurethane, hydrocolloids also provide insulation to the wound bed. Although it is very appealing due to its adaptability to various body shapes, residues of the gel can be left in the wound when the dressing is removed,⁷⁵ and can be mistaken for infection due to its colour and odour.

Hydrofiber dressings are hydrocolloids produced in the shape of hydrophilic, non-woven flat sheets. These dressings have the same ability to form a gel when they come in contact with the exudate but have improved mechanical properties. These properties may overcome the problem of residue being left in the wound and provide an enhanced, faster absorption capacity that is capable of handling high exudate levels.¹⁴

A key feature of hydrocolloid dressings is their occlusive nature that is responsible for a highly hypoxic wound environment. The analysis of the oxygen tensions of chronic wounds dressed with hydrocolloids and semi-permeable film dressings confirmed values very close to zero.⁷⁶ While hypoxia around the wound is one of the critical factors that enhances the progression of chronic wounds, it is also positively correlated with epithelialisation¹⁶ and angiogenesis.⁷⁷ However, as for the film, the anticipated mechanism of action of occlusive hydrocolloid dressings has primarily been associated with what has been revealed about the healing process under moist conditions.⁷⁸ Therefore, the content of the wound fluids, in this case generated under the hypoxic conditions, is again a major factor to be considered. So far, in addition to the oxygen tension and the pH levels, which are acidic due to the chemical nature of the

Table 4. Randomised controlled trials evaluating wound dressings' efficiency for the treatment of VLU and mixed aetiology wounds

Author	Material	No. of patients	Compared conditions	Follow up (days)	Results	Comments
Dini et al. ⁵⁹ 2013	Foam	46	Cellulose-based foam vs polyurethane foam (control)	84	Higher healing rate	
Alvarez et al. ⁶⁰ 2012		50	Cellulose-based foam vs gauze (control)	Up to 84	Faster achievement of >50% re-epithelialisation (36 vs 50 days)	
Kelechi et al. ⁶¹ 2012		71	Polyurethane foam vs film	Up to 140	Lower proportion of completely healed ulcers (45% vs 86.4%)	
Wild et al. ⁶² 2010		40	Cellulose-based foam vs carboxymethyl-cellulose hydrocolloid (control)	28	Higher reduction in ulcer size after 28 days (45.53% vs 17.94%)	
Andriessen et al. ⁶³ 2009		12	Polyurethane-based foam vs collagen-based foam vs paraffin gauze (control)	28	Higher reduction in ulcer size for collagen-based foam, followed by polyurethane-based foam and lastly by paraffin gauze	Low number of patients
Franks et al. ⁶⁴ 2007		156	Polyurethane PEG-based foam vs polyurethane-based foam (control)	Up to 365	Similar ulcer closure	
Meaume et al. ⁶⁵ 2017		187	Foam impregnated with TLC-NOSF vs the same foam without NOSF (nano-oligosaccharide factor). Double blind RCT	56 days	Accelerated wound healing but not significantly different rate of wound closure	
Meaume et al. ⁶⁶ 2014	Hydro-colloids	156	Polyacrylate hydrocolloid vs carboxymethyl-cellulose hydrocolloid (control)	42	Similar impact in reduction of wound surface area (34.1% vs 34.4%)	
Dereure et al. ⁶⁷ 2012		143	Hyaluronic acid impregnated-gauze vs polysaccharide-based hydrocolloid (control)	Up to 60	Similar efficiency in the reduction of wound area	VLU and mixed aetiology
Meaume et al. ⁶⁸ 2008		125	Hyaluronic-based hydrocolloid vs hydrocolloid (control)	Up to 42	Similar efficiency in the reduction of wound area	VLU and mixed aetiology
Schmutz et al. ⁶⁹ 2008		138	Contact layer impregnated with TLC-NOSF vs ORC (Promogran)	96	Wound area reduction (61.4% vs 7.7%)	VLU and mixed aetiology
Nelson et al. ⁷⁰ 2007		124	Hydrocolloid vs film (control)	168	Similar proportion of healed wounds	
Romanelli et al. ⁷¹	Acellular matrices	50	Natural acellular xenograft vs gauze	Up to 56	Higher proportion of complete healing (80% vs 65%); p<0.05 Higher area of granulation tissue (65% vs 38%); p<0.05	VLU and mixed aetiology
Romanelli et al. ⁷²		54	Natural acellular xenograft vs artificial acellular matrix	112	Higher proportion of complete healing (82.6% vs 46.2%)	

VLU—venous leg ulcer

dressings,⁷⁶ not much further is known. The pH drop has also been correlated with a reduced probability of wound infection. However, when the effectiveness of hydrocolloid and permeable dressings to control burn infections were compared, the occlusive dressings were found more susceptible to microbial contamination and infections.⁷⁹ A similar tendency was also confirmed for the treatment of autogenous skin donor sites with hydrocolloids.⁸⁰

Safety and technical performance of hydrocolloids based on their ability to absorb and retain exudate with healthy periwound skin and minimised pain has been well-demonstrated.⁸¹⁻⁸⁴ The comparison of hydrocolloids, for the treatment of split-thickness skin graft (STSG) donor site, with other advanced dressings showed a diverse range of results. These confirm the great variability among the trials that do not allow definitive conclusions about the clinical relevance of one dressing over the other for a specific wound type^{32,85,86} (Table 3). Despite this, hydrocolloid dressings are more commonly used to treat chronic wounds. Several systematic reviews have analysed the effectiveness of hydrocolloid dressings in the treatment of DFUs. One of the reviews reported that hydrocolloid dressings were suggested to be associated with a higher likelihood of healing compared to other advanced dressings. It did, however, also highlight the very low quality of the studies and conveyed uncertainty concerning this conclusion.⁵⁷ In the four studies (511 participants) included in another review, no significant difference between hydrocolloids and traditional wound dressings (RR: 1.01; 95% CI: 0.74 to 1.38) was observed regarding ulcer healing.⁸⁷ The comparison between hydrocolloids and traditional and other advanced wound dressings, which was further analysed in a recent review with meta-analysis, reported that no significant differences were found among the pairwise groups in terms of achieving complete DFU healing.⁵⁵

This same review found similar results regarding the effectiveness of hydrocolloids in promoting complete healing of venous ulcers.⁵⁵ This is in agreement with what was reported by another systematic review and meta-analysis of 42 studies.⁸⁸ From eight selected trials, it was concluded that hydrocolloid dressings were not more effective than the low adherent dressings (RR 1.02, 95% confidence interval 0.83 to 1.28) in the control group.⁸⁸ More recently, other reviews⁸⁹ concluded that limited quality data is available regarding RCTs using hydrocolloids to treat VLU to be able to confidently make comparisons (Table 4).

Regarding the effectiveness of hydrocolloid dressings in the healing of PUs, based on 646 identified studies, 69 were evaluated, nine were selected, and four were used for the meta-analysis that showed no significant difference between the hydrocolloid and the foam groups (RR 1.06, CI: 95% 0.61 to 1.86; p value=0.84). A slight inferiority was observed for the hydrocolloid dressings, but the collected evidence was not sufficient to either confirm or deny superior/inferior effectiveness.⁹⁰ This is in agreement with another review that also reported a lack of evidence to support conclusions about different performance in relation to other dressings in the management of category III and category IV PUs, including in seniors in long-term care.⁹¹ Two older systematic reviews reported that hydrocolloid dressings were superior in comparison to traditional gauze dressings in terms of complete healing of PUs and VLUs.^{52,92} However, the lack of evidence supporting that hydrocolloids are better than any other advanced dressing was also confirmed.⁵²

Recent trials have also demonstrated the possibility of using hydrocolloid dressings in the management of partial thickness burns. A RCT (50 patients/group) that compared hydrocolloid and film dressings showed significantly increased comfort for patients when a hydrocolloid dressing was

used. However, no difference in healing time was found.⁹³ Another randomised study that included 70 patients and compared the effectiveness of hydrocolloid dressing versus standard of care treatment for partial-thickness burns, showed shorter time for healing in the hydrocolloid group (10±3 versus 13.7±4 days, $p<0.02$).⁹⁴ Although these are interesting outcomes, it must be highlighted that the tested dressings contained silver. Thus, clear clinical evidence on the benefit of using hydrocolloid dressings without additional antimicrobial components for burns management has not yet been examined.

Hydrogels

Hydrogels have been used in a wide range of medical applications. Originally proposed in the 1950s; they were only explored in wound management in the 1980s. Hydrogels are gels, which contain more than 99.9% water. Gels are materials composed of a three-dimensional crosslinked polymer network, usually soft and weak, immersed in a fluid. The degree of chemical interactions within this network can be changed by promoting its crosslinking or enhancing interactions, which make it harder and tougher.⁹⁵ Hydrogel dressings comprise both amorphous gels and sheets, which can be similar in terms of polymer composition but are physically very different. Contrary to the amorphous gels, sheets have a higher crosslinking degree and are insoluble in water. Depending on this crosslinking, the different sheets have different fluid exchange properties that provide moisture to the wound bed or absorb wound exudate.⁶ In addition, as the hydration of the hydrogels dressings is high (inconsistent data are available about the exact value which accounts for the differences among them) the amount of exudate that can be absorbed is relatively low. Therefore, these dressings are useful in situations where drainage is of secondary concern. The unprecedented amount of water in hydrogels is also responsible for their unique

ability to immediately cool the wound surface, which provides a soothing effect.⁹⁶ Importantly, this cooling effect should be temporary since prolonged reduced temperatures may delay healing due to the temperature's dependence on key biochemical and cellular elements.⁹⁷ Because hydrogels are dressings with high water content, and autolytic debridement has been highly associated with moist environments allowing natural enzymatic reactions to take place, hydrogels dressings have long been recognised as the standard treatment for necrotic and sloughy wounds.⁹⁸

The mode of action of hydrogel dressings is not known beyond the general considerations regarding the effect of a moist wound environment in wound healing. From the high number of studies reporting the potential application of hydrogels in a wide range of areas, it can be extrapolated that the 'bioactivity' of hydrogels depends on microstructural parameters, such as the chemical composition, crosslinking density, and mesh size, and on the macroscopic properties, such as mechanical stiffness and degradation rates, which may directly and indirectly affect cells and may be important for remodelling within the host tissue.⁹⁹ *In vivo* works, both in murine¹⁰⁰⁻¹⁰⁴ and pig^{101, 105} models of burns, it was shown that hydrogels can be tailored to modulate different stages of the wound healing, for example inflammation, which consequently affects neovascularisation within the granulation tissue. This leads to the progression of the healing and re-epithelialisation. Nonetheless, these types of analyses have not been the focus of attention for the different hydrogel dressings, but they are critical due to the dependence of the response on the materials that are being tested.

The comfort in the use of hydrogel dressings, associated with the easy adaptation to the wound, reduced pain and resulting in an absence of trauma

has been well-demonstrated.^{106, 107} Moreover, their soft tissue-like properties, together with the cooling effect potentially provided by the high-water content, make them prime dressings for the treatment of burns. From a total of 30 RCTs covering the treatment of partial and full-thickness burns systematically analysed with different dressings, three trials showed that wounds treated with hydrogels appeared to heal faster than those treated with standard care.¹⁰⁸ A meta-analysis was, however, not conducted due to the poor quality of the results or the heterogeneity of the studies.

A series of systematic reviews also showed moderate quality-level of evidence that hydrogels were more effective in healing DFUs as compared to traditional gauze dressings.^{55,57,109} However, no difference was found when one hydrogel was compared to a different hydrogel¹⁰⁹ or another advanced wound dressings.^{55,57} Meta-analysis also revealed that hydrogel dressings are more effective (RR: 1.80; 95% CI: 1.27 to 2.56) in healing (lower grade) DFUs than basic wound contact dressings. However, this finding is uncertain due to risk of bias in the original studies.^{55,109}

A review with meta-analysis of RCTs for VLU showed that hydrogels dressings have equivalent efficacies, in terms of promoting complete ulcer healing, to traditional and other advanced wound dressings.⁵⁵

From the results of a systematic review that evaluated eleven studies that involved a total of 539 participants, it was not possible to confirm that the healing of PUs was faster with hydrogel dressings as compared to healing with traditional dressings or any other advanced wound dressing.¹¹⁰

Alginates

Although alginate has been explored in the wound management context early in the 1940s, it was not until 1983 that the first alginate wound dressing

was commercially available. Alginate dressings are made of sodium and calcium salts, usually in a ratio of 80:20, or of only calcium alginate salt obtained from a family of brown seaweed.¹¹¹ Upon contact with the wound, an exchange of ions between the dressing, the calcium ions, and the fluid, the sodium ions, occurs, which slowly converts the calcium alginate in the dressing into sodium alginate. This is water-soluble and, thus, forms a gel.¹¹² Originally, alginate dressings were available as a loose fleece formed from calcium alginate fibres, but current products are often made of woven and non-woven fibres that provided a more cohesive structure improving the handling of the hydrated dressings. Most of the alginate dressings are produced in the form of sheets, but other shapes, such as ribbons or rope, which are suitable for deep, cavity wounds, are also available.⁶

Alginate dressings have the capacity to absorb fluid 15 to 20 times their weight. This makes them very useful in highly exuding wounds and contraindicated in wounds with little to no exudate due to their adhesive nature, which can cause pain and damage healthy tissue upon removal. Nonetheless, the relative composition of the alginate in mannuronic and guluronic acid units influences the amount of exudate that can be absorbed due to the gelling properties of the alginates. Alginate dressings with high content of mannuronic acid are less stable and more gelatinous and need to be washed off from the wound, while those with a high content of guluronic acid can be removed in one piece.¹¹² Due to the ion exchanging properties, alginate dressings are useful haemostatic agents. The released calcium, factor IV in the haemostasis cascade, activates thrombocytes and serine proteases that lead to fibrin formation and clotting.¹¹³

As for all of the dressings that form a gel upon contact with the wound fluids, it has been

assumed that the mode of action of alginate dressings relies on their capacity to provide moisture to the wound. In fact, very little is known about the specificities of each alginate dressing, but several studies have highlighted the biological activity of alginates. Alginates high in mannuronic acid are 10 times more potent compared to those with a high content in guluronic acid with regard to stimulating *in vitro* monocytes to produce pro-inflammatory cytokines, such as TNF- α , IL-6 and IL-1.¹¹⁴ This occurs through a common receptor to pro-inflammatory lipopolysaccharides, potentially the beta 1-4-glycosidic linkage of the guluronic acid.¹¹⁵ Interestingly, this activity can be eliminated by the selection of the different oligomers present in the raw material.¹¹⁶ In addition, *in vitro* tests showed increased proliferation of fibroblasts and decreased proliferation of endothelial cells and keratinocytes in the presence of alginates.¹¹⁷ However, a confirmation of these observations in wounds dressed with alginates is still lacking. Thus, there is a need for further understanding about the mechanism of action of these dressings.

Confirmation that alginate dressings are comfortable in use and can be removed with no trauma, without pain and discomfort to the patient, has been delivered.¹¹⁸ Moreover, the suitability of alginate dressings to manage low to moderate levels of exudate was demonstrated.¹¹⁹

RCTs have shown a potentially improved healing of split-thickness skin graft donor sites treated with alginate dressings in comparison to those treated with paraffin gauze.^{33,118} Nonetheless, a recent systematic review with meta-analysis that assessed RCTs on DFUs (12 trials) and VLUs (19 trials) treated with alginate dressings did not show statistically significant differences in terms of achieving complete healing when compared with other advanced wound dressings.⁵⁵

Regarding the use of alginates in the treatment of PUs, a review of 54 RCTs evaluating absorbent wound dressings found one in which calcium alginate dressings improved healing (mean wound surface area) when compared with a dextranomer paste.¹²⁰ A more recent review that also considered the former one and aimed at analysing the effectiveness of commonly used dressings in the management of category III and category IV PUs, including seniors in long-term care, reported that there is no evidence to support consistent superiority of one dressing over the other.⁹¹ Interestingly, a RCT (110 patients) that compared the sequential (alginate followed by hydrocolloid) and non-sequential (hydrocolloid) treatment of category III or IV PUs showed an accelerated healing in the sequential group in comparison with the control group.¹²¹ In relation to burn wounds, a trial with 65 patients that compared the effectiveness of an alginate dressing with a standard of care cream in partial-thickness burns showed a significantly shorter healing time for the alginate dressing.¹²²

Despite the common use of alginate dressings in the clinic, there are few reports of trials that provide significant evidence to justify their use for a specific wound type. As for the other studies, the low number of patients involved, the relatively high risk of bias, the heterogeneity of the studies as well as the poor quality of the results prevent an analysis with a higher level of significance.

Acellular matrices

The recognition of the key role of the extracellular matrix (ECM) in wound healing has steered the development of products that aim at replacing and/or promoting the deposition of the ECM. These products, comprising natural or artificial tri-dimensional matrices, provide a substrate for host cell migrate acting as a template or temporary scaffold that gradually degrades when new tissue is formed.¹²³

Natural acellular matrices are derived from animal or human tissue from which cells are removed while artificial man-made manufactured matrices are made from purified biological molecules and derived from cells after the onset. Although intended to work as ECM mimics, acellular matrices are different from native tissue. Natural acellular matrices are derived from animal sources (porcine, equine)-xenografts or human skin (cadaver)-allografts and developed by processing the animal tissues (dermis, small intestine submucosa, pericardial) to remove the cells and deactivate or destroy pathogens. Although this processing (decellularisation and/or dehydration) intends to eliminate only the cellular content of the tissue, the ECM is also affected, which results in a loss of components (decellularised products are often mainly composed of collagen) and structural integrity (absence of basement membrane, additional chemical crosslinking required), which then may impact their biological performance.¹²⁴

Artificial acellular matrices have been proposed that aim at targeting those limitations by combining multiple animal-derived (bovine, shark, calf) ECM components such as collagen (types I, III and V), elastin, and glycosaminoglycans (GAGs – hyaluronic acid), and at promoting their crosslinking to increase mechanical stability. Collagen is often used as the main component (Fig 1). Other artificial acellular matrices can also combine those animal-origin components with synthetic ones, usually identified as bio-composites, to facilitate processing and tailoring of the properties of the product (Fig 2). However, they do not mimic native dermis in its entirety.¹²³

Independently of the type of acellular matrix, materials are mostly processed in a 3D porous structure using technologies that allow for the controlling of the amount and the size of the pores, which is known to influence host cells infiltration.¹²⁵ Additionally, the composition, the



Fig 1. Post traumatic chronic ulcer treated with toilette plus autologous skin graft and porous matrix of fibres of cross-linked bovine tendon collagen and glycosaminoglycan (chondroitin-6-sulfate): a) preoperative, b) immediately after the toilette, c) immediately after the application of autologous skin graft and porous matrix, d) follow-up at seven months

Table 5. Randomised, controlled trials evaluating wound dressings' efficiency in the treatment of skin burns

Author/ year	Type of material	N. of patients	Compared conditions	Follow up (days)	Results
Hundeshagen et al. ¹³⁹ 2017	Foam	60	Polyurethane foam vs lactic acid-based film	Day 1, every 3–7 days up to 30	Similar median re-epithelialisation time (12 days); re-epithelialisation time greater than 21 days (20% vs 7%); Reduced scar quality: 4.5 (foam) vs 2 (film); $p < 0.001$)
Li et al. ¹⁴⁰ 2015	Acellular Matrices	60	Natural acellular allograft vs STSG (control)	180 and 900	No scar formation in natural acellular allograft group
Lagus et al. ¹⁴¹ 2013		10	Artificial acellular matrix vs STSG (control) Artificial acellular matrix vs cellulose- based foam	Punch biopsy at days 3, 7, 14, and 21; assessment at 90 and 365 post-burn	Lower number of neutrophils, histiocytes, and lymphocytes at days 7 and 14 in artificial acellular matrix vs cellulose-based foam Later vascularisation for artificial acellular matrix vs control and vs cellulose-based foam Less myofibroblasts on day 14 (artificial acellular matrix vs control)
Wood et al. ¹⁴² 2012		13 (children)	Artificial acellular matrix vs LST	Reassessment for further surgical need at 10 days post-burn. Follow-up to 180 days	Reduced time for complete healing (16 vs 36.5 days)
Bloemen et al. ¹⁴³ 2012		86	Artificial acellular xenograft vs STSG (control)	4 to 7 days after surgery; weekly up to 90; 365 days	Similar graft takes. Scar surface roughness scores at 12 months were lower for acellular dressing but without significant differences
Ryssel et al. ¹⁴⁴ 2008		10	Artificial acellular matrix vs STSG (sheet and mesh; control)	90–120 after surgery	No differences (artificial acellular matrix vs controls) for the necessity of re-grafting Significant improvement for artificial acellular matrix in VBSS measurements (score of 3 and 5 and 6 and 7 for sheet and mesh respectively)
Branski et al. ¹⁴⁵ 2007		20 (children)	Artificial acellular matrix vs STSG (control)	At admission, on discharge, and at 180, 365, 540, and 720 months post-burn	Similar graft takes aesthetically improved scar at 12 months and 18–24 months post-injury. Reduction in Hamilton scoring (5.4 vs 7.7 at 12 months and 4.3 vs 6.6 at 18–24 months)
Cassidy ¹⁴⁶ 2005		72 (children)	Artificial acellular matrix vs polysaccharide-based hydrocolloid	Not available	Similar time to healing. Similar mean time for complete re-epithelialisation (12.24±5.1 vs 11.21±6.5 days)
Verbelen et al. ⁹³ 2014	Hydrocol- loid	100	Carboxymethyl- cellulose-based hydrocolloid vs polyester polyethylene- based film	Every 3 days up to 21 days or until wound healing	Similar mean healing time (15.06±3.42 vs 16.16±7.19 days)
Muangman et al. ⁹⁴ 2010		70	Carboxymethyl- cellulose-based hydrocolloid vs LST (SSD)	Day 1, every 3 days until wound healing	Time-to-wound closure significantly shorter (10±3 days vs 13.7±4 days) Pain scores at days 1, 3 and 7 lower (4.1, 2.1, 0.9 vs 6.1, 5.2, 3.3)
Opasanon et al. ¹²² 2010	Alginate	65	Calcium alginate vs LST (SSD)	Until healing occurred	Lower mean time to heal (7 vs 14 days)

STSG—split-thickness skin graft donor sites; LST—local standard treatment; SSD—silver sulfadiazine

type and amount of materials, of the products are tailored together with the form (chemical or physical) and degree (exposure conditions) of crosslinking. All of these are directly linked to the degradation and, consequently, to the matrix remodelling rate during the healing process of the wound. These differences are likely to affect multiple wound healing aspects since microarchitecture (porosity and pore size), mechanical features (elasticity) and chemistry (reactive groups, surface charge) are known to affect cell adhesion, migration and differentiation.¹²⁶⁻¹²⁹ In fact, the treatment of acute cutaneous wounds with autografts or acellular matrices resulted in variable fibrotic (amount and organisation of collagen I) outcomes with reduced scarring in relation to wounds healed by secondary intention.¹³⁰

Acellular matrices are not intended to directly replace dermal collagen. They are used as a way to achieve an environment that cells sense as native to promote a faster and better healing. Thus, if the degradation is not controlled to avoid a major foreign body reaction and an exacerbated inflammatory process, which are hallmarks of burns and chronic wounds, scarring or impaired healing are likely to occur.¹²³ Due to the permeable nature of these products, several of them comprise an outer silicone layer, which works as a temporary epidermis and serves to control moisture loss from the wound. These allow

vascularisation of the dermis under a protective layer, which can then be removed and replaced by an autologous STSG.¹³¹ On the other hand, in the absence of the outer layer, earlier wound closure is achieved but onto an avascular dermis.¹³² Independently of the strategy, vascularisation will depend on the composition (some materials or degradation products are intrinsically angiogenic) and properties of the materials to allow an influx of cells and the formation of a capillary network. Improved vascularisation before the application of a split skin graft has been shown to lead to better take rates, reduced wound contraction and good aesthetic outcomes.^{123,133,134}

Natural skin-derived acellular matrices, in opposition to artificial ones, usually contain parts of the native basement membrane. This has been shown to promote the adhesion and further *in vitro* differentiation of keratinocytes due to the presence of laminin and collagen IV.¹³⁵ In fact, a significantly higher proportion of completely healed wounds was attained with a natural acellular matrix as compared with an artificial one.⁷²

Acellular matrices have been tested as an option for burn and chronic wound management with growing evidence for the use in diabetic and VLUs (Fig 3). A recent systematic review included seven studies (205 patients) to compare the efficiency




Fig. 2. Squamocellular carcinoma of the back treated with porcine-dermal matrix and autologous skin graft: a) at 15 days after skin graft plus porcine-dermal matrix we can see that the skin graft has not survived completely, b) 90% re-epithelialisation at one month, c) complete re-epithelialisation at two months



Fig 3. Vascular chronic ulcer treated with acellular dermal matrix and autologous skin graft: a) pre-operative, b) immediately after toilette, c) intraoperative with artificial dermal matrix (ADM), d) intra-operative autologous skin graft, e) at 15 days

of acellular dermal matrices and or split-thickness skin grafting in burns, focusing on the graft take, infection rate and scar quality.¹³⁶ Similar wound coverage was reported, but four out of the seven trials included did not show a significant difference in scar quality, which does not provide

conclusive evidence about the effectiveness of the acellular dermal dressing.¹³⁷ Another systematic review that analysed six trials, using a different acellular dermal dressing to treat partial thickness burns in children, concluded that the acellular dressing performed better than the standard of care regarding the epithelialisation rate. However, hardly any of the studies assessed long-term performance, such as scar quality¹³⁸ (Table 5).

Regarding the use of acellular dressings to treat chronic/non-healing wounds, a recent RCT (60 patients were included and 46 selected) compared the performance of an artificial acellular dermal matrix with a traditional gauze dressing in DFUs up to six weeks based on epithelialisation and granulation tissue formation (Table 6). The results with the acellular dermal matrix were significantly superior (86.95% versus 52.17% complete healing in the total 69.56%; $p=0.001$) with lower amputation ($p=0.0019$) and re-hospitalisation ($p=0.028$) rates.¹⁴⁷ Another RCT (168 patients, 36 withdrew due to either an adverse event or significant noncompliance) compared two different acellular allografts, one or two applications, with standard of care treatment (patients randomised at a ratio of 2:1:2) for DFUs up to 16 weeks. This trial showed that the two acellular dressings performed differently, but not at significant levels (67.9% versus 47.8%; $p=0.1149$), although the one with the higher proportion of completely healed ulcers had a significantly better result than the standard of care group (67.9% versus 48.1%; $p=0.0385$) and independent of the number of applications. Interestingly, the two acellular grafts showed a significantly different average percent of reduction of the wound area (91.4% vs 73.5%; $p=0.0762$).¹⁴⁸

The performance of acellular matrices in the treatment of DFUs was also recently compared with other advanced wound dressings. In a small trial (17 patients) that compared a natural acellular xenograft with a foam, the incidence of wound

Table 6. Randomised controlled trials evaluating wound dressings' efficiency for the treatment of diabetic foot ulcers (DFUs)

Author/ year	Type of material	No. of patients	Compared conditions	Follow up (days)	Results
Zhang et al. ¹⁵¹ 2014	Foam	50	Polyurethane-based foam vs gauze (control)	84	Reduced wound area and time of healing (49.9 vs 65.5 days)
Alvarez et al. ¹⁵² 2017	Acellular	17	Natural acellular xenograft vs polyurethane-based foam (control)	84; 112; 365	Reduced time of healing (62.4 vs 92.8 days) Reduced incidence of ulcer recurrence at one year (10% vs 50%)
Campitiello et al. ¹⁴⁷ 2017		46	Artificial acellular matrix vs gauze	42	Greater wound closure (86.95% vs 52.17%) (p=0.001)
Walters et al. ¹⁴⁸ 2016		168	Natural acellular allograft I vs standard of care Natural acellular allograft I vs natural acellular allograft II	112	<i>Reduction of wound area:</i> (91.4% acellular I vs 80.3% standard of care; p=0.0791); (91.4% acellular I vs 73.5% acellular II – p=0.0762) <i>Proportion of healed wounds:</i> (67.9% acellular I vs 48.1% standard of care; p= 0.0385); (67.9% acellular I vs 47.8% standard of care)
Driver et al. ¹⁵⁰ 2015		307	Artificial acellular matrix vs sodium chloride-based hydrogel (control)	112 or until confirmation of wound closure	Greater ulcer closure (51% vs 32%) Wound size reduction (7.2%/week vs 4.8% / week)

DFU—diabetic foot ulcers

healing was 90% and 100% versus 33% and 83.3% (p=0.062) respectively, at 12 and 16 weeks. Additionally, the mean time for healing was 62.4 days for the acellular matrix in opposition to the 92.8 days in the foam group (p=0.031). Importantly, the incidence of ulcer recurrence at one year was 10% (1/11) in the acellular matrix group and 50% (3/6) in the control group.¹⁴⁹ A larger multicentred trial (307 patients) evaluated the safety and efficacy of an artificial acellular matrix in comparison to a sodium chloride gel for the treatment of non-healing DFUs. Complete ulcer closure was significantly greater with the acellular matrix (51%) than with the control (32%; p=0.001) treatment at 16 weeks. The median time for complete closure was 43 days for the experimental group and 78 days for control in the wounds that healed. Moreover, the rate of wound size reduction was 7.2% (acellular matrix) versus 4.8% (control) per week (p=0.012).¹⁵⁰

Two different RCTs compared the ability of a natural acellular xenograft (natural acellular matrix) with a traditional dressing (54 patients)⁷¹ and an artificial acellular matrix (50 patients)⁷² for the treatment of mixed arterial/VLUs. Faster achievement of complete healing was observed for the natural acellular xenograft compared to the artificial acellular matrix (82.6% versus 46.2%; p<0.05), in a significantly shorter time (5.4 versus 8.3 weeks; p=0.02)⁷² and as compared to the traditional dressing (80% versus 65%; p<0.05).⁷¹

Despite these results, two previous systematic reviews^{89,153} concluded that limited data were available regarding RCTs with acellular dressings. In particular, sufficient evidence to draw meaningful conclusions regarding the treatment of DF and arterial ulcers was lacking¹⁵³ while low-strength evidence was found for VLUs.^{89,153}

Table 7. Evaluation of evidence levels: materials

No.	Therapy	Indication for use	Level of evidence (for each indication)	Comments
1	Hydrocolloids (including hydrofibres)	STSG donor sites	2c	Likely to perform equal to other approaches; great variability among the trials
		DFUs	2c	Low-quality results; Likely to perform equal to other approaches; great variability among the trials; hydrofibres are less cost-effective than other non-adherent dressings
		VLUs	2c	Low-quality results; likely to perform equal to other approaches; great variability among the trials
		PU	2c	Low-quality results; likely to perform equal to other approaches; great variability among the trials
		Burns	2c	Potential benefits lack systematic analysis; RCT performed used dressing-containing silver
2	Films	STSG donor sites	1b	Moderate-quality evidence
3	Foams	STSG donor sites	2c	Any estimation of the effect is uncertain
		DFUs	2c	Low-quality results; likely to perform equal to other approaches; great variability among the trials
		VLUs	2c	Low-quality results; likely to perform equal to other approaches; great variability among the trials
4	Hydrogels	Burns	2c	Poor-quality results; heterogeneity of the studies
		DFUs	2c	Moderate-quality level of evidence in relation to traditional gauze dressing; likely to perform equal to other approaches
		VLUs	2c	Based on RCT results, other alternatives may be equally reasonable; high risk of bias; heterogeneous studies; poor quality of analysis performed
		PU	2c	
5	Alginates	DFUs	2c	
		VLUs	2c	
		PU	2c	
6	Acellular Matrices	Burns	2c	Based on RCT results, other alternatives may be equally reasonable; short-term results
		DFUs	2c	Potential benefits lack systematic analysis; RCT performed under different conditions and different inclusion criteria
		VLUs	2c	

STSG—split-thickness skin graft; DFU—diabetic foot ulcer; VLU—venous leg ulcer; PU—pressure ulcer

Future perspectives

As mentioned before, the performed analysis of the healing effectiveness of the available dressings was based on the premise that wounds have to be cleaned and the wound bed should be well-prepared for healing to proceed. Nonetheless, infection is a major issue in wound healing. Each type of dressing discussed is also available

with different antimicrobials, such as silver, betaine, chitosan, polyhexamethylene biguanide and honey, for preventing and treating wound infection. Dressings that provide a sustained release of silver, in sufficient concentrations, is one of the newer approaches taking advantage of nanocrystalline silver.^{93,154} Physical approaches that rely on dressings that irreversibly bind bacteria

due to their outer chemistry have been presented as alternatives, which do not include the risk of inducing bacteria resistance and avoid bacteriolysis and pro-inflammatory endotoxin being released into the wounds. While prophylaxis is limited for these types of dressings, current clinical results can be considered encouraging and a good basis for further development.¹⁵⁵ Despite all these possibilities, wound infections and biofilms, which represent a physical barrier to healing and an extension of the inflammatory phase, are still a major challenge.¹⁵⁶ Many antibiotic-containing topical formulations have also been developed, but the routine administration of these has not led to better outcomes. Instead, it has often resulted in patient discomfort along with the possibility of antibiotic resistance and contact dermatitis.¹⁵⁷ These results added to a general consensus that topical antibiotics should be used for clearly infected wounds and not for prophylaxis.¹⁵⁸

In what concerns the outcome of the performed analysis referring to the healing efficiency of the current wound dressings, it is consensual and common to all dressings that high-level evidence of the benefits of one over the other has yet to be demonstrated. This highlights the urgent need to better understand the pathophysiology of each wound as well its progression under specific dressing considering their particular properties. In most cases, these depend on their composition and/or processing methodology. New methods have been employed to create innovative matrices

with intrinsic features such as pH-sensitivity¹⁵⁹ envisioning their application as controlled release dressings, or calcium chelating ability¹⁶⁰ to modulate keratinocytes behaviour. In line with this, new research on novel molecules of interest in wound healing such as adrenomedullin (AM) and its binding protein-1 (AMBP-1),¹⁶¹ astragaloside IV¹⁶² as nitric oxide¹⁶³ has shown interesting results. However, complementary clinical research on the presence and activity of these molecules in the different wounds is still required. Although numerous case reports and non-controlled trials on the use of therapeutic molecules in different dressings have reported issues associated with cytokines and boarder growth and pleiotropic action that are determined by the wound environment. In addition to the need to achieve faster and better healing, particularly for chronic wounds, scarring associated with burns is another major concern in the field, particularly because wounds heal by a reparative rather than a regenerative process. While the differences between scarless foetal and adult healing are currently under study, the knowledge generated so far has not been profoundly explored and mostly relies on taking advantage of isolated factors that are up- or down-regulated in foetal wound healing based on all of the associated limitations that were already discussed.

An evaluation of evidence levels for use of the therapies covered in this chapter, related to indications for use, can be found in Table 7.

Cell- and tissue-based therapies

Cell therapies

Regenerative medicine has far-reaching origins and is currently considered as a 'multidisciplinary medicine involving life, physical sciences and engineering'. The objective is to develop cells, tissues and functional organs to repair, replace or improve a biological function that has been lost due to congenital anomalies, injuries, illness or ageing. Already in the eighth century BC, Hesiod addressed the liver's ability to regenerate. He described this in the poem, *Theogony*, about the myth of Prometheus. Also, Aristotle speaks about tissue regeneration in a salamander, hypothesising the development of a biological tissue from an 'undifferentiated matter', thus giving rise to what would then be recognised as epigenetic theory.

It is only in 1868 that the academic world, for the first time, learnt about the concept of stem cells. The term was coined by Ernst Haeckel, who indicated progenitor cells of multicellular organisms. Since then, stem cells and their potential use have created great interest in the scientific communities and led to a number of experiments. In 2003, Haseltine identified all of the potential for the development of an adult human being within a single cell. In 2004, the international introduction of the term 'regenerative medicine' took place. On 2 November 2004, the US Federal Government approved Proposition 71, which included funding for a research institute called the 'Californian Institute of Regenerative Medicine'. The purpose of this institute was to carry out scientific research on stem cells.

Today, it is possible to define a stem cell as an undifferentiated cell that is capable of producing both copies of itself and mature cells that are completely differentiated for a particular type of tissue.

Although it was initially believed that only embryonic cells had this potential, worldwide research has, from the late 1990s to the first decade of 2000, shown the presence of stem cells, which come from a different origin. These are defined as multi-potential cells that can differentiate into a specific tissue with which they have come into contact. Such stem cells, called mesenchymal, are also present in adult tissues. For example, adult stem cells can be derived from adipose tissue. However, in order to properly use these cells within so-called cell therapy, the branch of medicine that deals with 'replacing' damaged tissue by injection or application of healthy cells, it has become necessary to define the 'minimum' requirements needed to define a stem cell as well as its ideal features.¹⁶⁴⁻¹⁶⁶

The ideal stem cells

In order to standardise stem cell detection and at the same time to facilitate a better analysis of scientific papers in literature and the correct use of the term 'stem cells' in wound healing, the International Society for Cellular Therapy proposed the 'minimum' criteria needed to define a human 'mesenchymal stem cell' in 2006:

- The cell must adhere to the surface under standard culture conditions *in vitro*

- The cell must express CD105, CD73 and CD90 but not CD45, CD34, CD11b or 14 CD79 alfa or CD1) and HLA DR
- The cell must be able to differentiate, *in vitro*, in osteoblastic, adipocyte and chondrocyte.

In light of these criteria, it was also attempted to understand what the ideal characteristics for a therapeutic stem cell could be by identifying the following criteria:

- The cell must be able to multiply infinite times without increasing the risk of oncogenic mutations in its DNA
- Cell differentiation must be controllable
- Cellular collection should be easily accessible, abundant and with minimal discomfort and/or morbidity for the patient.

In order to identify the 'ideal' cell, many of the cell lines have been studied and used, but only a few of them are actually usable.

Initially, it was thought that stem cells were present exclusively in embryonic/foetal tissue, where they were able to differentiate in any cell line in order to form the individual.

These were known as ESCs or stem cells of embryonic origin. Today's research has shown the presence of numerous stem cells in adult tissues also. These are named mesenchymal stem cells.¹⁶⁷⁻¹⁷⁴

The stem cells and other therapeutically active cells

Nowadays, many cells are studied for wound healing. Some of them are stem cells, and others are living cells. The most studied and used cells within tissue healing include the types listed in Table 8.

To date, significant shortcomings have been documented with the clinical application of live cell therapies. It has been established that stem cells typically do not survive, engraft, or differentiate long-term following clinical implantation.¹⁷⁵⁻¹⁷⁷ Especially within a harsh wound environment, cells rapidly undergo apoptosis and are cleared by the body within 24 hours to one week after implantation.¹⁷⁶ While stem cell differentiation has been demonstrated *in vitro*, differentiation of implanted mesenchymal stem cell (MSCs) has yet to be definitively shown *in vivo*. Additional concerns persist with maintaining the phenotype of live stem cells during expansion in culture, cryopreservation, and rapid thawing of MSCs before implantation.^{178,179} Therefore, recent research has largely focused on the signalling properties of MSCs, particularly related to the release of cytokines and modulation of inflammation.^{180,181}

Bone marrow stem cells

These cells are already considered the best stem cell reserve, and the cells derived from bone marrow are certainly the class, which has been studied the most extensively. Their ability to differentiate in any cellular line, from bone to cartilage, to muscle,

Table 8. Stem cells and other therapeutically active cells

Type	Pro	Con
Bone marrow stem cells	Ability to differentiate in any cell lines	Complex acquisition, low number of cell obtainable
Keratinocytes and fibroblasts	Derived from skin biopsies	High culture time, friable and easily damageable skin, cannot be used to cover large areas
Adipose derived stem cells	Easy to acquire; ability to differentiate in any cell lines; regenerative and volumetric effect	Not recommended for use in cancer diseases
Platelets	Rich in growth factors, can be used as support for other cell therapies	Requires at least 20cc/blood sample
Leukocytes	Rich in growth factors, antibacterial potential, immunomodulating, orchestrating wound healing	Requires at least 20cc/blood sample
Monocytes	Accelerates neovascularisation, easy to acquire, <i>in vitro</i> differentiation	No differentiation in epithelial cells <i>in vivo</i>
Epithelial stem cell (hair follicle)	Easy acquisition	Low number of studies

stromal cells, tendon and fat, has suggested that this cell class could be the most suitable for various uses.

However, a much deeper analysis, though confirming the great potentiality of bone marrow cells, demonstrated how the process of acquiring these cells is complex and rather painful for the patient. An acquisition from the sternum or iliac crest was expected, and it has little efficacy in terms of the number of cells obtainable. Thus, these types of cells fail to comply with two of the criteria previously considered. Most important of these factors are the reduction of the suffering of the patient and the unlimited multiplication.

Keratinocytes and fibroblasts

Since the late 1990s, keratinocytes and fibroblasts have been widely used in the treatment of chronic wounds and burns. They have been used alone or in association with other cell lines, such as melanocytes. The possibility to use skin biopsies in order to produce new skin for the patient by manipulating the skin biopsy with hyaluronic acid, suggested that the use of keratinocytes and fibroblasts could be a decisive choice. Even in this case, however, experience has shown concern

about the potential of this 'artificial' skin, such as: 1) the culture time is too high since it takes at least two weeks to get usable skin; 2) the method cannot be used to cover large areas since large number of biopsies are needed in this case, and this is not always possible, especially in case of large burns; 3) the skin obtained, while being 'complete' with both epidermis and dermis, is very friable and, therefore, easily damageable. It has also been found that the extraction is too traumatic for the patient.

Adipose derived stem cells (ADSCs)

Obtained by a lipoaspiration procedure, adult stem cells derived from adipose tissue are multipotent cells. These are very similar to those obtained from the bone marrow, and since the year 2000, they have been used extensively in the field of tissue healing and regenerative medicine. They are currently becoming the most widely-used cellular line.

They are popular thanks to the easy extraction process and the low patient morbidity. ADSCs can be found in large quantities, representing a fraction of 1/500 to 1/1500 cells for a total of 5000/cell each gram of fatty tissue extracted,

with a stem potential 500 times higher than the medullary equivalent.

These cells have excellent plasticity, are 'self-healing' and can, *in vitro*, differentiate in any other cell line. They also offer the patient the opportunity to obtain not only a regenerative effect, but also a trophic and volumetric effect in the grafting area. These cells are contained in the vascular stromal fraction of the lipoaspirate when they are separated from the remaining cellular parts. These are present in the aspirate by a process known as decantation or centrifugation and can be reinstated directly in the same patient (lipofilling) during the same session without the need of any delivery system. ADSCs grafting, therefore, induces neoangiogenesis stimulation, partly by promoting paracrine, and their presence can modulate the formation of granulation tissue, extracellular matrix, and immune response, thereby promoting tissue healing. ADSCs also have an antioxidant effect, and by secretion of lymphoangiogenic factors, they improve tissue lymphoedema by stimulating re-absorption. Finally, by use of chemokines, they are able to recruit other endogenous stem cells to the graft site.

In the last decade, the above mentioned characteristics have made the adult stem cell derived from adipose tissue, the ideal cell for use in wound healing.

Other cells

Platelets

Platelets are a good source of growth factors. They are frequently used in combination with other treatments, such as lipofilling. Once you have a blood test of at least 20cc, it is possible to separate the platelets from other cellular elements, such as white blood cells, in order to obtain plasma rich plasma (PRP) or products rich in growth factors derived from the platelets. This happens via a 'filtered centrifugation process. This plasma

can be used alone or in combination with other treatments to assist in the healing of wounds, such as ulcers or skin grafts, and for aesthetic purposes, such as a revitalising treatment for the skin, ageing skin or in the treatment of alopecia.

Leukocytes

Both *in vitro* and *in vivo* studies have proven the key importance of leukocytes in wound healing. Neutrophils are known to be a key part of the innate immune response key in the clearance of bacteria and debris as well as important in transferring the wound from the initial inflammatory phases into the proliferative wound healing phases.¹⁸² In addition, recently both B- and T-cells have shown importance in the resolution of inflammation and, eventually, wound healing.¹⁸³ However, the most well described leukocyte to be involved in wound healing is the monocytes.

Monocytes

In vitro studies have shown that mononuclear fraction is a source of stem cells that can accelerate neovascularisation and differentiate into epithelial, smooth, and endothelial muscle cells. However, epithelial differentiation has not yet been shown *in vivo*.

Epithelial stem cells collected from a hair follicle

Acquired by biopsy or by scraping of the scalp, these cells were used *in vitro* for cellular vitality studies. These experiments have shown that it is possible to obtain 0.5 million stem epithelial stem cells from 100 hair follicles, and these cells are positive for cytokeratin K15, thus retaining the potential for transdifferentiation in similar epithelial corneal cells. This feature could make them readable, not so much for the treatment of chronic wounds, but for the treatment of ocular pathologies, such as Limbal Stem Cell Deficiency, which provides a patient the possibility of ensuring a corneal transplant.

The application modes of cell therapies

In order to promote growth, differentiation of stem cells, and their positioning in the area to be treated, so-called scaffolds and/or vehicle systems are needed. This is especially true if it is impossible to make a direct graft, and the procedure is similar to the previously explained procedure for lipofilling.

Scaffolds

Scaffolds are absolutely necessary to promote proper cell differentiation and above all the construction of a 3D-tissue. The ideal scaffold should be characterised by a functional plan, and one that is structurally similar to the native extracellular matrix of the tissue is required. It should also be biodegradable, not stimulate an inflammatory response, have surface properties capable of promoting adhesion, proliferation and cell differentiation, and should be able to mimic the skin *in vitro*, and have effective mechanical properties. Finally, it should be sufficiently plastic to be moulded into various shapes, depending on the receiving area. Biological and synthetic scaffolds can be found on the market today.

Organic scaffolds are characterised by a base consisting of, for example, collagen, glycosaminoglycans, hyaluronic acid or chitosan. They are composed of up to three layers. A category belonging to the biological scaffolds is represented by so-called decellularised scaffolds that are derived from dermic matrix, which are more complex architecturally and in the matrix composition. The latter have found extensive use as the absence of cells would avoid the formation of an inflammatory process. However, the processes necessary to obtain proper decellularisation are very complex and critical because they have to maintain the matrix proteins, the architecture of this and the growth factors in the proteins.

Synthetic scaffolds, on the contrary, are more readily obtainable and customisable as needed.

These can also be produced in large quantities. Formulated, for example, by polylactideglycolic acid or even polycaprolactone, they can host fibroblasts, keratinocytes and ADSCs. In the latter case, they support stem cell growth and differentiation in epithelial cells and fibrovascular components by promoting tissue healing in the event of acute and chronic lesions.

At the moment, 'hybrids' scaffolds made of organic material are designed to provide the ideal environment for cell proliferation and differentiation, and inorganic materials are most useful to facilitate cellular production and quality.

Carrier systems

Carrier systems are useful to convey cells *in vivo*, without the use of three-dimensional scaffolds. Carrier systems include topical sprays, direct grafts or systemic delivery.^{100,172,184–187}

Possible uses of cell therapies

Stem cell therapy, as mentioned above, has found widespread use in wound healing, whether acute or chronic. Of the approximately 500 clinical trials currently taking place worldwide, 23 trials are closely related to the use of stem cells in healing wounds. More precisely, trials are in progress for the use of haematopoietic stem cells, ADSCs, BMSCs and MSCs in PUs, vascular and diabetic ulcers and burns. Finally, trials are being conducted to evaluate the possible use of scaffolds that favour neural proliferation in the treatment of chronic spinal cord injuries (for further details on all clinical trials, see clinicaltrials.gov).^{188–191}

Autologous blood-derived products for wound care

The use of autologous blood-derived biomaterials in the treatment of chronic wounds was introduced in the mid-1980s by Dr David Knighton and his colleagues.¹⁹² They developed a platelet-derived wound healing factor (PDWHF) formula

derived from autologous blood. Platelets were first isolated from anticoagulated whole blood and then activated by the addition of thrombin (1U/ml) in a specific buffer. The supernatant from the activated platelets were mixed with a 1g jar of microcrystalline bovine collagen to generate an acellular salve containing a plethora of growth factors at super-physiological concentrations.

Since the launch of PDWHF, several different platelet-derived or platelet concentrate products have been developed. From the generic platelet-rich plasma (PRP) products, four distinct product categories have evolved.¹⁹³ These autologous products are classified according to their specific cell composition and fibrin content as follows:

- Pure platelet-rich plasma (P-PRP) products consist of platelets without leukocytes in plasma and can be used either as a fluid for injection into orthopaedic injuries or can be activated by calcium and thrombin to release growth factors and polymerise fibrin to form a gel for topical application to skin wounds (Fig 4). The level of fibrin (2–3mg/ml) generally matches that of plasma.
- Leukocyte- and platelet-rich plasma (L-PRP) products are similar to P-PRPs, but they contain leukocytes in addition to the platelets. Typically, leukocytes are concentrated by 3–5 times as compared with the concentration in whole blood. L-PRPs are administered as a liquid without activation or in the form of a gel entangling cells and platelets after activation.¹⁹⁴
- Pure platelet-rich fibrin (P-PRF) preparations constitute activated platelets in a polymerised fibrin matrix. The fibrin content is higher than in P-PRP and L-PRP products and the cohesiveness typically prevents P-PRF products from being injected. Instead, P-PRF products are applied directly to the wound.¹⁹⁵




Fig 4. Venous ulcer treated with platelet-rich plasma (PRP) and autologous skin graft: PRP device (a), PRP (b), intraoperative PRP injection after autologous skin graft (c)

- Leukocyte- and platelet-rich fibrin (L-PRP) preparations are similar to P-PRF products with respect to their high fibrin content. As opposed to P-PRFs, they contain leukocytes apart from the platelets derived from the blood.¹⁹⁶

Products in groups one, two and three are made from anticoagulated, whole blood in multiple steps. L-PRF products of group four are prepared in two steps without extra chemicals. L-PRF is isolated manually from the fibrin clot that forms after instant centrifugation at a low speed in whole blood where 'most platelet aggregates and leukocytes are concentrated within the end of the PRF clot, close to the border with the base of red blood cells. The way the clot is separated considerably influences the final biologic content of the PRF'.¹⁹⁷ In other words, L-PRF will vary in composition depending on the individual preparing the product.

In general, PRP/PRFs is obtainable by a blood sample of 20–140cc depending on the procedure used. All systems provide platelets that release growth factors, including PDGF, TGF- β , VEGF, IGF-1, FGF, and EGF, thus promoting tissue repair, modulating inflammatory processes and neoangiogenesis and, ultimately, regulation of tissue homeostasis and regenerative processes.

Easily obtainable by the patient without morbidity, PRP/PRFs has recently found employment also in aesthetics in order to treat aging skin and in the trichological field in cases of alopecia. Finally, it is increasingly associated with autologous and lipofilling grafts, in order to favour its intake and differentiation. It can also be used in the presence of skin substitutes.

The autologous leukocyte and platelet-rich fibrin patch (APFP) is a newer advanced therapy without chemical additives. As such, it belongs to the 4th group described above. The APFP, however, has a

layered structure and is produced mechanically by use of the 3CP procedure, via a single use closed sterile device. The bedside production is performed in three steps: 1) blood is drawn by venepuncture into a sterile vacuumed device in a process identical to normal blood sampling; 2) the device is positioned in a specially designed centrifuge insert and spun in an automated two-step process at the bedside; and 3) the device is opened and the formed patch is transferred directly to the wound of the patient. The process takes approximately 20 minutes of which the hands-on time is 2–3 minutes including the drawing of the blood.¹⁹⁸

Platelets and leukocytes are concentrated by 8–18 times as compared with the total quantity of blood.

The APFP is a three-layered patch composed of: 1) a polymerised and cross-linked fibrin matrix; 2) a layer of compacted platelets; and 3) a layer of concentrated leukocytes on the lower surface. In Fig 5, the three-layered structure and the leucocytic accumulation at the surface of this dressing is shown.

Extract analyses of the APFP have shown that high levels of growth factors are released continuously from the patch for up to a week. The addition of chronic wound fluid increased the speed of the growth factor release, and this feature may be relevant in the treatment of chronic wounds.

When comparing the levels of selected growth factors and cytokines in the APFP to P-PRP generated by standard procedures, higher levels of the platelet-derived growth factors (PDGF) by a factor of three and 10, for PDGF-AB and VEGF, respectively, were found. The leukocyte-derived cytokine IL-8 is more than 280 times higher in the APFP, which demonstrates a clear difference from P-PRP. *In vitro* studies in the culturing of fibroblasts and keratinocytes in the presence of these dressings have shown an enhancing effect on both cell growth




Fig 5. The physical structure of the autologous leucocyte and platelet-rich fibrin patch (APFP)¹⁹⁹ H&E stain of the three-layered structure of the autologous leucocyte and platelet rich fibrin patch shows the fibrin layer up, platelet layer in the middle and the Leucocyte layer downwards (a). The leucocyte layer containing several leucocyte types; monocytes, neutrophils and lymphocytes (b). Scanning electron microscopy (SEM) of the leucocyte surface (c)

and migration of these cell types in response to the APFP.¹⁹⁹ Furthermore, studies done with *Pseudomonas aeruginosa* cultures have shown the ability of these cells to phagocytise and kill bacteria.²⁰⁰

Recently, a number of preclinical and clinical studies have been performed to test the safety and effectiveness of the APFP with generally positive results.^{201,202} More information is expected from a large multi-centre trial that was conducted in Europe but has not yet been published. No RCT has been published to date.

Clinical evidence for platelet-derived products in wound care

Only a near-physiological concentration P-PRP gel has been tested in a properly conducted, RCTs on DFUs. Despite the fact that no statistically significant improvement of healing could be demonstrated in this RCT, the gel was cleared by the FDA for wound management.²⁰³ Meta-analyses of small-sized trials on platelet products indicated a positive effect on the healing of DFUs, and a retrospective analysis of a US database indicated an effect of platelet releasate in healing DFUs.^{204–206}

This analysis may be biased due to the differences in treatment regimens among the included trials. This is one reason why neither the National

Institute for Health and Care Excellence (NICE) of England nor the Center for Medicare Services (CMS) of the US have recommended nor reimbursed these products for routine use in wound treatment.^{207,208}

Other cell therapies/advanced cell therapies

Defined as new medical products based on genes, cells and tissues, the ‘advanced cell therapies’ can be used to promote wound healing also in recalcitrant wounds. Nowadays, some novel and very promising cell therapies have been developed.

The use of safe food-grade lactic acid bacteria

In order to stimulate a ‘personalised’ production of therapeutically active proteins within the damaged tissues, such as in chronic wounds, it is now possible to use genetically modified lactic acid bacteria as a delivery method. The modified bacteria serve as a local bioreactor in the wounds by producing and secreting certain proteins, such as FGF-2, IL-4 and CSF-1, which are known to promote wound healing. This approach enables continuous exposure to these therapeutic factors and by producing more than only one factor, these bacteria are able to address several aspects of the aberrant wound healing at the same time, such as fibroblast/keratinocyte proliferation, angiogenesis



Fig 6. A recalcitrant venous leg ulcer which showed insufficient healing tendency for >10 years (a) was treated with a dehydrated human amnion-chorion membrane (dHACM), resulting in immediate pain reduction and rapid healing after 4 (b) and 10 weeks (c)

and anti-inflammation. This method can modulate the local immune system by switching the

production of therapeutic proteins on and off directly in the damaged tissues. The method is safe, cost-effective and easy-to-apply. It can be used for ulcers from different aetiologies and also for cancer treatment.^{198,200,201,209,210}

Placental-based allografts

Use of amniotic tissue allografts has been cited in clinical literature for over 100 years. Placental-based allografts have surfaced as an effective allograft option for the treatment of chronic ulcerations (Fig 6). Placental-based allografts are derived from multiple tissue types collected from the afterbirth post-delivery of a live baby. These tissue sources include the amniotic sac, the umbilical cord and the placental itself (Fig 7). After placental-based allografts have been processed, they can be configured into many different forms, such as sheets grafts, tissue morsels or 'mini' grafts, and powders or 'micro' grafts. Each configuration has a specific utility. The sheets can cover large areas with minimal clinician effort, morselised tissue can be used to pack tissue voids, and powders can be used as a paste or to inject directly into soft tissue.

Modern processing techniques for placental-based allograft membranes have been developed to improve storage and availability of these tissues. For example, dehydration has been used to support storage of allografts in ambient conditions. While dehydrated amniotic tissues do not contain viable cells, the cellular components and regulatory proteins are preserved within the tissues. This diverse array of regulatory proteins that are naturally found within amniotic tissues are able to modulate the activity of endogenous cells, including the patients' own population of stem cells, to promote healing and reduce scar tissue formation. Additionally, improvements in donor screening, aseptic processing, and terminal sterilisation have significantly reduced the risk of disease transmission by allograft tissues.




Fig 7. The donated afterbirth obtained from consenting mothers undergoing caesarean section delivery is processed to yield three major tissue allografts, which are the amniotic sac consisting of amnion/chorion, the placenta and the umbilical cord

These allografts are available in many forms — cryopreserved, lyophilised, and dehydrated, and are widely available in most countries in Europe from local tissue banks or imported from third country tissue banks.

The ability to effectively screen donors and tissues coupled with new methods to cleanse, preserve, and sterilise placental based allografts have facilitated a dramatic increase in their use over the past few years. A proprietary process used for dHACM (a placental-based allograft consisting of a dehydrated human amnion/chorion membrane) composite allograft^{211–217} combines the amnion layer with the chorion layer. There have been 285 regulatory proteins identified in dHACM, including growth factors, specialised

cytokines and enzyme inhibitors,^{211–218} which deliver clinically relevant bioactive factors and inflammatory mediators to assist in the healing process of acute and chronic wounds.²¹⁸ Another proprietary process allows for the preservation of the spongy layer between the amnion and chorion, which has been shown to contain high levels of proteoglycans, glycoproteins and hyaluronic acid as well as a high level of growth factors.²¹⁹

Notably, recent multiple, randomised clinical studies evaluating the treatment of DFUs and VLUs have been published in peer-reviewed literature on the use of placental allografts (dHCAM), which have demonstrated clinical superiority over the standard of care for the treatment of DFUs^{220–222} and for the treatment of VLUs.^{223,224}

A randomised and parallel group trial was implemented at eight clinical sites in which patients with DFU received either standard of care (foam dressing) (n=14) or a dehydrated amniotic membrane (n=15) until wound closure or six weeks, the first to occur. This showed complete wound closure in 35% and 45.5% of the patients in the experimental group, respectively, in the intent-to-treat (p=0.017 in relation to 0% of standard of care) and per a group population (p=0.0083 in relation to 0% of standard of care).²²⁵

The efficacy of a dehydrated amniotic membrane as an adjuvant to multilayer compression therapy for the treatment of non-healing full-thickness VLU was addressed in a multicentre RCT. The 109 patients were assigned to placental-based allograft plus a compression group (n=52) or a compression therapy alone (n=57). Participants receiving weekly application of the placental-based allograft plus compression were more likely to experience complete wound healing (60% versus 35% at 12 weeks, p=0.0128, and 71% versus 44% at 16 weeks, p=0.0065) and a significantly improved time of healing using the allograft (log-rank p=0.0110), as seen in Table 11.²²⁶

A multicentre trial also compared the healing effectiveness of a placental-based allograft with a live skin tissue substitute or with an alginate dressing (n=60, 20 per group). The respective proportion of patients that had complete wound closure at four and six weeks was 85% and 95% (p<0.003), as compared to patients receiving standard of care 35% and 45%, or 30% and 35%. Similarly, the respective median time for healing was 13 days (p<0.001), compared to live skin tissue substitute (49 days) or standard of care (49 days).²²⁰ This study was continued in order to address the rates and the time for closure at a longer time interval, by including at least 100

patients. The proportion of patients achieving complete closure within the 12-week study period were 97% (31/32), 73% (24/33) or 51% (18/35) (p=0.00019). Mean time-to-heal within 12 weeks was 23.6 days (95% CI: 17.0–30.2), 47.9 days (95% CI: 38.2–57.7) or 57.4 days (95%CI: 48.2–66.6) (p=3.2 x 10⁻⁷), respectively, as seen in Table 9.²²⁷

Cultured tissue-based therapies

In this chapter, therapies based on cultured cells and their application as tissue-engineered or bioengineered skin substitutes are highlighted.^{228–232} The use of non-cultured or cultured cells in suspension and acellular materials have been described in the previous chapters.

Bioengineered tissue-based therapies are composed of skin cells or living cells and extracellular matrix components. Over the last 30 years, the industry has presented a large number of tissue-based therapies that can be applied essentially for two purposes, which are: 1) experimental, such as cellular permeability models or toxicological screening and 2) clinical, as actual skin substitutes bases for autologous grafts, or for delivering growth factors.

Most of the world's need for these substitutes is due to a demand for materials for clinical purposes. It is expected that in 2019 at least 6.4 million people will need a cutaneous substitute.^{188,231,233–240}

Tissue-based therapies for *in vitro* application

These therapies are used as models to study tissue-healing processes and can also be considered for testing the skin toxicity of chemicals as well as drug permeability (Table 10). The possibility to obtain a correct differentiation of the epidermal layers is fundamental, and a support that works as a skin barrier comparable to the natural barrier in its properties should be obtained.

Table 9. Randomised controlled trials evaluating wound dressings and placental-based allograft efficiency for the treatment of diabetic foot ulcer (DFU), venous leg ulcer (VLU) and mixed aetiology wounds

Author/year	Type of material	No. of patients	Compared conditions	Follow-up	Results	Ulcer type
Snyder et al. ²²⁵ 2106	Non-viable cellular matrices	29	Dehydrated amniotic membrane vs foam dressing	42 days	Complete wound closure in 35% of the patients (p=0.017 in relation to 0% for standard of care in the intent-to-treat group). Complete wound closure in 45.5% of the patients (p=0.0083 in relation to 0% for the standard of care) in the per group population	Diabetic foot ulcer
Zelen et al. ^{220,227} 2015	Non-viable cellular matrices	100	Dehydrated amnion/chorion membrane vs Live skin substitute vs alginate dressing	Up to 84 days	Higher proportion of patients with closed wounds at 4, 6 and 12 weeks (85%, 95% (p<0.003, 97% (p=00019)) vs 35%, 45%, 73% vs 30%, 35%, 51% Lower mean time to healing within 12 weeks 23.6 days (95% CI: 17.0-30.2) vs 47.9 days (95% CI: 38.2-57.7 vs 57.4 days (95%CI: 48.2-66.6) (p=3.2x10 ⁻⁷)	Diabetic foot ulcer
Bianchi et al. ²²⁶ 2017	Non-viable cellular matrices	109	Dehydrated amnion/chorion membrane plus compression vs compression	112 days	Higher probability to complete healing (60% vs 35% at 12 weeks, p=0.0128, and 71% vs 44% at 16 weeks, p=0.0065)	Venous leg ulcer and mixed aetiology

Table 10. Tissue-based therapies for *in vitro* application

Name	Cell involved
Epidermal Skin Test 1000	Human keratinocytes: epidermal model with fully differentiated epidermis
Advanced Skin Test 2000	Full thickness model with fibroblasts and keratinocytes
Epiderm	Neonatal human-derived epidermal keratinocytes
EpidermFT	Neonatal human-derived epidermal keratinocytes and fibroblasts
Episkin	Human keratinocytes on a collagen base
StrataTest	Skin model from a near diploid keratinocytes cell line
SkinEthic Reconstructed Human Epidermis	Human keratinocytes on a polycarbonate filter in medium

Tissue-based therapies for *in vivo* application

In general, living cellularised tissue-based therapies can be divided into the following categories: 1) epidermal, 2) dermal, and 3) bilayered or dermo-epidermal substitutes (Table 11). Further, tissue-based therapies can contain autologous (patient's own) or allogenic (from other humans) cells. The

tissue-based therapies that are clinically applied can be permanent remaining on the patient or temporary. The temporary skin grafts need to be replaced or modified by additional techniques at a certain time after application.

Tissue-based therapies for *in vivo* application are not applicable in the case of infected wounds.




Fig 8. Timeline of developments of dermal and skin substitutes²⁴⁵

History of tissue-based therapies

A main development in the field of (cellular) skin substitutes was the introduction of cultured epithelial autografts (CEA) in 1975 (Fig 8). Rheinwald and Green managed to culture primary epidermal cells that they isolated from human skin samples on a so-called feeder layer of lethally irradiated fibroblasts.²⁴² They could grow and expand the keratinocytes in serial cultures that made it possible to prepare keratinocyte sheets or CEAs. Although they were already clinically applied onto small burn wounds in the 1980s,²⁴³ the breakthrough for CEAs was in 1983 when two siblings were treated after life-threatening large burns with the culture keratinocyte sheets as compassionate therapy.²⁴⁴ Since they survived because of the CEA application, epidermal sheets have been used ever since for clinical applications.

Box 1: Tissue engineering

Definition by Robert S. Langer and Joseph P. Vacanti:

'An interdisciplinary field that applies the principles of engineering and life sciences toward the development of biological substitutes that restore, maintain, or improve [biological tissue] function or a whole organ'.²⁴¹

Regarding dermal substitutes, the first clinically usable acellular dermal grafts were available in the mid-1980s. They consisted mainly of a porous collagen type I matrix.¹³¹ Subsequently, cellularised dermal substitutes evolved from this. They are mostly used as temporary biological dressings in chronic wounds to stimulate wound healing as they contain allogenic fibroblasts.

Once it was realised that a matrix or scaffold provides not only mechanical stability but in addition provides good biological properties by resembling more the normal extracellular microenvironment, the use of collagen for skin substitutes was intensified. In the 1980s, based on a porous collagen type I matrix, the first attempts began to incorporate not only fibroblasts into the porous collagen (the dermis) but also to add keratinocytes onto the fibroblast-populated dermis. This resulted in autologous dermo-epidermal skin substitutes that were first clinically applied in the late 1980s.^{246,247}

Further, in another approach, allogenic fibroblasts were mixed with collagen, and after additional days of dermal maturation, allogenic keratinocytes were also seeded onto the formed dermis.²⁴⁸ These allogenic dermo-epidermal skin substitutes have

been used clinically for chronic wounds since the 1990s.²⁴⁹

In general, although dermo-epidermal skin substitutes resemble normal skin, they still lack skin appendages, such as hair follicles or sweat glands.²⁵⁰ However, in many cases, the mechanism of action of tissue-based therapies in wound healing is not to replace the skin, but it is to deliver growth factors and therefore change the wound environment from chronic to acute.

Epidermal substitutes (CEAs)

Today, several commercial suppliers provide epidermal substitutes for clinical use.²³⁹ Most of the cultured epithelial autografts (CEA) are still prepared according to the technique developed by Rheinwald and Green. A small split-thickness skin biopsy or hairs from the eyebrows/scalp are taken from the patient, and keratinocytes are isolated and

Table 11. Tissue-based therapies for *in vivo* application

Type	Features
Epidermal	From a small superficial autologous skin biopsy (2-5cm ²): keratinocytes are isolated, cultured and applied onto a supportive layer
Dermal	Allogenic human fibroblasts are cultured onto scaffolds
Dermo-epidermal	Composed of autologous or allogenic epidermidis and dermis with the presence of keratinocytes and fibroblasts seeded on extracellular matrix (for example, Collagen type I)

cultured in the presence of so-called feeder cells. The keratinocytes are propagated to result in some layers representing the epidermis. For better handling properties, as the epidermal sheets are very fragile and thin, they are then applied onto supportive materials (Fig 9, Table 12). Various approaches have been employed for supporting layers such as culturing the keratinocytes on a layer containing




Fig 9. Application of an epidermal substitute (CEA)²²⁸

Table 12. Epidermal substitutes

Product (company)	Description	Indications	Approval
Epichel (Genzyme Corp.)	Cultured epidermal autograft: Autologous keratinocytes are cultured in the presence of murine fibroblasts to form cultured epidermal autografts. These are processed into sheets and attached to gauze.	Burn wounds	FDA
Epidex (Euroderm GmbH)	Cultured epidermal autograft: Autologous outer root sheet hair follicle cells are cultured to form epidermal equivalents. These are attached to silicone membranes and can be placed onto the wound bed.	Venous ulcers Diabetic ulcers	Currently under evaluation by SwissMedic
MySkin (Altrika Ltd.)	Cultured epidermal autograft: Autologous keratinocytes are grown in the presence of irradiated murine fibroblasts. It is supplied as a circular disk for application.	Burn wounds Venous ulcers Diabetic ulcers	MHRA (United Kingdom)

Abbreviation: FDA: Food and Drug Administration; MHRA: Medicines and Healthcare Products Regulatory Agency

inactivated mouse fibroblasts or a membrane of hyaluronic acid which is perforated by laser (Fig 10). Keratinocytes have also been delivered as a spray.

As they have been applied clinically, a number of studies have been published regarding the outcomes of CEAs for chronic wounds.^{251–253} In particular, an epidermal skin substitute based on autologous cultured outer root sheath cells was commercially available in some European countries




Fig 10. Autologous keratinocytes on a membrane of hyaluronic acid, perforated with laser

for a few years.^{254,255} This cell type was chosen for the cultures as it displays a high proliferative potential even in older people, who are the largest population with chronic wounds. A prospective randomised trial involving 77 patients with recalcitrant leg ulcers showed an equivalence of this skin substitute with autologous split thickness skin graft with regards to healing time and the number of healed ulcers after 12 and 24 weeks.²⁵⁶ Due to the logistics and cost of the product, it is currently not commercially available anymore.

Another approach to treat diabetic neuropathic foot ulcers used autologous keratinocytes isolated from split-thickness skin biopsies from the patient's thigh. The isolated basal keratinocytes were cultured and then applied onto a medical grade PVC carrier for clinical handling. Based on the twelve included patients, five displayed complete healing. The remaining patients showed a reduction of the ulcer's size of at least 50%. Although between five to 12 applications of the autologous keratinocytes were needed, the outcome was much more beneficial compared with the control group that was treated with acellular carriers.²⁵⁷




Fig 11. Application of a dermal substitute²²⁸

Dermal substitutes

Beside the use of pure epidermal substitutes, the application of cellularised dermal substitutes is also used. Human (allogenic) fibroblasts are cultured onto or into supportive materials, such as bioabsorbable scaffolds (Fig 11, Table 13). The dermal substitutes should stimulate wound healing responses as fibroblasts deposit extracellular matrix proteins and secrete growth/angiogenic factors if applied onto wounds. They show great mechanical stability and might prevent scar contraction.

An allogenic dermal substitute using cultured neonatal human dermal fibroblasts was investigated for patients with DFUs. The neonatal fibroblasts were seeded onto a bioabsorbable polyglactin mesh scaffold and produced a three-dimensional matrix containing several types of collagen. Patients (n=130) were treated with the dermal substitute if the ulcer had not decreased in size by 50% after two

Table 13. Commercially available dermal skin substitutes

Product (company)	Description	Indications	Approval
Dermagraft	Cellular dermal substitute, bioabsorbable polyglactin mesh scaffold seeded with cultured allogeneic neonatal fibroblasts from neonatal foreskins	Diabetic ulcers	FDA – PMA approved

weeks of standard therapy. A weekly application for a maximum of eight weeks, if necessary, was performed. The trial revealed a significant increase in healed wounds using the dermal substitute compared to the control group (n=115) after twelve

Table 14. Commercially available dermo-epidermal skin substitutes.²²⁸

Product (company)	Description	Indications	Approval
Apligraf (Organogenesis Inc.)	Cultured allogeneic dermo-epidermal substitute. A bovine collagen type I matrix seeded with allogeneic keratinocytes and fibroblasts cultured from neonatal foreskins.	Venous ulcers Diabetic ulcers	FDA/PMA approved for VLUs and DFUs

FDA—US Food and Drug Administration

weeks. This study showed that complete wound closure was achieved significantly faster with the group.²⁵⁸

Interestingly, another survey suggested that the use of the dermal substitute resulted in a moderate reduction of all types of amputation (below the knee, foot, toe) and the necessity of bone resections as compared to standard care.²⁵⁹

Furthermore, a clinical trial using this dermal

substitute for VLUs was described as well.²⁶⁰ The allogenic substitute plus four-layer compression therapy (n=186) was compared with compression therapy (n=180) alone. The VLU was present between the knee and ankle for at least two months and a maximum five years for the included patients. The trial described that the dermal substitute is comparable to standard therapy in regard to safety. Furthermore, the cellular substitute did not reveal a statistically significant improvement compared to control compression therapy for overall healing




Fig 12. Application of a dermo-epidermal substitute²²⁸

by week twelve. By week 24, 96 (52%) of the 186 patients from the dermal substitute group and 88 (49%) of the 180 patients from the compression therapy group achieved complete healing. In general, a better healing effect of the dermal skin substitute was observed in VLU of 12 months' duration or less, but not in those of with over 12 months' duration.

Nevertheless, although the results for DFU patients were encouraging, other reports pointed out the high costs of this dermal cellular substitute when compared with the use of non-cellular dermal substitutes, which result in similar outcomes.²⁶¹

Dermo-epidermal substitutes

These are characterised by the presence of keratinocytes and fibroblasts. Today, almost only allogenic dermo-epidermal skin substitutes are applied clinically on a regular basis.²⁶² These allogenic skin grafts are produced from cells collected from skin biopsies or from neonatal foreskin by healthy donors, which can be stored for a certain period until their delivery and use. This procedure reduces the costs for the production of such sophisticated skin substitutes (Fig 12, Table 14). Also, keratinocytes and fibroblasts can be seeded in a spongy matrix containing collagen. A skin substitute can fulfil an additional role in cases of large leakage of the skin, such as significant traumas or burns.^{246,247}

The manufacturing of autologous dermo-epidermal skin grafts containing patients' own fibroblasts and keratinocytes is more expensive as they are produced and used only for one person. Today, several autologous skin substitutes are applied in clinical trials (phases I – IV), but they are not commercially available on a regular basis yet.^{263,264}

The use of dermo-epidermal skin substitutes, particularly allogenic substitutes, and their effects on the healing of chronic wounds has



Fig 13. Application of a dermo-epidermal skin substitute on an extremely recalcitrant leg ulcer which showed no healing tendency with conventional therapies. a) presentation at the treatment start and b) healing progress after two and c) eight weeks

been documented in a large number of peer-reviewed studies.^{265,266} Two pivotal trials led to FDA approval in 1998 of a bilayered dermo-



Fig 14. Dermo-epidermal substitute derived by a co-culture of keratinocytes and fibroblasts applied on post-traumatic knee wound. a) before toilette and negative pressure wound therapy, (NPWT) b) after 2 weeks of NPWT, c) application of the dermoepidermal substitute, d) after seven days, e) after two months follow-up

epidermal skin substitute produced from cultures of neonatal foreskin on a bovine collagen matrix for the stimulation of wound healing in VLU and DFUs (Figs 13 and 14). In 2008, the product was approved as a transplantation product and used in

clinical practice in Switzerland. A RCT involving 240 patients with VLUs resistant to previous conservative treatment for at least three months showed ulcer healing at 24 weeks in 57% of patients versus 40% in the control group ($p=0.022$). Of note, the effects were greater in a subgroup analysis of recalcitrant ulcers showing no healing progress for over one year (47% healing after 24 weeks versus 19% in the control group, $p>0.005$).²⁶⁷ In a study with 208 patients with DFUs, weekly application of the bilayered skin substitute led to wound closure in 53% of patients after 12 weeks, compared to 38% of patients treated with moist gauze.²⁶⁶

Since then, more than 250 peer-reviewed studies have been published that show successful stimulation of wound healing. The mode of action of this allogenic skin substitute has not been fully elucidated. Per Stone et al., the application of a bilayered skin substitute changes the wound dynamics from chronic to acute.²⁵⁰ A range of cytokines and growth factors that are present in the wound after its application have been demonstrated, but the product does not remain on the wound for the long-term. It has been shown *in vitro* that the wound healing microenvironment of chronic wounds after the application of this tissue-based therapy resembles more closely the wound milieu of acute wounds.²⁵⁰ Although the absolute reduction of time for healing with this tissue-based therapy in the published studies was limited, it is one of the few therapeutic interventions for chronic wounds that has been shown to improve wound healing in a large number of prospective RCTs. Therefore, it is an interesting therapeutic option for hard-to-heal wounds. Data comparing its efficacy with autologous split thickness skin graft would strengthen the basis for its clinical use.

Future outlook

Melanocytes, vessels, genetic manipulation

The major drawback of all the above described

cellular tissue-engineered skin substitutes is the lack of other main skin components or main cell types besides keratinocytes and fibroblasts. All commercially available products are free of other cellular components, for instance pigment producing melanocytes, or immunoregulatory Langerhans cells, and structures such as hair follicles, sebaceous and sweat glands, nerves, lymphatic and blood capillaries/vessels, and lack a hypodermis, the fat, as well.²⁶⁸⁻²⁷¹

Research is currently ongoing in this field, regarding the integration of melanocytes, fat,

and hair follicles, especially for large wounds (e.g. burn wounds). Regarding small and chronic wounds, research currently focuses on exaggerating vascularisation of the skin substitutes. A faster and better vascularisation supports ingrowth of the grafts and enhances wound healing, in general. Different strategies have been investigated. One approach is to tissue-engineer preformed (branched) capillaries in the skin substitutes *in vitro*. This is based on the concept of full-thickness skin transplantation, which contains vessels and capillaries rapidly connecting to the vascular structures already present in the wound bed. This process is known as inosculation,




Fig 15. Concept of inosculation²⁷¹




Fig 16. Schematic components of inkjet, extrusion and laser-assisted bioprinters²⁷⁷

which results in a faster blood supply and a greater likelihood of survival for the full-thickness skin transplant (Fig 15).

There is also interest in genetically manipulating cells, such as fibroblasts or keratinocytes. This idea is based on a diagnosis of bacterial contamination of the wound or molecular deficiency of the patients' tissue resulting in non-healing wounds. According to the results and needs, different strategies to manipulate cells *in vitro* could be employed. The cells could then overexpress factors increasing an inflammatory response, angiogenic factors, such as vascular endothelial growth factor (VEGF), or factors enhancing re-epithelialisation, such as platelet-derived growth factor (PDGF). The so-manipulated cells could be applied in the above-described manner, similar to the method use for CEAs or cellular dermal substitutes.

Automation

The tissue-engineered skin grafts mentioned before display several limitations. In particular, they are all still almost completely manually produced by well-trained and experienced persons. Therefore, the production of such skin substitutes is time-

consuming, labour intensive, bears a risk of contamination and are not perfectly reproducible, which influences the quality and are costly.

Automation of the production of skin grafts, or at least parts of the production, could allow for higher reproducibility, better safety, larger-scale production, and higher efficacy. A complete automation to produce three-dimensional (3D) skin, containing epidermis, dermis, and even hypodermis, requires a bio-reactor essential for gas concentrations, nutrient exchange, pH, and temperature in order to culture different cells types and a compartment in which to eventually generate the skin.

In general, the complete system needs to include sensors/surveillance to record and analyse the complete production process to fulfil the criteria created by authorities for clinical application in health care.

Today, the technology of 3D-printing offers, besides the well-known fields of automotive or aerospace, the possibility to print medical devices that can be used clinically. As an example, patients displaying craniofacial bone defects can benefit

as medical scaffolds are custom-made printed that perfectly fit in place to reconstruct the bone defects. 3D-printing has emerged not only as a useful potential tool to fabricate acellular but also cellular structures. Hence, 3D bioprinting became a tremendous area of research in tissue-engineering and regenerative medicine.²⁷²⁻²⁷⁵

The material for the bioprinting process needs to be suitable for printing technology, biocompatible, support cellular viability, growth and function, and thereby provide structural and mechanical properties. So far, natural materials for bioprinting include substances such as collagen, fibrin, alginate, laminin, hyaluronic acid, gelatine, chitosan and fibronectin. On the other hand, synthetic materials, such as modified copolymers and acrylates, are also a potential option.

Three major bioprinting techniques based on different principles are used, namely inkjet, extrusion, and laser-assisted (Fig 16).

The inkjet printers are based on the known 2D printers that are used to print ink onto paper for a document. An electronically controlled elevator stage was introduced to control the third dimension, the z-axis. Thermal or acoustic forces are used to eject controlled volumes of liquid droplets out of the print head onto a certain substrate to a predefined location.

Extrusion bioprinters deposit, via an extrusion head, continuous beads of material onto a substrate. Directed robotically by CAD-CAM software, beads of material are deposited in two dimensions. The extrusion head is then moved along the z-axis, whereas the already deposited two dimensions layer serves as a foundation for the third-dimensional layer.

The less common laser-assisted bioprinting is based on principles of laser-induced forward transfer.

Focused laser pulses are directed onto an absorbing layer of a ribbon to generate high-pressure bubbles that propel cell-containing materials towards a collector substrate.

Of course, each technique has advantages and disadvantages with respect to its automation, printing and resolution capabilities, precision in ejection and deposition, compactness and scalability.

A general challenge is to produce an architecture that at least resembles extracellular matrix (ECM) components so that skin cells can recapitulate their biological function. With the major techniques, several approaches were already performed to bioprint skin for preclinical investigations, including keratinocytes, melanocytes, fibroblasts and endothelial cells.

An alternative approach to the classical idea of bioprinting *in vitro/ex vivo* and subsequent transplantation onto a patient is the idea of bioprinting directly *in situ*. Cells and ink/materials are directly printed into the wound of a patient in this approach. This might be feasible, and preclinical research in this field is ongoing. It might become clinical reality to bioprint immediately after an injury or during surgery.

Taken together, although automation of skin substitutes for clinical applications is still not practicable, automation can result in fabricating

Box 2:

Biofabrication can be defined as "the automated generation of biologically functional products with structural organisation from living cells, bioactive molecules, biomaterials, cell aggregates such as microtissues, or hybrid cell-material constructs through bioprinting or bioassembly and subsequent tissue maturation processes," according to the International Society for Biofabrication (ISBF).²⁷⁶

Table 15. Evaluation of evidence levels: cells and tissues

No.	Therapy	Indication for use	Level of evidence (for each indication)	Comments
1	Mesenchymal stem cells	Acute wounds (such as burns)	IA	High-quality studies and good evidence of effectiveness and safety
2	Mesenchymal stem cells	Chronic wounds/ulcers	IA	High-quality studies and good evidence of effectiveness and safety
3	Platelet rich plasma	Acute wounds (such as burns)	IC	Few studies but good evidence of effectiveness and safety
4	Platelet rich plasma	Chronic wounds/ulcers	IC	Few studies but good evidence of effectiveness and safety
5	Platelet rich plasma	Aesthetic procedures	IC	Few studies but good evidence of effectiveness and safety
6	Monocytes	<i>In vitro</i> application	2C	Very few studies and low-quality evidence of effectiveness. Further research is requested
7	Epidermal skin substitutes	Acute wounds (such as burns)	IA	High-quality studies and good evidence of effectiveness and safety
8	Epidermal skin substitutes	Chronic wounds/ulcers	IA	High-quality studies and good evidence of effectiveness and safety
9	Dermal skin substitutes	Acute wounds (such as burns)	IA	High-quality studies and good evidence of effectiveness and safety
10	Dermal skin substitutes	Chronic wounds/ulcers	IA	High-quality studies and good evidence of effectiveness and safety
11	Dermo-epidermal skin substitutes	Acute wounds (such as burns)	IA	High-quality studies and good evidence of effectiveness and safety
12	Dermo-epidermal skin substitutes	Chronic wounds/ulcers	IA	High-quality studies and good evidence of effectiveness and safety
13	Acellular dermal matrix	Acute wounds (such as burns)	2C	Few studies with weak evidence
14	Acellular dermal matrix	Chronic wounds/ulcers	2C	Few studies with weak evidence
15	Placental-based allografts	Acute wounds (such as burns)	IC	Few studies but good evidence of effectiveness and safety
16	Placental-based allografts	DFU	IB	High-quality studies with good evidence of effectiveness and safety
		VLUs	IC	Few high-quality studies but good evidence of effectiveness and safety
17	Food-grade lactic acid bacteria	Chronic wounds/ulcers	IC	Few studies but good evidence of effectiveness and safety
18	Dressings based on autologous platelet-rich fibrin and leucocyte	Chronic wounds/ulcers	IC	Few studies but good evidence of effectiveness and safety

large-scale effective and highly sophisticated therapeutic skin grafts for patients in the near future.

Algorithm for the use of cell therapies

As advanced dressings are usually associated with high costs, their use has to follow strict indication criteria. However, in the case of 'hard-to-heal' wounds, it can be argued that costs may be reduced with earlier use of advanced products.

It is therefore important to recognise early, when a wound is not proceeding through the regular wound healing phases and will eventually become a candidate for an advanced wound healing

protocol. For this, it is useful to adopt surrogate markers: it was shown that healing of DFU after 12 weeks is unlikely, if the wound surface is not reduced by 50% after 4 weeks of appropriate moist wound treatment and proper off-loading.²⁷⁸

Likewise, it was shown for VLU that healing after 24 weeks is unlikely if there is less than 40% wound area reduction after 4 weeks.⁷⁻⁹ These surrogate markers should prompt clinicians to consider using an advanced wound healing protocol already early in the wound healing process.

An evaluation of evidence levels for use of the therapies covered in this chapter, related to indications for use, can be found in Table 15.

Physical therapies

Introduction

The physical approach to wound healing was probably the first approach ever implemented since physical means, such as compression, lavage and closure, have been available to physicians since ancient times and were used primarily in the case of acute wounds or traumas.²⁷⁹

In modern times, biological discoveries have emphasised a 'biochemical' approach to the management of wounds with the basic idea that the interaction between a substance/compound and the surface of the wound would affect its evolution positively due to the modifications that the substance/compound would induce in the biology of the wound.²⁸⁰

A typical example of this concept is the use of local antiseptics to contrast infection /contamination or the application of enzymes to debride the wound.^{281,282}

Very recently, physical therapies regained an important role in the management of wounds, and new technologies and devices have been developed with this indication. With the term 'physical therapy', we refer to the interaction between the wound and a physical system in which there is a transfer of energy to/from the wound, which in turn translates into observable and measurable modifications in the system as well as in the wound.

A paradigmatic example regards the application of pressure, both positive (PPWT), for compression and oedema control in the case of VLUs, and

negative (NPWT), for the treatment of a number of different chronic wounds.²⁸³

Although we will not cover PPWT and NPWT in this section, since both of them have been extensively treated in two recent position documents released by EWMA, they are probably the most successful and widely applied physical therapies with such a diffusion and success that they are considered nowadays the standard of care for a number of chronic ulceration.²⁸⁴

Other aspects of physical therapies which will not be treated in this section are those related to systemic and topical oxygen therapy and to physical means for debridement (hydrosurgery, ultrasound debriders) since both of them have recently been addressed in other EWMA documents, as well.^{285,286}

The physical field has been progressively populated in recent times by a number of new technologies, ranging from shock waves to electrical fields, from magnetic fields to nanotechnologies, from light to laser, all with indications for wound management and all with some level of evidence behind them, although to a variable extent, due to the novelty of the proposals. We will try to critically examine the most significant of these new technologies and to provide relevant information needed to decide if and when a specific technology could eventually be beneficial to include in clinical practice.

Shock waves

From its first clinical application for urolithiasis in the eighties, extracorporeal shock waves

therapy (ESWT)²⁸⁷ progressively moved to other indications, such as the treatment of tendons and fascia calcification,^{288,289} bone fracture malunion and malalignment,²⁹⁰ until a casual observation of a possible effectiveness in promoting wound repair prompted their adoption for a wide range of chronic wounds, including DFU,²⁹¹ VLU²⁹² and PU.²⁹³

According to this shift in the clinical indication, the technology beyond ESWT underwent an evolution from large equipment that generated focused high energy shock waves which could transfer a high amount of energy deep into the tissues and fragment stones to radial equipment that can produce lower energy waves on a wider surface, such as the surface of a chronic superficial wound.²⁹⁴

In both cases, shock waves are generated by a high voltage spark in a water medium (electrohydraulic) or in a metallic membrane (electromagnetic), which cause the rapid increase (nanoseconds) of pressure, generating a spike which may reach an intensity that is 100 times higher than the normal barometric pressure in less than five milliseconds.

The shape of the probe makes it possible to concentrate the waves and focus them according to the intensity set in the generator. This makes it possible to transfer the energy to the tissues in a higher or lower intensity and in concentrated shapes.²⁹⁵

While the mechanisms of action of high energy focused ESWT is clearly related to a sudden transfer of energy, which is able to disrupt

gallstones, the effect of low intensity ESWT on wound healing still needs to be clarified. There is, however, evidence available, which supports that the application of stress to the cytoskeleton of the cells in the lesion (mechano-biological interaction) is able to produce a number of effects, including the repression/depression of genes²⁹⁶ and changes in protein synthesis²⁹⁷ of a number of cells, including keratinocytes,²⁹⁸ fibroblasts,²⁹⁹ endothelial cells,³⁰⁰ and bone marrow stromal cells.³⁰¹

ESWT have been demonstrated to increase vascular endothelial growth factor (VEGF)³⁰² and nitric oxide (NO)³⁰³ concentrations, which promote angiogenesis.³⁰⁴ Other observations are related to the reduction in the production of pro-inflammatory cytokines³⁰⁵ and to the increase of the proliferation of fibroblast induced by ESWT *in vitro* and *in vivo*.²⁹⁹

Safety was also explored in all of the studies performed on ESWT, and from this point of view, the results were unanimous and positive, confirming a high safety standard for the technology.

These promising observations are unfortunately not paralleled by an adequate level of evidence generated via clinical trial. Two recent reviews on the subject are concordant in stating that according to the Cochrane standards, ESWT is not adequately supported by evidence.^{306,307}

This is not necessarily related to the results of the available studies, which were generally positive,

Table 16. Studies on extracorporeal shock waves therapy (ESWT)

Author/ year	Condition(s)	No. of wounds	ESWT specifications	Healing rate	Comments
Aschermann et al. ³⁰⁸ 2017	CLUs	75	EFD: 0.136mj/mm ² Amount of pulses: 100 pulses/cm ² Frequency: 4 pulses/sec	41%	No control group
Jeppesen et al. ³⁰⁹ 2016	DFUs	11	EFD: not available Amount of pulses: 250/500 pulses/cm ² Frequency: not available	35%	Significant (p<0.01) reduction in the area of ulcers compared with controls
Omar et al. ³¹⁰ 2014	DFUs	24	EFD: 0.11mj/mm ² Amount of pulses: 100 pulses/cm ² . Frequency: not available	54%	Faster healing than in control group (p<0.05)
Arnò et al. ³¹¹ 2010	Burns	15	EFD: 0.15mj/mm ² Amount of pulses: 100 Frequency: not available	80%	No control group
Larking et al. ²⁹³ 2010	PU	9	EFD: 0.1mj/mm ² Amount of pulses: 200 + 100 pulses/ cm ² Frequency: 5 pulses/sec	56%	Crossover study favouring ESWT
Ottoman et al. ²⁹⁸ 2010	Donor sites	28	EFD: 0.1mj/mm ² Amount of pulses: 100 pulses/cm ² Frequency: not available	100%	Faster re-epithelialisation than in control group (p<0.0001)
Moretti et al. ³¹² 2009	DFUs	30	EFD: 0.03mj/mm ² Amount of pulses: 100 pulses/cm ² Frequency: not available	53%	Faster healing and higher healing rates than control group (p<0.001)
Wang et al. ²⁹¹ 2009	Recurrent DFUs	36	EFD: 0.11mj/mm ² Amount of pulses: 100 pulses/cm ² . Frequency: not available	31%	HBOT control group healing rates 22% (p<0.001)
Saggini et al. ³¹³ 2008	VLU, DFUs, PTUs	32	EFD: 0.037mj/mm ² Amount of pulses: 100 pulses/cm ² Frequency: 4 pulses/sec	50%	Only 10% of ulcers in the standard of care control group healed (p<0.01)
Shaden et al. ³¹⁴ 2007	Mixed chronic ulcers but not DFUs	208	EFD: 0.1mj/mm ² Amount of pulses: 100 pulses/cm ² . Frequency: 5 pulses/sec	75%	No control group

ESWT—extracorporeal shock wave therapy; DFU—diabetic foot ulcer; EFD—energy flux density; VLU—venous leg ulcer;
PTU— post-traumatic ulceration; HBOT—hyperbaric oxygen therapy; PU—pressure ulcers; CLU—chronic leg ulcers

but rather to the poor quality of the trials, which either targeted a mixed population of chronic wounds,²⁹⁴ were not sufficiently dimensioned,³⁰⁷ or omitted important information about the details of the treatment, such as the number of impulses, the frequency of impulses and energy flux density (in millijoules per square millimetre).

In Table 16, a synopsis of the clinical studies on ESWT for the management of chronic wounds is reported.

Since the first report by Shaden et al. in 2007,³¹⁴ 440 chronic ulcers have been treated with ESWT in a study aimed to evaluate the efficacy of this

approach, with a mean healing rate of 57% (range: 31–80%). These results should be taken into consideration with prudence, specifically in view of the high healing rates in the control groups, when present, when standard of care was followed for the different aetiologies of chronic ulcers. At this point, more trials, and especially trials with more dimensions, are needed to confirm the indications of ESWT for chronic wound management. It is, however, unlikely that this information will be available in the near future due to the difficulty and costs of these trials.

On this basis, considering the high safety profile and the varying documentation of effectiveness, we can consider ESWT as an adjunct therapy in addition to good quality standards of care to hasten healing rates of DFUs, VLU and PUs. A possible limitation includes the high costs of the

equipment needed to generate the shock waves, which may limit the use of this technology to hospital-based practices.^{294,306,307}

Electromagnetic fields (EMF)

Since the experiments of Galvani on frogs' isolated limbs in 1794, our understanding of the role that electricity and magnetism exerts on human physiology continuously grows. A wide range of interactions have been demonstrated and described, in virtually all of the mechanisms of function within an organism.³¹⁵

Our body is able to produce electricity and magnetic fields and use them for a range of functions, including the nerve conduction of information, muscle contraction, polarising cells, inducing biochemical reactions, separating body fluids along with a number of other functions.^{316–318}




Fig 17. The cell as a dielectric structure and the compartmentalisation of electric charges

The main source of self-produced electricity is the ion exchange through the cellular membrane, which is a natural dielectric structure, normally charged with negative potentials on the outside and positive potentials on the inside (Fig 17).³¹⁹

This potential can be measured and the changes are related to cells and tissues functions as well as dysfunctions. An interesting observation, from this point of view, is that the reduction or nullification of this electric potential is a sign of sufferance and death of cells.³²⁰

Our tissues are also able to react to the application of electricity and magnetic fields from the outside, sensing them and reacting according to a complex paradigm in relation to the intensity, polarity, time and point of application.³²¹

The intensity and frequency of both electric fields (EFs) and magnetic fields (MFs) are crucial to determine the interactions with the tissues. There are 'windows' for both intensity and frequencies of currents that allow the interaction to occur in a way so that the organism is modified by the application of EF and MF. Outside these 'windows', the interaction simply does not occur or is destructive.³²²

Among the many aspects of human physiology which are influenced or regulated by EF and MF, tissue repair and wound healing are probably the health-care areas that have accumulated the most evidence. The diagnostic and therapeutic applications of EMF have strong roots in these areas.³²³

The discovery that any tissue lesion produces an interruption in the normal polarisation of tissues, and that this in turn generates an electric current, opened a new window for interpreting the biology of tissue repair and the mechanisms that regulates wound healing.³²⁴

As illustrated schematically in Fig 18, the development of a difference in the polarity at the edge of a lesion is one of the mechanisms, which starts and sustain the movements of the edges of the ulcer towards the centre of the ulcers. The application of EF with an adequate intensity is able to stimulate or, vice-versa, stop and even invert the progression of such movement according to the polarity of EF in relation to the margin of the wound. Thus, it seems that EFs are the fast-responders to creation of a wound, overriding all of the other biochemical and hormonal mechanisms, at least in the initial moments.^{317,322,323}

This has been demonstrated in different animal models and verified by use on human wounds of different aetiologies.^{315,317}

It has been demonstrated how the direct application of EFs may:

- Stimulate and orient the movements of different kinds of cells, including keratinocytes and fibroblasts
- Stimulate the production of cytokines and other proteins
- Guide the homing of bone-marrow-derived mesenchymal cells
- Activate/depress genes via intracellular second messengers: all oriented in promoting wound healing.³²⁵⁻³²⁸

A very elegant experiment in a cell culture demonstrated how by inverting the polarity of EF, fibroblasts not only inverted their active movements, but also shifted the polarity of their protein synthesis inside the Golgi's apparatus, orienting both movements and protein synthesis according to polarity, towards the negative electrode (Fig 19).³²⁹




Fig 18. (A–C) The distribution of polarity in normal (a) and wounded (b) skin and the behaviour of lesions' edges to the application of an electric field to the wound (c)

All the cells involved in wound repair are EF-sensitive, from those of the inflammatory phase (neutrophils and macrophages actively migrate towards the cathode as well as lymphocytes) to epithelial cells, fibroblasts and endothelial cells, which characterise the reparative phase. The reparative phase is not only actively moving when inserted in an EF, but also it increases the proliferative rate as well as the production of cytokines and growth factors, such as VEGF and EGF. This way it demonstrates an interplay between electrical and biochemical/hormonal regulation of wound healing.^{331–334}

These observations have been translated into the production of devices and dressings that can apply EF directly to the wounds to stimulate wound repair.^{335,336} Clinical trials have been carried out in different chronic ulcerative pathologies, such as PUs, VLUs and DFUs, over the last 30 years. Generally, positive results have been achieved (Table 17).

A meta-analysis of these trials, including only RCTs with control groups and adequate

design, follow-up and reports, identified 15 studies. In total, these included 876 patients (497 treated with EF and 379 controls) with an average duration of treatment of 6.53 weeks. The reduction of the area of the lesion at four weeks of treatment that was almost double in the EF-treated groups as compared with the controls (57.08% vs 29.34%).³⁵² The same authors calculated a positive odds ratio (OR) of 26.77% for the use of EFs in a mixed chronic ulcer population. For the PUs, an OR of 42.70% was reached.

Unlike EFs, MFs are not produced by the cells and living tissue but can be generated by EFs when they change rhythmically. In the body, these changes are generally very short-lived. The generated MFs are therefore called pulsatile electromagnetic fields (PEMF).

Another difference between EFs and MFs is that MFs can penetrate the cells and tissue while EFs are stopped by the cell membranes. MFs can interact with a number of functions of the cells in a subtle way.³¹⁵ In addition, MFs are ubiquitous in our environment and can be divided into the following categories:

- Natural MFs, which have a very low intensity [5×10^{-5} Tesla (T); $1\text{T} = 100 \text{Vs/cm}^2$] but may affect many of our biological rhythms with its periodical variations
- Technical MFs, which are all the MFs that are artificially produced by technological means (any electric current generates a MF), which usually reach much higher intensities (up to 7T in MRI machines, more than 10T in the particle accelerator).

MFs have a much lower intensity, but are more intense than the Earth's background MFs. These are generated by any electricity driven equipment from electric lamps to mobile phones. All of these,




Fig 19. Electric-field-directed activation of PI3 kinases³³⁰ reproduced with the kind permission of Humana Press.

at least potentially, interact with our organisms, exerting a variety of effects of tissue and organ physiology. This happens either by directly interfering with the magnetic-sensitive molecules (all of the ones that contains charged ions or metallic components) or by directing and orienting the movements of molecules and organelles.³⁵³

PEMF are more frequently and constantly generated inside our body compared with static MFs. These are generated by endogenous and exogenous EFs, like those of neural action potential, or by a piezoelectric mechanism, generated by the movement of muscles, tendons, bones , joints and, in general, all of the moving proteic structure of our body.³⁵⁴

In the same way, any PEMF applied to a proteic structure is able to determine a movement and

a change in its structure, and a typical example of this is the alignment that collagen fibres show when solicited by PEMFS.³⁵⁵ This is one of the bases of the therapeutic application of PEMFs for tissue repair and wound healing.³⁵⁶

The first and more documented applications of PEMFs in therapeutic fields was the reparation of bone malunions. In this, the application of MFs was associated with faster and more stable, stabilisation of the fractures with an increase in the speed and amount of callus formed and with a better alignment of the matrix fibres and an improved calcification.³⁵⁷

More recent evidence, including *in vitro* and *in vivo* studies, focused on the many positive effects that MFs can exert on virtually all of the phases of tissue repair. This was mediated both by the

Table 17. Studies on electric fields (EF)

Author/ year	Condition	No. of wounds	Type of ES	ES-treated No. patients (PAR4)	Controls N0. patients (PAR4)
Franek et al. ³³⁷ 2012	PU	50	Uni	26 (68.83%)	24 (23.24%)
Houghton et al. ³³⁸ 2010	PU	34	Uni	16 (37.02%)	18 (13.83%)
Petrofsky et al. ³³⁹ 2010	DFU	20	Bi	10 (68.40%)	10 (30.10%)
Ahmad et al. ³⁴⁰ 2008	PU	60	Uni	45 (62.35%)	15 (20.76%)
Jankovic et al. ³⁴¹ 2008	VLU	43	Bi	24 (89.62%)	19 (56.42%)
Junger et al. ³⁴² 2008	VLU	39	Uni	20 (15.11%)	19 (03.04%)
Franek et al. ³⁴³ 2006	VLU	55	Uni	28 (42.05%)	27 (28.27%)
Houghton et al. ³⁴⁴ 2003	VLU	42	Uni	22 (44.30%)	20 (16.00%)
Barczak et al. ³⁴⁵ 2001	PU	33	Uni	16 (69.21%)	17 (44.04%)
Peters et al. ³⁴⁶ 2001	DFU	40	Uni	20 (56.09%)	20 (34.17%)
Baker/Chambers ³⁴⁷ 1997	PU	114	Bi	61 (64.77%)	53 (41.78%)
Baker/Rubayi ³⁴⁸ 1996	DFU	192	Bi	125 (38.49%)	67 (51.00%)
Wood et al. ³⁴⁹ 1993	PU	74	Uni	43 (60.37%)	31 (06.77%)
Feedar/Kloth ³⁵⁰ 1991	Mixed	50	Uni	26 (56.18%)	24 (32.82%)
Carley et al. ³⁵¹ 1985	Mixed	30	Uni	15 (83.46%)	15 (37.92%)
Total	----	876	----	497 (57.08%)	379 (29.34%)

ES—electric stimulation; PAR4—percentage area reduction in four weeks; PU:—pressure ulcers; DFU—diabetic foot ulcer; VLU—venous leg ulcer; Uni—unipolar stimulation; Bi—bipolar stimulation

interaction with cells and their behaviour and by the modulation of cytokines and growth factors production, which promoted the therapeutic use of MFs in wound healing.³²³

MFs have been associated with an intense anti-inflammatory action, mediated by the shift in the production of cytokines from a pro-inflammatory pattern to an anti-inflammatory pattern. This can speed up the movement from the chronic inflammatory phase, which is typical for chronic wounds, to a more pro-reparative phase of tissue repair. This has also prompted the use on MFs not only in chronic ulceration, but also in a variety of chronic inflammatory conditions of both skin and the osteo-muscular apparatus, such as tenosynovitis, arthrosis, and traumas.^{358,359}

In addition, MFs promote the proliferation and activation of fibroblasts and increase neoangiogenesis alongside the aforementioned orientating effect on collagen fibres. This promoted their application in the reparative phases of wound healing as well as in other conditions characterised by poor regenerative activity, such as osteoporosis.^{360,361}

In Table 18, a report of the studies on the application of MFs for wound healing is summarised.

The application of MFs in humans is not used without concerns. Indications have been presented that the chronic exposure to MFs, especially in the case of high frequency and high intensity, is associated with carcinogenesis. For

Table 18. Studies on electromagnetic fields (EMF)

Author/year	Condition	No. of pt.	EMF specifications	Follow-up (days)	Results
Piaggese et al. ³⁶² 2016	DFU	140	TMR 24 + 24 min/day Exposure 4 weeks	70	Significant (p<0.05%) increase in rate of granulation tissue and symptom score in treated patients vs controls
Abbruzzese et al. ³⁶³ 2015	DFU	20	TMR 20 + 20 min/day Exposure 2 weeks	180	Significant (p<0.05%) increase in healing rate in treated patients (90%) vs controls (30%)
Gupta et al. ³⁶⁴ 2009	PU	12	PEMF - 1 Hz sine wave, 45 min 5 x week Exposure 24 weeks	170	No significant differences between treated group and controls
Canedo-Dorantes et al. ³⁶⁵ 2002	ALU and VLU	26	PEMF 3.63 mT, 2-3 hour/day, 3 x week Exposure 16 weeks	120	69% wound closure in treated group, healing lasted at least 6 months and up to 2 years
Stiller et al. ³⁶⁶ 1992	VLU	31	PEMF - 2.2mT, 3 hour/day Exposure 8–12 weeks	90	50% healing in treated group vs 0 in control group, significant (p<0.04) reduction in depth and pain perception in treated patients
Todd et al. ³⁶⁷ 1991	VLU	17	PEMF - 5Hz, 15 min 2 x week Exposure 5 weeks	45	Not significant improvement of clinical parameters in treated group
Ieran et al. ³⁶⁸ 1990	VLU	37	PEMF - 75Hz, 2.8 mT, 3–4 hour/day Exposure 13 weeks	90	Significant (p<0.02) increase in re-epithelialisation rate in treated patients compared to controls

EMF—electro-magnetic fields; DFU—diabetic foot ulcer; ALU—arterial leg ulcers; VLU—venous leg ulcer; PU—pressure ulcers; PEMF—pulsatile electro-magnetic fields; TMR—therapeutic magnetic resonance




Fig 20. Therapeutic optical window.³⁷⁶ The 'Optical Therapeutic Window' is the range of wavelengths at which light may interact with photoreceptors to exert a photobiomodulatory effect.

this reason, standards for the exposure to MFs of humans have been developed by the International Commission on Non-Ionizing Radiation Protection (ICNIRP) and applied in several countries. These guidelines set the standards and limitations for the intensity and length of exposure and describe the possible long-term effects, which are not yet fully documented but cannot be excluded.³⁶⁹

A new generation of PEMF have been implemented and tested in chronic wounds with positive results. Their way of interaction with the biologic systems is different from the traditional versions as they do not act directly due to their extremely low intensity. Instead, they 'communicate' with the MFs present inside the cells by frequency modulation sequences that characterise these MFs. This is phenomenon is known as bioresonance. It modifies the

frequencies of the MFs inside the cells. For this reason, they have been identified with the generic term 'therapeutic magnetic resonance' (TMR).³⁷⁰

The average intensity of TMR used is similar to the terrestrial magnetic field (approximately 40 microtesla), and this does not fully exploit the energetic parameters but rather the frequency of the electromagnetic signal. The system emits 'wave trains', which are picked up in spite of the low intensity, for example via a 'stochastic resonance' mechanism, which has already amply observed in nature. These produce a therapeutic effect. The cells affected by the signal are those requiring a re balancing of function. It is assumed that, in the targeted tissue, the sick cells are affected by the signal through a realignment in frequency, whereas the other cells remain in tune with the signal transmitted. They receive the signal but are not affected by it.^{370,371}

Recent studies on DFUs have demonstrated how TMR is able to increase the granulation tissue formation on recalcitrant ulceration after four weeks of application and how this clinical result is paralleled by histological and biomolecular findings of pro-reparative shifting in biopsies taken from the lesion under treatment.³⁶²

Photobiomodulation (PBM)

The use of light for medical purposes dates back to ancient times when phototherapy was empirically prescribed for a number of clinical conditions ranging from skin pathologies to asthma, behavioural disorders and, eventually, wounds.

More recently, advancements in human physiology, which elucidated many of the mechanisms behind the interaction between the organism and light, added many new dimensions to this field.³⁷² These mechanisms include its role in the synthesis of vitamin D, the photomodulation of biorhythms and the antidepressive effects.

Wound healing was probably one of the first and most important areas in which the application of light as a therapeutic tool was applied. This cumulated a body of evidence in the different pathologies, ranging from PUs to DFUs and VLU.s.³⁷³

Despite its wide application, especially in the last 20 years, phototherapy was only recently defined in its different components. This separated the applications relying on the thermal effects of light application from the ones that are non-thermal and imply an interaction of light with endogenous photoacceptors.³⁷⁴

The latter were comprehensively grouped under the term 'photobiomodulation therapy', which in November of 2015 were included in the MeSH index of the US National Library of Medicine.³⁷⁵

The definition of photobiomodulation is 'a form of light therapy that utilises non-ionising forms of light sources, including lasers, LEDs and broadband light, in the visible and infrared spectrum. It is a nonthermal process which involves endogenous light absorbing molecules (chromophores) that elicit photophysical and photochemical events at various biological scales. This process results in beneficial therapeutic outcomes including, but not limited to, the alleviation of pain or inflammation, immunomodulation, and promotion of wound healing and tissue regeneration'.³⁷⁵

The interaction between light and our organism is conditioned by a number of different factors:

1. The 'optical therapeutic window': there is currently a relatively narrow range of wavelengths that can actually interact with the photoacceptors to exert photobiomodulation, and they are comprised between 600 and 1300nm; wavelengths of <600nm are absorbed by melanin and oxyhaemoglobin while wavelengths >1300nm are absorbed by the body's water. This window is located near the infra-red portion of the spectrum of visible light and is denominated near-infrared light (NIR) (Fig 20).³⁷⁶
2. There is also a range of doses on energy transfer that has to be taken in account when one considers the biological effects induced by photobiomodulation, and they are within the Arndt-Shultz curve (Fig 21).³⁷⁷
3. The sources of light:light for medical purposes may be generated either by LED (light emitting diode) or by LASER (light amplification by stimulated emission of radiation). In both cases, the emitted light is monochromatic. In the case of LED generated light, the emission is not unidirectional while LASER generated light is unidirectional and coherent, reaching much higher intensity with the same amount of energy, concentrating the area of application.³⁷⁸

To exert its effect, light has to interact with the structures of our cells. Although there are still some controversies regarding the possible targets for this interaction, cytochrome C oxidase appears to be the best candidate as the principal photoacceptor. This is due to its conformation with four possible sites of photoacceptation, the two copper centres (CuA and CuB) and the two iron centres (HemeA and HemeB). These are all involved in the transfer of electrons in the respiratory chain on the mitochondrial membrane of the eukaryotic cells.³⁸⁰

Other candidates, possibly with complementary roles, are phlavoproteins and porphyrins, which are implicated in the generation of reactive oxygen species (ROS) after an interaction with photons.³⁸¹

In both cases, and eventually in the other cases in which light may interact with biological structures, this has to be considered a so-called primary reaction. The secondary reactions include the effects that the first interaction induce within the metabolism of the cells and the tissue by transduction and amplification of the original signal, leading to a photoresponse.³⁸²

Secondary reactions include the production of NO, the intracellular increase of ROS, the increase in permeability of cell membrane, the increase of intracellular calcium levels, the increase in cell metabolism, the increase of RNA and DNA synthesis, fibroblast proliferation, activation of lymphocytes, macrophages and mast cells, and increased synthesis of interleukins and growth factors.³⁸³

An interesting emerging action of photobiomodulation on the wound healing process is the modulation of MMPs and their inhibitors TIMP.¹⁻⁴ Studies have demonstrated how irradiating chronic wounds with a laser (660nm 6.2 J/cm²) results in a reduction of MMP-2/TIMP2 and




Fig 21. The Arndt-Shultz curve; with a peak around 5J/cm²; smaller doses of energy do not provoke effects, and higher doses may have negative effects.³⁷⁷

MMP-9/TIMP2 as compared with non-irradiated controls.³⁸⁴ A report confirmed by other studies in periodontitis models³⁸⁵ opened a window on to what could be a next area of research in photobiomodulation and wound healing.³⁸⁶

Beyond the general concept that light exerts an important anti-inflammatory action, the new acquisitions of knowledge that are presented in the more recent studies, demonstrated many other effects, not only from a local, but also from a systemic, point of view.³⁸⁷

Photobiomodulation has now accumulated evidence of a positive action on all phases of wound repair from the first inflammatory phases to the remodelling phase (Fig 22).

In Table 19, a selection of clinical studies on the application of photobiomodulation therapy to wound healing is reported.

While NIR is the main driver of photobiomodulation in wound healing, ultraviolet (UV) light has been proven to exert an

important role in contrasting infections within chronic wounds.³⁹⁶

Depending on wavelength, UV light can be divided in four groups:

- Vacuum UV (100–200nm)
- UVC (200–280nm)
- UVB (280–315nm)
- UVA (315–400nm)

Vacuum UV and UVC are completely blocked by the ionosphere while UVB and UVA are in

contact with our bodies with different grades of penetration, and UVA can penetrate deeper than UVB.³⁹⁷

Recent studies have demonstrated how it was possible to eradicate MRSA and *Pseudomonas aeruginosa* infections with short-interval (<1hour) applications³⁹⁸ by irradiating chronically infected ulcers with UVC (254nm, 15.54mW/cm²).

The antimicrobial effect of photobiomodulation has been confirmed for use on biofilm-producing bacteria, which include the majority of the cases of chronic wounds colonisation, and which are particularly resistant to systemic antibiotic therapy. Laser-generated light application can

Table 19. Studies on photo biomodulation (PBM)

Author/ year	Condition	No. of patients	PBM specifications	Follow up (days)	Results
Romaneli et al. ³⁸⁸ 2017	DFU,VLU,PU	33	440–460nm (55–129J/cm ²)	224	QoL: 26.4% improvement of CWIS (Cardiff Wound Impact Score) post- vs pre-treatment (p=0.001). 52% achieved total wound closure with the study treatment
Nikolis et al. ³⁸⁹ 2016	FSR	32	400–470nm	84	Improvement of skin scores
Kajagar et al. ³⁹⁰ 2012	DFU	64	wavelength not specified (2–4J/cm ²)	15	Significant (p<0.05) reduction in ulcer area. Treated group 1043mm ² control group 322mm ²
Kaviani et al. ³⁹¹ 2011	DFU	23	685nm (10J/cm ²)	140	Significantly (p<0.05) greater reduction in ulcer size in treatment group, no differences in healing rates and healing times between groups
Landau et al. ³⁹² 2011	DFU	16	400–800 nm (43.2 J/cm ²)	116	90% healing in treated group vs 33% in control group (p<0.05), significant (p<0.05) shortening of healing time in treated (7 weeks) vs control (11 weeks) group
Minatel et al. ³⁹³ 2009	DFU	28	890nm + 660nm (3 J/cm ²)	90	53% healed in treated group vs 7% in control group (p<0.05)
Shubert ³⁹⁴ 2001	PU	72	956nm + 637nm x 9 min pulsed (15.6Hz - 8.58kHz)	70	Healing rate 49% higher in treated group than in controls (p<0.05)
Papageorgiou et al. ³⁹⁵ 2000	AV	107	415nm (320J/cm ²) + 660nm (202J/cm ²)	84	76% improvement of inflammatory lesions at 12 weeks in treated group

PBM—photobiomodulation; AV—acne vulgaris; PU—pressure ulcers; DFU—diabetic foot ulcer; VLU—venous leg ulcers, FSR—facial skin rejuvenation

eradicate biofilm and infected wounds efficiently and safely.³⁹⁹

Other authors also observed pro-reparative effects of UV on various in vitro and in vivo models of chronic wounds, but the clinical experiences are so far too limited to result in any clear conclusions on these effects.

A novel and very promising approach to photobiomodulation in wound healing has been developed in recent years. This associates with the irradiation of a gel containing chromophores activated by LED generated visible light. When activated with a LED light (440 to 460nm), the light absorbing molecules release large spectra of photons at different wavelengths in the visible range from 532nm to 615nm. The gel is applied on the wound surface and is not absorbed by the tissue, but it is activated by the light, which is applied for a duration of 5 minutes twice a week.⁴⁰⁰

This new way of realising photobiomodulation therapy has been named biophotonic treatment, and it has been successfully applied in PUs, DFUs, VLUs, and acne vulgaris with positive effects on pain perception, healing rates and the patients' quality of life.^{389,394}

A non-secondary positive aspect of the biophotonic treatment is that it reduces the number of applications and the time required for effectively obtaining a therapeutic effect on wound healing, which allows for a containment of the costs of management for these typically very costly chronic pathologies. This is both in terms of a reduced use of antibiotics and in terms of better resource use.⁴⁰¹

Romanelli et al., in an interim analysis of prospective multicentred observational trials on 100 patients with DFU, VLU and PU from seven highly specialised centres in Italy, aimed to evaluate the safety and effectiveness of BPT on different models of chronic ulcers in a real-life




Fig 22. Photobiomodulation can positively influence all phases of wound repair from the early inflammatory response to the late remodelling of scar tissue³⁸⁰

setting, found a rate of closure of wounds of 53.8% for VLU, 52.9% for DFU and 33.3% for PU. The percentage of full responders, which were defined by a decrease of the wound size area of more than 90% at study end and/or decrease of more than 50% of the size in 15 days or less, ranged from 33.3% in PU, to 61.5% in VLU and 70.6% in DFU. Moreover, the Cardiff Wound Index Score, an indicator of the quality of life in ulcerated patients, was found to be significantly ($p=0.001$) increased in all patients, irrespective of if they were full or partial responders probably due to the positive effects of BPT on pain.³⁸⁸

Despite the fact that the field of photobiomodulation is one of the most stimulating and rich among the physical therapies for wound healing with regard to clinical experiences, some controversies and uncertainties remain both from a methodological and clinical point of view.³⁷⁴

1. Optical parameters are extremely variable from study to study, and either frequencies, intensities and times of exposures change to an extent that it is difficult to compare the results between the different studies
2. There are many different photo-acceptors on the human cells, and the role of each of these are not yet fully understood. If more than one react to certain wavelengths, it may be difficult to determine the relationship between each stimulus and reaction to establish a causal pathway
3. The mechanisms of action of photobiomodulation are still not completely understood. We know that NIR and long visible wavelengths act via the cytochrome c oxidase while short visible wavelengths produce NO and ROS from nitrosated proteins and NADPH. However, these two mechanisms do

not fully explain all of the observed effects of photobiomodulation in wound healing.

For all these reasons, there is still work to be done in this exciting field before we can promote it as a primary treatment option in wound management.

Nanotechnologies (NT)

On 29 December 1959, at a conference for the opening of the annual congress of the American Physics Society entitled 'There's Plenty of Room at the Bottom', the Nobel physicist Richard P. Feynman introduced for the first time the concept of a technology at the atomic dimensions, which can operate at the molecular level in a variety of environments. Although Feynman exposed the basic concepts, the term nanotechnology was actually coined by Kim E. Drexler in her book, entitled *Engines of Creation: The Coming Era of Nanotechnology* in 1986.⁴⁰²

With the term nanotechnology (NT), we refer to the research and application fields, which in the nanoscale dimension, range between one and 100 nanometres (nm: 1nm = 1 billionth of a metre); NT has potential within a number of different areas of development, ranging from electronic to engineering. Within medicine, many promising applications have been realised within a range of fields, from oncology to diagnostics and pharmacology and many others, including wound healing.⁴⁰³

The interest that NTs raises within wound healing relates to the physical characteristics of nanoparticles (NP) as well as their versatility and tunability, which make them suitable for use in the different phases of tissue repair.⁴⁰⁴

The high surface area/volume ratio makes it possible for NPs to have a high probability of

interaction with the cellular elements and an enhanced penetration deep into the tissues. This also allows a higher bioavailability at lower concentration with a lower toxicity as a result.⁴⁰⁵

NTs have been explored in all phases of wound repair, from the acute inflammatory phase, in which they have primarily been tested as antibacterial agents, and for their modulatory effect on inflammation, to the reparative phases in which they have been applied due to their intrinsic properties and as vehicles of bioactive agents (Fig 23).⁴⁰⁴

In the acute inflammatory phase, the antibacterial properties of metallic and non-metallic nano-materials have been tested in a number of preclinical studies *in vitro* and *in vivo* in animal models.⁴⁰⁶

Silver NPs and nanocrystals have been widely experimented with, also in clinical trials, for their ability to kill bacteria and to disrupt biofilms. The cytotoxicity of these heavy metal ions has been reduced, thereby decreasing the concentration due to the higher bioavailability in the NPs. The release of ions from NPs have been demonstrated to be more sustained over time, thus giving added value to this therapy in chronic wound infections.^{407,408}

Zinc oxide (ZnO) NPs have demonstrated analogue effects at an even lower degree of toxicity, making them a very interesting alternative to silver, and also due to the possibility to insert them in different NM-dressings.^{409,410}

Moreover, the efficacy of both Gram-and Gram+ strains and the activity against biofilm formation make both silver and ZnO NPs complementary or even alternative to the use of systemic antibiotic therapies. This may support the general efforts to reduce the risk of antibiotic resistance in chronically infected wounds.⁴¹¹

Non-metallic NMs have also been applied to the acute phase models with successful outcomes, mainly related to the anti-inflammatory effects that they exert on the wound biology. Carbon fullerenes has been demonstrated to significantly reduce inflammation and reduce the oxidative stress level in models of chronically inflammatory wounds.⁴¹²

In the acute phase, NMs have also been tested as vehicles and carriers for bio-active molecules, such as nitric oxide (NO), antibiotic compounds and antioxidants.

NO is a molecule that plays many different functions in wound repair, especially in the acute phases, when it has a vasodilatory effect, an antibacterial effect and acts as a scavenger for cellular and bacterial debris.⁴¹³

The possibility to convey NO into the wound more efficiently and to extend the release of NO inside the lesion have been tested with positive results using nanocarriers [poly(lactic-CO-glycolic acid) (PLGA)-polyethyleneimine (PEI)] that satisfied these conditions.⁴¹⁴

The same approach has been used for delivering antibiotics and antioxidants inside the wounds in a time/dose efficient method. In the first case, a nanoparticle, made by gold nanodots joined with the cyclic lipopeptide surfactin (SFT), showed much more intense antibacterial activity compared to SFT used alone.⁴¹⁵ This nanoparticle demonstrated antibacterial activity and included 1-dodecanethiol (DT). In the second case, curcumin, a molecule with antibacterial and antioxidant properties, was successfully encapsulated in a number of different nanocarriers.⁴¹⁶

In the reparative phases, NM have been proposed as carriers for growth factors and cytokines and as a novel type of scaffold and matrices

on which newly-formed tissue can grow in a more physiological way as compared with traditional methods.

The possibility to protect growth factors from enzymatic degradation by the use of the proteases present in the chronic wound environment put nanoscale systems in the position of being taken into consideration as carriers for those proteins.⁴¹⁷ This method extended their release and bio-activity.

A recombinant epidermal growth factor (rhEGF) has been successfully encapsulated in PLGA nanoparticles and in solid lipid nanocarriers. In both cases, its release and activity on chronic wounds was extended, and the activity was prolonged. This was demonstrated on mouse models.^{418–420}

In addition, a recombinant vascular endothelial growth factor (rhVEGF) has been successfully inserted in PGLA nanoparticles together with platelet derived growth factor (PDGF). This was done in a combined way to support the integration of the activities of these growth factors (VEGF pro-angiogenetic and PDGF pro-regenerative) in a chronic wound model.^{421,422}

The possibility to realise 3-dimensional structures within the nanoscale dimension has been exploited for realising scaffolds that mimic the characteristics of extracellular matrix (ECM). PLGA/silk fibroin hybrid nanofibres have been used to promote attachment and proliferation of fibroblasts in a diabetic ulcer model.⁴²³ Highly-branched nanopolymers (dendrimers) with anti-inflammatory properties like gelatine-dendrimer with polyethylenglycole and silver ions have been released and tested for antibacterial properties.⁴²⁴

The possibility to orientate the nanofibres at the nanoscale dimension has also been tested.^{425,426} This aims to promote a faster migration of the

cellular elements that form the granulation tissue during the reparative phase and to promote the use of materials, such as silicon wafers. Silicon wafers minimise the scar formation while maintaining pro-reparative properties.

Newer and even more interesting applications of NM in wound healing are the applications related to the possibility of using them to carry gene fragments into the wounds. This application aims to 're-condition' the deranged biology of the chronic environments, such as by reducing the production of matrix metalloproteinases or mesenchymal stem cells, which may speed up the healing process.^{427–429}

Despite the signs of a very promising and bright future of nanotechnology research, only a few clinical studies have so far been carried out on real patients with chronic wound pathologies. In Table 20 (NM), the available clinical studies on nanotechnologies are summarised.

In a prospective observational trial on silver nanocrystalline (SN), including 103 patients with chronic wounds of mixed aetiologies, which were followed for a median of 42.5 days, Soriano et al. found a significant ($p < 0.05$) positive difference in the healing curves as compared to the controls.⁴³⁰

Miller et al. compared SN and cadexomer iodine in a study including 291 chronic ulcers outpatients with a prospective, randomised design. Despite a superimposable overall healing rate in the group, they found a faster healing rate in the group treated with silver.⁴³¹

Tsang et al. performed an RCT with three arms, comparing SN to manuka honey (MH) and conventional dressings (CD). In this trial, they found a higher, but not significant, healing rate of 12 weeks for SN (81.8%) as compared to MH (50%) and CD (40%), respectively.⁴³²



Source: Hamdan et al. Nanotechnology-driven therapeutic interventions in wound healing: potential uses and applications. American Chemical Society, 2016

Fig 23. Schematic representation of the nanotechnology-based therapies employed in wound healing⁴⁰⁴ reproduced with the kind permission of ACS Central Science

Table 20. Studies on nanotechnologies (NT)

Author/year	Condition	No. of Pt.	Nanotechnology specifications	Follow-up	Results
Tsang et al. ⁴³² 2017	DFU	31	SN vs manuka honey MH and CT	84 days	Higher but not significant healing rate at 12 weeks for SN (81.8%) as compared with MH (50%) and CT (40%), respectively
Miller et al. ⁴³¹ 2010	VLU	281	SN vs CI	84 days	No differences in healing rates, faster healing time in SN
Verdù Soriano et al. ⁴³⁰ 2010	Mixed chronic ulceration	103	SN vs CT	42.5 days	SN showed a significant ($p<0.05$) positive difference in the healing curves as compared with CT
Banchellini et al. ⁴³³ 2008	DF pre-ulcerative condition	30	Nano-liposomes charged with phosphatidylcholine vs CT	42 days	Significant ($p<0.05$) improvement in skin hardness, moisture and TEWL

NT—nanotechnology; DF—diabetic foot; DFU—diabetic foot ulceration; VLU—venous leg ulceration; TEWL—transepidermal water loss; CT—conventional treatment; MH: manuka honey; SN—silver nanocrystalline; CI—cadexomer iodine

Table 21. Evaluation of evidence levels: physical therapies

Therapy	Indication	Level of evidence (for each indication)	Comments
ESWT	DFU, PU, VLU	1C	Few studies, very good risk/benefit ratio, can be considered an adjuvant therapy in a wide range of clinical conditions
EF	DFU, PU, VLU	1C	Good evidence of effectiveness in experimental models, but few studies with poor-quality in clinical fields, useful in stimulating wound edges' progression
MF	DFU, PU, VLU	1C	Relatively recent evidence, still few studies, few good-quality clinical trials, solid evidence in bone fracture repair; some indication of anti-inflammatory effects, evidence in stimulating collagen synthesis and granulation tissue formation
PBM	DFU, PU, VLU	2B	Still controversial mechanisms of action, not clear the full range of effects on wound repair; few studies of low- or very low-quality, some evidence of antibacterial activity and pain reduction
NT	DFU, MU, VLU	1C	Promising results, but a sufficient evidence base is not yet available, good results in prevention of DFU and antibacterial activity, few RCTs

ESWT—extracorporeal shock wave therapy; EF—electric fields; MF—magnetic fields; PBM—photobiomodulation; NT—nanotechnologies; DFU—diabetic foot ulcer; MU—mixed ulcer; PU—pressure ulcer; VLU—venous leg ulcer

Banchellini et al. prospectively compared nanoliposome carriers, charged with phosphatidylcholine (NLPP), with conventional

treatment in a RCT involving neuropathic patients with anhidrosis in the feet. At six weeks, they found a significant ($p<0.05$) improvement in skin moisture,

skin hardness and trans-epidermal water loss (TEWL) in NLPP-treated patients compared to the control patients.⁴³³

In Table 20, a synopsis of the studies on NT in relation to wound management and repair is provided.

Smart technologies in wound management

Introduction

The prevalent and long neglected DFU and its related complications rank among the most debilitating and costly sequelae of diabetes. Currently, every six seconds somebody is diagnosed with diabetes, and every 20 seconds a limb is lost because of it.

Diabetes foot care costs represent the single largest category of excess medical costs associated with diabetes. It is estimated that one-third of all diabetes-related costs are spent on DFU care in the US, with two thirds of these costs incurred in the inpatient settings, constituting a substantial cost to society.^{434,435} The lifetime incidence of DFU has been estimated to be between 19% and 34% among people with diabetes.⁴³⁶ One in every 11 adults has diabetes (425 million worldwide), according to the latest report by the International Diabetes Federation (IDF) in 2017.⁴³⁷ Ulcers requiring acute care can result in treatment costs of up to US\$28,000 per event, varying with the severity of the wound.⁴³⁸ Unfortunately, even after the resolution of a DFU, recurrence is common and is estimated to be 40% within one year after ulcer healing, almost 60% within three years, and 65% within five years, according to the recent study by Armstrong et al.⁴³⁶ A significant risk related to DFU is the 10-20% rate of lower extremity amputation (LEA); approximately 70% of such amputations are potentially preventable.⁴³⁹ The consequences of DFU are not limited to amputation. In particular, DFU may put patients at risk for other adverse events, such as falls, fractures, reduced mobility, frailty and mortality.⁴⁴⁰⁻⁴⁴² For example, mortality

after amputation because of diabetes is estimated to be 70% at five years, which exceeds many common cancers, such as breast cancer and prostate cancer.⁴⁴³

Fortunately, we live in a world where technology is increasingly being integrated into every aspect of our lives, representing an opportunity for creative solutions to prevent this devastating condition. In particular, thanks to the new 'smart' sensors and communication technologies available today, new opportunities have opened to smartly manage DFUs with personalised screenings and timely interventions. More importantly, with the given advances in wearable technologies and telecommunication, patients and their caregivers can be more engaged in enabling an optimised health-care ecosystem. This chapter aims to provide an overview of the recent technological advances from wearables to mobile health, telemedicine and 'internet of things' with a great potential to revolutionise the smart management and/or effective prevention of DFU and its consequences, including lower extremity amputation. While the major focus of this chapter is on managing DFU, other types of chronic wounds including VLU, PU, and some types of acute wounds, such as severe burns, are also discussed.

Even, if a DFU is successfully treated, patients may often suffer from significant lower extremity muscle atrophy, in particular if irremovable offloading was used for the duration of more than four weeks.⁴⁴¹ This may lead to premature frailty




Fig 24. Pathway toward amputation because of frailty induced by offloading⁴⁴⁴ Source Roser MC, Canavan PK, Najafi B et al. Novel in-shoe exoskeleton for offloading of forefoot pressure for individuals with diabetic foot pathology. *J Diabetes Sci Technol* 2017; 11(5):874–882

and reduced mobility. Fig 24 illustrates a general limitation of current DFU management inspired by a study conducted by Roser et al.⁴⁴⁴ This illustration is intended to highlight the high frequency of re-ulceration (40% within 12 months of treatment⁴³⁶ for people in DF ‘remission’⁴⁴⁵), which places them at higher risk of future amputation. In particular, a recent study, in which daily physical activities of people with DFU was monitored every week, it was found that the activity level in those who were treated with irremovable offloading will be reduced on average by 49%. This may lead to muscle wasting in the lower extremities.⁴⁴¹ The amount of activity observed in the patient population after four weeks with treatment by offloading was less than 3000 steps per day, which is almost the same level of activity observed in a frail population.⁴⁴⁶

This suggests potential frailty induced by offloading, which may have serious long-term consequences, including higher frequency of recurrence of ulcers, falls, higher risk of adverse events, disability, hospitalisation and mortality.⁴⁴⁷ These data suggest an important gap in effectively managing and preventing DFUs, particularly in community hospitals and clinics.

In light of the impending diabetes epidemic and the high prevalence of DFU and its associated complications, the need for enhancing prevention of DFUs is clear. Thanks to the new ‘smart’ sensors and communication technology that is available today, new opportunities have opened to smartly manage DFUs with personalised screenings and timely interventions. With the help of automation,

Table 22. Selected studies related to wearable devices designed to stimulate wound healing and/or reduce risk of DFU/chronic wounds

Author/year	Condition(s)	N. of patients	Type of intervention	Primary outcome (s)	Treatment duration	Results
Edmonds et al. ⁴⁵³ 2018	DFU	240	Nano-oligosaccharide (sucrose-octasulfate) and SOC vs best practice (SOC)		20 weeks	18 points increase in healing rates (48% vs 30%) (p=0.002) and 60 days shortening of healing time (p=0.029) vs control
Najafi et al. ⁴⁵⁴ 2017	Diabetes neuropathy	28	Electrical stimulation RCT design	Balance Gait Neuropathy severity Vascular health	6 weeks	Significant improvement in balance, gait, neuropathy severity, vascular health was only improved in sub-sample with peripheral arterial disease
Najafi et al. ⁴⁵⁰ 2017	Patients with history of foot ulcers	17	Smart insoles + real-time notification (case series)	Change in rate of adherence to prescribed footwear; reduction of recurrence of ulcers	Up to 12 weeks	Significant improvement in adherence for those who are receiving at least one alert every two hours; no recurrence of ulcers was reported during the follow-up period
Najafi et al. ⁴⁴¹ 2017	Diabetic foot ulcers	49	Activity dosage (RCT design)	Success of wound healing at 12 weeks, weekly speed of wound healing	Up to 12 weeks	Significant correlation between number of daily steps with speed of wound healing irrespective of type of offloading (removable vs irremovable), significant association between duration of daily standing and success of wound healing at 12 weeks
Niederauer et al. ⁴⁵⁵ 2017	Chronic and non-chronic diabetic foot ulcers	100	Modern dressing – continuous diffusion of oxygen (RCT design)	Rate of successful wound healing at 12 weeks; time to heal	Up to 12 weeks	Significant higher rate of wound healing (46% vs 22%) with higher rate of success for chronic wounds (43% vs 14%), significant shorter time for healing
Kadry et al. ⁴⁵⁶ 2016	Chronic lower limb ulcers	40	Pulsed radio frequency energy (RCT design)	Wound area reduction	6 weeks	Significant reduction in wound area compared with controls
Driver et al. ¹⁵⁰	Neuropathic non-ischaemic chronic ulcers	307	Nano-technology-based therapy- integra dermal regeneration template (RCT study)	Success of wound healing at 12 weeks; weekly wound size reduction; time to health; adverse events	Up to 16 weeks (follow up for primary outcomes up to 12 weeks)	Significant higher rate of healing at 12 weeks compared to controls (51% vs 32%), significantly higher rate of weekly wound size reduction (7.2% vs 4.8%), less time for healing and less adverse events
Lewin et al. ⁴⁵⁷ 2015	Chronic venous ulcer	25	20 kHz ultrasound assisted treatment (case-control)	Success of wound healing; Rate of wound healing	Minimum 3 sessions	Significant improvement in average rate of wound healing (20.6%/week) compared to the control group (5.3%/week)

Thakral et al. ⁴⁵⁸ 2013	DFU; PU; VLU; Leprosy; ulcers; Mixed ulcers	21 RCT studies Total: 544 subjects	Electrical stimulation - RCT design	Wound area reduction (speed of wound healing)	Range from 3 weeks to 23 weeks	Significant wound area reduction compared with the controls
Rawe et al. ⁴⁵⁹ 2012	Diabetic and venous stasis ulcers	4	Pulsed radio frequency energy (case series)	Pain Reduction in wound size	6 weeks	Reduction in pain and wound size have been reported, but the sample is too small for any statistical power
Marston et al. ⁴⁶⁰ 2003	Chronic diabetic foot ulcers	314	Nano-technology-based therapy- fibroblast-derived dermal substitute (RCT study)	Success of wound healing at 12 weeks; adverse events	Up to 12 weeks	Significant improvement in rate of successful wound healing at 12 weeks compared to conventional therapy (30% vs 18%) with similar adverse events between groups
Veves et al. ²⁶⁶ 2001	Nonischaemic chronic plantar diabetic foot ulcers	208	Nano-technology-based therapy- bioengineered human skin equivalent (RCT study)	Success of wound healing at 12 weeks; adverse events	4 weeks	Significant improvement in success of wound healing at 12 weeks compared to control, adverse events rate was the same between groups
Smiell et al. ⁴⁶¹ 1999	Chronic ulcers diabetic foot ulcers	4 RCT studies Total: 922 subjects	Nano-technology-based therapy- becaplermin gel (systematic review)	Rate of successful complete healing, time to complete healing	Up to 20 weeks	Significant healing rate compared to controls (50% vs 36%), reduction in the time to complete healing by 30% (14.1 vs 20.1 weeks)
DFU—diabetic foot ulcer; PU—pressure ulcer; VLU—venous leg ulcer; significant level was defined as p<0.050. The data with ' - 'means' data is missing or not clearly reported.						

patients can even be prompted to check their feet, glucose level or weight and can enter the results into mobile patient portals. Even better, they can transmit the results to their doctors in real-time. These fast-growing, low cost, and widely available resources can help predict the patient's risk of developing foot ulcers, infections, peripheral arterial disease, frailty and other diabetes associated complications, which can ultimately save limbs and lives. In the rest of this chapter, some of the emerging technologies, which could revolutionise smart management of DFU, are presented. This includes wearables used to screen mobility, management of activity, dosage, and 'internet of things' infrastructures that support the empowerment of patients and/or their care givers to effectively co-manage these chronic conditions and enable an optimised health-care ecosystem.

The same considerations can be applied to other chronic ulcerations, like VLUs and PUs, which are the other major players in the field of chronic lesions, and which together account for the majority of ulcerated patients in the world. For all of these, the possibility of being adequately diagnosed, monitored and treated would increase significantly due to the introduction of sensors and IT. In light of this, DFUs can be used as a primer and a paradigm, which can be extended eventually to other types of ulcerations.

Wearables and applications to smartly manage chronic ulcers

Smart watches, smart pendants, other smart wearables or mobile-based applications already marketed to the young and healthy population will take on an ever-growing presence in the patient-care marketplace, including the management

of the DF. Wearable devices can track nearly everything, from early stroke detection, to monitoring physiological parameters, quantifying physical activity, monitoring sleep quality, determining gait structures and standing plantar pressures and shear.⁴⁴⁸⁻⁴⁵² Their versatility and portability appeal to consumers and make them a consideration for insurance providers, who want to cut down on in-person visits by allowing physicians to remotely check in on patients, track patients' adherence to therapy and detect the early stages of serious medical conditions to triage those, who need an immediate supervised care. In addition, it enables the patient to receive personalised and targeted therapy and empowers them to take care of their chronic conditions themselves by engaging them in routine care and facilitates communication with their care-provider. Besides wearable inertial sensors, which are used for monitoring physical activities, gait assessment, and as a detection of falls, a variety of sensors have been designed, which facilitate monitoring of key risk factors associated with wound healing. These include pH, skin temperature, physiological stress response, moisture, oxygen, microfluidic analysis, and many more. Wearable technologies are not limited to monitoring. These technologies also enable daily interventions outside of the clinic via advanced wound dressings and nanotechnology-based therapy.

Different wearables have been designed to stimulate wound healing. These wearables include the use of electrical or mechanical stimulation, which may improve skin perfusion, smart wound dressing devices, which enable effective delivery of oxygen to the wound bed to hasten wound healing and vacuum-assisted technology to support the closure of the wound to reduce the risk of infection. This section discusses whether or not and how such technology may assist in effective prevention and/or management of DFU or other types of wounds, including VLUs, PUs, or other chronic wounds like severe burns. Table

22 summarises the identified studies in which the benefits of wearables and advanced technologies have been compared with conventional therapy and were reported by *in vivo* testing in human subjects. Where a systematic review of RCT studies were available, only the results of the systematic reviews were summarised in this table.

Wearable device designed to stimulate wound healing and/or reduce risk of DFU

A recent systematic review by Thakral and colleagues,⁴⁵⁸ which included 21 RCTs that used electrical stimulation for healing wounds such as DFU, VLU, PU, and mixed ulcers. This review suggested that electrical stimulation may offer a unique treatment option to hasten the healing of complicated and recalcitrant wounds, improve flap and graft survival, and even improve surgical results. This systematic review concluded that electrical stimulation is effective to accelerate wound healing and increase cutaneous perfusion in human subjects. However, there are very few studies that have examined the effectiveness of electrical stimulation to prevent DFU or reduce the risk factors associated with DFU. A recent study, by Najafi et al.,⁴⁵⁴ using a double-blind, RCT, demonstrated that daily home use of plantar electrical stimulation for people who are suffering from diabetes and peripheral neuropathy (DPN) is effective to improve plantar sensation, which is one of the key risk factors associated with DFU, as quantified by vibratory plantar threshold (VPT). In addition, this study also suggested that vascular health could be improved in the subgroup with peripheral arterial disease. Other observed significant improvements as compared to those of the control group were gait, balance and overall pain. In this study, off-the-shelf wearable technology (SENSUS, Neurometrix Inc, Waltham, MA, US) was used. This is a transcutaneous electrical nerve stimulator (TENS) system. However, the system was modified to provide electrical

stimulation (~30 milliamps) to the plantar area via two electrodes placed on the hind and forefoot area rather than the leg. Considering the lack of plantar sensation in people with DPN, this configuration seems to be more acceptable and less inconvenient. This was supported by a near to 100% compliance in daily use as a therapy, according to the survey. The study consisted of a six-week treatment phase of daily-use of plantar electrical stimulations. The outcomes were assessed every two weeks.

Electrical stimulation is not the only modality that has been suggested to be effective for wound healing or reducing DFU risk factors. Other technologies, such as low frequency ultrasound, mechanical stimulation, and pulsed radio frequency energy, have also been demonstrated to be effective in accelerating wound healing. In 2015, Lewin et al.⁴⁵⁷ demonstrated that low frequency (tens of KHz frequency) ultrasound could improve wound healing outcomes in those with chronic venous ulcer if it was used in at least three sessions. However, this study was too underpowered to be clinically conclusive. In 2012, Rawe et al.⁴⁵⁹ developed a lightweight battery-powered wearable device, which provides pulsed radio frequency energy for a duration of 6–8 hours. They suggested that daily use of this device for a period of six weeks could be effective to hasten wound healing. However, only four patients were tested using the device, and no control group was used as a comparator. Later on, in 2016, Kadry et al.⁴⁵⁶ investigated the efficacy of pulsed radio frequency energy as a physical therapy modality in the treatment of chronic lower limb ulcers. Forty patients with chronic unhealed lower limb ulcers (DFUs) for over three months participated in this study. They randomly assigned patients to two groups. The intervention group received pulsed radio frequency with a pulse width of 400 msec, 70 pulses per second with an average power of 23W for 30 minutes,

three sessions per week for six weeks, and medical care. The control group received medical care only. Their results suggested that the magnitude of the wound area reduction in the intervention group was significantly higher compared with the control group.

Very recently, the results of a prospective multicentric RCT on neuro-ischaemic DFU management using nano-oligosaccharides-impregnated dressing (sucrose-octasulfate dressing; TLC-NOSF) on top of the best practice treatment in highly specialised centres in five western European countries were published, bringing new information and evidence for the use of this component in the clinical management of chronic ulcerative pathologies in diabetic patients.⁴⁵³

In the study, which was implemented for 20 weeks, 240 DFU patients were randomised into two groups: one treated with the best standard care and the other with TLC-NOSF dressing in association with the same standard of care.

The results of this paramount study (EXPLORER), the first adequately dimensioned RCT in the field of wound dressings were extremely positive. The patients treated with TLC-NOSF showed a healing rate of 48% at 20 weeks as compared with 30% observed in the control group ($p = 0.002$). These very significant results were strengthened by those of four sensitivity analyses including a blind review done by external physicians.

Moreover, the healing time in the TLC-NOSF group showed a mean time of closure at 120 days vs 180 days in the control group ($p=0.029$). No significant differences were observed between the two groups when considering the adverse events.

This is the first time that a dressing proved its efficacy in improving healing rates and healing times in neuro-ischaemic DFU, and sucrose-

octasulfate dressing has been indicated as a paradigm shift in the local management of neuro-ischemic DFU

Wearable wound therapy using nanotechnology

Nanotechnology-based therapy is another emerging technology, which has been demonstrated as a promising next generation therapy to advance wound healing and cure chronic wounds. In a recent review, Hamdan and colleagues⁴⁰⁴ highlighted the most recently developed nanotechnology-based therapeutic agents and assessed the viability and efficacy of each treatment with an emphasis on chronic cutaneous wounds. They identified four FDA-approved therapies used for chronic cutaneous wounds, including a bioengineered human skin equivalent,²⁶⁶ two dermal substitutes^{460,462} and recombinant human platelet derived growth factor (rhPDGF).⁴⁶¹ They concluded that nanotechnology-based diagnostics and treatment approaches offer an excellent opportunity to target the complexity of the normal wound-healing process, cell type specificity, and the plethora of regulating molecules as well as pathophysiology of chronic wounds.⁴⁰⁴ The major advantage of nanomaterials over their bulk counterparts is the versatility and tunability of the nanomaterial's physicochemical properties, such as hydrophobicity, charge and size. This allows a higher probability of interaction with the biological target and an enhanced penetration into the wound site that thus accelerates the healing process.⁴⁰³

Modern wound dressing

Modern dressings are another emerging, wearable technology that could revolutionise wound management in people with diabetes. These active dressings enable a suitable microenvironment for successful healing by controlling the level of wound moisture and absorbing excess exudate.⁴⁶³ Hydroconductive dressings and biologic dressings

have also proven efficacious in advancing the wound-healing process through a variety of mechanisms.⁴¹ One of the recent developments in the area is enhancing the tissue oxygenation using dressings with continuous diffusion of oxygen. Recently, Niederauer et al.⁴⁵⁵ demonstrated in a RCT model that dressings with a continuous diffusion of oxygen are effective to improve the chance of successful wound healing at twelve weeks, in particular in those with chronic wounds. In this study, 100 subjects with DFUs were randomised to receive either active continuous diffusion of oxygen (CDO) therapy using an active CDO device or an otherwise fully operational sham device that provided moist wound therapy (MWT) with-out the delivering oxygen. The results suggested that continuously diffused oxygen over wounds leads to significantly higher rates of closure and reduced closure time as compared to similarly treated patients receiving standard therapy coupled with a sham device.

Wearables to monitor risks factors associated with poor wound healing or infection

The developed technologies were not limited to measuring those risks associated with DFU. Some recent efforts have also shown the benefits of technologies in monitoring the risks associated with a delay in wound healing and/or potential adverse events, such as infection. Aligned with these efforts, Farrow et al.⁴⁶⁴ designed a real-time sensor system to monitor bacteria levels in the wound dressings. Their device is based on impedance sensors that could be placed at the wound-dressing interface that would potentially monitor bacterial growth in real time. Impedance was measured using disposable silver-silver chloride electrodes. The bacteria *Staphylococcus aureus* was chosen for the study as a species commonly isolated from wounds. Their results suggested that the impedance profiles obtained by silver-silver chloride sensors in bacterial

suspensions could detect the presence of high cell densities, which may suggest that there is a potential to create a real-time infection monitoring system for wounds based upon impedance sensing. In 2015, Mehmood et al.⁴⁶⁵ proposed a flexible and low-power telemetric sensing and monitoring system that would enable the measuring of wound-site temperature, sub-bandage pressure and moisture levels within the wound dressing. The clinical usefulness and the impact of the device for effective management of wounds still need to be confirmed. Other studies suggest new technologies for monitoring parameters of interest associated with wound healing, including Sharp's study in 2013,⁴⁶⁶ which suggested printed composite electrodes that enable the interference-free pH measurement even in the presence of high ascorbic acid concentrations across a wide analytical range (pH 4–10) in simulated wound fluid. A few other studies suggest technologies for measuring physiological and climate parameters that may contribute to delayed wound healing. In 2010, Sharp et al.⁴⁶⁷ suggested a carbon fibre sensor for electrochemical pyocyanin detection, which could be used for intelligent infection diagnosis. In another study published in 2008, Sharp et al.⁴⁶⁸ suggested carbon fibre composites to monitor uric acid in wound fluid. However, no study has, to date, been identified to demonstrate the clinical effectiveness of these technologies for management of wounds in people with diabetes.

Wearable technologies have also been used to monitor parameters, which may indirectly impact wound healing outcomes. In 2014 Parvaneh et al.⁴⁶⁹ suggested the use of a chest-worn sensor to monitor the physiological stress response in patients with active DFU. In this study, physiological stress was continuously monitored in twenty patients with DFU for duration of approximately 45 minutes, including waiting, dressing change and the post-dressing period. Stress was quantified using a custom algorithm

based on standard deviation of R-R intervals named heart rate variability (HRV). To identify the change in the level of stress, change in HRV was compared to the baseline HRV. Medium and high-stress periods were defined when HRV was in the range of 60–85% and below 60% of baseline HRV, respectively. Their results revealed that patients with DFUs experience moderate to high stress while visiting a wound clinic. This may impact wound healing outcomes negatively. In a follow up study, Razjouyan et al.⁴⁵⁰ used a similar wearable sensor to examine whether stress could slow down wound healing. They recruited 25 patients with DFUs and monitored HRV during pre-wound dressing, using a wearable sensor attached to participants' chest. HRVs were quantified in both time and frequency domains to assess the patients' physiological stress response and vagal tone (relaxation). Change in the wound size between two consecutive visits was used to estimate healing speed. Their results confirmed an association between stress/vagal tone and wound healing in patients with DFUs. In particular, it highlighted the importance of vagal tone (relaxation) in expediting wound healing. It also demonstrated the feasibility of assessing physiological stress responses using wearable technology in an outpatient clinic during routine clinic visits.

Wearables to personalise wound care management

Recently, some efforts have been made to personalise wound care. These efforts were mainly based on measuring parameters such as moisture, pressure, temperature and pH inside the dressings, which have been shown to be indicative of the healing rate, infection, and wound healing phase.⁴⁷⁰ In 2014, Mehmood et al.⁴⁶⁵ proposed a low-power, portable telemetric system for wound condition sensing and monitoring, which enables the measurement and transmission of real-time information about the wound-site temperature, sub-bandage pressure and moisture level within

the wound dressing. The proof of concept of the system was assessed on a mannequin leg using commercial compression bandages and dressings. A number of trials on a healthy human volunteer were performed where treatment conditions were emulated using various compression bandage configurations. They have also evaluated the level of comfort for the participants. Their results suggested that this non-invasive and flexible sensing device enables wireless reporting of instantaneous changes in bandage pressure, moisture level and local temperature at a wound site with average measurement resolutions of 0.5mmHg, 3.0% RH, and 0.2°C, respectively. Effective range of data transmission was 4–5 metres in an open environment. However, the results need to be confirmed in a patient population, and its validity for assessing wound healing should be determined. In 2016, Milne and al.⁴⁷¹ proposed a wearable sensor to measure wound moisture status without disturbing or removing the dressing. The technology was designed to determine when the dressings needed to be changed. In an observational study with no alteration of the usual care, it was demonstrated that of the 588 dressing changes recorded, 44.9% were performed when the moisture reading was in the optimum moisture zone. Of the 30 patients recruited for this study, eleven patients had an optimal moisture reading for at least 50% of the measurements before the dressing change. They concluded that a large number of unnecessary dressing changes are being made. Thus, this technology may reduce the likelihood of unnecessary dressing changes and, thus, limit the disturbance of the healing process. Other measurements, which could enable personalised wound care, are wound fluid pH and wound matrix metalloproteinases enzyme activity.⁴⁷² As described above, a few studies have suggested wearable sensors to measure these metrics. However, to date, we could not identify any published papers demonstrating their clinical validity.

Some other emerging technologies to improve management of wound healing are based on capturing wounds image and analysing healthy wound healing processes. In 2015, Aldaz et al.⁴⁷³ presented the development and assessment of a hands-free image capture system named SnapCap. By leveraging the sensor capabilities of Google Glasses, SnapCap enables a hands-free digital image to be captured, tagged and transferred to a patients' electronic medical record (EMR). To evaluate of the perceived benefit of their system, they interviewed sixteen wound care nurses. They report that the features preferred by the wound care nurses are hands-free navigation features, such as barcode scanning for patient identification, double-blinking to take a photograph, and the ability of the system to allow sterile images to be captured.

Mobile health (m-health) to manage non-healing wounds

Cell phones and other consumer digital technologies have emerged as potentially powerful tools to empower patients to take care of their own chronic condition from accurate diagnosis to patient education, engaging them in their own care, monitoring the risk of DFU, and determining any complications associated with wound healing. However, many of these technologies are still in the early stages. To improve the classification of wounds in community health clinics, Ge et al.⁴⁷⁴ developed a wound information management system that was created using an acquisition terminal, wound descriptions, a data bank, and related software. In this system, a 3G mobile phone was applied as acquisition terminal, which could be used to access the data bank and determine wound classification. However, no clinical study was conducted to demonstrate its clinical value. In 2015, Parmanto et al.⁴⁷⁵ proposed a mobile app to support self-skincare tasks, skin condition monitoring, adherence to self-care regimens, skincare consultations, and secure two-way communications between patients and clinicians.

The system may help in supporting self-care and adherence to care management while facilitating communication between patients and clinicians. Wang et al.⁴⁷⁶ developed an app for analysing wound images. The developed app enables capturing wound images with the assistance of an image capture box. The software allows for the detection of the wound boundaries and determination of healing status. Mammias et al.⁴⁷⁷ proposed a smart phone as a mobile-telemedicine platform. They evaluated the feasibility and reliability of a platform based on simulating experimentation by ten specialists, who remotely examined a DF using the proposed mobile platform. They demonstrated that this platform allowed for the remote classification of a wound as well as an evaluation of the risk of amputation with an accuracy of 89% on average. In addition, the acceptability of the platform was in range of 89–100% among specialists. A similar concept was proposed by Foltynski et al.⁴⁷⁸ in which an app was designed to measure the wound area, send the data to a clinical database, and create a graph of the wound area changes over time. The team also suggested an elliptical method⁴⁷⁹ to improve wound size estimation from 16 different wound shapes. Sanger et al.⁴⁸⁰ proposed a mobile app to engage patients in wound tracking, which in turn could assist in identifying signs of wound infection. However, their study was limited to a design concept with no clinical study. An interesting application of mHealth was proposed by Quinn et al.⁴⁸¹ to improve the patient referral strategy from tertiary centres. Specifically, they proposed using mobile phone technology to decentralise care from tertiary centres into the community, improving efficiency and patient satisfaction, while maintaining the patients' safety. Their designed app enables the remote collection of patient wound images, prospectively, as well as the transmission of the image attached to clinical queries between the primary health-care team to the tertiary centre. They tested this platform with

five public health nurses in geographically remote areas of the region. They demonstrated that images could be transmitted securely and that the app is safe and reliable and could be used for remote wound bed assessment and to determine skin integrity and colour. They concluded that with minor adjustments, this application could be used across the community to reduce the necessity of patient visits at vascular outpatient clinics while still maintaining active tertiary specialist input to the patients' care.

Telemedicine/tele-monitoring in wound management

Telemedicine, also referred to as telehealth, telecare, remote care, or virtual care, has been defined as 'medicine practiced at a distance' and is mainly used for remote management of chronic disease.⁴⁸² The telemedicine interactions between the patient and the health-care provider have so far been of two types, either taking place synchronously, in real-time through video conferencing or the telephone or asynchronously, such as store-and-forward transmission of data using email. Monitoring applications have been either automatic (e.g. passive monitoring of activity using room sensors) or have required the patient to do something (e.g. transmit plantar wound pictures using buttons on a tablet or smartphone). Educational applications have employed specially designed home devices or depended on web access from PCs or smartphones.⁴⁸²

In recent years, thanks to the advances in telecommunication systems, telemedicine has emerged as one of the potentially most economic and patient-friendly methods for delivering follow-up care to patients with wounds.⁴⁸³ In addition, considering that some wounds may take months to heal and can also lead to osteomyelitis and amputation, another way to track wound healing rather than traditional clinic visits is desperately

needed. In particular, due to the shortage of wound care specialists (it is estimated that less than 0.2% of all nurses in the US are wound care specialists), it is necessary to lessen the need for consultation with wound care specialists, which has promoted the application of telemedicine particularly in remote/rural areas. In addition, in the current organisation of wound management, it is often reported that the collaboration between primary health professionals and wound specialists is not sufficient. This may cause problems with regard to ensuring timely referral practices between primary and wound specialist and health-care services. A severe consequence of this is an increased risk of emergency and hospital admission.^{435,484} Furthermore, telemedicine may assist in improving communication with wound care specialists, improving access to care, optimising patient referral, reducing the need for transportation to outpatient clinics, and potentially reducing the cost of care while improving patient satisfaction and quality of care.

Increased connectivity among people via use of smartphones, tablets and the internet has made it possible to develop and implement telecare programmes for people with diabetes and foot problems, varying from the monitoring of wound healing to consultations concerning the prevention of DFU. The use of telemedicine to manage chronic conditions is increasing worldwide due to its promise of cost-effectiveness, decreased resource consumption, as well as timely and patient-centred care. While the use of telemedicine for managing chronic conditions, such as asthma, heart failure, COPD, diabetes, and hypertension, has been well established, high-quality studies on the effectiveness of telemedicine to manage DF and wound management are scarce, which make the generalisability of most findings limited. However, in this section, an overview of telemedicine applications available for the management of DFU, which were identified via our systematic search, is provided.

Telemedicine for wound care: patient acceptability and providers' perceptions of benefits

There are very few studies that examined how the incorporation of telemedicine impacts the experiences of the patients, who are receiving wound care. In-depth knowledge of patients' experiences as well as perceptions of the care providers regarding the implementation of telemedicine intervention can help evaluate whether the use of telemedicine is an appropriate method to improve wound care. In 2016, Strom et al. used individual semi-structured interviews to study patients' experiences with telemedicine during their follow-up wound care as compared to traditional care. A total of 24 patients were recruited and randomised in the intervention group (use of telemedicine, n=13) and the control group (use of traditional care, n=11). The results demonstrated clearly that competence in the wound management by the health professionals was of great importance to patients' experience of security during their wound care, irrespective of the type of follow-up care. Specifically, patients lost confidence in the wound-care process if they doubted the competence of the health professionals and if the continuity of care was absent. They concluded that telemedicine can be an important supplement in the wound care process, but its efficacy will depend on whether it is used as intended and whether continuity of care is present. They also recommended that education and practical training in the use of telemedicine should be provided to all health professionals in primary health care and not simply to a few. In 2015, Rasmussen et al.⁴⁸⁵ explored the key organisational factors in the successful implementation of telemedicine in wound care. They conducted eight semi-structured interviews, including individual interviews with leaders, and an IT specialist, as well as focus group inter-views with clinical staff. A qualitative data analysis of the interviews was performed in order

to analyse the health professionals' and leaders' perceptions of the organisational changes caused by the implementation of the intervention. They reported that the telemedical setup enhanced confidence among collaborators and improved the wound care skills of the visiting nurses in the municipality. The need for a focus on the training of the visiting nurses was highlighted as a key factor in the success of implementation. Several concerns have also been identified, such as lack of multidisciplinary wound care teams, patient responsibility and a lack of effective patient interactions with the physician. Finally, this study concluded that telemedicine may provide an additional option to offer patients after an individual assessment of their healthy condition. In 2017, Kolltveit et al.⁴⁸⁶ conducted a qualitative study in ten focus groups to identify the perceptions of health professionals in different work settings concerning the facilitators support of engagement and participation in the application of telemedicine. They identified four key conditions for successful implementation of telemedicine for wound care, including user-friendly technology and training, a telemedicine champion located in the work setting, support of committed and responsible leaders, and effective communication channels at the organisational level. They concluded that attention to the distinct needs of each staff group is an essential condition for effective implementation of telemedicine in wound care.

Does telemedicine improve wound care and wound outcomes?

A few studies have examined the effectiveness of telemedicine to improve wound outcomes and wound care. However, convincing evidence to support the clinical efficacy of telemedicine in wound management as compared to traditional care is still lacking. In 2015, Zarchi et al.,⁴⁸⁷ using a prospective cluster, controlled study,

examined whether advice on wound management provided by a team of wound-care specialists via telemedicine would significantly improve the likelihood of wound healing compared with the best available conventional practice. A total of 90 chronic wound patients in home care, of which 50 received telemedicine care and 40 received the conventional care, were recruited. During the one-year follow-up, complete wound healing was achieved in 35 patients (70%) in the telemedicine group compared with 18 patients (45%) in the conventional group. After adjusting for several covariates, between-group differences were statistically significant with an adjusted hazard ratio of 2.19. They concluded that telemedicine is effective to connect homecare nurses to a team of wound experts in order to improve the management of their chronic wounds. In 2013, Vowden et al.,⁴⁸⁸ proposed the use of digital pen-and-paper technology and a modified smartphone to remotely monitor and support the effectiveness of wound management in nursing home residents. To demonstrate the effectiveness of this programme, they conducted a randomised, controlled pilot study conducted in 16 selected nursing homes. In these, 39 patients with a wound were identified. They reported that the proposed telemedicine care delivery system provided improved patient outcomes and that it may offer cost savings by improving dressing product selection, decreasing inappropriate onward referral and decreased healing time. They have also reported that, despite initial anxiety related to the technology, most nursing-home staff found the system of value, and many were keen to see the trial continue to form part of the routine patient management. In 2009, Terry et al. compared wound outcomes in subjects randomly assigned into three groups: Group A (n=40) received weekly visits via telemedicine consulting with a wound care specialist, group B (n=28) had weekly visits with in-person consulting with a wound specialist, and group C (n=35) received the

usual and customary care. Their results suggested that group A had increased time for healing, increased length of stay, increased costs, and more visits as compared with groups B and C despite a similar wound status in all groups. They did, however, conclude that telemedicine is a useful communication tool in wound management, but its efficacy depends on the wound size and type. They also recognised several limitations in their study, including insufficient power and a large distribution in the wound severity with-in their recruited subjects. In 2015, using a RCT study design, Ramussen et al.⁴⁸⁹ compared telemedical and standard outpatient monitoring in the care of patients with DFUs. A total of 401 cases with DFUs met the study inclusion and exclusion criteria and were randomised to telemedicine (n=119) or standard outpatient monitoring (n=181). Telemedical monitoring protocol consisted of two consultations in the patient's own home and one consultation at the outpatient clinic. Standard practice consisted of three outpatient clinic visits. The three-visit cycle was repeated until the study's endpoints. The study's endpoints were defined as complete ulcer healing, amputation or death. While a trend in increasing wound healing ratio (hazard ratio=1.11) and reducing foot amputation (hazard ratio=0.87) were found in telemedicine monitoring, these trends were not statistically significant (p>0.40). However, a mortality incident was observed in the telemedicine group (hazard ratio=8.68, p<0.001). They recommended further study to better identify these patient subgroups that may have a poorer outcome through telemedicine monitoring. In a critique of the Ramussen et al. study, Muller et al.⁴⁹⁰ shared their experience implementing telemedicine with home nurses in France. They claimed that they stopped their trial prematurely because they realised that the homecare nurses and private nurses involved in their study were not adequately trained to deal with chronic

wounds, and such training is essential for a successful implementation of telemedicine in wound care. They also claimed that this challenge was not addressed in the Ramussen et al. study. Furthermore, they claimed the quality of data and wound pictures, which are needed for an effective judgment, were not controlled in the study done by Ramussen et al. These factors may partly explain the poor outcomes observed from the telemedicine implementation in the Rasmussen et al. study. They further concluded that a successful implementation of telemedicine in wound care would require initial training and ongoing support.

Does telemedicine optimise wound care delivery and the quality of care?

Inefficiencies and communication gaps continue to hamper effective delivery of care and progress towards improving the quality of health care and improving the population's health outcomes at a lower cost.⁴⁹¹ With the rapid evolution in the health-care industry, health-care delivery organisations are leveraging innovative solutions to meet these challenges. Several studies have suggested that telemedicine is an effective tool to improve care access for patients with a need for wound care and a facilitation of the communication between wound care specialists and patients. In 2017, Turnin et al.⁴⁹² examined whether telemedicine could improve health care access in rural areas for the management of DFUs. A vehicle was equipped with a satellite dish and medical equipment for screening ophthalmological, renal, vascular, and neuropathic damage and assessing the level of risk of DF ulceration. Onboard, a nurse performed some or all of the tests on patients, who have received no diabetes care review for over a year. The data was entered into a computer and transmitted via satellite for interpretation by designated specialists. The results were sent to patients, general practitioners

(GPs), and diabetologists. Over approximately three years, 228 screening days were performed in six rural departments, in which 1545 patients were screened in whom 93.4% were diagnosed with type 2 diabetes. Pathologies were detected in 17–32% of the tests including 18.7% diabetic retinopathy, 31.9% microalbuminuria, 17.2% lower limb arteriopathy, 28.3% peripheral neuropathy, and 28.2% high risk of foot ulceration (grade 2: 20.6% and grade 3: 7.6%). They concluded that telemonitoring created an opportunity to screen a larger number of patients who are in need of urgent care and thus helped improve health-care access through its innovative organisation and the use of satellite technology. In 2016, Kolltveit et al.⁴⁹³ explored health professionals' experiences in the initial phases of introducing telemedicine technology in 10 different wound care groups, which included home-based care, primary care and outpatient hospital clinics. The participants reported experiencing meaningful changes to their practice arising from telemedicine, especially associated with increased wound assessment knowledge and skills and improved quality of documentation. They concluded that using a telemedicine intervention enabled the participating health-care professionals to approach their patients with DFUs with more knowledge, better wound assessment skills and increased confidence.

Does telemedicine reduce the cost of wound care?

The main purpose of telemedicine is to facilitate a productive interaction between the patient and the health-care provider in order to achieve improved treatment results and lower treatment costs. While, as described above, several studies have examined the benefit of telemedicine to facilitate interaction between patients and specialists and the potential benefits with regard to improved outcomes and timely care, very few studies have examined whether telemedicine could also reduce the cost of care as compared to conventional face-

to-face patient consultation. In 2013, Sparsa et al.⁴⁹⁴ proposed the use of telemedicine to manage chronic wounds (leg ulcers, PUs, and DFUs) in older adults living in retirement homes. Specifically, they explored whether telemedicine intervention for wound care could reduce the number of ambulance transportations. Of the 40 establishments invited to take part, 22 agreed to do so, but only the first 10 respondents were accepted for participation in their study. Each participating establishment was provided with a digital camera and its own secure e-mail address in order to allow photographs to be sent anonymously. To demonstrate the effectiveness of their telemedicine programme, they documented the number of tele-expertise consultations provided, the chronic wound type, the number of hospitalisations or medical consultations, and the number of ambulance trips avoided over the two years of follow-up. During this period, photographs of 34 patients presenting 26 chronic wounds, including 10 PUs, two diabetic feet and 14 leg ulcers, were sent by the recruited establishments to receive telemedicine consultations. They concluded that this programme helped avoid 20 trips for patients over a two year period, and enabled rapid hospitalisation of nine patients in the university hospital, which in turn helped to provide timely and optimised chronic wound management for patients residing in establishments for the elderly. In 2008, Dobke et al.⁴⁹⁵ evaluated the impact of the telemedicine consultations on patients with chronic wounds by recruiting 30 patients from long-term care skilled nursing facilities, referred to the ambulatory wound care programme for wound assessment and preparation of management plans. To facilitate communication with a surgical wound care specialist, telemedicine feedback was provided before the face-to-face consultation for 15 randomly selected patients out of 30 recruited patients. The telemedicine consult included a virtual consultation with a field wound nurse, who provided remote wound assessment, described the rationale for the suggested wound management

with an emphasis on wound risk projections, and explained the prevention and benefits of surgical intervention. The telemedicine impact was measured by assessing the duration of the subsequent face-to-face consultation and patient satisfaction with further care decisions as well as by a validation of a decisional conflict scale. Their results suggested a significant reduction in the duration of the face-to-face consultation time on average by 70% and an increase in the patient satisfaction rate by 46% on average. They concluded that telemedicine consultations preceding face-to-face evaluations improved patients' satisfaction and understanding of their care as well as an increase in the perception of a shared decision-making process regarding the wound care. In 2016, FASTERHOLDT et al.⁴⁹⁶ examined the cost-effectiveness of telemedicine of DFU patients using a RCT study design. A total of 374 patients were randomised to either telemonitoring or standard monitoring groups. Telemonitoring consisted of two teleconsultations in the patient's own home and one consultation at the outpatient clinic. Standard monitoring consisted of three outpatient clinic consultations. Total health-care costs were estimated over a six-month period at the individual patient level from a health-care sector perspective. Amputation rates were similar in the two groups; however, a reduction of costs—on average by €2039 per patient—was observed, thanks to telemonitoring care. However, the observed reduction in cost was not statistically significant, and it was therefore concluded that a telemonitoring service in this form had similar costs and effects as standard monitoring. In 2007, LITZINGER et al.⁴⁹⁷ examined the potential benefits of telemedicine with regard to reducing the need for wound ostomy continence (WOC) nurses' visits over a two-year prospective study design. In their study, home health aides, specifically trained in telehealth technology, assisted with the evaluations of severe wounds using video teleconferencing (VTC) equipment and advanced camera technology

that enabled the WOC nurse to evaluate wounds from a remote location. This decreased the travel time for the WOC nurse, increased the frequency of specialised wound consultations, and facilitated the development of comprehensive treatment plans for multiple patients. To estimate the cost benefits from telemedicine, they recruited 35 patients receiving multiple wound care evaluation, averaging seven visits in the first year to 11.3 visits in the second year, with a total number of virtual visits of 470. They reported that nursing visits saved by the video programme totalled 421.2 hours, reducing the health-care costs by \$9,449. Miles-not-travelled totalled 30,500, which reduced the costs by an additional \$11,875.87 (mileage reimbursement), and the travel time saved totalled 916.8 hours, which reduced the costs still further by \$20,850. After deducting the administrative cost, they claimed that the net saving of this programme was \$25,208. However, the costs of the equipment were not factored into the savings.

Is telemedicine as reliable as the in-person visit for purpose of wound care?

Very few studies have compared telemedicine care and in-person care head-to-head. Telemedicine for wound care is mainly dependent on the quality of the wound images. Even with high-quality pictures, some valuable information needed for care decisions may be limited in order to accurately determine the need for debridement or to detect signs of infection. In 2011, BOWLING et al.⁴⁹⁸ examined the ability of wound inspections using wound images in comparison with in-person wound inspections. They requested two clinicians to document some primary, clinically relevant features by reviewing 12 different wound images captured using a novel wound imaging system, which provides three-dimensional wound images, including wound area and depth. As a validation, the wounds were also inspected in a face-to-face consultation, and the results were compared

via the written notes. They reported an overall agreement between the remote and in-person assessments. However, a lower degree of agreement was identified with regard to the subjective clinical assessments, such as the value of debridement to improve healing, which was linked with the limitation of imaging techniques to capture certain characteristics, such as moisture or exudation. It was, however, reported that clinicians gave positive feedback on visual fidelity and concluded that the three-dimensional wound images could accurately measure and assess a DF wound remotely. In 2007, Binder et al.⁴⁹⁹ conducted a case series study including 16 patients with 45 leg ulcers of different origins. After an initial outpatient visit where the leg ulcers were assessed and classified, teledermatological follow-ups were performed via home care nurses. Relevant clinical information, and one to four digital images of the wound and surrounding skin, were transmitted weekly via a secure website to an expert in the wound care centre. The expert assessed the wound and made therapeutic recommendations. They claimed that 89% of transmitted images (644 out of 707) had excellent or sufficient quality for providing confident therapeutic recommendations. They concluded that the acceptance of telemedicine in wound care for recommendation of treatment by wound experts is very high, and that telemedicine offers great potential for long-term wound care.

'Internet of things' and remote management of wounds

One of the fastest developing infrastructures, promising to revolutionise the wound care industry, is the 'internet of things' (IoT).⁵⁰⁰ It is expected that 50% of health care over the next few years will be delivered through virtual platforms. This has accelerated the development of a new market named 'digital wellness', which combines digital technology and health care.⁵⁰⁰ Digital technology-based health care is regarded as a natural and ultimate choice for remote,

home-based, and long-term care for patients with chronic conditions due to its low cost, high accuracy and continuous monitoring and tracking capabilities. The IoT involves a system of devices, machines, or anything with the ability to transfer data without the need for a human to implement the communication.⁵⁰¹ Fuelled by the recent adaptation of a variety of enabling wireless technologies, such as radio-frequency identification (RFID) tags and wearable sensor and actuator nodes, the IoT has stepped out of its infancy and is the next revolutionary technology in transforming the internet into a fully integrated 'Future Internet'.⁵⁰¹ As we move from www (static pages web) to web2 (social networking web) to web3 (ubiquitous computing web), the need for data-on-demand using sophisticated intuitive queries increases significantly. What has made IoT the next big thing is not just its machine-to-machine component but the potential of sensor-to-machine interactions. With the increasing development of health sensors, there is a growing opportunity to utilise the IoT for medical data collection and analysis. It is expected that an integration of these tools into the health-care model has the potential of lowering annual costs for chronic disease management by close to one-third.⁵⁰² The use of the IoT for medical applications is, however, still in infancy. In particular, our systematic search did not identify any studies related to the application of IoT for management of DFUs. However, significant business decisions have been undertaken recently by major information and communication technology (ICT) players, like Google, Apple, Cisco, and Amazon, to position themselves in the IoT landscape. For example, in 2014, Novartis was working with Google on sensor-technologies, such as the smart lens and a wearable device to measure blood glucose levels.⁵⁰³ In 2017, Amazon teamed up with Merck and Luminary Labs on an effort called the Alexa Diabetes Challenge, with the goal of finding the ultimate way to monitor diabetes using voice-enabled solutions.⁵⁰⁴ As the IoT continues to develop, further potential is estimated

Table 23. Evaluation of evidence levels: smart technologies

No.	Therapy	Indication for use	Level of evidence (for each indication)	Comments
1	Electrical stimulation	Wound healing DFU PU VLU Mixed ulcers	1B	There is a clear effectiveness evidence, including a systematic review of 21 RCT studies that confirmed benefit and safety of TENS to accelerate wound healing irrespective of the type of ulcers. The major hurdles seem to be poor adherence to regular therapy and difficulty of stimulation parameters adjustment by none-tech savvy patients. Thus, successful implementation at large remains unclear
2	Electrical stimulation	Improving postural control and gait	2A	Recent RCT studies confirmed acceptability, safety, and efficacy of TENS for use to improve balance, gait, and skin perfusion. It seems delivering electrical stimulation via plantar region could improve acceptability and adherence particularly among people with a loss of plantar sensation, who may not feel uncomfortable tingling caused by the electrical stimulation
3	Nanotechnology-based therapy	Wound healing —chronic DFU, deep wounds, ischaemic wounds	1A	Several level one evidence studies, including few systematic reviews, are supportive of the benefit of dermal substitutes and its low risks. However, there are very few comparative studies to demonstrate which dermal substitute product is superior to the others. While in low complicated wounds, there is no noticeable difference between products, it seems the difference is more pronounced for complicated wounds, such as ischemic wounds. However, most studies excluded those with ischaemic wounds, which makes a fair comparative comparison difficult
4	Ultrasonic assisted treatment	Chronic VLU	2A	There is level two evidence (case-control) indicating the effectiveness and the low risk in its ability to accelerate wound healing
5	Pulsed radio frequency energy	VLU	1C	There few studies including a recent level one study (RCT trial) supporting the safety and effectiveness of this therapy to speed up wound healing
6	Active dressing with continuous diffusion of oxygen	Chronic and non-chronic DFU	1C	A recent RCT study and multicentre study is supportive for benefit of active dressing with continuous diffusion oxygen to speed up wound healing. However, more independent studies are needed to confirm the effectiveness of such therapy
7	Physical activity dosage management	DFU	2B	There is a recent RCT study supporting the importance of managing the dosage of physical activity including the total number of daily steps and standing bouts to hasten wound healing. However, more studies are required to confirm the ease of implementation for this guideline to hasten wound healing
8	Stress management	DFU	2C	Few recent studies suggest that stress management could speed up wound healing. However, there is no level one study to confirm the effectiveness of implementing stress management strategies to speed up wound healing

9	Mobile health	DFU	2C	Few recent studies have suggested that mobile health and smart phones could assist in improving adherence to therapy, which in turn could assist in speeding up wound healing, reducing costs, improving patients' satisfaction, monitoring outcomes, and prevention of ulcers. However, most of the studies are underpowered or poorly designed. There is no level one study to date to confirm the benefits and disadvantages
10	Telemedicine	DFU, VLU, PU, and mixed ulcers	2B	Several recent studies suggested that telemedicine could reduce costs, improve outcomes and improve patients' satisfaction. However, results are still controversial. It seems the key challenges are having access to high-quality images, which are essential for effective decision-making as well as adequate training for the staff, which is essential for successful implementation
11	Sensorised dressing		2C	Few recent studies have suggested that sensorised dressing could assist in reducing the cost of wound healing by reducing the number of dressing changes, and it could assist in reducing adverse events, such as infection, which potentially would accelerate wound healing. However, to date, no level one study exists to confirm the benefit versus the disadvantages and cost
12	'Internet of things'	DFU, VLU, PU, Mixed Ulcers	2C	Recent developments in the area of 'Internet of Things,' including voice-enabled technologies, have opened up new opportunities to effectively manage wound, assist care givers, improve communications between care providers and patients/caregivers and potentially reduce costs. However, to date, there is no quality study to confirm the benefit vs disadvantages/cost.

to be developed to facilitate the management of chronic conditions at home including effective and timely management of diabetic feet at risk as well as facilitating the delivery of care for accelerated wound healing.

Conclusions

We live in a world where technology is increasingly being integrated into almost every aspect of our lives. With the miniaturisation of processors, advancements in sensing technologies, consistent availability of electrical power, ubiquity of access to the internet, and significant strides in machine learning and artificial intelligence, new emerging solutions have been developed to improve health-care delivery, patient satisfaction, and the population's health across different

disciplines while simultaneously reducing the cost of care. Recent studies have suggested that technologies are effective to promote patient involvement, care coordination, and effective communication between patients and caregivers. Technologies, such as telemedicine and wearables, enable a reduction of in-person visits and allow physicians to remotely check in on patients, track patients' adherence to therapy, and detect early stages of serious medical conditions and triage those who are in need of immediate supervised care. Technology can be used to supplement health-care provided wound care by offering both educational and motivational support. The advances in sensing technologies enable physicians to collect valuable objective data from wounds, such as moisture levels, pH,

temperature, and many more, to track healthy wound healing, reducing unnecessary wound dressing change, providing timely intervention to prevent infection and reducing the likelihood of amputation. While, the application of such technology for effectiveness of wound care is still in its infancy, and its cost effectiveness is still debated, by the exponential speed of technology development and the exponential

increase in technology investment for health-care applications, it is anticipated that health care and care delivery

An evaluation of evidence levels for use of the therapies covered in this chapter, related to indications for use, can be found in Table 23. For chronic conditions, such as the DF, will be dramatically changed in the near future.

The economic scenario

Wound healing is a complex cascade of events that have a significant impact on patients, society and the economy.

Across Europe, 2–4% of health-care expenditure is spent on wounds; in the US, wound care affects 5.7 million people (~2% of the population) at an annual cost of US\$20 billion.⁵⁰⁵ The mean cost of treating wounds in Europe ranges from €6,000 to €10,000 per year.⁵⁰⁶ A recent study performed in Wales showed that the cost of managing patients with chronic wounds is 5.5% of the total health-care expenditure. Most of the costs are accumulated by hospital stays and nursing time dedicated to treat patients in the hospital or at home while the materials, such as dressings, represent a smaller portion of the total costs.⁵⁰⁷ The costs of wound management are different with respect to wound type, complexity and site of care. In the US, the average cost of VLU amounts to \$4,000 per month per patient; the mean cost of DFUs in 2012 ranged from \$9,650 to \$19,431.⁵⁰⁸ In the US, the cost of treating PUs is estimated to be \$11 billion/year.⁵⁰⁹ In Europe, the cost of managing DFUs is €4–6 billion/year.⁵⁰⁶ Furthermore, an important issue is represented by the incidence of complications with a significant impact on patients and the health-care system; these constitute a third of the cost drivers after hospitalisation and nursing time. These complications, such as infections, may lead to hospital admission, surgical intervention, and extended or increased use of resources.

Cost items are direct costs, such as dressings and devices, diagnostic equipment, clinician time, hospital/clinical overheads (e.g. administration

services, building costs, etc.) and transport of the patient to the health-care services. Indirect costs include the loss of income by the patients and/or their caregivers due to reduced time or ability to work, and costs due to a reduced ability to undertake domestic responsibilities⁵¹⁰ (Table 24). An important driver of cost is represented by the necessity of changing dressings several times during the week. The wound care also creates a human cost, such as a decrease in the physical, mental and social wellbeing that can affect families and caregivers, as well as the patients. Wound management is complex, prolonged and expensive. In this scenario, it is necessary to reflect on the role and contribution of advanced wound dressings. If the advanced treatments are often more expensive than traditional ones, it might make sense to use these products when the traditional therapy is not efficient and effective and has not reached the defined clinical and economic outcomes.

Since the turn of the 20th century, medical innovation has produced extraordinary improvements both in the diagnostic fields and in the therapeutic fields, contributing to an improvement in the quantity and quality of patients' lives. On the economic side, the growing number of procedures, the aging of the population and, most importantly, the chronic nature of many diseases, which were previously fatal up until now, are driving up health-care costs and raising serious concerns over the economic sustainability of the health-care systems. In this context, the role of the economic evaluations in health care as 'the comparative analysis of

Table 24. Cost of items related to hospitalisation⁵¹⁰

<p>Initial patient and wound assessment</p>	<ul style="list-style-type: none"> • Clinician time • Facility cost • Diagnostic tests • Laboratory test • Dressing, drugs and other disposable • Patient and carer travel time • Patient out of pocket payments • Patient/carer lost work time
<p>Wound treatments</p>	<ul style="list-style-type: none"> • Clinician time for dressing changes • Facility cost • Clinician travel time • Dressings, drugs and other disposables • Antibiotics • Diagnostics and laboratory tests • Special equipment • Patient and carer travel time • Patient out of pocket payments • Patient/carer lost work time
<p>Inpatient costs</p>	<ul style="list-style-type: none"> • Inpatient bed days • Dressings, drugs and other disposables • Antibiotics • Diagnostic and laboratory tests • Surgical procedures • Rehabilitation costs • Outpatient follow-up visits • Special equipment • Patient out of pocket payments • Patient/carer lost work time

alternative courses of action in terms of both their cost and consequence’ is becoming more and more important in supporting the decision-makers at the European, country and the local level with respect to the technologies to invest in and reimburse with available resources.^{511,512} There is an increasing need for scientifically robust cost and resource-use studies. Currently, there are few studies with regard to wound management, and there is confusion as to how these studies should be performed, especially with regard to endpoints and resource use. Furthermore, there is a limited number of health economic studies on advanced therapies that conduct a cost-effectiveness analysis. The selected economic studies on advanced therapies are presented below.

Health economics of advanced technologies

For the purpose of this document, a literature search was performed in major clinical and economic databases, such as Pubmed, Embase and Cochrane. Of the 14 economic articles retrieved, two focused on cell/tissue therapy, seven on materials and dressing, four on physical therapy and one on smart technology.

The paucity of economic studies on cell/tissue therapy, physical therapies and smart technology underlines how the economic evaluation of these fields is still under/unexplored. In the area of advanced physical therapies, no studies on electromagnetic fields, show waves and

photobiomodulation have been yet performed. Only one economic study has been performed on nanotechnology.

In February 2018, research into the economic aspects of the use of wearable technologies and telecommunication to manage patients with DFUs and wounds in people with diabetes was conducted, and that one article was included.

Economic impact of cell/tissue therapy

In cell/tissue therapy, four cost-effectiveness analyses were retrieved.^{513,514} The cost-effectiveness and the comparative analysis were focused on DFUs and VLUs treatments using cellular/tissue skin substitutes: Apligraf, Dermagraft and OASIS (Table 25).

The cost-effectiveness study conducted by Carter et al.⁵¹³ compared Apligraf (HSE), Dermagraft (LSE) and OASIS (ECM) used as adjunct therapies to standard of care (SC) with standard of care alone (compression therapy) for VLUs over a period of one year. A Markov model derived from the four RTCs and wound care specialists' interviews were developed. The final model outputs included cumulative costs, clinical outcomes as ulcer-free weeks and the incremental cost-effectiveness ratio (ICER). Regarding the clinical outcome, ulcer-free weeks were 31 for OASIS, 24 for standard of care, 29 Apligraf and 27 Dermagraft. With respect to the costs, Dermagraft showed a higher expected cost of \$11,237, followed by Apligraf \$10,638, OASIS at \$6732 and standard of care at \$6132.

Although wound closure time was similar among the three skin products, costs for the application of the product were substantially higher for Apligraf (\$1578) and Dermagraft (\$1518) than for OASIS (\$152).

The direct costs include initial and established clinic visit costs, cellular and/or tissue-derived

products costs, prescription drugs costs, hospitalisation costs, home health-care costs, and compression stockings costs. Indirect costs were not evaluated. The data cost is based on Medicare's national average reimbursement rates. However, the probabilistic sensitivity analysis showed that OASIS is economically dominant with lower total costs and better clinical outcomes compared with the other two products. The ICER for OASIS relative to standard care was approximately \$86 per ulcer-free week. This indicates that if a patient is willing to pay an additional \$86 (approximately \$12/d), he/she will gain one additional ulcer-free week. This work is one of the first to investigate the cost-effectiveness of three different cell/tissue substitutes in the management of VLUs.

A second cost-effectiveness study compared two cellular/tissue-derived products presented in the previous article. The number of the medical devices, type of chronic wounds, the length of the study and the country were different when compared with the previous study.

Gilligan et al.⁵¹⁴ determined the cost-effectiveness of OASIS and Dermagraft on DFU wound closure. A Markov model was developed to compare the costs and outcomes of OASIS versus Dermagraft using data from a 12-week, randomised clinical trial. The clinical outcome was an average wound closure time of 36 days for OASIS and 41 days for Dermagraft. There was no significant difference between these results. The average cost is \$2522 for OASIS and \$3889 for Dermagraft. In this study, direct costs have been considered as costs for low and high-cost substitutes, cost of hospital established clinic visit, physician rate skin substitute application, cost for application of a skin substitute, physician rate evaluation and management visit level. The perspective of the analysis is the third person payer perspective, specifically the centres for Medicare and Medicaid services. The total treatment cost using Dermagraft

Table 25. Cells and tissues

Author year	Country	Condition	Treatment	Objective	Methods
Gilligan et al. ⁵¹⁴ 2015	US	DFUs	OASIS ECM Dermagraft LSE	Determine cost-effectiveness of OASIS relative to Dermagraft for the treatment of DFU	A Markov model was developed to compare the costs and outcomes of OASIS vs Dermagraft using data from a randomised clinical trial. Time horizon: 12 weeks Perspective: third-party payer
Carter et al. ⁵¹³ 2014	UK	VLUs	Three cellular tissue derived products (CTPs): -OASIS (ECM), -Apligraf (HSE), -Dermagraft (LSE) vs. standard of care (compression therapy)	Develop a cost-effectiveness model derived from a systematic literature review to compare three CTPs used as adjunct therapies to SC to SC alone	A three-state Markov model derived from the medical literature was developed. 10 studies: <ul style="list-style-type: none"> • 5 used to populate the clinical outcomes • 5 used to supply information on health economic, resource use, and ulcer recurrence. Time horizon: one year Perspective: payer
Marston et al. ⁵¹⁵ 2014	USA	VLU	Two cellular/tissue derived products (CTPs): -OASIS (ECM), -Apligraf (BLCC)	Compare the effectiveness of BLCC and SIS for the treatment of VLUs	Using de-identified EMRs from wound care facilities across the US for a three-year period
Rice et al. ⁵¹⁶ 2015	USA	DFU	Two cellular/tissue derived products (CTPs): -Apligraf (BLCC), -Dermagraft (HFDS) vs standard of care	To assess the real-world medical services use and associated costs of Medicare patients with DFU treated with BLCC or HFDS compared with those receiving conventional care (CC)	DFU patients were selected from Medicare de-identified administrative claims using ICD-9-CM codes. The analysis followed an 'intent-to-treat' design, with cohorts assigned based on use of BLCC, HFDS, or CC from 2006–2012. Propensity score models were used to separately match BLCC and HFDS patients to CC patients with similar baseline demographics, wound severity, and physician experience measures (matched pair analysis). Medical resources used during the 18 months following treatment initiation were compared among the resulting matched samples

No. patients	Costs/outcome	Results
<p>40 patients screened. 26 of the 31 patients who met the inclusion criteria completed the study 12 in OASIS group 12 in Dermagraft group</p>	<p>Only direct medical costs of care:</p> <ul style="list-style-type: none"> • costs for low and high-cost substitutes, • cost of hospital established clinic visit • physician rate skin substitute application • cost for application of a skin substitute, • physician rate evaluation and management visit level two. <p>Clinical outcomes: number of ulcer-free weeks. Total cost:</p> <ul style="list-style-type: none"> • 2,522\$ ECM • 3,889\$ LSE <p>Outcome: average days wound closure time</p> <ul style="list-style-type: none"> • 36 ECM • 41 LSE <p>No significant difference</p>	<p>ECM yielded similar clinical outcomes to LSE, but a lower cost, with an additional cost savings of more than 1,360\$.</p>
<p>No patients</p>	<p>Cost</p> <ul style="list-style-type: none"> • Initial clinic visit • Established clinic visit • Cellular and/or tissue-derived products • Prescription drugs • Hospitalisation costs • Home health care costs • Compression stockings. <p>Total cost: SC= 6,133\$ ECM+SC=6,732\$ HSE+SC=10,638\$ LSE+SC=11,237\$</p> <p>Clinical outcomes: number of ulcer-free weeks</p>	<p>OASIS is the most cost-effective CTP when used in the management of VLU as an adjunct to standard care</p>
<p>ECM Group n=302 BLCC Group n= 1187</p>	<p>19-week difference in median healing time (week 24 vs 43) in the current analysis should result in substantial cost savings (between \$7,000 and \$10,000 additional savings) Difference in healing time was significant p=0.01</p>	<p>More BLCC patients healed faster in a shorter period of time, using significant fewer treatment applications as compared to ECM</p>
<p>BLCC & CC, n=502 HFDS & CC, n=222</p>	<p>Increased costs associated with outpatient service use relative to matched CC patients were offset by lower amputation rates (-27.6% BLCC, -22.2% HFDS), statistically significantly (p<0.05) fewer days hospitalised (-33.3% BLCC, -42.4% HFDS), and emergency department visits (-32.3% BLCC, -25.7% HFDS) among BLCC/HFDS patients</p>	<p>Consequently, BLCC and HFDS patients had per-patient average health-care costs during the 18-month follow-up period that were lower than their respective matched CC counterparts (-\$5,253 BLCC, -\$6,991 HFDS)</p>

is approximately 54% higher than using OASIS. Although this study is different in duration, number of medical devices, and pathology from the previous one, it also demonstrated that OASIS yields similar clinical outcomes relative to Dermagraft at a lower cost.

Martson et al.⁵¹⁵ used wound care specific electronic medical records (NetHealth) from 158 wound centres to compare the effectiveness of a bilayered living cellular construct (BLCC) and an acellular porcine small intestine submucosa collagen dressing (SIS) for the treatment of VLU. Data from 1489 patients with 1801 refractory VLUs (as defined by failure to have >40% reduction in size in the four weeks before treatment) with surface areas between one and 150cm² in size, who were treated between July 2009 and July 2012 at 158 wound care facilities across the US, were analysed. Patients' baseline demographics and wound characteristics were comparable between the groups. Kaplan-Meier-derived estimates of wound closure for BLCC (1451 wounds) was significantly greater ($p=0.01$, log-rank test) by weeks 12 (31% versus 26%), 24 (50% versus 41%), and 36 (61% versus 46%), respectively, compared with SIS (350 wounds). BLCC treatment reduced the median time for wound closure by 44%, achieving healing 19 weeks sooner (24 versus 43 weeks, $p=0.01$, log-rank test). Treatment with BLCC increased the probability of healing by 29% compared with porcine SIS dressing (hazard ratio=1.29 [95% confidence interval 1.06 to 1.56], $p=0.01$). The authors concluded that the 19-week difference in median healing time (week 24 versus 43) in the current analysis should result in substantial cost savings (between \$7000 and \$10,000 additional savings), considering that each additional week for non-healed ulcers may cost more than US\$377 per week.

Rice et al.⁵¹⁶ analysed DFU patients, who were selected from Medicare deidentified administrative

claims using ICD-9-CM codes. The analysis followed an 'intent-to-treat' design, with cohorts assigned based on the use of (1) BLCC, (2) HFDS, or (3) CC (i.e., ≥ 1 claim for a DFU-related treatment procedure or podiatrist visit and no evidence of skin substitute use) for treatment of DFU in 2006–2012. Propensity score models were used to separately match BLCC and HFDS patients to CC patients with similar baseline demographics, wound severity, and physician experience measures. Medical resource use, lower-limb amputation rates, and total health-care costs (2012 USD; from payer perspective) during the 18 months following treatment initiation were compared among the resulting matched samples. Data for 502 matched BLCC-CC patient pairs and 222 matched HFDS-CC patient pairs were analysed. Increased costs associated with outpatient service utilisation relative to their matched CC patients were offset by lower amputation rates (–27.6% BLCC, –22.2% HFDS), statistically significantly ($p<0.05$) fewer days hospitalised (–33.3% BLCC, –42.4% HFDS), and emergency department visits (–32.3% BLCC, –25.7% HFDS) among the BLCC/HFDS patients. Consequently, BLCC and HFDS patients had per-patient average health-care costs during the 18-month follow-up period that were lower than their respective matched CC counterparts (–\$5253 BLCC, –\$6991 HFDS).

Economic impact of materials

Selected articles related to the materials have presented differences in terms of condition, treatment and methodology: six articles covered studies performed in Europe (UK, Germany, France, Italy and Spain) and two were conducted in the US; five papers covered VLUs, one covered DFUs, one examined chronic wounds with exposed bones and/or tendons due to trauma, and one reviewed postoperative wounds (Table 26).

In the field of dressings which stimulate wound healing, a German study performed by Augustin

et al. evaluated the cost-effectiveness of two neutral foam dressings (UgroCell versus UgoStart) used in the hydroactive treatment of exuding chronic wounds in venous and mixed leg ulcers.⁵¹⁷ The innovative foam dressing UgoStart is based on the same matrix and carrier of the standard of care (SC) including lipo-colloid technology (TLC) plus a nano-oligosaccharide factor (NOSF technology). This technology is able to inhibit supernatant MMPs, which are responsible for the lack of extracellular matrix compound synthesis and the persistence of an inappropriate local inflammatory process. Cost-effectiveness analysis was carried out from a German statutory health insurances perspective using a decision tree model for a period of eight weeks. Clinical outcomes and resulting costs obtained by the clinical trial have been combined.⁵¹⁸ The study included 187 patients (93 on UgoStart and 94 on SC) with venous and mixed leg ulcers. After eight weeks of treatment, the trial showed an average reduction of wound size of 6.9cm² in the top of care versus 2.6cm² in the comparator. The primary endpoint of the study was the reduction of wound size within eight weeks: 65.6% for UgoStart and 39.4% for the standard of care. The economic model included only direct medical costs, such as cost of nursing, wound care products, medical devices, hospital treatment, outpatient care and pharmacotherapy costs. In the model, the total treatment costs for eight weeks were €557.51 in the UgoStart group as compared with €526.17 in the SC group, resulting in a mean difference of €31.32. Effect-adjusted costs advantage generated were €485.64 in the advanced therapy, UgoStart, coming from an effect-adjusted costs of €849.86 in UgoStart and €1335.51 in the SC.

The clinical trial designed by Meaume et al.⁵¹⁸ illustrated that the advance foam dressing with Nano-oligosaccharide factor accelerates wound healing two times faster as compared with the non-NOSF foam dressing. The effect-adjusted costs

demonstrated that UgoStart is superior in cost-effectiveness to the SC. Furthermore, the quality of life for the patients was also explored showing significant improvement in the advanced therapy group for two of the five dimensions, pain-discomfort and anxiety-depression.⁶⁵

Guest et al.⁵²⁵ used a decision model to estimate the clinical outcome and the cost-effectiveness of using a skin protectant compared with not using a skin protectant in the management of VLU. Patients' data was derived from The Health Improvement Network (THIN) database. Patients had their first diagnosis between January 2008 and December 2009. The number of patients included was 510: 255 patients received a Cavillon formulation (166 Cavillon no sting barrier film (NSBF), 89 received a Cavillon durable barrier cream (DBC)), and 255 received no skin protectant. The model showed a significant difference among groups in terms of the reduction of the wound size (NSBF: 31%, DBC: 23% and control: 9%, p<0.001). Mean six-monthly NHS cost of resource use per patient did not present significant differences since the cost was about £2200 in all groups. There were no significant differences in clinical outcomes. The therapy with NSBF was the preferred treatment as it leads to a significant reduction in the wound size. Like the Guest study, the study performed by Panca et al.⁵²⁴ was based on patients' data collected from the THIN database. It evaluated the clinical outcome and the cost-effectiveness of using sodium carboxymethylcellulose dressing (CMC) and four superabsorbent dressings (Dry Max Extra (DM), Filvasorb (F), Kerramax (K) and sachet (S)) in the treatment of highly exuding VLUs. The study showed that the cost-effective therapy was the S: the six-month NHS cost of managing VLUs was £3700 per patient, which was 15–28% lower with respect to the other treatments and more QALYs. The Italian study by Romanelli et al.⁵²¹ aimed to assess the cost-effectiveness of single-layer ECM in addition to SC (petrolatum-impregnated gauze)

Table 26: Materials cost studies

Author	Country	Condition	Treatment	Objective	No. patients
Guest et al. ⁵¹⁹ 2017	US	DFUs	OASIS Ultra + SC (silver dressing, hydrogel, wet-to-dry dressing, alginate dressing, Manuka honey and triple antibiotic dressing) vs SC alone	Estimate the cost-effectiveness of using Oasis Ultra as an adjunct to SC compared with SC alone in managing DFUs in the US over 12 months after the start of treatment	Adult patients with diagnosis of type 1 or 2 diabetes mellitus
Nherera et al. ⁵²⁰ 2016	US	VLUs	Cadexomer Iodine (topical antimicrobial dressing) plus SC vs SC alone (compression bandages)	To estimate the clinical and cost difference between Cadexomer+SC vs SC alone according to payer's perspective	No patients
Romanelli et al. ⁵²¹ 2016	Italy	Mixed arterial/venous (AVV) or VLUs	Single layer extracellular matrix (ECM) as an adjunct therapy to standard of care (SC) compared with standard care alone (compression therapy, debridement and maintenance of a moist wound environment)	To assess the cost effectiveness of single layer ECM plus SC vs SC	ECM group: 25 patients SC: 23 patients
Arroyo et al. ⁵²² 2015	Spain	Post-operative wounds.	Polyurethane film surgical dressing vs gauze surgical dressings	To evaluate the clinical and cost-effectiveness of polyurethane film with absorbent pad (OPQV) respect to the use of gauze and tape	416 patients (15 hospitals): <ul style="list-style-type: none"> • 199 gauze/tape group • 217 polyurethane film group

Methods	Costs	Results
<p>A Markov model was constructed based on patient-level data obtained from clinical trial:</p> <ul style="list-style-type: none"> information pertaining to patient management from the clinical authors published literature <p>Perspective: Medicare</p>	<p>The model only analysed direct health-care costs borne by Medicare and excluded direct costs incurred by patients and indirect costs incurred by society as a result of employed patients taking time off work.</p> <p>Total costs: 13,962.23\$ SC vs 13,857.61\$ OA-SIS+SC</p>	<p>The use of OASIS instead of standard care alone improves outcome for less cost and OASIS was found to be a dominant strategy when compared with starting treatment with SC alone</p>
<p>Markov model to simulate the expected cost and outcomes of managing VLU. Outcomes (wound healing, infection rate, HQOL and health resource use) over one year</p>	<p>Expected healing rates at 52 weeks: Cadexomer: 61% SC: 54% Ulcer-free weeks: Cadexomer: 25 SC: 19 Expected total cost at 52 weeks: Cadexomer: \$7901 SC: \$7259 QALYs at 52 weeks: Cadexomer: 0.82 SC: 0.86</p>	<p>Cadexomer iodine+SC is dominant treatment for chronic VLUs. It is needed to perform prospective, controlled clinical studies to confirm the results of the study</p>
<p>Data derived from an eight-week RCT of patients with VLU or mixed A/V ulcer: 50 patients (23 with A/V and 27 with VLU) visited in outpatient setting at University of Pisa</p> <p>Markov model to compare clinical outcomes and costs of ECM vs SC using wound closure rates to estimate n. closed wound weeks and A/V and VLU cost per patient</p> <p>Costs came from standard cost references and medical supply in US</p> <p>Perspective: third payers</p> <p>Direct medical costs (2015 US dollars)</p>	<p>Wounds healed after eight weeks: ECM: in 5.4 weeks; SC: 8.3 weeks Complete wound closure: ECM: 80% (20 pts); SC: 65% (15 pts) Expected cost per ulcer at the end of 32 weeks: ECM: \$2527; SC: \$2540 ICER: \$-3.75</p>	<p>ECM provides better clinical outcome at a slightly lower cost</p>
<p>Primary endpoint: rate of superficial site surgical infection</p> <p>Secondary endpoints:</p> <ul style="list-style-type: none"> rate of complications related to the surgical dressings used number of dressings changes during patient's hospital stay <p>Dressing performance: Likert scale from 0 to 4</p>	<p>Economic analysis base on the outcome of the study. Infection rate refers to a hypothetical cohort of 1000 surgical patients treated with either polyurethane film and with gauze/tape.</p> <p>Direct costs of postoperative management of surgical site Gauze/tape: €22,350; OPOV: €12,740 The difference is due to the nursing time costs (€19,350 in gauze vs €7740 in OPOV) Cost of managing superficial SSI Gauze/tape: €59,400; OPOV: €22,400 Difference due to cost of hospitalisation (€46,200 in gauze vs €19,600 in OPOV) and antibiotic treatment (€13,200 vs €2,800)</p>	<p>The use of polyurethane film can significantly reduce the rate of surgical site infections and other type of wound complications respect to the use of gauze and tape.</p> <p>In gauze/tape group the incidence of surgical wound was 6.6% vs 1.4% in OPOV group.</p> <p>The perception of professionals and patients is significantly better respect to polyurethane film vs gauze/tape (p<0.001)</p>

Table 26: Materials cost studies (continued)

Author	Country	Condition	Treatment	Objective	No. patients
Guest et al. ⁵²³ 2015	France Germany UK	Chronic wounds with exposed bones and/or tendons due to trauma	Polyheal (non-biodegradable, chemically inert, synthetic, negatively charged 5-micron polystyrene microsphere) vs surgery	To assess the cost-effectiveness of using Polyheal vs surgery	No patients
Augustin et al. ⁵¹⁷ 2014	Germany	VLU	UrgoStart (U) vs UrgoCell (SC)	Evaluate cost-effectiveness of NOSF (nano-oligosaccharide factor) containing wound dressing (U) in vascular leg ulcers compared with SC (without NOSF) for eight weeks	187 patients: <ul style="list-style-type: none"> • 93 U • 94 SC
Panca et al. ⁵²⁴ 2013	UK	VLU	Sodium carboxymethyl-cellulose dressing (CMC) and four superabsorbent dressings (DryMax Extra (DM), Flivasorb (F), Kerramax (K) and sachet (S))	To evaluate the clinical and cost-effectiveness of using CMC and four dressings	
Guest et al. ⁵²⁵ 2012	UK	VLU	Skin protectant: Cavillon No Sting Barrier Film (NSBF) or Cavillon Durable Barrier Cream (DBC) vs not using a skin protectant.	To assess the clinical and cost-effectiveness of skin protectant vs not using skin protectant	

compared with SC alone for patients with VLUs and mixed arterial/venous ulcers. Clinical data were derived from an eight-week randomised clinical trial (RCT) of adults ≥ 18 years with VLUs or mixed A/V ulcer. Patients were randomised to a ECM group (n=25) or a standard of care group (n=23) and were followed monthly for 32 weeks

to assess wound closure. Economic data originated from Markov models were developed to compare the clinical outcome and costs of ECM versus SC using wound closure rates and expected VLU and mixed A/V ulcer cost per patient. The study did not present significant differences in terms of costs, but ECM was more clinically effective with respect

Methods	Costs	Results
Three decision models based on published clinical outcomes related to surgery; predicted healing rates with Polyheal derived from clinical studies, and patient pathway and associated health-care resources derived from interviews with clinicians	Initial management Total health care costs (€2010/2011) per patient Polyheal vs Surgery France: €7984/€12,300 Germany: €7571/€18,137 UK: €8860/€11,330 Polyheal group: Primary cost driver Nurse visits: 36% in France and 42% in UK Surgery and hospitalisation: 50% of total in Germany Surgery group: Primary cost driver Hospitalisation 72% in France; 67% in Germany; 69% in UK	Polyheal potentially provides a cost-effective treatment in France, Germany and UK respect to surgery but it is dependent on Polyheal's healing rates in the clinical practices in terms of when it will be commonly available
Decision analytic model based on clinical outcomes and costs by a two arm, randomised, multicentred phase III study conducted in France but with real-world conditions in Germany. Perspective: German statutory health insurance	Direct medical costs: Costs for nursing; wound care products; medical devices; hospital treatment; ambulant care; pharmacotherapy	Wound size reduction: 65.6% U vs 39.4% SC Total treatment costs: 557.51€ U vs 526.19€ SC (difference: 31.32) Effect-adjusted costs: 849.86€ vs 1335.51€ Difference: 485.64 U is cost-effective
Decision model based on patients' data from a database	Mean 6-monthly NHS cost of resources per patient (2010/2011 prices): CMC: £2452.8; DM: 4346.7; F: £5127.6; K: 4768.1; S: £3647.3 Primary cost driver: practice nurse visits CMC: 33% of total; DM: 22%; F: 14%; K: 19% S: 19% Community nurse visits: range from 42% in CMC and 64% in F.	The use of S is lower costly: over 6 months of the start of treatment with S, the NHS cost of venous leg ulcer management is -£3,800 (15-28% less than the cost of other super-absorbent).
Decision model based on case records of cohort of matched patients from a database First diagnosis: between January 2008 and December 2009	Mean 6-monthly NHS cost of resources per patient (2009/2010): DBC: £2152.88; NSBF: £2245.02 Control: £2234.18 Main driver cost: practice nurses visits (58% of total costs in 3 groups) Dressings costs are higher in control group and accounted for <10% of the total cost.	NSBF leads to significantly greater wound size reduction respect to other groups (31% vs 23% in DBC and 9% in control).

to SC as the number of open-wound weeks was lower (six weeks versus 10 weeks); and complete wound closure was significantly higher in patients with ECM ($p < 0.05$). The study of Nherera et al.⁵²⁰ used a Markov model to compare the expected cost and outcomes of managing patients with VLU with a topical antimicrobial dressing (Cadexomer

Iodine (CI)) plus compression bandages (standard of care) versus standard of care alone. Patients treated with CI-SC experienced 25 ulcer-free weeks and 0.86 QALYs versus 19 ulcer-free weeks and 0.82 in SC group. Total cost per patient in CI+SC treatment over 52 weeks was \$7259 versus \$7901 in the standard of care. The authors affirmed that

prospective, controlled clinical studies were needed to confirm the results of their study.

A recent study performed by Guest et al.⁵¹⁹ assessed the cost-effectiveness of using adjunctive porcine small intestine submucosa tri-layer matrix (SIS), a three dimensional biomaterial consisting of a biocompatible, acellular, collagen-based extracellular matrix, as adjunct to SC versus SC alone (one of the following: silver dressing, hydrogel wet-to-dry dressing, alginate dressing, Manuka honey and triple antibiotic dressing) in patients with DFUs according to Medicare's perspective. This was a decision-modelling study populated with data derived from a clinical trial, information related to the patients obtained from the clinical authors, and published literature. The Markov model simulated the management of diabetic neuropathic lower extremity ulcers over a period of one year in US. The effectiveness measures were the number of ulcer-free months, probability of having a healed ulcer at twelve months, probability of avoiding a complicated ulcer at 12 months and probability of avoiding an amputation over 12 months. At 12 months after start of treatment, the use of adjunctive SIS instead of SC alone led to a 42% increase of number of ulcer-free months, a 32% increase in the probability of healing, a 3% increase in the probability of avoiding a complicated ulcer and a 1% increase in the probability of avoiding an amputation.

Expected health-care costs (2016 prices) over the 12 months after the start of therapy amount were at \$13,857.61 in adjunctive SIS and \$13,962.23 in SC alone. Debridement procedures represented 42% of the total cost in SC alone and SIS application 22% in the SIS group. SIS plus SC improved clinical outcomes for less cost.

A study performed by Guest et al.⁵²³ assessed the cost-effectiveness of using Polyheal compared

with surgery in chronic wounds with exposed bones and/or tendons due to trauma in France, Germany and UK from the payer's perspective. Total health-care cost following initial use of Polyheal were €7984 in France, €7517 in Germany and €8860 in UK; total health-care costs after surgery were €12,300, €18,137 and €11,330, respectively. Polyheal resulted in a dominant treatment in each country as compared with surgery. These results will be dependent on Polyheal's healing rate in clinical practice when the product becomes more accessible.

Arroyo et al.⁵²² compared the clinical outcomes and cost-effectiveness of using polyurethane film surgical dressing (OPOV) versus gauze surgical dressings in postoperative care. The study involving 416 patients (OPOV group=217, gauze=199) in 15 Spanish hospitals had as a primary endpoint the rate of superficial surgical site infection (SSI) during initial hospitalisation and as a secondary endpoint the rate of complications related to the surgical dressing used and the number of dressing changes during the hospital stay. Data showed that the polyurethane film dressing had a significant reduction of SSI (1.4% versus 6.6% in gauze, $p=0.006$). The unit of cost of the polyurethane film dressing was higher in respect to gauze/tape, but the polyurethane film was associated with fewer dressing changes which implies a reduction of auxiliary dressings and nurse time.

Economic impact of physical therapies

Table 27 presents four papers related to the physical therapies for VLU treatment. In the arena of electromagnetic fields, no economic evaluation studies were available. In literature concerning the externally applied electrocutaneous device in managing VLUs, two studies on electric fields were found.

The aim of the first study performed by Taylor et al.⁵²⁷ was to evaluate the cost-effectiveness

of treating patients with chronic, non-healing VLU's using electric stimulation (ES) (AccelHeal) therapy in addition to dressings and compression bandaging from an NHS perspective in the UK. A Markov model spanned a period of five months, which was the maximum period in which patients were followed. Clinical evaluation of ES therapy among 22 patients with chronic, non-healing VLU's was performed. Data originated from patient's case report forms completed during the clinical evaluation were evaluated to measure clinical outcomes and the use of health-care resources for each wound. Furthermore, data over a period of six months before the start of ES treatment from the patients' medical records were considered. The model estimated the cost-effectiveness of ES therapy based on 2008–2009 prices.

Patients receive three units of ES therapy in addition to dressings and compression bandaging; during the clinical evaluation, patients continued to use the same bandages and dressings used before the start of ES therapy.

The model generated two measures of cost-effectiveness as an expected probability of being healed and the expected number of QALYs at five months after ES therapy. The expected outcomes at five months after the start of electric stimulation therapy reported that 38% of all wounds were expected to heal in the ES plus dressings and compression with respect to 9% in the previous care plan. The use of ES therapy can lead to a 27% reduction of required nurses' visits (from 49.0 to 35.9 visits per patient) and a minor reduction in the number of bandages required from 7.9 to 3.5 (–56%). These improvements were expected to lead to a 6% of health gain of 0.0017 QALYs over five months.

From an economic standpoint, the expected total health-care costs at five months from the start of ES therapy were £748.94 in the ES plus dressings

and bandaging versus £879.90 in the patients without ES (difference £131). The cost of electric stimulation amounted to £120 (£40 per unit) and represented 16% of the total health-care costs. The nurse visits amounted to 67% in the ES plus dressings and compression bandaging versus 77% in the dressings and compression bandaging alone. With respect to cost-effectiveness analysis, the ES therapy was a dominant treatment and potentially afforded the NHS a cost-effective treatment for patients with chronic venous ulcers of >6 months duration, depending on the number of ES therapy units, the unit cost of the device, and the number of required nurse visits.

A study performed by Guest et al.⁵²⁶ evaluated the cost-effectiveness of treating patients with VLU using an applied electroceutical device (EAE) (AccelHeal) in addition to dressings and compression bandaging according to the NHS in the UK.

The aim of the prospective, single-arm, non-blinded study was to estimate clinical outcomes, cost impact and cost-effectiveness of EAE therapy in patients affected by VLU's in 2013–2014. Data associated with the wound over 12 months before the start of EAE therapy were compared with the first twelve months after the start of the therapy.

Professionals involved were 13 nurses based at 11 centres of which six centres were community-based clinics, and five were hospital outpatient clinics. Patients involved (n=28) were treated with six active units of EAE therapy (each unit for two days) plus dressings and compression bandaging over 12 days. Hereafter, the patients were treated with dressings and bandages. Data collected over a period of 12 months from the start of the therapy included age, gender, wound duration, wound size, pain, exudate levels (classified as low, medium or heavy), clinical visits and the use of bandages and topical treatments. This data was compared with the information collected from the patients'

Table 27: Physical therapies cost studies

Author	Country	Condition	Treatment	Objective
Guest et al. ⁵²⁶ 2015	UK	VLU	Externally applied electroceutical (EAE) device+dressing+compression vs combination dressing+ bandage (SC)	Estimate cost-effectiveness of treating patients with VLU with an EAE device plus dressings and compression bandaging VS SC
Zhou et al. ⁵⁰⁸ 2015	US	<ul style="list-style-type: none"> • VLU, • traumatic/ surgical wounds (SW) • PU • DFU • Other type (OT) 	Primary treatment: 45 minutes of high voltage pulsed current electric therapy. Occasionally: <ul style="list-style-type: none"> • whirlpool therapy • ultrasound • ultraviolet C therapy (UVC) 	Calculate the healing rates, the costs and time required for closure wound care (CWC) to assess the cost difference between healing and non-healing wounds and to compare cost-effectiveness between VLU and non-VLU as DFU, PU, OT in a PT outpatient wound care clinic in US
Taylor et al. ⁵²⁷ 2011	UK	Non-healing VLS	Externally applied electroceutical (EAE) device+dressing+compression VS combination dressing+ bandage (SC) of >6 months duration	Estimate cost-effectiveness of treating patients with non-healing VLU with an EAE device plus dressings and compression bandaging vs SC

VLU—venous leg ulcer; PU—pressure ulcer; DFU—diabetic foot ulcer

clinical records over the 12 months before the start of the EAE treatment. A computer-based decision model was performed to represent the treatment pathways and associated management of the wounds in the data set.

The patients' mean age was 66.0 years, 62% were female, 8.7cm² was the mean size of VLU, and 2.2 years was the mean duration of their wound before the start of EAE therapy.

At 12 months after the start of the treatment, 77% of all wounds had healed, and 23% had improved. The number of dressings was decreased by 26% (from 197.0 to 146.1) over 12 months after the start of the treatment. Total health-care costs over the 12 months prior to the treatment amounted

to £1908.99 versus £1753.87 after the therapy. Before the therapy, the costs related to the practice nurse visits represented 40% of the total cost, and after the therapy, they only represented 18% of the total. The cost absorbed by the electroceutical device was 14% of the NHS total cost. The difference in effectiveness between before and after EAE therapy yielded a 12% improvement in health gain of 0.09 QALYs (p<0.01). The EAE therapy results thus supported EAE therapy as a dominant treatment for VLUs, which could potentially provide the NHS with a cost-effective treatment for patients with VLUs.

The study does have some limitations since the nurses were self-selected, patients were not randomised to a treatment, and the study had no

	Methods	No. of patients	Costs	Results
	Decision model based on clinical outcome, resource use and costs from prospective, single-arm, non-blinded, clinical and economic evaluation of EAE therapy in the management of VLUs in 2013–2014 (over 12 months before-12 month after the start of treatment) Perspective: NHS	30	Direct medical costs <ul style="list-style-type: none"> • health-care resource (community nurse visits, practice nurse visits, tissue viability nurse visits) • dressings and bandages (dressings, compression bandages, non-compression bandages) • electric stimulation 	EAE therapy affords the NHS a cost-effective treatment although this was dependent on the duration of the wound Incremental cost per QALY gained was £2,522
	Retrospective cohort study based on patient data extracted from the electronic medical database from September 2012 to January 2015	261: 159 included: <ul style="list-style-type: none"> • 72 VLU • 48 SW • 11 PU • 16 PDF • 12 OT 	Costs included: <ul style="list-style-type: none"> • dressing cost • reimbursement rate from insurance companies • breakeven rate for the clinic 	Respect to the comparison between VLU (n=63) and non-VLU (n.56) in the healed group the only significant difference was in wound dressing costs (p=0.001) Incorporation of PT in wound care appeared to be cost effective
	A five-month Markov model based on clinical, resource use and utility coming from patients' case report forms, medical case notes Perspective: NHS	22	Direct medical costs <ul style="list-style-type: none"> • electric stimulation, • nurse visits • bandages • dressings • creams, ointments and emollients 	<ul style="list-style-type: none"> • EAE therapy is expected to reduce the NHS cost by 15% from £880 to £749 due to a reduction in the requirement for nurse visits over the first five months after the start of treatment • 6% health gain of 0.017 QALYs (from 0.299 to 0.316 QALY) over five months

comparator group. Within the model's limitations, the cost-effectiveness of treating patients with VLU with EAE therapy depends on healing rates, duration and size of the wound. It is necessary to collect and use more clinical data in the data set for an accurate final estimation of the cost-effectiveness of the device.

A retrospective study performed by Zhou et al.⁵⁰⁸ aimed to calculate the healing rates, the costs and the time required for closure wound care (CWC) in patients with VLUs and non-VLUs like DFUs, PUs and other types of wounds in an outpatient wound care clinic in the US. The patients received 45 minutes of high voltage pulsed current electric therapy as primary treatment, and Whirlpool therapy, ultrasound and ultraviolet C therapy were occasionally used. The study aimed to assess the

cost difference between healing and non-healing wounds and to compare the cost-effectiveness between VLU and non-VLUs, such as DFUs, PUs and other types of wounds with physical therapy (PT).

Data referred to patients treated from September 2010 to January 2015 in a single centre (n= 261). Included are 159 patients (75 males and 84 females), and 72 had venous ulcers, 48 had traumatic/surgical wounds, 11 had PUs, 16 had pressure DFUs, and 12 had other wound types. Of these patients, 151 received 45 minutes of high voltage pulsed current electric therapy as their primary treatment. Sometimes, the patients were also treated with Whirlpool therapy, ultrasound and ultraviolet C. The mean age was 63.78 years. 74.84% of patients (n=119) represented the healing group and 25.16% the non-healing group

(n=40). Treatment duration was 98.01±76.12 days in the healed group versus 144.50±133.84 in non-healing group (p<0.001). The number of visits was 27.10±22.64 in the healed group with respect to 37.48±32.23 in non-healing group.

Costs included reimbursement rates from insurance companies and breakeven costs for the clinic. Reimbursement rate included electric stimulation ranging from \$18 to \$40 per patient visit, plus \$70 for initial evaluation, and \$40 for re-evaluation every 30 days. Dressing costs were not reimbursed from insurances companies, so it also considered the total dressing cost per treatment episode. Breakeven cost for episode were \$83 for the number of visits plus total dressing costs (operational costs were \$83/hour and included the salaries for one full-time therapist and one full-time PT aid).

The reimbursement rate (USD) was 1327±1143.53 in the healed and 1751±1536.58 for the non-healed; the breakeven rate (USD) was 2492.58±2106.88 versus 3362.50±2914.03 (p=0.002), respectively.

With respect to the comparison between VLU (n=63) and non-VLU (n.56) in the healed group, the only significant difference was in wound dressing costs (p=0.001).

The study presented preliminary data on the cost-effectiveness of wound care when physical therapy is included, but further studies are necessary.

Economic impact of smart technologies

From an economic literature search, covering the period January 2007–January 2018, 263 articles were retrieved, but four papers were considered, and only one was included in the report. The Danish study performed by FASTERHOLDT et al.⁴⁹⁶ compared the cost-

effectiveness of telemonitoring (TM) versus standard monitoring (SM) in patients with DFUs. An economic evaluation was related to the clinical trial performed in seven departments and outpatient clinics of five hospitals in Southern Denmark. The patients enrolled in the TM group performed two teleconsultations in the patient's own home conducted by telephone or online written consultations and one consultation at the outpatient clinic. The SM group performed three visits at outpatient clinic. A total of 374 patients were enrolled (193 in TM group and 181 in SM group). Groups did not present significant differences in terms of demographic and clinical characteristics. Total health-care costs per patient over a six months period were lower in telemonitoring as compared to standard monitoring, €12,356 versus €14,395 (cost difference: €2039), but the difference was not statistically significant. The difference was related to fewer hospital admissions and lower outpatient costs. A significant difference was related to the total staff time used on outpatient consultation, amounting to 156 minutes for the TM group versus 266 minutes in standard group. The amputation rate was similar in the two groups.

This was the first study that employed a strong methodology in terms of economic evaluation for telemonitoring of patients with DFUs in a field with limited previous research.

Conclusions

Due to the scarcity and limited robustness of the available economic studies on advanced therapies in wound management, further analyses on advanced therapies in chronic wound care are necessary to shed more light on the economic implications of alternative technologies, procedures and therapeutic approaches.

For these reasons, we would encourage public and private organisations, the scientific societies,

and the professional associations to promote prospective, multicentred studies that could allow for the accurate assessment of direct and, no less important, indirect costs, such as loss of productivity, individual patient and his/her family's costs. Moreover, as patients suffer because of pain, lack of sleep, immobility and social isolation, with substantial impairment in their daily life, more detailed analyses should focus also

on the assessment of the different therapeutic strategies in regard to the patients' QoL.

In our opinion, all of these factors should be taken into account to perform future clinical and economic evaluations and to provide to different stakeholders—clinicians, patients, hospital administrators, payers, industry, and health policy makers—valuable information.

Regulatory issues: what needs to be considered for an integrated strategy

Development of advanced therapy medicinal products for wound management—a challenging field

The great potential of regenerative medicines in wound care was just recently demonstrated by a case study describing the regeneration of an entire human epidermis for a boy with junctional epidermolysis bullosa (JEB) by a gene therapy product consisting of autologous transgenic keratinocyte cultures.⁵²⁸ Cell and gene therapies and their use in regenerative medicine are one of the most innovative achievements in the medical field. They hold enormous promise to cure some of the most troubling and intractable diseases. In wound healing, technologies that have the potential to regenerate as opposed to repair tissue are also gaining ground as demonstrated by the JEB case above. Wound healing is a logical target for early development of regenerative strategies due to the regenerative nature of wound healing and the physical features of the skin since it is relatively avascular, flat and accessible.⁵²⁹ Moreover, new and highly effective treatments are urgently needed for wound care as chronic wounds show a high prevalence, produce high treatment costs and are extremely debilitating for patients.

Despite regenerative medicines' game changing potential, the success rate of a marketing

authorisation application (MAA) for regenerative medicines in the EU remains rather poor as they face substantial challenges regarding the transition from a research to a development stage. Within wound care, the success rates of new drugs in general also remain poor. Over the last eighteen years just two products, Regranex (beclapiermin)⁵³⁰ and Episalvan (birch bark extract)⁵³¹ were centrally approved for wound healing in the EU whereas the Marketing Authorisation Holder of Regranex has in the meantime withdrawn the marketing authorisation due to commercial reasons. The poor success rate of medicinal products for wound management medicinal products is attributed to the challenging indications, which especially lack well-designed, comparative clinical trials in well-defined patient cohorts.⁵²⁹ Thus, companies, who are engaged in developing innovative regenerative medicines in the field of wound care, are facing both innovative products and a demanding indication. Therefore, it is of the utmost importance to have a well thought-out integrated regulatory strategy in place in order to successfully develop regenerative medicines for wound healing.

Relevant legislation overview

Though most new regenerative medicines are classified by the European Medicines Agency as Advanced Therapy Medicinal Products (ATMPs), the wound healing area comprises diverse products, such as medical devices (MD), combination products

and advanced therapy medicinal products (ATMPs). Different legislations for these products exist, which are partly overlapping. An overview of the different legal frameworks is provided in the following.

For MDs the most relevant piece of legislation is currently the Medical Device Directive (MDD 93/42/EC),⁵³² defines the CE certificate as a prerequisite for placing a MD on the market in Europe and in European Free Trade Association (EFTA) countries. CE certificates are issued by a Notified Body, who is designated to perform this task by the designating authority in their country, and since the classification of devices is based on risk, the scrutiny applied for conformity assessment depends mainly on the classification and risk of the device.⁵³³ Currently, the European regulatory framework for medical devices is undergoing significant changes, and the MDD will soon be replaced by the Medical Device Regulation (MDR) 2017/745/EC (534), which will take effect beginning in mid-2020. Changes occurring under MDR concern, amongst others, are the introduction of a life-cycle approach to ongoing CE-marking compliance, more complex conformity assessment procedures, increased post-market surveillance, post-market clinical follow-up studies and delivery of periodic safety update reports (Class IIa devices and above).⁵³⁵

In case a product consists of a MD and a medicinal product (MP), the product is called a combination

product. Here, it is critical to understand the primary mode of action of the product since this will determine whether it will be regulated as a MD or as a MP in the EU. For example, a wound dressing containing an antimicrobial agent will be regulated as a MD whereas a wound treatment product for the delivery of an antimicrobial agents will be considered as a MP.⁵³⁶

A third possible scenario for the regulation of a combination of a MP and a MD would be the classification as an ATMP, for example with autologous chondrocytes seeded onto a collagen membrane to repair cartilage. The autologous chondrocytes represent the integral part of the product, and thus, the whole product falls under the Advanced Therapy Medicinal Product Regulation (EC) No 1394/2007.⁵³⁷ ATMPs comprise four distinct product categories, which are gene therapy medicinal products (GTMP), somatic cell therapy medicinal products (sCTMP), tissue-engineered products (TEP) as well as combined ATMPs. Table 28 provides an overview of the characteristics of each of these categories. Following the implementation of the ATMP Regulation, it became mandatory for ATMPs to follow a centralised procedure to obtain a marketing authorisation pursuant to Regulation (EC) No. 726/2004.⁵³⁸ As a consequence, ATMPs have to fulfil the same high regulatory standards as other pharmaceuticals.

Table 28. Overview of GTMP, sCTMP, TEP and combined ATMP definitions

Category	Definition
GTMP	<ul style="list-style-type: none"> • Contains an active substance which contains or consists of a recombinant nucleic acid used in or administered to human beings with a view to regulating, repairing, replacing, adding or deleting a genetic sequence • Its therapeutic, prophylactic or diagnostic effect relates directly to the recombinant nucleic acid sequence it contains, or to the product of genetic expression of this sequence
sCTMP	<ul style="list-style-type: none"> • Contains or consists of cells or tissues that have been subject to substantial manipulation so that biological characteristics, physiological functions or structural properties relevant for the intended clinical use have been altered, or of cells or tissues that are not intended to be used for the same essential function(s) in the recipient and the donor • Is presented as having properties for or is used in or administered to human beings with a view to treating, preventing or diagnosing a disease through the pharmacological, immunological or metabolic action of its cells or tissues
TEP	<ul style="list-style-type: none"> • Contains or consists of engineered cells or tissues, and • Is presented as having properties for, or is used in or administered to human beings with a view to regenerating, repairing or replacing a human tissue
Combined ATMP	<ul style="list-style-type: none"> • It must incorporate, as an integral part of the product, one or more medical devices within the meaning of Article 1(2)(a) of Directive 93/42/EEC or one or more active implantable medical devices within the meaning of Article 1(2)(c) of Directive 90/385/EEC, and • Its cellular or tissue part must contain viable cells or tissues, or • Its cellular or tissue part containing non-viable cells or tissues must be liable to act upon the human body with action that can be considered as primary to that of the devices referred to

Where do we stand with ATMPs in wound management?

Over the last 18 years, only two medicinal products for wound healing were granted marketing authorisation in the EU. Both products do not fall under the ATMP classification, which shows that despite ATMPs' game changing potential, no ATMP with an indication in wound management has been approved yet. However, when looking at the Committee for Advanced Therapies (CAT) classification procedures since 2011, 27 procedures refer to products with a wound management related indication, in detail 24 TEPs, two sCTMPs and one GTMP.⁵³⁹ The classified products comprise various TEPs based on human autologous keratinocytes, an sCTMP consisting of autologous adipose tissue-derived mesenchymal stem cells and the one GTMP composed of living, genetically modified *Lactobacillus reuteri* bacteria with a plasmid containing the gene for human CXCL2-1a indicated for chronic skin wounds in

patients with diabetes.⁵³⁹

In the US, StrataGraft Regenerative Skin Tissue (Mallinckrodt plc) indicated for the treatment of severe burns and other complex skin defects received, just recently, Regenerative Advanced Therapy (RMAT) designation. This designation aims in speeding up the time frame for approval of innovative and promising regenerative therapies and speaks to the strength of the clinical data generated with StrataGraft during phase I and II clinical trials.⁵⁴⁰

This demonstrates that diverse efforts are being made to take advantage of the great potential of regenerative medicines to transform wound management, and this gives reason to be optimistic that innovative products for wound healing can be expected to reach the Marketing Authorisation Application (MAA) status over the next few years.

How to best address challenges during ATMP development for wound management?

Despite ATMPs being a heterogeneous group of products, developers of ATMPs face common development features. The awareness of this is important to ATMP developers in order to steer drug development effectively. Figure 25 summarises important points to be considered at key transition points in drug development of ATMPs for wound management.⁵⁴¹

Points to consider at the R&D stage
In order to select the lead indication where

a pathophysiology matches a mechanism of action (MoA), it is of the utmost importance to characterise the MoA thoroughly and to understand the pathophysiology of the target disease. Already at this early stage, drafting a target product profile is helpful to guide lead candidate selection and to guide the development and regulatory strategy.

Points to consider for manufacturing
Unlike for other proprietary medicinal products, the manufacturing process of certain ATMPs starts already at the patient's bedside, which is not necessarily a qualified Good Manufacturing Practice (GMP) unit. In addition, the set-up of an ATMP manufacturing process including its




Fig 25. Points to consider at key transition points in drug development⁵⁴¹

qualification and validation is not a trivial task. The identification of key quality attributes of an ATMP is critically important and helps set up the process and ensure consistency. Likewise, the identification of a suitable potency assay is important as this represents the only direct link to the product's clinical efficacy. In addition, it is highly recommended to consider cost of goods already early on, such as when the initial GMP process is being designed, to lower the expected commercial challenges.

Non-clinical challenges

For the non-clinical development of ATMPs in wound care management, there are rarely off-the-shelf solutions available. Sufficiently sensitive and relevant models are frequently lacking to accurately assess safety and pharmacodynamic properties and to guide clinical development. Therefore, ATMPs require careful considerations and tailor-made solutions more than any other class of products. Currently, there are no ideal animal models available for areas such as chronic wounds or extensive burns. Therefore, multiple animal models should be used to assess the activity of wound-treatment products.⁵⁴²

Based on our practical experience, two models complementing each other can be used for chronic inflammatory wounds, such as the diabetic mouse model and a common minipig model. Thereby, the diabetic mouse model reflects the inflammatory status, and the minipig model is more representative of the human skin architecture.

When no appropriate *in vivo* model can be identified or is known to be able to complement *in vivo* studies, *ex vivo* surrogate models or *in vitro* data can be used to provide valuable information.

The extent of pharmacodynamic, pharmacokinetic or shedding studies will depend on the particular nature of the ATMP. While detailed investigations

will be feasible and needed for genetically modified cells or bacterial based products in wound care management, this might not be feasible nor necessary for a non-genetically modified skin graft. For the latter, engraftment and graft survival will be important pharmacokinetic and pharmacodynamic properties to examine.

Clinical challenges

Under consideration of the non-clinical limitations, which the majority of ATMPs face, it is important to design a well thought-through risk mitigation strategy for the First in Human (FIH) study. A proper risk mitigation strategy combined with an in depth knowledge of the MoA and the pathophysiology guides the selection of the most appropriate patient population. The critical selection of inclusion and exclusion criteria for enrolment and the choice of relevant efficacy endpoints are also important. Some authorities, particularly the FDA, accept only complete wound healing as an efficacy outcome for chronic wound treatment, which might be difficult to demonstrate since many patients' wounds may not heal over the course of the study.⁵⁴³ This aspect can be addressed by the addition of other endpoints, such as wound measurements or health-related measurements of quality of life. At the late stage of clinical development and specifically when changes have been introduced into the manufacturing process, it is important to carefully assess comparability to ensure that the clinical performance is not impaired by a changed quality profile of the ATMP.

What regulatory tools should be considered for setting up an integrated development and regulatory strategy?

Drug development times have increased enormously over the past decades, and the cost of bringing a drug to market has more than doubled

Table 29. Overview on regulatory tools

Tool	Description
Specific guidelines from agencies	<ul style="list-style-type: none"> FDA guidance for industry- Chronic Cutaneous Ulcer and Burn Wounds- Developing Products for Treatment⁵⁴⁵ Specific ATMP guidelines⁵⁴¹
Small- and medium-sized enterprises (SME) status ⁵⁴⁶	<ul style="list-style-type: none"> Administrative, regulatory and financial support provided by EMA Annual head count <250 and an annual turnover ≤50 million Euros Substantial fee reductions for regulatory procedures
Classification of the ATMP ⁵⁴⁷	<ul style="list-style-type: none"> Confirmation if a medicine meets the scientific criteria for defining an ATMP and under which category it falls
Certification of CMC and non-clinical documentation ⁵⁴⁸	<ul style="list-style-type: none"> Pre-assessment of quality data and, when available, non-clinical data Aims to identify any potential issues early on CAT may recommend issuing a certification confirming the extent to which the available data comply with the standards
Support from the EMA innovation task force ⁵⁴⁹	<ul style="list-style-type: none"> EMA Innovation Task Force (ITF) is a multidisciplinary group that includes scientific, regulatory and legal competencies Establishes a discussion platform for early dialogue with applicants For companies not yet experienced in the regulatory arena
PRIME scheme ⁵⁵⁰	<ul style="list-style-type: none"> Aim: to enhance support for the development of medicines that target an unmet medical need Offers more frequent interaction and early dialogue with developers of promising medicines
Scientific advice procedures by National Competent Authorities or European Medicines Agency ⁵⁵¹	<ul style="list-style-type: none"> Authorities give advice to developers on the appropriate tests and studies in the development of a medicine to avoid major objections regarding the design of the tests during evaluation of the MAA Authorities give scientific advice by answering questions posed by medicine developers Received advice is not legally binding




Fig 26. When to best use the regulatory tools

in the past 10 years. Today, it takes far more than a decade to bring a new drug from discovery to the market. A well-considered regulatory strategy is key to success at the time of approval and aims at aligning the regulatory activities involved in bringing a product to market with the drug development process and business strategy.⁵⁴⁴

Tools are available to support the development strategy and should be considered at dedicated time points during the development to increase the chances for a successful drug development (Table 29, Fig 26).

Outlook and conclusion

Regenerative medicines are on the rise and about to shift the focus of medicine from replacing and repairing tissue to regenerating it. Although regenerative medicine is not yet a reality in wound management, the ongoing development activities in the field of ATMPs hold the realistic promise of revolutionising the standard treatment. Gene therapies producing wound healing factors may soon become reality and open new horizons for

treatments. Gene editing might also find its way into the area of wound management. For example, Aushev et al. demonstrated the elimination of dominant-negative mutations in keratin genes in epidermal stem cells by transcription activator-like effector nucleases (TALENs).⁵⁵² This might be a promising approach for the treatment of keratopathies, like EB, in the future.

As was outlined in this article, most regenerative medicines are classed as ATMPs and are, thus, confronted with high product and development standards. Thus, their development can be very challenging for companies due to the inert complexity of the products. In addition, detailed EU guidance related to emerging gene editing technologies, in particular, but also to wound management related indications, is missing. Timely engagement with regulatory authorities can be key for a successful development process. Therefore, the integration of regulatory tools in the overall development strategy is crucial as it enhances early dialogue with regulatory bodies.

The wish list – for a better future

Based on an extensive review and critical reappraisal of the existing evidence and of the problems related to the implementation of new technologies in wound healing, the authors responsible for this EWMA position document agree on the following recommendations for future developments:

1. **Development of new technologies:** As the development of new technologies is a time- and resource-consuming process, often lasting several years, companies interested in developing and introducing both new technologies and medical devices for wound healing are advised to consult preliminarily with an interdisciplinary team of stakeholders, including basic scientists, bioengineers and clinicians with a specific expertise in wound healing, in order to test the originality and applicability of their ideas/projects.
2. **Health technology assessments (HTAs):** The limited financial resources in all health-care systems across Europe, which are typically financed via a taxpayer system, emphasise the need for an adequate allocation of resources based on updated evidence and principles of cost-effectiveness. HTAs have become the standard approach whenever new technologies are proposed for introduction into the field. The fact is that HTA procedures vary from country to country, or, in some cases, from region to region within a country. As part of a rationalisation process, which should be promoted and endorsed by the EU in the

framework of legislative action, HTA procedures should be defined and standardised across the EU. This would simplify the process of bringing new technologies from the lab to the patients. It would also reduce the amount of resources that companies must invest in these procedures, eventually saving those funds for further research activities.

3. **Implementation of new technologies in clinical practice:** In order to bridge the gaps that almost unavoidably develop between the realisation of new technologies and their implementation in clinical practice, it is important to define minimum standard requirements for testing/implementation in clinical practice. These requirements must be related to Items 1 and 2 in this list, tested under controlled conditions and following the recommendations of good clinical research. RCTs are the preferred approach. However, due to the cost- and method-related difficulties linked with the organisation of an RCT, prospective observational trials may be considered if they are independent and relevant for wound management.
4. **Translational science:** Despite the increasing number of options in terms of the variety and quality of technologies available for clinical use in wound management, there is a diffuse under use of new technologies when they initially become available to clinicians. Often, the implementation in clinical practice does not meet the expectations of the manufacturers. One major component of this bias is related to

a poor understanding of the basic principles of the new technologies and their materials among health professionals. Their level of knowledge may eventually be improved by translational science initiatives aimed at bridging this technological gap.

5. The need for investments in research: Important economic resources are needed to sustain the growth of research and the development of new technologies for wound management. Beyond the commercial interests of the industries in the field, institutions at the European level must also recognise the importance of investing in a field that will be of interest to one out of every four EU citizens over the next decades.
6. Access to new technologies in the EU: The possibility of accessing new technologies varies significantly across the different countries in the EU, not only for the reasons described below in Items 7 and 8 in this list. Another key factor in ensuring the accessibility of new technologies is that the companies must be willing to market the new technologies in all European countries despite the economic arguments for targeting certain countries before others. When new technologies are not available across the European health-care systems, this creates idiosyncrasies in the actual possibility of patients being treated with new technologies. Therefore, companies are advised to extend their diffusion of new technologies across Europe to the extent that it is possible.
7. Regulatory controversies: Detailed EU guidance related to emerging gene editing technologies is available, but for wound management-related endeavours, it is so far missing. It would be advisable to engage with regulatory authorities in the future in order to make them aware of the challenges related to the development of medical products for wound management and this lack of guidance. This will hopefully lead to the development of specific guidelines from which product developers can benefit in the future.
8. Definition of outcomes, direct and indirect costs: Cost studies vary in approach and quality. The wide variety of outcome measures and costs hinder comparisons of interventions and progress. Thus, there is an increasing need to define outcomes, direct costs and indirect costs that should be included in the economic evaluations, clearly. Promoting research and clinical trials on advanced therapies and involving health economists and health statisticians in the planning, execution and analysis of the studies, is essential for ensuring the appropriate economic assessment of the impact of these interventions. Moreover, given the paucity of studies on the quality of life for patients, more analyses focused on this dimension should be performed.
9. The growth of a wound care centred research field within the telemedicine and wearables milieus: Technologies, such as telemedicine and wearables, enable the reduction of in-person visits and allow physicians to check on patients remotely, track patient adherence to prescribed therapies, detect the early stages of serious medical conditions and triage those who are in need of immediate supervised care. While the application of such technology for effectiveness on DF care is still in its infancy, and its cost-effectiveness is still debated, it is anticipated that general health-care and chronic wound care delivery will change due to this technology dramatically in the near future. Thus, more research is recommended in this field to translate these telehealth technologies into a better management system for chronic wounds and improved patient-centred outcomes, including the number of in-person visits required.

10. Evaluation of outcomes: A major challenge for a fair comparison between new technologies and conventional therapies is the lack of consensus and guidelines for the standardisation of reporting of outcomes. In addition, new outcomes that are more sensitive to new technologies should be defined and standardised, such as the number of in-person visits for telehealth applications and levels of restriction in mobility during the wound healing phase. Moreover, most research in the area of chronic wound management is currently focused on wound outcomes during the wound-healing phase without taking into consideration the high rate of recurrences. It is recommended that the time of recurrence for ulcers, as well as their frequency, should also be taken into consideration when examining the effectiveness of new technologies.

Contributions from EWMA

1. With regards to the development of new technologies (NTs), EWMA puts forward its 25-year long experience in the field and candidates for a pivotal position in an initiative to establish an interdisciplinary consultancy committee, including basic scientists, bioengineers, clinicians, and industry.
2. With regards to pushing for health technology

assessments (HTAs) to be conducted on new technologies in wound management, EWMA offers to act as a consultant in the process of developing wound repair-related HTA procedures.

3. EWMA is available to initiate a programme, in collaboration with other stakeholders, offering endorsement for NTs, as well as dissemination and advertisement, via EWMA's communication and network platforms, such as the EWMA Journal and scientific meetings.
4. EWMA will promote actions targeting EU-level stakeholders and decision-makers to promote politics that facilitate the process of ensuring equal access to NTs across the European countries.
5. EWMA will work to influence the politics of the EU with an aim to increase the public investments in NT research.
6. EWMA will commit to initiatives supporting translational science that aims to bridge the technological gaps between research and clinical practice. This should take place in collaboration with all of the stakeholders involved in this fields, including clinicians, caregivers and industry leaders.

References

- 1 Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; 336(7650):924–926. <https://doi.org/10.1136/bmj.39489.470347.AD>
- 2 Forrest RD. Early history of wound treatment. *J R Soc Med* 1982; 75(3):198–205
- 3 Shah JB. The history of wound care. *J Am Col Certif Wound Spec* 2011; 3(3):65–66. <https://doi.org/10.1016/j.jcws.2012.04.002>
- 4 Dhivya S, Padma VV, Santhini E. Wound dressings – a review. *BioMedicine* 2015; 5(4):22. <https://doi.org/10.7603/s40681-015-0022-9>
- 5 Winter GD. Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig. *Nature* 1962; 193(4812):293–294. <https://doi.org/10.1038/193293a0>
- 6 Broussard KC, Powers JG. Wound dressings: selecting the most appropriate type. *Am J Clin Dermatol* 2013; 14(6):449–459. <https://doi.org/10.1007/s40257-013-0046-4>
- 7 Mulder G, Jones R, Cederholm-Williams S et al. Fibrin cuff lysis in chronic venous ulcers treated with a hydrocolloid dressing. *Int J Dermatol* 1993; 32(4):304–306. <https://doi.org/10.1111/ij.1365-4362.1993.tb04275.x>
- 8 Han G, Ceilley R. Chronic Wound Healing: A Review of Current Management and Treatments. *Adv Ther* 2017; 34(3):599–610. <https://doi.org/10.1007/s12325-017-0478-y>
- 9 Junker JP, Kamel RA, Caterson EJ, Eriksson E. Clinical Impact Upon Wound Healing and Inflammation in Moist, Wet, and Dry Environments. *Adv Wound Care* 2013; 2(7):348–356. <https://doi.org/10.1089/wound.2012.0412>
- 10 Rippon M, Davies P, White R. Taking the trauma out of wound care: the importance of undisturbed healing. *Journal of wound care*. 2012; 21(8):359–60, 62, 64–8.
- 11 Debels H, Hamdi M, Abberton K, Morrison W. Dermal matrices and bioengineered skin substitutes: a critical review of current options. *Plast Reconstr Surg Glob Open* 2015; 3(1):e284. <https://doi.org/10.1097/GOX.0000000000000219>
- 12 Seymour J. On view: film dressing. *Nurs Times* 1996; 92(43):46–48
- 13 Lee SM, Park IK, Kim YS et al. Physical, morphological, and wound healing properties of a polyurethane foam-film dressing. *Biomaterials Research* 2016; 20(1):15. <https://doi.org/10.1186/s40824-016-0063-5>
- 14 Jones V, Grey JE, Harding KG. Wound dressings. *BMJ* 2006; 332(7544):777–780. <https://doi.org/10.1136/bmj.332.7544.777>
15. Cutting KF. Wound exudate: composition and functions. *Br J Community Nurs* 2003; 8(9 Suppl):suppl 4–9
- 16 Madden MR, Nolan E, Finkelstein JL et al. Comparison of an occlusive and a semi-occlusive dressing and the effect of the wound exudate upon keratinocyte proliferation. *J Trauma Inj Infect Crit Care* 1989; 29(7):924–931. <https://doi.org/10.1097/00005373-198907000-00004>
- 17 Amano S, Akutsu N, Ogura Y, Nishiyama T. Increase of laminin 5 synthesis in human keratinocytes by acute wound fluid, inflammatory cytokines and growth factors, and lysophospholipids. *Br J Dermatol* 2004; 151(5):961–970. <https://doi.org/10.1111/ij.1365-2133.2004.06175.x>
- 18 Aiba-Kojima E, Tsuno NH, Inoue K et al. Characterization of wound drainage fluids as a source of soluble factors associated with wound healing: comparison with platelet-rich plasma and potential use in cell culture. *Wound Repair Regen* 2007; 15(4):511–520. <https://doi.org/10.1111/ij.1524-475X.2007.00259.x>
- 19 Di Vita G, Patti R, D'Agostino P et al. Cytokines and growth factors in wound drainage fluid from patients undergoing incisional hernia repair. *Wound Repair Regen* 2006; 14(3):259–264. <https://doi.org/10.1111/ij.1743-6109.2006.00120.x>
- 20 Widgerow AD, King K, Tocco-Tussardi I et al. The burn wound exudate—an under-utilized resource. *Burns* 2015; 41(1):1–7. <https://doi.org/10.1016/j.burns.2014.06.002>
- 21 Jonkman MF, Hoeksma EA, Nieuwenhuis P. Accelerated epithelization under a highly vapor-permeable wound dressing is associated with increased precipitation of fibrin(ogen) and fibronectin. *J Invest Dermatol* 1990; 94(4):477–484. <https://doi.org/10.1111/1523-1747.ep12874624>
- 22 Kubo M, Van De Water L, Plantefaber LC et al. Fibrinogen and fibrin are anti-adhesive for keratinocytes: a mechanism for fibrin eschar slough during wound repair. *J Invest Dermatol* 2001; 117(6):1369–1381. <https://doi.org/10.1046/j.0022-202x.2001.01551.x>
- 23 Weckroth M, Vaheri A, Myohanen H et al. Differential effects of acute and chronic wound fluids on urokinase-type plasminogen activator; urokinase-type plasminogen activator receptor; and tissue-type plasminogen activator in cultured human keratinocytes and fibroblasts. *Wound Repair Regen* 2001; 9(4):314–322
- 24 Barrick B, Campbell EJ, Owen CA. Leukocyte proteinases in wound healing: roles in physiologic and pathologic processes. *Wound Repair Regen* 1999; 7(6):410–22. <https://doi.org/10.1046/j.1524-475X.1999.00410.x>
- 25 Nwomeh BC, Liang HX, Diegelmann RF et al. Dynamics of the matrix metalloproteinases MMP-1 and MMP-8 in acute open human dermal wounds. *Wound Repair Regen* 1998; 6(2):127–134
- 26 Trengove NJ, Stacey MC, MacAuley S et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. *Wound Repair Regen* 1999; 7(6):442–452.
- 27 Nissen NN, Gamelli RL, Polverini PJ, DiPietro LA. Differential angiogenic and proliferative activity of surgical and burn wound fluids. *J Trauma Inj Infect Crit Care* 2003; 54(6):1205–1210. <https://doi.org/10.1097/01.TA.0000061884.28845.5A>
- 28 Stephen-Haynes J, Callaghan R, Wibaux A et al. Clinical evaluation of a thin absorbent skin adhesive dressing for wound management. *J Wound Care* 2014; 23(11):532, 4, 6 passim. <https://doi.org/10.12968/jowc.2014.23.11.532>
- 29 Salemark KP, Salemark L. How to dress donor sites of split thickness skin grafts: a prospective, randomised study of four dressings. *Scand J Plast Reconstr Surg Hand Surg* 2000; 34(1):55–59. <https://doi.org/10.1080/02844310050160178>
- 30 Kazanavičius M, Cepas A, Kolaityte V, Simoliuniene R, Rimdeika R. The use of modern dressings in managing split-thickness skin graft donor sites: a single-centre randomised controlled trial. *J Wound Care* 2017; 26(6):281–291. <https://doi.org/10.12968/jowc.2017.26.6.281>

- 31 Terrill PJ, Goh RC, Bailey MJ. Split-thickness skin graft donor sites: a comparative study of two absorbent dressings. *J Wound Care* 2007; 16(10):433–438. <https://doi.org/10.12968/jowc.2007.16.10.27912>
- 32 Brölmann FE, Eskes AM, Goslings JC et al. Randomized clinical trial of donor-site wound dressings after split-skin grafting. *Br J Surg* 2013; 100(5):619–627. <https://doi.org/10.1002/bjs.9045>
- 33 Kaiser D, Hafner J, Mayer D et al. Alginate dressing and polyurethane film versus paraffin gauze in the treatment of split-thickness skin graft donor sites: a randomized controlled pilot study. *Adv Skin Wound Care* 2013; 26(2):67–73. <https://doi.org/10.1097/01.ASW.0000426715.57540.8d>
- 34 Kazanavičius M, Cepas A, Kolaityte V et al. The use of modern dressings in managing split-thickness skin graft donor sites: a single-centre randomised controlled trial. *J Wound Care* 2017; 26(6):281–291. <https://doi.org/10.12968/jowc.2017.26.6.281>
- 35 Brenner M, Hilliard C, Peel G et al. Management of pediatric skin-graft donor sites: a randomized controlled trial of three wound care products. *J Burn Care Res* 2015; 36(1):159–166. <https://doi.org/10.1097/BCR.0000000000000161>
- 36 Higgins L, Wasiak J, Spinks A, Cleland H. Split-thickness skin graft donor site management: a randomized controlled trial comparing polyurethane with calcium alginate dressings. *Int Wound J* 2012; 9(2):126–131. <https://doi.org/10.1111/ij.1742-481X.2011.00867.x>
- 37 Karlsson M, Lindgren M, Jarnhed-Andersson I, Tarpila E. Dressing the split-thickness skin graft donor site: a randomized clinical trial. *Adv Skin Wound Care* 2014; 27(1):20–25. <https://doi.org/10.1097/01.ASW.0000437786.92529.22>
- 38 Brölmann FE, Eskes AM, Goslings JC et al. Randomized clinical trial of donor-site wound dressings after split-skin grafting. *Br J Surg* 2013; 100(5):619–627. <https://doi.org/10.1002/bjs.9045>
- 39 Dornseifer U, Lonic D, Gerstung T et al. The ideal split-thickness skin graft donor-site dressing: a clinical comparative trial of a modified polyurethane dressing and aquacel. *Plast Reconstr Surg* 2011; 128(4):918–924. <https://doi.org/10.1097/PRS.0b013e3182268c02>
- 40 Fernández-Castro M, Martín-Gil B, Peña-García I et al. Effectiveness of semi-permeable dressings to treat radiation-induced skin reactions. A systematic review. *Eur J Cancer Care (Engl)* 2017; 26(6):e12685. <https://doi.org/10.1111/ecc.12685>
- 41 Sood A, Granick MS, Tomaselli NL. Wound Dressings and Comparative Effectiveness Data. *Adv Wound Care* 2014; 3(8):511–529. <https://doi.org/10.1089/wound.2012.0401>
- 42 Bullough L, Johnson S, Forder R. Evaluation of a foam dressing for acute and chronic wound exudate management. *Br J Community Nurs* 2015; Suppl Wound Care: S17–S24. <https://doi.org/10.12968/bjcn.2015.20.Sup9.S17>
- 43 Zehrer CL, Holm D, Solfest SE, Walters SA. A comparison of the in vitro moisture vapour transmission rate and in vivo fluid-handling capacity of six adhesive foam dressings to a newly reformulated adhesive foam dressing. *Int Wound J* 2014; 11(6):681–690. <https://doi.org/10.1111/iwj.12030>
- 44 Browning P, White RJ, Rowell T. Comparative evaluation of the functional properties of superabsorbent dressings and their effect on exudate management. *J Wound Care* 2016; 25(8):452–462. <https://doi.org/10.12968/jowc.2016.25.8.452>
- 45 McCarty SM, Percival SL, Clegg PD, Cochrane CA. The role of polyphosphates in the sequestration of matrix metalloproteinases. *Int Wound J* 2015 Feb; 12(1):89–99. <https://doi.org/10.1111/iwj.12058>
- 46 Wiegand C, White RJ. Binding and inhibition of protease enzymes, including MMPs, by a superabsorbent dressing in vitro. *J Wound Care* 2013; 22(5):221–227. <https://doi.org/10.12968/jowc.2013.22.5.221>
- 47 Cullen B, Watt PW, Lundqvist C et al. The role of oxidised regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action. *Int J Biochem Cell Biol* 2002; 34(12):1544–1556. [https://doi.org/10.1016/S1357-2725\(02\)00054-7](https://doi.org/10.1016/S1357-2725(02)00054-7)
- 48 Yamane T, Nakagami G, Yoshino S et al. Hydrocellular foam dressings promote wound healing associated with decrease in inflammation in rat periwound skin and granulation tissue, compared with hydrocolloid dressings. *Biosci Biotechnol Biochem* 2015; 79(2):185–189. <https://doi.org/10.1080/09168451.2014.968088>
- 49 Yamane T, Nakagami G, Yoshino S et al. Hydrocellular foam dressing promotes wound healing along with increases in hyaluronan synthase 3 and PPAR α gene expression in epidermis. *PLoS One* 2013; 8(8):e73988. <https://doi.org/10.1371/journal.pone.0073988>
- 50 Yoshino S, Nakagami G, Ohira T et al. Hydrocellular foam dressing increases the leptin level in wound fluid. *Wound Repair Regen* 2015; 23(5):703–710. <https://doi.org/10.1111/wrr.12349>
- 51 Bateman SD. 150 patient experiences with a soft silicone foam dressing. *Br J Nurs* 2015; 24(12):S16–S23. <https://doi.org/10.12968/bjon.2015.24.Sup12.S16>
- 52 Brenner M, Hilliard C, Peel G et al. Management of pediatric skin-graft donor sites: a randomized controlled trial of three wound care products. *J Burn Care Res* 2015; 36(1):159–166. <https://doi.org/10.1097/BCR.0000000000000161>
- 52 Chaby G, Senet P, Vaneau M, Martel P et al. Dressings for acute and chronic wounds: a systematic review. *Arch Dermatol* 2007; 143(10):1297–1304. <https://doi.org/10.1001/archderm.143.10.1297>
- 53 Guthrie J, Potter R. Clinical acceptability of a dressing with matrix technology: a multisite evaluation of acute and chronic wounds. *J Wound Care* 2016; 25(8):465–469. <https://doi.org/10.12968/jowc.2016.25.8.465>
- 54 Andersen KE, Franken CPM, Gad P et al. A randomized, controlled study to compare the effectiveness of two foam dressings in the management of lower leg ulcers. *Ostomy Wound Manage* 2002; 48(8):34–41.
- 55 Saco M, Howe N, Nathoo R, Cherpelis B. Comparing the efficacies of alginate, foam, hydrocolloid, hydrofiber, and hydrogel dressings in the management of diabetic foot ulcers and venous leg ulcers: a systematic review and meta-analysis examining how to dress for success. *Dermatol Online J* 2016; 22(8):13030/qt7ph5v17z
- 56 Dumville JC, Deshpande S, O'Meara S, Speak K. Foam dressings for healing diabetic foot ulcers. *Cochrane Database Syst Rev* 2013; (6):CD009111.
- 57 Dumville JC, Soares MO, O'Meara S, Cullum N. Systematic review and mixed treatment comparison: dressings to heal diabetic foot ulcers. *Diabetologia* 2012; 55(7):1902–1910. <https://doi.org/10.1007/s00125-012-2558-5>
- 58 O'Meara S, Martyn-St James M. Foam dressings for venous leg ulcers. *Cochrane Database Syst Rev* 2013; (5):CD009907
- 59 Dini V, Romanelli M, Andriessen A et al. Improvement of periwound skin condition in venous leg ulcer patients: prospective, randomized, controlled, single-blinded clinical trial comparing a biosynthetic cellulose dressing with a foam dressing. *Adv Skin Wound Care* 2013; 26(8):352–359. <https://doi.org/10.1097/01.ASW.0000431237.22658.15>
- 60 Alvarez OM, Phillips TJ, Menzoian JO, Patel M, Andriessen A et al. An

- RCT to compare a bio-cellulose wound dressing with a non-adherent dressing in VLU. *J Wound Care* 2012; 21(9):448–453. <https://doi.org/10.12968/jowc.2012.21.9.448>
- 61 Kelechi TJ, Mueller M, Hankin CS et al. A randomized, investigator-blinded, controlled pilot study to evaluate the safety and efficacy of a poly-N-acetyl glucosamine-derived membrane material in patients with venous leg ulcers. *J Am Acad Dermatol* 2012; 66(6):e209–e215. <https://doi.org/10.1016/j.jaad.2011.01.031>
- 62 Wild T, Eberlein T, Andriessen A. Wound cleansing efficacy of two cellulose-based dressings. *Wounds UK* 2010; 3:14–21.
- 63 Andriessen A, Polignano R, Abel M. Monitoring the microcirculation to evaluate dressing performance in patients with venous leg ulcers. *J Wound Care* 2009; 18(4):145–150. <https://doi.org/10.12968/jowc.2009.18.4.1606>
- 64 Franks PJ, Moody M, Moffatt CJ et al. Randomized trial of two foam dressings in the management of chronic venous ulceration. *Wound Repair Regen* 2007; 15(2):197–202. <https://doi.org/10.1111/j.1524-475X.2007.00205.x>
- 65 Meaume S, Domp Martin A, Lok C et al. Quality of life in patients with leg ulcers: results from CHALLENGE, a double-blind randomised controlled trial. *J Wound Care* 2017; 26(7):368–379. <https://doi.org/10.12968/jowc.2017.26.7.368>
- 66 Meaume S, Dissemond J, Addala A et al. Evaluation of two fibrous wound dressings for the management of leg ulcers: results of a European randomised controlled trial (EARTH RCT). *J Wound Care* 2014; 23(3):105–116. <https://doi.org/10.12968/jowc.2014.23.3.105>
- 67 Dereure O, Mikosinski J, Zegota Z, Allaert FA. RCT to evaluate a hyaluronic acid containing gauze pad in leg ulcers of venous or mixed aetiology. *J Wound Care* 2012; 21(11):539–547. <https://doi.org/10.12968/jowc.2012.21.11.539>
- 68 Meaume S, Ourabah Z, Romanelli M et al. Efficacy and tolerance of a hydrocolloid dressing containing hyaluronic acid for the treatment of leg ulcers of venous or mixed origin. *Curr Med Res Opin* 2008; 24(10):2729–2739. doi: 10.1185/03007990802367041.
- 69 Schmutz JL, Meaume S, Fays S et al. Evaluation of the nano-oligosaccharide factor lipid-colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. *Int Wound J* 2008; 5(2):172–182. <https://doi.org/10.1111/j.1742-481X.2008.00453.x>
- 70 Nelson EA, Prescott RJ, Harper DR et al. A factorial, randomized trial of pentoxifylline or placebo, four-layer or single-layer compression, and knitted viscose or hydrocolloid dressings for venous ulcers. *J Vasc Surg* 2007; 45(1):134–141. <https://doi.org/10.1016/j.jvs.2006.09.043>
- 71 Romanelli M, Dini V, Bertone MS. Randomized comparison of OASIS wound matrix versus moist wound dressing in the treatment of difficult-to-heal wounds of mixed arterial/venous etiology. *Adv Skin Wound Care* 2010; 23(1):34–38. <https://doi.org/10.1097/01.ASW.0000363485.17224.26>
- 72 Romanelli M, Dini V, Bertone M et al. OASIS wound matrix versus Hyalokin in the treatment of difficult-to-heal wounds of mixed arterial/venous aetiology. *Int Wound J* 2007; 4(1):3–7. <https://doi.org/10.1111/j.1742-481X.2007.00300.x>
- 73 Hundeshagen G, Collins VN, Wurzer P et al. A Prospective, Randomized, Controlled Trial Comparing the Outpatient Treatment of Pediatric and Adult Partial-Thickness Burns with Suprathel or Mepilex Ag. *J Burn Care Res* 2017; 1. <https://doi.org/10.1097/BCR.0000000000000584>
- 74 Hess CT. [Hydrocolloids: Healing by Occlusion.]. *Adv Wound Care* 2010(1). <https://doi.org/10.1089/9781934854013.110>
- 75 Ågren MS, Mertz PM, Franzén L. A comparative study of three occlusive dressings in the treatment of full-thickness wounds in pigs. *J Am Acad Dermatol* 1997; 36(1):53–58. [https://doi.org/10.1016/S0190-9622\(97\)70325-6](https://doi.org/10.1016/S0190-9622(97)70325-6)
- 76 Varghese MC, Balin AK, Carter DM, Caldwell D. Local environment of chronic wounds under synthetic dressings. *Arch Dermatol* 1986; 122(1):52–57. <https://doi.org/10.1001/archderm.1986.01660130056025>
- 77 Kimmel HM, Grant A, Ditata J. The Presence of Oxygen in Wound Healing. *Wounds* 2016; 28(8):264–270
- 78 Field CK, Kerstein MD. Overview of wound healing in a moist environment. *Am J Surg* 1994; 167(1A):S2–S6. [https://doi.org/10.1016/0002-9610\(94\)90002-7](https://doi.org/10.1016/0002-9610(94)90002-7)
- 79 Soltan Dallal MM, Safdari R et al. A comparison between occlusive and exposure dressing in the management of burn wound. *Burns* 2016; 42(3):578–582. <https://doi.org/10.1016/j.burns.2015.05.001>
- 80 Haith LR, Stair-Buchmann ME, Ackerman BH et al. Evaluation of Aquacel Ag for Autogenous Skin Donor Sites. *J Burn Care Res* 2015; 36(6):602–606. <https://doi.org/10.1097/BCR.0000000000000212>
- 81 Chadwick P, McCardle J. Open, non-comparative, multi-centre post clinical study of the performance and safety of a gelling fibre wound dressing on diabetic foot ulcers. *J Wound Care* 2016; 25(5):290–300. <https://doi.org/10.12968/jowc.2016.25.5.290>
- 82 Barnea Y, Amir A, Leshem D et al. Clinical comparative study of aquacel and paraffin gauze dressing for split-skin donor site treatment. *Ann Plast Surg* 2004; 53(2):132–136. <https://doi.org/10.1097/01.sap.0000112349.42549.b3>
- 83 Robinson BJ. The use of a hydrofibre dressing in wound management. *J Wound Care* 2000; 9(1):32–34. <https://doi.org/10.12968/jowc.2000.9.1.25941>
- 84 Meaume S, Perez J, Descamps H, Voinchet V, Jault P, Saunier V, et al. Use of a new, flexible lipidocolloid dressing on acute and chronic wounds: results of a clinical study. *J Wound Care* 2011; 20(4):180–185. <https://doi.org/10.12968/jowc.2011.20.4.180>
- 85 Karlsson M, Lindgren M, Jarnhed-Andersson I, Tarplia E. Dressing the split-thickness skin graft donor site: a randomized clinical trial. *Adv Skin Wound Care* 2014; 27(1):20–25. <https://doi.org/10.1097/01.ASW.0000437786.92529.22>
- 86 Dornseifer U, Lonic D, Gerstung T et al. The ideal split-thickness skin graft donor-site dressing: a clinical comparative trial of a modified polyurethane dressing and aquacel. *Plast Reconstr Surg* 2011; 128(4):918–924. <https://doi.org/10.1097/PRS.0b013e3182268c02>
- 87 Dumville JC, Deshpande S, O'Meara S, Speak K. Hydrocolloid dressings for healing diabetic foot ulcers. *Cochrane Database Syst Rev* 2012; (2):CD009099
- 88 Palfreyman S, Nelson EA, Michaels JA. Dressings for venous leg ulcers: systematic review and meta-analysis. *BMJ* 2007; 335(7613):244. <https://doi.org/10.1136/bmj.39248.634977.AE>
- 89 Valle MF, Maruthur NM, Wilson LM, Malas M, Qazi U, Haberl E, et al. Comparative effectiveness of advanced wound dressings for patients with chronic venous leg ulcers: a systematic review. *Wound Repair Regen* 2014; 22(2):193–204. <https://doi.org/10.1111/wrr.12151>
- 90 Pott FS, Meier MJ, Stocco JG et al. The effectiveness of hydrocolloid dressings versus other dressings in the healing of pressure ulcers in adults and older adults: a systematic review and meta-analysis. *Rev Lat Am Enfermagem* 2014; 22(3):511–520. <https://doi.org/10.1590/0104-1169.3480.2445>

- 91 Health CA/DA/Ti. Dressing Materials for the Treatment of Pressure Ulcers in Patients in Long-Term Care Facilities: A Review of the Comparative Clinical Effectiveness and Guidelines. Ottawa ON. Canadian Agency for Drugs and Technologies in Health. 2013; 2013(Nov):18.
- 92 Singh A, Halder S, Chumber S et al. Meta-analysis of randomized controlled trials on hydrocolloid occlusive dressing versus conventional gauze dressing in the healing of chronic wounds. *Asian J Surg* 2004; 27(4):326–332. [https://doi.org/10.1016/S1015-9584\(09\)60061-0](https://doi.org/10.1016/S1015-9584(09)60061-0)
- 93 Verbelen J, Hoeksema H, Heyneman A et al. Aquacel((R)) Ag dressing versus Acticoat dressing in partial thickness burns: a prospective, randomized, controlled study in 100 patients. Part 1: burn wound healing. *Burns* 2014; 40(3):416–427. <https://doi.org/10.1016/j.burns.2013.07.008>
- 94 Muangman P, Pundee C, Opananon S, Muangman S. A prospective, randomized trial of silver containing hydrofiber dressing versus 1% silver sulfadiazine for the treatment of partial thickness burns. *Int Wound J* 2010; 7(4):271–276. <https://doi.org/10.1111/j.1742-481X.2010.00690.x>
- 95 Hoffman AS. Hydrogels for biomedical applications. *Adv Drug Deliv Rev* 2012; 64:18–23. <https://doi.org/10.1016/j.addr.2012.09.010>
- 96 Eisenbud D, Hunter H, Kessler L, Zulkowski K. Hydrogel wound dressings: where do we stand in 2003? *Ostomy Wound Manage* 2003; 49(10):52–57
- 97 Sawada Y, Urushidate S, Yotsuyanagi T, Ishita K. Is prolonged and excessive cooling of a scalded wound effective? *Burns* 1997; 23(1):55–58
- 98 Atkin L, Rippon M. Autolysis: mechanisms of action in the removal of devitalised tissue. *Br J Nurs* 2016; 25(20 Suppl):S40–S47. <https://doi.org/10.12968/bjon.2016.25.20.S40>
- 99 Madaghiale M, Sannino A, Ambrosio L, Demitri C. Polymeric hydrogels for burn wound care: Advanced skin wound dressings and regenerative templates. *Burns Trauma* 2014; 2(4):153–161. <https://doi.org/10.4103/2321-3868.143616>
- 100 Sun G, Zhang X, Shen YI et al. Dextran hydrogel scaffolds enhance angiogenic responses and promote complete skin regeneration during burn wound healing. *Proc Natl Acad Sci USA* 2011; 108(52):20976–20981. <https://doi.org/10.1073/pnas.1115973108>
- 101 Poranki D, Whitener W, Howse S et al. Evaluation of skin regeneration after burns in vivo and rescue of cells after thermal stress in vitro following treatment with a keratin biomaterial. *J Biomater Appl* 2014; 29(1):26–35. <https://doi.org/10.1177/0885328213513310>
- 102 Nacer Khodja A, Mahlous M et al. Evaluation of healing activity of PVA/chitosan hydrogels on deep second degree burn: pharmacological and toxicological tests. *Burns* 2013; 39(1):98–104. <https://doi.org/10.1016/j.burns.2012.05.021>
- 103 Meng H, Chen L, Ye Z et al. The effect of a self-assembling peptide nanofiber scaffold (peptide) when used as a wound dressing for the treatment of deep second degree burns in rats. *J Biomed Mater Res B Appl Biomater* 2009; 89B(2):379–391. <https://doi.org/10.1002/jbm.b.31226>
- 104 Loo Y, Wong YC, Cai EZ et al. Ultrashort peptide nanofibrous hydrogels for the acceleration of healing of burn wounds. *Biomaterials* 2014; 35(17):4805–4814. <https://doi.org/10.1016/j.biomaterials.2014.02.047>
- 105 Shen YI, Song HH, Papa AE et al. Acellular Hydrogels for Regenerative Burn Wound Healing: Translation from a Porcine Model. *J Invest Dermatol* 2015 Oct; 135(10):2519–2529. <https://doi.org/10.1038/jid.2015.182>
- 106 Guilbaud J. European comparative clinical study of Inerpan: a new wound dressing in treatment of partial skin thickness burns. *Burns* 1992; 18(5):419–422.
- 107 Loan F, Cassidy S, Marsh C, Simcock J. Keratin-based products for effective wound care management in superficial and partial thickness burns injuries. *Burns* 2016; 42(3):541–547.
- 108 Wasiaik J, Cleland H, Campbell F, Spinks A. Dressings for superficial and partial thickness burns. *Cochrane Database Syst Rev* 2013; (3):CD002106
- 109 Dumville JC, O'Meara S, Deshpande S, Speak K. Hydrogel dressings for healing diabetic foot ulcers. *Cochrane Database Syst Rev* 2011; (9):CD009101
- 110 Dumville JC, Stubbs N, Keogh SJ, Walker RM, Liu Z. Hydrogel dressings for treating pressure ulcers. *Cochrane Database Syst Rev* 2015; (2):CD011226
- 111 Thomas S. Alginate dressings in surgery and wound management — part 1. *J Wound Care* 2000; 9(2):56–60. <https://doi.org/10.12968/jowc.2000.9.2.26338>
- 112 Grizzi I, Braud C, Vert M. Calcium alginate dressings - I. Physico-chemical characterization and effect of sterilization. *J Biomater Sci Polym Ed* 1998; 9(2):189–204. <https://doi.org/10.1163/156856298X00514>
- 113 Thomas S. Alginate dressings in surgery and wound management: part 2. *J Wound Care* 2000; 9(3):115–119. <https://doi.org/10.12968/jowc.2000.9.3.25959>
- 114 Otterlei M, Ostgaard K, Skjåk-Braek G et al. Induction of cytokine production from human monocytes stimulated with alginate. *J Immunother* (1991) 1991; 10(4):286–291.
- 115 Otterlei M, Sundan A, Skjåk-Braek G et al. Similar mechanisms of action of defined polysaccharides and lipopolysaccharides: characterization of binding and tumor necrosis factor alpha induction. *Infect Immun* 1993; 61(5):1917–1925
- 116 Zimmermann U, Klöck G, Federlin K et al. Production of mitogen-contamination free alginates with variable ratios of mannuronic acid to guluronic acid by free flow electrophoresis. *Electrophoresis* 1992; 13(1):269–274. <https://doi.org/10.1002/elps.1150130156>
- 117 Doyle JW, Roth TP, Smith RM, et al. Effect of calcium alginate on cellular wound healing processes modeled in vitro. *J Biomed Mater Res* 1996; 32(4):561–568. [https://doi.org/10.1002/\(SICI\)1097-4636\(199612\)32:4<561::AID-JBM9>3.0.CO;2-P](https://doi.org/10.1002/(SICI)1097-4636(199612)32:4<561::AID-JBM9>3.0.CO;2-P)
- 118 Attwood AI. Calcium alginate dressing accelerates split skin graft donor site healing. *Br J Plast Surg* 1989; 42(4):373–379. [https://doi.org/10.1016/0007-1226\(89\)90001-5](https://doi.org/10.1016/0007-1226(89)90001-5)
- 119 Thomas S, Loveless P. Observations on the fluid handling properties of alginate dressings. *Pharm J* 1992; 248(6693):850–851.
- 120 Reddy M, Gill SS, Kalkar SR et al. Treatment of pressure ulcers: a systematic review. *JAMA* 2008; 300(22):2647–2662. <https://doi.org/10.1001/jama.2008.778>
- 121 Belmin J, Meaume S, Rabus MT et al. Sequential treatment with calcium alginate dressings and hydrocolloid dressings accelerates pressure ulcer healing in older subjects: a multicenter randomized trial of sequential versus nonsequential treatment with hydrocolloid dressings alone. *J Am Geriatr Soc* 2002; 50(2):269–274. <https://doi.org/10.1046/j.1532-5415.2002.50058.x>
- 122 Opananon S, Muangman P, Namviriyachote N. Clinical effectiveness of alginate silver dressing in outpatient management of partial-thickness burns. *Int Wound J* 2010; 7(6):467–471. <https://doi.org/10.1111/j.1742-481X.2010.00718.x>
- 123 van der Veen VC, van der Wal MB, van Leeuwen MC, Ulrich MM,

- Middelkoop E. Biological background of dermal substitutes. *Burns* 2010; 36(3):305–321.
- 124 Hughes OB, Rakosi A, Macquhae F et al. A Review of Cellular and Acellular Matrix Products. *Plast Reconstr Surg* 2016; 138(3 Suppl):138S–147S. <https://doi.org/10.1097/PRS.0000000000002643>
- 125 Dagalakis N, Flink J, Stasikelis P et al. Design of an artificial skin. Part III. Control of pore structure. *J Biomed Mater Res* 1980; 14(4):511–528. <https://doi.org/10.1002/jbm.820140417>
- 126 Rehfeldt F, Engler A, Eckhardt A et al. Cell responses to the mechanochemical microenvironment—Implications for regenerative medicine and drug delivery. *Adv Drug Deliv Rev* 2007; 59(13):1329–1339. <https://doi.org/10.1016/j.addr.2007.08.007>
- 127 Moiemens NS, Staiano JJ, Ojeh NO, et al. Reconstructive surgery with a dermal regeneration template: clinical and histologic study. *Plast Reconstr Surg* 2001; 108(1):93–103. <https://doi.org/10.1097/00006534-200107000-00015>
- 128 Hinz B. Masters and servants of the force: The role of matrix adhesions in myofibroblast force perception and transmission. *Eur J Cell Biol* 2006; 85(3-4):175–181. <https://doi.org/10.1016/j.jecb.2005.09.004>
- 129 Aarabi S, Bhatt KA, Shi Y et al. Mechanical load initiates hypertrophic scar formation through decreased cellular apoptosis. *FASEB J* 2007; 21(12):3250–3261. <https://doi.org/10.1096/fj.07-8218.com>
- 130 Greaves NS, Iqbal SA, Hodgkinson T et al. Skin substitute-assisted repair shows reduced dermal fibrosis in acute human wounds validated simultaneously by histology and optical coherence tomography. *Wound Repair Regen* 2015; 23(4):483–94. <https://doi.org/10.1111/wrr.12308>
- 131 Burke JF, Yannas I, Quinby WC Jr et al. Successful use of a physiologically acceptable artificial skin in the treatment of extensive burn injury. *Ann Surg* 1981; 194(4):413–428. <https://doi.org/10.1097/0000658-198110000-00005>
- 132 van Zuijlen PP, van Trier AJ, Vloemans JF et al. Graft survival and effectiveness of dermal substitution in burns and reconstructive surgery in a one-stage grafting model. *Plast Reconstr Surg* 2000; 106(3):615–623. <https://doi.org/10.1097/00006534-200009010-00014>
- 133 Nguyen DQ, Potokar TS, Price P. An objective long-term evaluation of Integra (a dermal skin substitute) and split thickness skin grafts, in acute burns and reconstructive surgery. *Burns* 2010; 36(1):23–38.
- 134 Böttcher-Haberzeth S, Biedermann T et al. Matriderm® 1 mm versus Integra® Single Layer 1.3 mm for one-step closure of full thickness skin defects: a comparative experimental study in rats. *Pediatr Surg Int* 2012; 28(2):171–177. <https://doi.org/10.1007/s00383-011-2990-5>
- 135 Ralston DR, Layton C, Dalley AJ et al. The requirement for basement membrane antigens in the production of human epidermal/dermal composites in vitro. *Br J Dermatol* 1999; 140(4):605–615. <https://doi.org/10.1046/j.1365-2133.1999.02758.x>
- 136 Cazzell S, Vayser D, Pham H, Walters J et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. *Wound Repair Regen* 2017; 25(3):483–97. <https://doi.org/10.1111/wrr.12551>
- 137 Widjaja W, Tan J, Maitz PK. Efficacy of dermal substitute on deep dermal to full thickness burn injury: a systematic review. *ANZ J Surg* 2017; 87(6):446–452. <https://doi.org/10.1111/ans.13920>
- 138 Vloemans AF, Hermans MH, van der Wal MB et al. Optimal treatment of partial thickness burns in children: a systematic review. *Burns* 2014; 40(2):177–190.
- 139 Hundeshagen G, Collins VN, Wurzer P et al. A Prospective, Randomized, Controlled Trial Comparing the Outpatient Treatment of Pediatric and Adult Partial-Thickness Burns with Suprathel or Mepilex Ag. *J Burn Care Res* 2017; 1. <https://doi.org/10.1097/BCR.0000000000000584>
- 140 Li X, Meng X, Wang X et al. Human acellular dermal matrix allograft: A randomized, controlled human trial for the long-term evaluation of patients with extensive burns. *Burns* 2015; 41(4):689–699.
- 141 Lagus H, Sarlomo-Rikala M, Bohlring T, Vuola J. Prospective study on burns treated with Integra (R), a cellulose sponge and split thickness skin graft Comparative clinical and histological study-Randomized controlled trial. *Burns* 2013; 39(8):1577–1587.
- 142 Wood F, Martin L, Lewis D et al. A prospective randomised clinical pilot study to compare the effectiveness of Biobrane (R) synthetic wound dressing, with or without autologous cell suspension, to the local standard treatment regimen in paediatric scald injuries. *Burns* 2012; 38(6):830–839.
- 143 Bloemen MC, van der Wal MB, Verhaegen PD, Nieuwenhuis MK et al. Clinical effectiveness of dermal substitution in burns by topical negative pressure: A multicenter randomized controlled trial. *Wound Repair Regen* 2012; 20(6):797–805. <https://doi.org/10.1111/j.1524-475X.2012.00845.x>
- 144 Ryssel H, Gazyakan E, Germann G, Ohlbauer M. The use of MatriDerm (R) in early excision and simultaneous autologous skin grafting in burns - a pilot study. *Burns* 2008; 34(1):93–7.
- 145 Branski LK, Herndon DN, Pereira C et al. Longitudinal assessment of Integra in primary burn management: A randomized pediatric clinical trial. *Crit Care Med* 2007; 35(11):2615–2623. <https://doi.org/10.1097/01.CCM.0000285991.36698.E2>
- 146 Cassidy C, Peter SDS, Lacey S et al. Biobrane versus Duoderm for the treatment of intermediate thickness burns in children: A prospective, randomized trial. *Burns* 2005; 31(7):890–893.
- 147 Campitiello F, Mancone M, Della Corte A et al. To evaluate the efficacy of an acellular flowable matrix in comparison with a wet dressing for the treatment of patients with diabetic foot ulcers: a randomized clinical trial. *Updates Surg* 2017; 69(4):523–529. <https://doi.org/10.1007/s13304-017-0461-9>
- 148 Robb GL, Gurtner GC, Pham H et al. healing rates in a multicenter assessment of a sterile, room temperature, acellular dermal matrix versus conventional care wound management and an active comparator in the treatment of full-thickness diabetic foot ulcers. *Eplasty* 2016; 16:e27
- 149 Alvarez OM, Smith T, Gilbert TW et al. Diabetic foot ulcers treated with porcine urinary bladder extracellular matrix and total contact cast: interim analysis of a randomized, controlled trial. *Wounds* 2017; WND520170227-1
- 150 Driver VR, Lavery LA, Reyzelman AM et al. A clinical trial of Integra Template for diabetic foot ulcer treatment. *Wound Repair Regen* 2015; 23(6):891–900. <https://doi.org/10.1111/wrr.12357>
- 151 Zhang Y, Xing SZ. Treatment of diabetic foot ulcers using Mepilex Lite Dressings: a pilot study. *Exp Clin Endocrinol Diabetes* 2014; 122(04):227–230. <https://doi.org/10.1055/s-0034-1370918>
- 152 Alvarez OM, Smith T, Gilbert TW et al. Diabetic Foot Ulcers Treated With Porcine Urinary Bladder Extracellular Matrix and Total Contact Cast: Interim Analysis of a Randomized, Controlled Trial. *Wounds* 2017; 29(5):140–146
- 153 Greer N, Foman NA, MacDonald R et al. Advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers: a

- systematic review. *Ann Intern Med* 2013 ; 159(8):532–542. <https://doi.org/10.7326/0003-4819-159-8-201310150-00006>
- 154 Fries CA, Ayalew Y, Penn-Barwell JG et al. Prospective randomised controlled trial of nanocrystalline silver dressing versus plain gauze as the initial post-debridement management of military wounds on wound microbiology and healing. *Injury* 2014; 45(7):1111–1116. <https://doi.org/10.1016/j.injury.2013.12.005>
- 155 Totty JP, Bua N, Smith GE et al. Diallylcarbamoyl chloride (DACC)-coated dressings in the management and prevention of wound infection: a systematic review. *J Wound Care* 2017; 26(3):107–114. <https://doi.org/10.12968/jowc.2017.26.3.107>
- 156 Dumville JC, Gray TA, Walter CJ et al. Dressings for the prevention of surgical site infection. *Cochrane Database Syst Rev* 2016; 12:CD003091
- 157 Draeos ZD, Rizer RL, Trookman NS. A comparison of postprocedural wound care treatments: Do antibiotic-based ointments improve outcomes? *J Am Acad Dermatol* 2011; 64(3 Suppl):S23–S29. <https://doi.org/10.1016/j.jaad.2010.11.010>
- 158 Levender MM, Davis SA, Kwatra SG et al. Use of topical antibiotics as prophylaxis in clean dermatologic procedures. *J Am Acad Dermatol* 2012; 66(3):445–451.e3. <https://doi.org/10.1016/j.jaad.2011.02.005>
- 159 Ninan N, Forget A, Shastri VP et al. Anti-bacterial and anti-inflammatory pH-responsive tannic acid-carboxylated agarose composite hydrogels for wound healing. *ACS Appl Mater Interfaces* 2016; 8(42):28511–28521. <https://doi.org/10.1021/acsami.6b10491>
- 160 Bullock AJ, Pickavance P, Haddow DB et al. Development of a calcium-chelating hydrogel for treatment of superficial burns and scalds. *Regen Med* 2010; 5(1):55–64. <https://doi.org/10.2217/rme.09.67>
- 161 Idrovo JP, Yang WL, Jacob A et al. Combination of adrenomedullin with its binding protein accelerates cutaneous wound healing. *PLoS One* 2015; 10(3):e0120225. <https://doi.org/10.1371/journal.pone.0120225>
- 162 Shan YH, Peng LH, Liu X et al. Silk fibroin/gelatin electrospun nanofibrous dressing functionalized with astragaloside IV induces healing and anti-scar effects on burn wound. *Int J Pharm* 2015; 479(2):291–301. <https://doi.org/10.1016/j.ijpharm.2014.12.067>
- 163 Dave RN, Joshi HM, Venugopalan VP. Biomedical evaluation of a novel nitrogen oxides releasing wound dressing. *J Mater Sci Mater Med* 2012; 23(12):3097–3106. <https://doi.org/10.1007/s10856-012-4766-4>
- 164 Horch RE, Popescu LM, Polykandriotis E. History of Regenerative Medicine. In: Steinhoff G, editor: *Regenerative Medicine - from Protocol to Patient: 4 Regenerative Therapies I*. Springer International Publishing, 2016
- 165 Maehle AH. Ambiguous cells: the emergence of the stem cell concept in the nineteenth and twentieth centuries. *Notes and Records of the Royal Society* 2011; 65(4):359–378. <https://doi.org/10.1098/rsnr.2011.0023>
- 166 Daar AS, Greenwood HL. A proposed definition of regenerative medicine. *J Tissue Eng Regen Med* 2007; 1(3):179–184. <https://doi.org/10.1002/term.20>
- 167 Balaji S, Keswani SG, Crombleholme TM. The role of mesenchymal stem cells in the regenerative wound healing phenotype. *Adv Wound Care* 2012; 1(4):159–165. <https://doi.org/10.1089/wound.2012.0361>
- 168 Bey E, Prat M, Duhamel P et al. Emerging therapy for improving wound repair of severe radiation burns using local bone marrow-derived stem cell administrations. *Wound Repair Regen* 2010; 18(1):50–58. <https://doi.org/10.1111/j.1524-475X.2009.00562.x>
- 169 Dash N, Dash S, Routray P et al Targeting nonhealing ulcers of lower extremity in human through autologous bone marrow-derived mesenchymal stem cells. *Rejuvenation Res* 2009; 12(5):359–366. <https://doi.org/10.1089/rej.2009.0872>
- 170 Hu MS, Leavitt T, Malhotra S et al. Stem cell-based therapeutics to improve wound healing. *Plast Surg Int* 2015; 2015:1–7. <https://doi.org/10.1155/2015/383581>
- 171 Martínez-Santamaría L, Conti CJ et al. The regenerative potential of fibroblasts in a new diabetes-induced delayed humanised wound healing model. *Exp Dermatol* 2013; 22(3):195–201. <https://doi.org/10.1111/exd.12097>
- 172 Mehanna RA, Nabil I, Attia N, et al. The effect of bone marrow-derived mesenchymal stem cells and their conditioned media topically delivered in fibrin glue on chronic wound healing in rats. *BioMed Res Int* 2015; 2015:1–12. <https://doi.org/10.1155/2015/846062>
- 173 Zollino I, Zuolo M, Gianesini S et al. Autologous adipose-derived stem cells: Basic science, technique, and rationale for application in ulcer and wound healing. *Phlebology* 2017; 32(3):160–171. <https://doi.org/10.1177/0268355516641546>
- 174 Bassetto F, Vindigni V, Scarpa C. Fat grafting in wound healing and scar control. *J Wound Tech*. 2016.
- 175 Wu KH, Mo XM, Han ZC, Zhou B. Stem cell engraftment and survival in the ischemic heart. *Ann Thorac Surg* 2011; 92(5):1917–1925. <https://doi.org/10.1016/j.athoracsur.2011.07.012>
- 176 Hocking AM, Gibran NS. Mesenchymal stem cells: Paracrine signaling and differentiation during cutaneous wound repair. *Exp Cell Res* 2010; 316(14):2213–2219. <https://doi.org/10.1016/j.yexcr.2010.05.009>
- 177 Volarevic V, Arsenijevic N, Lukic ML, Stojkovic M. Concise review: Mesenchymal stem cell treatment of the complications of diabetes mellitus. *Stem Cells* 2011; 29(1):5–10. <https://doi.org/10.1002/stem.556>
- 178 Moll G, Alm JJ, Davies LC et al. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? *Stem Cells* 2014; 32(9):2430–2442. <https://doi.org/10.1002/stem.1729>
- 179 Pollock K, Sumstad D, Kadidlo D et al. Clinical mesenchymal stromal cell products undergo functional changes in response to freezing. *Cytotherapy* 2015; 17(1):38–45. <https://doi.org/10.1016/j.jcyt.2014.06.008>
- 180 Caplan AI, Correa D. The MSC: an injury drugstore. *Cell Stem Cell* 2011; 9(1):1–15. <https://doi.org/10.1016/j.stem.2011.06.008>
- 181 Sorrell JM, Caplan AI. Topical delivery of mesenchymal stem cells and their function in wounds. *Stem Cell Res Ther* 2010; 1(4):30. <https://doi.org/10.1186/scrt30>
- 182 Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. *J Invest Dermatol* 2007; 127(3):514–525. <https://doi.org/10.1038/sj.jid.5700701>
- 183 Sirbulescu RF, Boehm CK et al. Mature B cells accelerate wound healing after acute and chronic diabetic skin lesions. *Wound Repair Regen* 2017; 25(5):774–791. <https://doi.org/10.1111/wrr.12584>
- 184 Kirsner R, Marston W, Snyder R et al. Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial. *Lancet (London, England)* 2012; 380(9846):977–985. [https://doi.org/10.1016/S0140-6736\(12\)60644-8](https://doi.org/10.1016/S0140-6736(12)60644-8)
- 185 Parcells AL, Karcich J, Granick MS, Marano MA. The use of fetal bovine dermal scaffold (primatrix) in the management of full-thickness hand burns.

Eplasty 2014; 14:e36

186 Zavan B, Vindigni V, Vezzù K et al. Hyaluronan based porous nanoparticles enriched with growth factors for the treatment of ulcers: a placebo-controlled study. *J Mater Sci Mater Med* 2009; 20(1):235–247. <https://doi.org/10.1007/s10856-008-3566-3>

187 Pandis L, Zavan B, Abatangelo G et al. Hyaluronan-based scaffold for in vivo regeneration of the rat vena cava: Preliminary results in an animal model. *J Biomed Mater Res A* 2010; 93(4):1289–1296

188 Sorice S, Rustad KC, Li AY, Gurtner GC. The role of stem cell therapeutics in wound healing. *Plast Reconstr Surg* 2016; 138(3 Suppl):31S–41S. <https://doi.org/10.1097/PRS.0000000000002646>

189 Vindigni V, Tonello C, Lancerotto L et al. Preliminary report of in vitro reconstruction of a vascularized tendonlike structure: a novel application for adipose-derived stem cells. *Ann Plast Surg* 2013; 71(6):664–670. <https://doi.org/10.1097/SAP.0b013e3182583e99>

190 Papanas N, Eleftheriadou I, Tentolouris N, Maltezos E. Advances in the topical treatment of diabetic foot ulcers. *Curr Diabetes Rev* 2012; 8(3):209–218. <https://doi.org/10.2174/157339912800563963>

191 Moiola EK, Bolotin D, Alam M. Regenerative medicine and stem cells in dermatology. *Dermatol Surg* 2017; 43(5):625–634

192 Knighton DR, Ciresi KF, Fiegel VD et al. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). *Ann Surg* 1986; 204(3):322–330. <https://doi.org/10.1097/0000658-198609000-00011>

193 Dohan Ehrenfest DM, Andia I, Zumstein MA et al. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: current consensus, clinical implications and perspectives. *Muscles Ligaments Tendons J* 2014; 4(1):3–9

194 Magalon J, Bausset O, Serratrice N et al. Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model. *Arthroscopy* 2014; 30(5):629–638.

195 Lundquist R, Dziegiel MH, Agren MS. Bioactivity and stability of endogenous fibrogenic factors in platelet-rich fibrin. *Wound Repair Regen* 2008; 16(3):356–363. <https://doi.org/10.1111/j.1524-475X.2007.00344.x>

196 Ågren MS, Rasmussen K, Pakkenberg B, Jørgensen B. Growth factor and proteinase profile of Vivostat® platelet-rich fibrin linked to tissue repair. *Vox Sang* 2014; 107(1):37–43. <https://doi.org/10.1111/vox.12120>

197 Del Corso MD. Letters to the Editor - Choukroun's platelet-rich fibrin membranes in periodontal surgery: understanding the biomaterial or believing in the magic of growth factors? *J Periodontol* 2009; 80:1694–1697. <https://doi.org/10.1902/jop.2009.090253>

198 Lundquist R, Holmstrom K, Clausen C et al. Characteristics of an autologous leukocyte and platelet-rich fibrin patch intended for the treatment of recalcitrant wounds. *Wound Repair Regen* 2013; 21(1):66–76. <https://doi.org/10.1111/j.1524-475X.2012.00870.x>

199 Lundquist R. Autologous Autologous cell-rich biomaterial (LeucoPatch) in the treatment of diabetic foot ulcers. In: Ågren M (eds). *Wound Healing Biomaterials* (Vol. 1). Woodhead Publishing, 2016.

200 Thomsen K, Trøstrup H, Christophersen L et al. The phagocytic fitness of leucopatches may impact the healing of chronic wounds. *Clin Exp Immunol* 2016; 184(3):368–377. <https://doi.org/10.1111/cei.12773>

201 Jørgensen B, Karlsmark T, Vogensen H et al. A pilot study to evaluate the safety and clinical performance of Leucopatch, an autologous,

additive-free, platelet-rich fibrin for the treatment of recalcitrant chronic wounds. *Int J Low Extrem Wounds* 2011; 10(4):218–223. <https://doi.org/10.1177/1534734611426755>

202 Londahl M, Tarnow L, Karlsmark T et al. Use of an autologous leucocyte and platelet-rich fibrin patch on hard-to-heal DFUs: a pilot study. *J Wound Care* 2015; 24(4):172–178

203 Driver VR, Hanft J, Fylling CP, Beriou JM. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. *Ostomy/Wound Management*. 2006; 52(6):68–70, 2, 4 passim

204 Villela DL, Santos VL. Evidence on the use of platelet-rich plasma for diabetic ulcer: A systematic review. *Growth Factors* 2010; 28(2):111–116. <https://doi.org/10.3109/08977190903468185>

205 Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I et al. Autologous platelet-rich plasma for treating chronic wounds. *Cochrane Database Syst Rev* 2016; (5):CD006899

206 Margolis DJ, Kantor J, Santanna J et al. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. *Diabetes Care* 2001; 24(3):483–488. <https://doi.org/10.2337/diacare.24.3.483>

207 Decision Memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds. FDA 2012. <https://tinyurl.com/y999una9> (accessed 22 March 2018).

208 NICE Clinical guideline 10. Type 2 Diabetes Foot Problems Prevention and Management of Foot Problems. UK; 2004:1–29. <https://www.nice.org.uk/guidance/cg10> (accessed 21 May 2018)

209 Law JX, Chowdhury SR, Saim AB, Idrus RB. Platelet-rich plasma with keratinocytes and fibroblasts enhance healing of full-thickness wounds. *J Tissue Viability* 2017; 26(3):208–215. <https://doi.org/10.1016/j.jtv.2017.05.003>

210 Park YG, Lee IH, Park ES, Kim JY. Hydrogel and platelet-rich plasma combined treatment to accelerate wound healing in a nude mouse model. *Arch Plast Surg* 2017; 44(3):194–201. <https://doi.org/10.5999/aps.2017.44.3.194>

211 Koob TJ, Lim JJ, Masee M et al. Properties of dehydrated human amnion/chorion composite grafts: implications for wound repair and soft tissue regeneration. *J Biomed Mater Res B Appl Biomater* 2014; 102(6):1353–1362. <https://doi.org/10.1002/jbm.b.33141>

212 Koob TJ, Lim JJ, Masee M et al. Angiogenic properties of dehydrated human amnion/chorion allografts: therapeutic potential for soft tissue repair and regeneration. *Vasc Cell* 2014; 6(1):10. <https://doi.org/10.1186/2045-824X-6-10>

213 Koob TJ, Lim JJ, Zabek N, Masee M. Cytokines in single layer amnion allografts compared to multilayer amnion/chorion allografts for wound healing. *J Biomed Mater Res B Appl Biomater* 2015; 103(5):1133–1140. <https://doi.org/10.1002/jbm.b.33265>

214 Maan ZN, Rennert RC, Koob TJ et al. Cell recruitment by amnion chorion grafts promotes neovascularization. *J Surg Res* 2015; 193(2):953–962. <https://doi.org/10.1016/j.jss.2014.08.045>

215 Masee M, Chinn K, Lei J et al. Dehydrated human amnion/chorion membrane regulates stem cell activity in vitro. *J Biomed Mater Res B Appl Biomater* 2016; 104(7):1495–1503. <https://doi.org/10.1002/jbm.b.33478>

216 Masee M, Chinn K, Lim JJ et al. Type I and II diabetic adipose-derived stem cells respond in vitro to dehydrated human amnion/chorion membrane allograft treatment by increasing proliferation, migration, and altering cytokine secretion. *Adv Wound Care* 2016; 5(2):43–54. <https://doi.org/10.1089/wound.2015.0661>

- 217 Willett NJ, Thote T, Lin AS et al. Intra-articular injection of micronized dehydrated human amnion/chorion membrane attenuates osteoarthritis development. *Arthritis Res Ther* 2014; 16(1):R47. <https://doi.org/10.1186/ar4476>
- 218 Lei J, Priddy LB, Lim JJ et al. Identification of extracellular matrix components and biological factors in micronized dehydrated human amnion/chorion membrane. *Adv Wound Care* 2017; 6(2):43–53. <https://doi.org/10.1089/wound.2016.0699>
- 219 Hopkinson A, McIntosh RS, Tighe PJ et al. Amniotic membrane for ocular surface reconstruction: donor variations and the effect of handling on TGF-beta content. *Invest Ophthalmol Vis Sci* 2006; 47(10):4316–4322. <https://doi.org/10.1167/iovs.05-1415>
- 220 Zelen CM, Gould L, Serena TE et al. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ul. *Int Wound J* 2015; 12(6):724–732. <https://doi.org/10.1111/iwj.12395>
- 221 Zelen CM, Serena TE, Denozieri G, Fetterolf DE. A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. *Int Wound J* 2013; 10(5):502–507. <https://doi.org/10.1111/iwj.12097>
- 222 Zelen CM, Serena TE, Snyder RJ. A prospective, randomised comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers. *Int Wound J* 2014; 11(2):122–128. <https://doi.org/10.1111/iwj.12242>
- 223 Serena TE, Carter MJ, Le LT et al. A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. *Wound Repair Regen* 2014; 22(6):688–693. <https://doi.org/10.1111/wrr.12227>
- 224 Bianchi C, Cazzell S, Vayser D et al. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix®) allograft for the treatment of venous leg ulcers. *Int Wound J* 2018; 15(1):114–122. <https://doi.org/10.1111/iwj.12843>
- 225 Snyder RJ, Shimozaki K, Tallis A et al. A prospective, randomized, multicenter, controlled evaluation of the use of dehydrated amniotic membrane allograft compared to standard of care for the closure of chronic diabetic foot ulcer. *Wounds* 2016; 28(3):70–77
- 226 Bianchi C, Cazzell S, Vayser D et al. A multicentre randomised controlled trial evaluating the efficacy of dehydrated human amnion/chorion membrane (EpiFix(R)) allograft for the treatment of venous leg ulcers. *Int Wound J* 2018; 15(1):114–122. <https://doi.org/10.1111/iwj.12843>
- 227 Zelen CM, Serena TE, Gould L et al. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. *Int Wound J* 2016; 13(2):272–282. <https://doi.org/10.1111/iwj.12566>
- 228 Berthiaume F, Maguire TJ, Yarmush ML. Tissue engineering and regenerative medicine: history, progress, and challenges. *Annu Rev Chem Biomol Eng* 2011; 2(1):403–430. <https://doi.org/10.1146/annurev-chembioeng-061010-114257>
- 229 Rennert RC, Rodrigues M, Wong VW et al. Biological therapies for the treatment of cutaneous wounds: Phase III and launched therapies. *Expert Opin Biol Ther* 2013; 13(11):1523–1541. <https://doi.org/10.1517/1471259.8.2013.842972>
- 230 Maver T, Maver U, Kleinschek KS et al. Advanced therapies of skin injuries. *Wien Klin Wochenschr* 2015; 127(S5 Suppl 5):187–198. <https://doi.org/10.1007/s00508-015-0859-7>
- 231 Vig K, Chaudhari A, Tripathi S et al. Advances in Skin Regeneration Using Tissue Engineering. *Int J Mol Sci* 2017; 18(4):789. <https://doi.org/10.3390/ijms18040789>
- 232 Jackson CJ, Tønseth KA, Utheim TP. Cultured epidermal stem cells in regenerative medicine. *Stem Cell Res Ther* 2017; 8(1):155. <https://doi.org/10.1186/s13287-017-0587-1>
- 233 Ho J, Walsh C, Yue D et al. Current Advancements and Strategies in Tissue Engineering for Wound Healing: A Comprehensive Review. *Adv Wound Care* 2017; 6(6):191–209. <https://doi.org/10.1089/wound.2016.0723>
- 234 Campitiello F, Della CA, Guerniero R et al. Efficacy of a New Flowable Wound Matrix in Tunneled and Cavity Ulcers: A Preliminary Report. *Wounds*. 2015; 27(6):152–157
- 235 Felder JM 3rd, Goyal SS, Attinger CE. A systematic review of skin substitutes for foot ulcers. *Plast Reconstr Surg* 2012; 130(1):145–164. <https://doi.org/10.1097/PRS.0b013e318254b1ea>
- 236 Candage R, Jones K, Luchette FA et al. Use of human acellular dermal matrix for hernia repair: Friend or foe? *Surgery* 2008; 144(4):703–711. <https://doi.org/10.1016/j.surg.2008.06.018>
- 237 Zhang Z, Michniak-Kohn BB. Tissue engineered human skin equivalents. *Pharmaceutics* 2012; 4(1):26–41. <https://doi.org/10.3390/pharmaceutics4010026>
- 238 Guerra O, Maclin MM. Non-crosslinked porcine-derived acellular dermal matrix for the management of complex ventral abdominal wall hernias: a report of 45 cases. *Hernia* 2014; 18(1):71–79. <https://doi.org/10.1007/s10029-013-1148-x>
- 239 Greaves NS, Iqbal SA, Baguneid M, Bayat A. The role of skin substitutes in the management of chronic cutaneous wounds. *Wound Repair Regen* 2013; 21(2):194–210. <https://doi.org/10.1111/wrr.12029>
- 240 Werber B, Martin E. A prospective study of 20 foot and ankle wounds treated with cryopreserved amniotic membrane and fluid allograft. *J Foot Ankle Surg* 2013; 52(5):615–621. <https://doi.org/10.1053/j.jfas.2013.03.024>
- 241 Langer R, Vacanti J. Tissue engineering. *Science* 1993; 260(5110):920–926. <https://doi.org/10.1126/science.8493529>
- 242 Rheinwatd JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation keratinized colonies from single cell is. *Cell* 1975; 6(3):331–343. [https://doi.org/10.1016/S0092-8674\(75\)80001-8](https://doi.org/10.1016/S0092-8674(75)80001-8)
- 243 O'Connor N, Mulliken JB, Banks-Schlegel S et al. Grafting of burns with cultured epithelium prepared from autologous epidermal cells. *Lancet* 1981; 317(8211):75–78. [https://doi.org/10.1016/S0140-6736\(81\)90006-4](https://doi.org/10.1016/S0140-6736(81)90006-4)
- 244 Gallico GG 3rd, O'Connor NE, Compton CC et al. Permanent coverage of large burn wounds with autologous cultured human epithelium. *N Engl J Med* 1984; 311(7):448–451. <https://doi.org/10.1056/NEJM198408163110706>
- 245 Biedermann T, Boettcher-Haberzeth S, Reichmann E. Tissue engineering of skin for wound coverage. *Eur J Pediatr Surg* 2013; 23(05):375–382. <https://doi.org/10.1055/s-0033-1352529>
- 246 Hansbrough JF, Boyce ST, Cooper ML, Foreman TJ. Burn wound closure with cultured autologous keratinocytes and fibroblasts attached to a collagen-glycosaminoglycan substrate. *JAMA* 1989; 262(15):2125–2130. <https://doi.org/10.1001/jama.1989.03430150093032>

- 247 Boyce ST, Goretzky MJ, Greenhalgh DG et al. Comparative assessment of cultured skin substitutes and native skin autograft for treatment of full-thickness burns. *Ann Surg* 1995; 222(6):743–752. <https://doi.org/10.1097/00000658-199512000-00008>
- 248 Bell E, Ehrlich H, Buttle D, Nakatsuji T. Living tissue formed in vitro and accepted as skin-equivalent tissue of full thickness. *Science* 1981; 211(4486):1052–1054. <https://doi.org/10.1126/science.7008197>
- 249 Falanga V, Sabolinski M. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. *Wound Repair Regen* 1999; 7(4):201–207
- 250 Stone RC, Stojadinovic O, Rosa AM et al. A bioengineered living cell construct activates an acute wound healing response in venous leg ulcers. *Sci Transl Med* 2017; 9(371):eaaf8611. <https://doi.org/10.1126/scitranslmed.aaf8611>
- 251 Limova M, Mauro T. Treatment of leg ulcers with cultured epithelial autografts: clinical study and case reports. *Ostomy Wound Manage* 1995; 41(8):48–60.
- 252 Slonkova V, Kino-oka M, Mazza S et al. Cultured epithelial autografts for the management of a chronic pretibial leg ulcer due to congenital valvular aplasia. *Dermatology* 1999; 198(1):101–103. <https://doi.org/10.1159/00018079>
- 253 Wille JJ, Burdge JJ, Pitttelkow MR. Rapid healing of chronic venous stasis leg ulcers treated by the application of a novel serum-free cultured autologous epidermis. *Wound Repair Regen* 2011; 19(4):464–474. <https://doi.org/10.1111/j.1524-475X.2011.00702.x>
- 254 Tausche AK, Skaria M, Bohlen L et al. An autologous epidermal equivalent tissue-engineered from follicular outer root sheath keratinocytes is as effective as split-thickness skin autograft in recalcitrant vascular leg ulcers. *Wound Repair Regen* 2003; 11(4):248–252.
- 255 Renner R, Harth W, Simon JC. Transplantation of chronic wounds with epidermal sheets derived from autologous hair follicles—the Leipzig experience. *Int Wound J* 2009; 6(3):226–232. <https://doi.org/10.1111/j.1742-481X.2009.00609.x>
- 256 Ortega-Zilic N, Hunziker T, Lächli S et al. EpiDex® Swiss field trial 2004–2008. *Dermatology* 2010; 221(4):365–372. <https://doi.org/10.1159/000321333>
- 257 Moustafa M, Bullock AJ, Creagh FM et al. Randomized, controlled, single-blind study on use of autologous keratinocytes on a transfer dressing to treat nonhealing diabetic ulcers. *Regen Med* 2007; 2(6):887–902. <https://doi.org/10.2217/17460751.2.6.887>
- 258 Hart CE, Loewen-Rodriguez A, Lessem J. Dermagraft: Use in the Treatment of Chronic Wounds. *Adv Wound Care* 2012; 1(3):138–141. <https://doi.org/10.1089/wound.2011.0282>
- 259 Frykberg RG, O'Connor RM, Tallis A, Tierney E. Limb salvage using advanced technologies: a case report. *Int Wound J* 2015; 12(1):53–58. <https://doi.org/10.1111/iwj.12050>
- 260 Harding K, Sumner M, Cardinal M. A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers. *Int Wound J* 2013; 10(2):132–137. <https://doi.org/10.1111/iwj.12053>
- 261 Frykberg RG, Cazzell SM, Arroyo-Rivera J et al. Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis. *J Wound Care* 2016; 25(Sup7 Suppl 7):S18–S25. <https://doi.org/10.12968/jowc.2016.25.Sup7.S18>
- 262 Zaulyanov L, Kirsner RS. A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers. *Clin Interv Aging* 2007; 2(1):93–98. <https://doi.org/10.2147/cia.2007.2.1.93>
- 263 Duranceau L, Genest H, Bortoluzzi P et al. Successful grafting of a novel autologous tissue-engineered skin substitutes (dermis and epidermis) on twelve burn patients. *J Burn Care Res* 2014; 35:S121.
- 264 Boyce ST, Simpson PS, Rieman MT et al. Randomized, Paired-Site Comparison of Autologous Engineered Skin Substitutes and Split-Thickness Skin Graft for Closure of Extensive, Full-Thickness Burns. *J Burn Care Res* 2017; 38(2):61–70. <https://doi.org/10.1097/BCR.0000000000000401> Medline
- 265 Falanga V, Margolis D, Alvarez O et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. *Arch Dermatol* 1998; 134(3):293–300. <https://doi.org/10.1001/archderm.134.3.293>
- 266 Veves A, Falanga V, Armstrong DG et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. *Diabetes Care* 2001; 24(2):290–295. <https://doi.org/10.2337/diacare.24.2.290>
- 267 Falanga V. Wound healing and chronic wounds. *J Cutan Med Surg* 1998; 3 Suppl 1:S1–S1
- 268 Girard D, Laverdet B, Buhé V et al. Biotechnological management of skin burn injuries: challenges and perspectives in wound healing and sensory recovery. *Tissue Eng Part B Rev* 2017; 23(1):59–82. <https://doi.org/10.1089/ten.teb.2016.0195>
- 269 Berthod F, Symes J, Tremblay N et al. Spontaneous fibroblast-derived pericyte recruitment in a human tissue-engineered angiogenesis model in vitro. *J Cell Physiol* 2012; 227(5):2130–2137. <https://doi.org/10.1002/jcp.22943>
- 270 Klar AS, Guven S, Biedermann T et al. Tissue-engineered dermo-epidermal skin grafts prevascularized with adipose-derived cells. *Biomaterials* 2014; 35(19):5065–5078. <https://doi.org/10.1016/j.biomaterials.2014.02.049>
- 271 Tremblay PL, Hudon V, Berthod F et al. Inosculation of tissue-engineered capillaries with the host's vasculature in a reconstructed skin transplanted on mice. *Am J Transplant* 2005; 5(5):1002–1010. <https://doi.org/10.1111/j.1600-6143.2005.00790.x>
- 272 Mir TA, Nakamura M. Three-dimensional bioprinting: toward the era of manufacturing human organs as spare parts for healthcare and medicine. *Tissue Eng Part B Rev* 2017; 23(3):245–256. <https://doi.org/10.1089/ten.teb.2016.0398>
- 273 Cubo N, Garcia M, Del Canizo JF et al. 3D bioprinting of functional human skin: production and in vivo analysis. *Biofabrication* 2016; 9(1):015006. <https://doi.org/10.1088/1758-5090/9/1/015006>
- 274 El-Serafi AT, El-Serafi IT, Elmasry M et al. Skin regeneration in three dimensions, current status, challenges and opportunities. *Differentiation* 2017; 96:26–29. <https://doi.org/10.1016/j.diff.2017.06.002>
- 275 Pouchet LJ, Thepot A, Albouy M et al. Human skin 3D bioprinting using scaffold-free approach. *Adv Healthc Mater* 2017; 6(4). <https://doi.org/10.1002/adhm.201601101>
- 276 Groll J, Boland T, Blunk T et al. Biofabrication: reappraising the definition of an evolving field. *Biofabrication* 2016; 8(1):013001. <https://doi.org/10.1088/1758-5090/8/1/013001>
- 277 Murphy SV, Atala A. 3D bioprinting of tissues and organs. *Nat Biotechnol* 2014; 32(8):773–785. <https://doi.org/10.1038/nbt.2958>

- 278 Sheehan P, Jones P, Caselli A et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. *Diabetes Care* 2003; 26(6):1879–1882
- 279 Robertson KR. Digby's receipts. *Ann Med Hist* 1925;7:216–219
- 280 Ennis WJ, Lee C, Meneses PA. A biochemical approach to wound healing through the use of modalities. *Clin Dermatol* 2007; 25(1):63–72. <https://doi.org/10.1016/j.clindermatol.2006.09.008>
- 281 Milne CT, Ciccarelli AO, Lassy M. A comparison of collagenase to hydrogel dressings in wound debridement. *Wounds* 2010; 22(11):270–274
- 282 Piaggese A, Goretti C, Mazzurco S et al. A randomized controlled trial to examine the efficacy and safety of a new super-oxidized solution for the management of wide postsurgical lesions of the diabetic foot. *Int J Low Extrem Wounds* 2010; 9(1):10–15. <https://doi.org/10.1177/1534734610361945>
- 283 Stanley BJ. Negative Pressure Wound Therapy. *Vet Clin North Am Small Anim Pract* 2017; 47(6):1203–1220
- 284 Apelqvist J, Willy C, Fagerdahl AM et al. EWMA Document: negative pressure wound therapy. *J Wound Care* 2017; 26(Sup3):S1–S154. <https://doi.org/10.12968/jowc.2017.26.Sup3.S1>
- 285 Gottrup F, Dissemont J, Baines C et al. Use of oxygen therapies in wound healing. *J Wound Care* 2017; 26(Sup5):S1–S43. <https://doi.org/10.12968/jowc.2017.26.Sup5.S1>
- 286 Strohal R, Apelqvist J, Dissemont J et al. EWMA Document: Debridement. An updated overview and clarification of the principle role of debridement. *J Wound Care* 2013; 22 (Suppl. 1):S1–S52. <https://doi.org/10.12968/jowc.2013.22.Sup1.S1>
- 287 Jocham D, Chaussy C, Schmiedt E. Extracorporeal shock wave lithotripsy. *Urol Int* 1986; 41(5):357–368
- 288 Haupt G. Use of extracorporeal shock waves in the treatment of pseudarthrosis, tendinopathy and other orthopedic diseases. *J Urol* 1997; 158(1):4–11. <https://doi.org/10.1097/00005392-199707000-00003>
- 289 Thiel M. Application of shock waves in medicine. *Clin Orthop Relat Res* 2001(387):18–21.
- 290 Schaden W, Fischer A, Sailler A. Extracorporeal shock wave therapy of nonunion or delayed osseous union. *Clin Orthop Relat Res* 2001(387):90–94
- 291 Wang CJ, Kuo YR, Wu RW et al. Extracorporeal shockwave treatment for chronic diabetic foot ulcers. *J Surg Res* 2009; 152(1):96–103. <https://doi.org/10.1016/j.jss.2008.01.026>
- 292 Al-Kurdi D, Bell-Syer SE, Flemming K. Therapeutic ultrasound for venous leg ulcers. *Cochrane Database Syst Rev* 2008(1):CD001180. <https://doi.org/10.1002/14651858.CD001180.pub2>
- 293 Larking AM, Dupont S, Clinton M et al. Randomized control of extracorporeal shock wave therapy versus placebo for chronic decubitus ulceration. *Clin Rehabil* 2010; 24(3):222–229. <https://doi.org/10.1177/0269215509346083>
- 294 Mittermayr R, Antonic V, Hartinger J et al. Extracorporeal shock wave therapy (ESWT) for wound healing: technology, mechanisms, and clinical efficacy. *Wound Repair Regen* 2012; 20(4):456–465. <https://doi.org/10.1111/j.1524-475X.2012.00796.x>
295. Shrivastava SK, Kailash. Shock wave treatment in medicine. *J Biosci* 2005; 30(2):269–275.
- 296 Stojadinovic A, Elster EA, Anam K et al. Angiogenic response to extracorporeal shock wave treatment in murine skin isografts. *Angiogenesis* 2008; 11(4):369–380 <https://doi.org/10.1007/s10456-008-9120-6>
- 297 Gotte G, Amelio E, Russo S et al. Short-time non-enzymatic nitric oxide synthesis from L-arginine and hydrogen peroxide induced by shock waves treatment. *FEBS Lett* 2002; 520(1–3):153–155.
- 298 Ottomann C, Hartmann B, Tyler et al. Prospective randomized trial of accelerated re-epithelization of skin graft donor sites using extracorporeal shock wave therapy. *J Am Coll Surg* 2010; 211(3):361–367. <https://doi.org/10.1016/j.jamcollsurg.2010.05.012>
- 299 Kuo YR, Wang CT, Wang FS et al. Extracorporeal shock wave treatment modulates skin fibroblast recruitment and leukocyte infiltration for enhancing extended skin-flap survival. *Wound Repair Regen* 2009; 17(1):80–87 <https://doi.org/10.1111/j.1524-475X.2008.00444.x>
- 300 Aicher A, Heeschen C, Sasaki K et al. Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia. *Circulation* 2006; 114(25):2823–2830. <https://doi.org/10.1161/CIRCULATIONAHA.106.628623>
- 301 Chen YJ, Wurtz T, Wang CJ et al. Recruitment of mesenchymal stem cells and expression of TGF-beta 1 and VEGF in the early stage of shock wave-promoted bone regeneration of segmental defect in rats. *J Orthop Res* 2004; 22(3):526–534. <https://doi.org/10.1016/j.jorthres.2003.10.005>
- 302 Wang FS, Wang CJ, Chen YJ et al. Ras induction of superoxide activates ERK-dependent angiogenic transcription factor HIF-1 alpha and VEGF-A expression in shock wave-stimulated osteoblasts. *J Biol Chem* 2004; 279(11):10331–10337. <https://doi.org/10.1074/jbc.M308013200>
- 303 Ciampa AR, de Prati AC, Amelio E et al. Nitric oxide mediates anti-inflammatory action of extracorporeal shock waves. *FEBS Lett* 2005; 579(30):6839–6845. <https://doi.org/10.1016/j.febslet.2005.11.023>
- 304 Zins SR, Amare MF, Tadaki DK. Comparative analysis of angiogenic gene expression in normal and impaired wound healing in diabetic mice: effects of extracorporeal shock wave therapy. *Angiogenesis* 2010; 13(4):293–304. <https://doi.org/10.1007/s10456-010-9186-9>
- 305 Davis TA, Stojadinovic A, Anam K et al. Extracorporeal shock wave therapy suppresses the early proinflammatory immune response to a severe cutaneous burn injury. *Int Wound J* 2009; 6(1):1–21. <https://doi.org/10.1111/j.1742-481X.2008.00540.x>
- 306 Dymarek R, Halski T, Ptaszkowski K et al. Extracorporeal shock wave therapy as an adjunct wound treatment: a systematic review of the literature. *Ostomy Wound Manage* 2014; 60(7):26–39
- 307 Qureshi AA, Ross KM, Ogawa R, Orgill DP. Shock wave therapy in wound healing. *Plast Reconstr Surg* 2011; 128(6):721e–7e. <https://doi.org/10.1097/PRS.0b013e318230c7d1>
- 308 Aschermann I, Noor S, Venturelli S et al. Extracorporeal shock waves activate migration, proliferation and inflammatory pathways in fibroblasts and keratinocytes, and improve wound healing in an open-label, single-arm study in patients with therapy-refractory chronic leg ulcers. *Cell Physiol Biochem* 2017; 41(3):890–906. <https://doi.org/10.1159/000460503>
- 309 Jeppesen SM, Yderstraede KB, Rasmussen BS et al. Extracorporeal shockwave therapy in the treatment of chronic diabetic foot ulcers: a prospective randomised trial. *J Wound Care* 2016; 25(11):641–649. <https://doi.org/10.12968/jowc.2016.25.11.641>
- 310 Omar MT, Alghadir A, Al-Wahhabi KK, Al-Askar AB. Efficacy of shock wave therapy on chronic diabetic foot ulcer: a single-blinded randomized

- controlled clinical trial. *Diabetes Res Clin Pract* 2014; 106(3):548–554. <https://doi.org/10.1016/j.diabres.2014.09.024>
- 311 Arno A, Garcia O, Hernan I et al. Extracorporeal shock waves, a non-surgical method to treat severe burns. *Burns* 2010; 36(6):844–849. <https://doi.org/10.1016/j.burns.2009.11.012>
- 312 Moretti B, Notarnicola A, Maggio G et al. The management of neuropathic ulcers of the foot in diabetes by shock wave therapy. *BMC Musculoskelet Disord* 2009; 10:54. <https://doi.org/10.1186/1471-2474-10-54>
- 313 Saggini R, Figus A, Troccola A et al. Extracorporeal shock wave therapy for management of chronic ulcers in the lower extremities. *Ultrasound Med Biol* 2008; 34(8):1261–2671. <https://doi.org/10.1016/j.ultrasmedbio.2008.01.010>
- 314 Schaden W, Thiele R, Kolpl C et al. Shock wave therapy for acute and chronic soft tissue wounds: a feasibility study. *J Surg Res* 2007; 143(1):1–12. <https://doi.org/10.1016/j.jss.2007.01.009>
- 315 Funk RH, Monsees T, Ozkucur N. Electromagnetic effects - From cell biology to medicine. *Prog Histochem Cytochem* 2009; 43(4):177–264. <https://doi.org/10.1016/j.proghi.2008.07.001>
- 316 Das S, Kumar S, Jain S et al. Exposure to ELF- magnetic field promotes restoration of sensori-motor functions in adult rats with hemisection of thoracic spinal cord. *Electromagn Biol Med* 2012; 31(3):180–194. <https://doi.org/10.3109/15368378.2012.695706>
- 317 Pasek J, Pasek T, Sieron-Stoltny K et al. Electromagnetic fields in medicine - The state of art. *Electromagn Biol Med* 2016; 35(2):170–175. <https://doi.org/10.3109/15368378.2015.1048549>
- 318 Sienkiewicz Z. Biological effects of electromagnetic fields and radiation. *J Radiol Prot* 1998; 18(3):185–193.
- 319 Zhao M, Pu J, Forrester JV, McCaig CD. Membrane lipids, EGF receptors, and intracellular signals colocalize and are polarized in epithelial cells moving directionally in a physiological electric field. *FASEB J* 2002; 16(8):857–859. <https://doi.org/10.1096/fj.01-0811.fje>
- 320 McCaig CD, Rajnicek AM, Song B, Zhao M. Controlling cell behavior electrically: current views and future potential. *Physiol Rev* 2005; 85(3):943–978. <https://doi.org/10.1152/physrev.00020.2004>
- 321 Callaghan MJ, Chang EI, Seiser N et al. Pulsed electromagnetic fields accelerate normal and diabetic wound healing by increasing endogenous FGF-2 release. *Plast Reconstr Surg* 2008; 121(1):130–141. <https://doi.org/10.1097/01.prs.0000293761.27219.84>
322. McCaig CD, Song B, Rajnicek AM. Electrical dimensions in cell science. *J Cell Sci* 2009; 122(Pt 23):4267–4276. <https://doi.org/10.1242/jcs.023564>
323. Costin GE, Birlea SA, Norris DA. Trends in wound repair: cellular and molecular basis of regenerative therapy using electromagnetic fields. *Curr Mol Med* 2012; 12(1):14–26.
324. Zhao M, Song B, Pu J et al. Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. *Nature* 2006; 442(7101):457–640. <https://doi.org/10.1038/nature04925>
- 325 Patruno A, Amerio P, Pesce M et al. Extremely low frequency electromagnetic fields modulate expression of inducible nitric oxide synthase, endothelial nitric oxide synthase and cyclooxygenase-2 in the human keratinocyte cell line HaCat: potential therapeutic effects in wound healing. *Br J Dermatol* 2010; 162(2):258–266. <https://doi.org/10.1111/j.1365-2133.2009.09527.x>
- 326 Rodemann HP, Bayreuther K, Pfleiderer G. The differentiation of normal and transformed human fibroblasts in vitro is influenced by electromagnetic fields. *Exp Cell Res* 1989; 182(2):610–621
- 327 Vianale G, Reale M, Amerio P et al. Extremely low frequency electromagnetic field enhances human keratinocyte cell growth and decreases proinflammatory chemokine production. *Br J Dermatol* 2008; 158(6):1189–1196. <https://doi.org/10.1111/j.1365-2133.2008.08540.x>
- 328 Zimolag E, Borowczyk-Michalowska J, Kedracka-Krok S et al. Electric field as a potential directional cue in homing of bone marrow-derived mesenchymal stem cells to cutaneous wounds. *Biochim Biophys Acta* 2017; 1864(2):267–279. <https://doi.org/10.1016/j.bbamcr.2016.11.011>
- 329 Pullar CE. The biological basis for electrical stimulation as a therapy to heal chronic wounds. *J Wound Technol*. 2009;(6): 3–7
- 330 Tian J, Dale H. (eds.) *Chemotaxis, Methods and Protocols (Methods in Molecular Biology)*. Humana Press, 2009
- 331 Kim MS, Lee MH, Kwon BJ et al. Golgi polarization plays a role in the directional migration of neonatal dermal fibroblasts induced by the direct current electric fields. *Biochem Biophys Res Commun* 2015; 460(2):255–260. <https://doi.org/10.1016/j.bbrc.2015.03.021>
- 332 Sivamani RK, Pullar CE, Manabat-Hidalgo CG et al. Stress-mediated increases in systemic and local epinephrine impair skin wound healing: potential new indication for beta blockers. *PLoS Med* 2009; 6(1):e1000012. <https://doi.org/10.1371/journal.pmed.1000012>
- 333 Sun Y, Do H, Gao J, Zhao R et al. Keratocyte fragments and cells utilize competing pathways to move in opposite directions in an electric field. *Curr Biol* 2013; 23(7):569–574. <https://doi.org/10.1016/j.cub.2013.02.026>
- 334 Ud-Din S, Sebastian A, Giddings P et al. Angiogenesis is induced and wound size is reduced by electrical stimulation in an acute wound healing model in human skin. *PLoS One* 2015; 10(4):e0124502. <https://doi.org/10.1371/journal.pone.0124502>
335. Debus ES, Diener H, Bultemann A, Larena-Avellaneda A, Augustin M. Use of topical applied electrical stimulation therapy (woundEL(R)) in wound healing - Case studies. *J Wound Technol*. 2009;(6): 9-11
- 336 Weber SA, Vonhoff PA, Owens FJ, et al. Development of a multi—electrode electrical stimulation device to improve chronic wound healing. *Conf Proc IEEE Eng Med Biol Soc* 2009; 2009:2145–2148
- 337 Franek A, Kostur R, Polak A et al. Using high-voltage electrical stimulation in the treatment of recalcitrant pressure ulcers: results of a randomized, controlled clinical study. *Ostomy Wound Manage* 2012; 58(3):30–44
- 338 Houghton PE, Campbell KE, Fraser CH et al. Electrical stimulation therapy increases rate of healing of pressure ulcers in community-dwelling people with spinal cord injury. *Arch Phys Med Rehabil* 2010; 91(5):669–678. <https://doi.org/10.1016/j.apmr.2009.12.026>
- 339 Petrofsky JS, Lawson D, Berk L, Suh H. Enhanced healing of diabetic foot ulcers using local heat and electrical stimulation for 30 min three times per week. *J Diabetes* 2010; 2(1):41–46. <https://doi.org/10.1111/j.1753-0407.2009.00058.x>
- 340 Ahmad ET. High-voltage pulsed galvanic stimulation: effect of treatment duration on healing of chronic pressure ulcers. *Ann Burns Fire Disasters* 2008; 21(3):124–128
- 341 Janković A, Binić I. Frequency rhythmic electrical modulation system in the treatment of chronic painful leg ulcers. *Arch Dermatol Res* 2008; 300(7):377–383. <https://doi.org/10.1007/s00403-008-0875-9>
342. Junger M, Arnold A, Zuder D et al. Local therapy and treatment costs of chronic, venous leg ulcers with electrical stimulation (Dermapulse): a

- prospective, placebo controlled, double blind trial. *Wound Repair Regen* 2008; 16(4):480–487. <https://doi.org/10.1111/j.1524-475X.2008.00393.x>
- 343 Franek A, Krol P, Chmielewska D et al. [The venous ulcer therapy in use of the selected physical methods--circumstances for clinical application]. [Article in Polish] *Pol Merkuriusz Lek* 2006; 20(119):622–624.
- 344 Houghton PE, Kincaid CB, Lovell M et al. Effect of electrical stimulation on chronic leg ulcer size and appearance. *Phys Ther* 2003; 83(1):17–28
- 345 Barczak CA, Barnett RI, Childs EJ, Bosley LM. Fourth national pressure ulcer prevalence survey. *Adv Wound Care* 1997; 10(4):18–26.
- 346 Peters EJ, Lavery LA, Armstrong DG, Fleischli JG. Electric stimulation as an adjunct to heal diabetic foot ulcers: A randomized clinical trial. *Arch Phys Med Rehabil* 2001; 82(6):721–725. <https://doi.org/10.1053/apmr.2001.23780>
- 347 Baker LL, Chambers R, DeMuth SK, Villar F. Effects of electrical stimulation on wound healing in patients with diabetic ulcers. *Diabetes Care* 1997; 20(3):405–412. <https://doi.org/10.2337/diacare.20.3.405>
348. Baker LL, Rubayi S, Villar F, Demuth SK. Effect of electrical stimulation waveform on healing of ulcers in human beings with spinal cord injury. *Wound Repair Regen* 1996; 4(1):21–28. <https://doi.org/10.1046/j.1524-475X.1996.40106.x>
- 349 Wood JM, Evans PE 3rd, Schallreuter KU et al. A multicenter study on the use of pulsed low-intensity direct current for healing chronic stage II and stage III decubitus ulcers. *Arch Dermatol* 1993; 129(8):999–1009. <https://doi.org/10.1001/archderm.1993.01680290071011>
- 350 Feedar JA, Kloth LC, Gentzkow GD. Chronic dermal ulcer healing enhanced with monophasic pulsed electrical stimulation. *Phys Ther* 1991; 71(9):639–649. <https://doi.org/10.1093/ptj/71.9.639>
- 351 Carley PJ, Wainapel SF. Electrotherapy for acceleration of wound healing: low intensity direct current. *Arch Phys Med Rehabil* 1985; 66(7):443–446
- 352 Koel G, Houghton PE. Electrostimulation: current status, strength of evidence guidelines, and meta-analysis. *Adv Wound Care* 2014; 3(2):118–126. <https://doi.org/10.1089/wound.2013.0448>
- 353 Markov MS. Magnetic field therapy: a review. *Electromagn Biol Med* 2007; 26(1):1–23. <https://doi.org/10.1080/15368370600925342>
- 354 Hastings GW, Mahmud FA. Electrical effects in bone. *J Biomed Eng* 1988; 10(6):515–521. [https://doi.org/10.1016/0141-5425\(88\)90109-4](https://doi.org/10.1016/0141-5425(88)90109-4)
- 355 Becker RO, Selden G. *The Body Electric: Electromagnetism and the foundation of life*. Morrow, 1985
- 356 Funk RH, Monsees TK. Effects of electromagnetic fields on cells: physiological and therapeutical approaches and molecular mechanisms of interaction. A review. *Cells Tissues Organs* 2006; 182(2):59–78. <https://doi.org/10.1159/000093061>
- 357 Garland DE, Moses B, Salyer W. Long-term follow-up of fracture nonunions treated with PEMFs. *Contemp Orthop* 1991; 22(3):295–302
- 358 Johnson MT, Waite LR, Nindl G. Noninvasive treatment of inflammation using electromagnetic fields: current and emerging therapeutic potential. *Biomed Sci Instrum* 2004; 40:469–474
- 359 Ross CL, Harrison BS. The use of magnetic field for the reduction of inflammation: a review of the history and therapeutic results. *Altern Ther Health Med* 2013; 19(2):47–54
- 360 Pesce M, Patrino A, Speranza L, Reale M. Extremely low frequency electromagnetic field and wound healing: implication of cytokines as biological mediators. *Eur Cytokine Netw* 2013; 24(1):1–10
- 361 Saliev T, Mustapova Z, Kulsharova G, Bulanin D, Mikhailovsky S. Therapeutic potential of electromagnetic fields for tissue engineering and wound healing. *Cell Prolif* 2014; 47(6):485–493. <https://doi.org/10.1111/cpr.12142>
- 362 Piaggese A, Sambataro M, Nicoletti C, Goretti C, Iacopi E, Coppelli A. Safety and effectiveness of therapeutic magnetic resonance in diabetic foot ulcers: a prospective randomised controlled trial. *J Wound Care* 2016; 25(12):704–711. <https://doi.org/10.12968/jowc.2016.25.12.704>
- 363 Abbruzzese L, Iacopi E, Coppelli A et al. Safety and effectiveness of therapeutic magnetic resonance in the management of postsurgical lesion of the diabetic foot. *Int J Low Extrem Wounds* 2015; 14(1):4–10. <https://doi.org/10.1177/1534734614568374>
- 364 Gupta A, Taly A, Srivastava A et al. Efficacy of pulsed electromagnetic field therapy in healing of pressure ulcers: a randomized control trial. *Neurol India* 2009; 57(5):622–626. <https://doi.org/10.4103/0028-3886.57820>
- 365 Cañedo-Dorantes L, García-Cantú R, Barrera R et al. Healing of chronic arterial and venous leg ulcers through systemic effects of electromagnetic fields. *Arch Med Res* 2002; 33(3):281–289. [https://doi.org/10.1016/S0188-4409\(02\)00357-0](https://doi.org/10.1016/S0188-4409(02)00357-0)
- 366 Stiller MJ, Pak GH, Shupack JL et al. A portable pulsed electromagnetic field (PEMF) device to enhance healing of recalcitrant venous ulcers: a double-blind, placebo-controlled clinical trial. *Br J Dermatol* 1992; 127(2):147–154. <https://doi.org/10.1111/j.1365-2133.1992.tb08047.x>
- 367 Todd DJ, Heylings DJ, Allen GE, McMillin WP. Treatment of chronic varicose ulcers with pulsed electromagnetic fields: a controlled pilot study. *Ir Med J* 1991; 84(2):54–55
- 368 Ieran M, Zaffuto S, Bagnacani M et al. Effect of low frequency pulsing electromagnetic fields on skin ulcers of venous origin in humans: A double-blind study. *J Orthop Res* 1990; 8(2):276–282. <https://doi.org/10.1002/jor.1100080217>
- 369 Vecchia P. Exposure of humans to electromagnetic fields. Standards and regulations. *Ann Ist Super Sanita* 2007; 43(3):260–267
- 370 Brizhik L, Zavan B, Fermi E. The working principle of magnetic resonance therapy. *Cornell Univ Library arXiv:150904475 [physics.med-ph]*. 2015.
- 371 Touitou Y. [Evaluation of the effects of electric and magnetic fields in humans]. [Article in French] *Ann Pharm Fr* 2004; 62(4):219–232. [https://doi.org/10.1016/S0003-4509\(04\)94306-4](https://doi.org/10.1016/S0003-4509(04)94306-4)
- 372 Jarrett P, Scragg R. A short history of phototherapy, vitamin D and skin disease. *Photochem Photobiol Sci* 2017; 16(3):283–290. <https://doi.org/10.1039/C6PP00406G>
- 373 Kuffler DP. Photobiomodulation in promoting wound healing: a review. *Regen Med* 2016; 11(1):107–122. <https://doi.org/10.2217/rme.15.82>
- 374 Mignon C, Botchkareva NV, Uzunbajakava NE, Tobin DJ. Photobiomodulation devices for hair regrowth and wound healing: a therapy full of promise but a literature full of confusion. *Exp Dermatol* 2016; 25(10):745–749. <https://doi.org/10.1111/exd.13035>
- 375 Anders JJ, Lanzafame RJ, Arany PR. Low-level light/laser therapy versus photobiomodulation therapy. *Photomed Laser Surg* 2015; 33(4):183–184. <https://doi.org/10.1089/pho.2015.9848>
- 376 Schindl A, Schindl M, Pernerstorfer-Schön H, Schindl L. Low-intensity laser therapy: a review. *J Investig Med* 2000; 48(5):312–326

- 377 Sommer AP, Pinheiro AL, Mester AR et al. Biostimulatory windows in low-intensity laser activation: lasers, scanners, and NASA's light-emitting diode array system. *J Clin Laser Med Surg* 2001; 19(1):29–33. <https://doi.org/10.1089/104454701750066910>
- 378 Chaves ME, Araújo AR, Piancastelli AC, Pinotti M. Effects of low-power light therapy on wound healing: LASER x LED. *An Bras Dermatol* 2014; 89(4):616–623. <https://doi.org/10.1590/abd1806-4841.20142519>
- 379 Schubert EF. Light emitting diodes. Cambridge University Press, 2003.
- 380 Prindeze NJ, Moffatt LT, Shupp JW. Mechanisms of action for light therapy: A review of molecular interactions. *Exp Biol Med* 2012; 237(11):1241–1248. <https://doi.org/10.1258/ebm.2012.012180>
- 381 Karu TI, Kolyakov SF. Exact action spectra for cellular responses relevant to phototherapy. *Photomed Laser Surg* 2005; 23(4):355–361. <https://doi.org/10.1089/pho.2005.23.355>
- 382 Karu TI. [Molecular mechanisms of the therapeutic effect of low intensity laser radiation]. [Article in Russian] *Laser life sci.* 1988; 2:53–74.
- 383 Karu T. Primary and secondary mechanisms of action of visible to near-IR radiation on cells. *J Photochem Photobiol B* 1999; 49(1):1–17. [https://doi.org/10.1016/S1011-1344\(98\)00219-X](https://doi.org/10.1016/S1011-1344(98)00219-X)
- 384 Oton-Leite AF, Silva GB, Morais MO et al. Effect of low-level laser therapy on chemoradiotherapy-induced oral mucositis and salivary inflammatory mediators in head and neck cancer patients. *Lasers Surg Med* 2015; 47(4):296–305. <https://doi.org/10.1002/lsm.22349>
- 385 Saglam M, Kantarci A, Dundar N, Hakki SS. Clinical and biochemical effects of diode laser as an adjunct to nonsurgical treatment of chronic periodontitis: a randomized, controlled clinical trial. *Lasers Med Sci* 2014; 29(1):37–46. <https://doi.org/10.1007/s10103-012-1230-0>
- 386 Ayuk SM, Abrahamse H, Houreld NN. The role of matrix metalloproteinases in diabetic wound healing in relation to photobiomodulation. *J Diabetes Res* 2016; 2016:1–9. <https://doi.org/10.1155/2016/2897656>
- 387 Rodrigo SM, Cunha A, Pozza DH et al. Analysis of the systemic effect of red and infrared laser therapy on wound repair. *Photomed Laser Surg* 2009; 27(6):929–935. <https://doi.org/10.1089/pho.2008.2306>
- 388 Romanelli M, Piaggese A, Scapagnini G et al. EUREKA study – the evaluation of real-life use of a biophotonic system in chronic wound management: an interim analysis. *Drug Des Devel Ther* 2017; 11:3551–3558. <https://doi.org/10.2147/DDDT.S142580>
- 389 Nikolis A, Bernstein S, Kinney B et al. A randomized, placebo-controlled, single-blinded, split-faced clinical trial evaluating the efficacy and safety of KLOX-001 gel formulation with KLOX light-emitting diode light on facial rejuvenation. *Clin Cosmet Invest Dermatol* 2016; 9:115–125
- 390 Kajağar BM, Godhi AS, Pandit A, Khatri S. Efficacy of low level laser therapy on wound healing in patients with chronic diabetic foot ulcers—a randomised control trial. *Indian J Surg* 2012; 74(5):359–363. <https://doi.org/10.1007/s12262-011-0393-4>
- 391 Kaviani A, Djavid GE, Ataie-Fashtami L et al. A randomized clinical trial on the effect of low-level laser therapy on chronic diabetic foot wound healing: a preliminary report. *Photomed Laser Surg* 2011; 29(2):109–114. <https://doi.org/10.1089/pho.2009.2680>
- 392 Landau Z, Migdal M, Lipovsky A, Lubart R. Visible light-induced healing of diabetic or venous foot ulcers: a placebo-controlled double-blind study. *Photomed Laser Surg* 2011; 29(6):399–404. <https://doi.org/10.1089/pho.2010.2858>
- 393 Minatel DG, Frade MA, França SC, Enwemeka CS. Phototherapy promotes healing of chronic diabetic leg ulcers that failed to respond to other therapies. *Lasers Surg Med* 2009; 41(6):433–441. <https://doi.org/10.1002/lsm.20789>
- 394 Schubert V. Effects of phototherapy on pressure ulcer healing in elderly patients after a falling trauma. A prospective, randomized, controlled study. *Photodermatol Photoimmunol Photomed* 2001; 17(1):32–38. <https://doi.org/10.1034/j.1600-0781.2001.017001032.x>
- 395 Papageorgiou P, Katsambas A, Chu A. Phototherapy with blue (415 nm) and red (660 nm) light in the treatment of acne vulgaris. *Br J Dermatol* 2000; 142(5):973–978. <https://doi.org/10.1046/j.1365-2133.2000.03481.x>
- 396 Gupta A, Avci P, Dai T, Huang YY, Hamblin MR. Ultraviolet Radiation in Wound Care: Sterilization and Stimulation. *Adv Wound Care* 2013; 2(8):422–437. <https://doi.org/10.1089/wound.2012.0366>
- 397 Hockberger PE. A history of ultraviolet photobiology for humans, animals and microorganisms. *Photochem Photobiol* 2002; 76(6):561–579. [https://doi.org/10.1562/0031-8655\(2002\)076<0561:AHOUJPF>2.0.CO;2](https://doi.org/10.1562/0031-8655(2002)076<0561:AHOUJPF>2.0.CO;2)
- 398 Thai TP, Houghton PE, Campbell KE, Woodbury MG. Ultraviolet light C in the treatment of chronic wounds with MRSA: a case study. *Ostomy Wound Manage* 2002; 48(11):52–60
- 399 Percival SL, Francolini I, Donelli G. Low-level laser therapy as an antimicrobial and antibiofilm technology and its relevance to wound healing. *Future Microbiol* 2015; 10(2):255–272. <https://doi.org/10.2217/fmb.14.109>
- 400 Nikolis A, Scapagnini G, Romanelli M. Photobiomodulation with LumiHeal made easy. *Wounds International*. 2016; 1:1–3.
- 401 Posnett J, Franks PJ. The burden of chronic wounds in the UK. *Nurs Times* 2008; 104(3):44–45
- 402 Drexler KE. *Engines of Creation: The Coming Era of Nanotechnology*. Anchor Books, 1986.
- 403 Parani M, Lokhande G, Singh A, Gaharwar AK. Engineered nanomaterials for infection control and healing acute and chronic wounds. *ACS Appl Mater Interfaces* 2016; 8(16):10049–10069. <https://doi.org/10.1021/acsami.6b00291>
- 404 Hamdan S, Pastar I, Drakulich S et al. Nanotechnology-Driven Therapeutic Interventions in Wound Healing: Potential Uses and Applications. *ACS Central Science* 2017; 3(3):163–175. <https://doi.org/10.1021/acscentsci.6b00371>
- 405 Mordorski B, Rosen J, Friedman A. Nanotechnology as an innovative approach for accelerating wound healing in diabetes. *Diabetes Management* 2015; 5(5):329–332. <https://doi.org/10.2217/dmt.15.28>
- 406 Wang L, Hu C, Shao L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. *Int J Nanomedicine* 2017; 12:1227–1249. <https://doi.org/10.2147/IJN.S121956>
- 407 Adhya A, Bain J, Dutta G et al. Healing of burn wounds by topical treatment: A randomized controlled comparison between silver sulfadiazine and nano-crystalline silver. *J Basic Clin Pharm* 2015; 6(1):29–34. <https://doi.org/10.4103/0976-0105.145776>
- 408 Pal S, Tak YK, Song JM. Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium *Escherichia coli*. *Appl Environ Microbiol* 2007; 73(6):1712–1720. <https://doi.org/10.1128/AEM.02218-06>
- 409 Bondarenko O, Juganson K, Ivask A et al. Toxicity of Ag, CuO and ZnO nanoparticles to selected environmentally relevant test organisms and

- mammalian cells in vitro: a critical review. *Arch Toxicol* 2013; 87(7):1181–1200. <https://doi.org/10.1007/s00204-013-1079-4>
- 410 Jammongkan T, Sukumaran SK, Sugimoto M et al Towards novel wound dressings: antibacterial properties of zinc oxide nanoparticles and electrospun fiber mats of zinc oxide nanoparticle/poly(vinyl alcohol) hybrids. *Journal of Polymer Engineering* 2015; 35(6):575–586. <https://doi.org/10.1515/polyeng-2014-0319>
- 411 Rice LB. The clinical consequences of antimicrobial resistance. *Curr Opin Microbiol* 2009; 12(5):476–481. <https://doi.org/10.1016/j.mib.2009.08.001>
- 412 Zhou Z, Joslin S, Dellinger A et al. A novel class of compounds with cutaneous wound healing properties. *J Biomed Nanotechnol* 2010; 6(5):605–611. <https://doi.org/10.1166/jbn.2010.1157>
- 413 Schwentker A, Vodovotz Y, Weller R, Billiar TR. Nitric oxide and wound repair: role of cytokines? *Nitric Oxide* 2002; 7(1):1–10. [https://doi.org/10.1016/S1089-8603\(02\)00002-2](https://doi.org/10.1016/S1089-8603(02)00002-2)
- 414 Nurhasni H, Cao J, Choi M et al. Nitric oxide-releasing poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles for prolonged nitric oxide release, antibacterial efficacy, and in vivo wound healing activity. *Int J Nanomedicine* 2015; 10:3065–3080.
- 415 Chen WY, Chang HY, Lu JK et al. Self-assembly of antimicrobial peptides on gold nanodots: against multidrug-resistant bacteria and wound-healing application. *Adv Funct Mater* 2015; 25(46):7189–7199. <https://doi.org/10.1002/adfm.201503248>
- 416 Krausz AE, Adler BL, Cabral V et al. Curcumin-encapsulated nanoparticles as innovative antimicrobial and wound healing agent. *Nanomedicine* 2015; 11(1):195–206. <https://doi.org/10.1016/j.nano.2014.09.004>
- 417 Korrapati PS, Karthikeyan K, Satish A et al. Recent advancements in nanotechnological strategies in selection, design and delivery of biomolecules for skin regeneration. *Mater Sci Eng C* 2016; 67:747–765. <https://doi.org/10.1016/j.msec.2016.05.074>
- 418 Chu Y, Yu D, Wang P, Xu J, Li D, Ding M. Nanotechnology promotes the full-thickness diabetic wound healing effect of recombinant human epidermal growth factor in diabetic rats. *Wound Repair Regen* 2010; 18(5):499–505. <https://doi.org/10.1111/j.1524-475X.2010.00612.x>
- 419 Gainza G, Pastor M, Aguirre JJ et al. A novel strategy for the treatment of chronic wounds based on the topical administration of rhEGF-loaded lipid nanoparticles: In vitro bioactivity and in vivo effectiveness in healing-impaired db/db mice. *J Control Release* 2014; 185:51–61. <https://doi.org/10.1016/j.jconrel.2014.04.032>
- 420 Zhou W, Zhao M, Zhao Y, Mou Y. A fibrin gel loaded with chitosan nanoparticles for local delivery of rhEGF: preparation and in vitro release studies. *J Mater Sci Mater Med* 2011; 22(5):1221–1230. <https://doi.org/10.1007/s10856-011-4304-9>
- 421 Brem H, Kodra A, Golinko MS et al. Mechanism of sustained release of vascular endothelial growth factor in accelerating experimental diabetic healing. *J Invest Dermatol* 2009; 129(9):2275–2287. <https://doi.org/10.1038/jid.2009.26>
- 422 Xie Z, Paras CB, Weng H et al. Dual growth factor releasing multi-functional nanofibers for wound healing. *Acta Biomater* 2013; 9(12):9351–9359. <https://doi.org/10.1016/j.actbio.2013.07.030>
- 423 Shahverdi S, Hajimiri M, Esfandiari MA et al. Fabrication and structure analysis of poly(lactide-co-glycolic acid)/silk fibroin hybrid scaffold for wound dressing applications. *Int J Pharm* 2014; 473(1–2):345–355. <https://doi.org/10.1016/j.ijpharm.2014.07.021>
- 424 Dongargaonkar AA, Bowlin GL, Yang H. Electrospun blends of gelatin and gelatin-dendrimer conjugates as a wound-dressing and drug-delivery platform. *Biomacromolecules* 2013; 14(11):4038–4045. <https://doi.org/10.1021/bm401143p>
- 425 Kim HN, Hong Y, Kim MS et al. Effect of orientation and density of nanotopography in dermal wound healing. *Biomaterials* 2012; 33(34):8782–8792. <https://doi.org/10.1016/j.biomaterials.2012.08.038>
- 426 Lamers E, te Riet J, Domanski M et al. Dynamic cell adhesion and migration on nanoscale grooved substrates. *Eur Cell Mater* 2012; 23:182–194. <https://doi.org/10.22203/eCM.v023a14>
- 427 Castleberry SA, Almquist BD, Li W et al. Self-Assembled Wound Dressings Silence MMP-9 and Improve Diabetic Wound Healing In Vivo. *Adv Mater* 2016; 28(9):1809–1817. <https://doi.org/10.1002/adma.201503565>
- 428 Chueng ST, Yang L, Zhang Y, Lee KB. Multidimensional nanomaterials for the control of stem cell fate. *Nano Convergence* 2016; 3(1):23. <https://doi.org/10.1186/s40580-016-0083-9>
- 429 Tartarini D, Mele E. Adult stem cell therapies for wound healing: biomaterials and computational models. *Front Bioeng Biotechnol* 2016; 3:206. <https://doi.org/10.3389/fbioe.2015.00206>
- 430 Verdú Soriano J, Nolasco Bonmati A. [ALEA study. Treatment of chronic wounds infected by the application of silver dressings nanocrystalline combined with dressings hydrocellular]. *Rev Enferm* 2010; 33(10):6–14
- 431 Miller CN, Newall N, Kapp SE et al. A randomized-controlled trial comparing cadexomer iodine and nanocrystalline silver on the healing of leg ulcers. *Wound Repair Regen* 2010; 18(4):359–367. <https://doi.org/10.1111/j.1524-475X.2010.00603.x>
- 432 Tsang KK, Kwong EW, To TS et al. A pilot randomized, controlled study of nanocrystalline silver, manuka honey, and conventional dressing in healing diabetic foot ulcer. *Evid Based Complement Alternat Med* 2017; 2017:1–15. <https://doi.org/10.1155/2017/5294890>
- 433 Elisa B, Silvia M, Valentina D et al. Use of nanotechnology-designed footsock in the management of preulcerative conditions in the diabetic foot: results of a single, blind randomized study. *Int J Low Extrem Wounds* 2008; 7(2):82–87. <https://doi.org/10.1177/1534734608318138>
- 434 Barshes NR, Sigireddi M, Wrobel JS et al. The system of care for the diabetic foot: objectives, outcomes, and opportunities. *Diabet Foot Ankle* 2013; 4(1):21847. <https://doi.org/10.3402/dfa.v4i02.1847>
- 435 Skrepnek GH, Mills JL Sr, Armstrong DG. A diabetic emergency one million feet long: disparities and burdens of illness among diabetic foot ulcer cases within emergency departments in the United States, 2006–2010. *PLoS One* 2015; 10(8):e0134914. <https://doi.org/10.1371/journal.pone.0134914>
- 436 Armstrong DG, Boulton AJ, Bus SA. Diabetic Foot Ulcers and Their Recurrence. *N Engl J Med* 2017; 376(24):2367–2375. <https://doi.org/10.1056/NEJMra1615439>
- 437 IDF 2017. IDF Diabetes Atlas - 8th Edition: International Diabetes Federation 2017. (<http://www.diabetesatlas.org/key-messages.html>)
- 438 Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. *JAMA* 2005; 293(2):217–228. <https://doi.org/10.1001/jama.293.2.217>
- 439 Rogers LC, Andros G, Caporusso J et al. Toe and flow: Essential components and structure of the amputation prevention team. *J Vasc Surg* 2010; 52(3 Suppl):235–275. <https://doi.org/10.1016/j.jvs.2010.06.004>

- 440 Allen L, Powell-Cope G, Mbah A et al. A retrospective review of adverse events related to diabetic foot ulcers. *Ostomy Wound Manage* 2017; 63(6):30–33
- 441 Najafi B, Grewal GS, Bharara M et al. Can't stand the pressure: the association between unprotected standing, walking, and wound healing in people with diabetes. *J Diabetes Sci Technol* 2017; 11(4):657–667. <https://doi.org/10.1177/1932296816662959>
- 442 Toosizadeh N, Mohler J, Armstrong DG et al. The influence of diabetic peripheral neuropathy on local postural muscle and central sensory feedback balance control. *PLoS One* 2015; 10(8):e0135255. <https://doi.org/10.1371/journal.pone.0135255>
- 443 Lavery LA, Hunt NA, Ndjip A et al. Impact of chronic kidney disease on survival after amputation in individuals with diabetes. *Diabetes Care* 2010; 33(11):2365–2369. <https://doi.org/10.2337/dc10-1213>
- 444 Roser MC, Canavan PK, Najafi B et al. Novel In-Shoe Exoskeleton for Offloading of Forefoot Pressure for Individuals With Diabetic Foot Pathology. *J Diabetes Sci Technol* 2017; 11(5):874–882. <https://doi.org/10.1177/1932296817726349>
- 445 Armstrong DG, Mills JL. Toward a change in syntax in diabetic foot care: prevention equals remission. *J Am Podiatr Med Assoc* 2013; 103(2):161–162. <https://doi.org/10.7571/1030161>
- 446 Schwenk M, Mohler J, Wendel C et al. Wearable sensor-based in-home assessment of gait, balance, and physical activity for discrimination of frailty status: baseline results of the Arizona frailty cohort study. *Gerontology* 2015; 61(3):258–267. <https://doi.org/10.1159/000369095>
- 447 Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. *J Gerontol A Biol Sci Med Sci* 2001; 56(3):M146–M157. <https://doi.org/10.1093/gerona/56.3.M146>
- 448 Miller JD, Najafi B, Armstrong DG. Current standards and advances in diabetic ulcer prevention and elderly fall prevention using wearable technology. *Curr Geriatr Rep* 2015; 4(3):249–256. <https://doi.org/10.1007/s13670-015-0136-7>
- 449 Razjouyan J, Lee H, Parthasarathy S et al. Improving sleep quality assessment using wearable sensors by including information from postural/sleep position changes and body acceleration: a comparison of chest-worn sensors, wrist actigraphy, and polysomnography. *J Clin Sleep Med* 2017; 13(11):1301–1310. <https://doi.org/10.5664/jcs.m.6802>
- 450 Najafi B, Ron E, Enriquez A et al. Smarter sole survival: will neuropathic patients at high risk for ulceration use a smart insole-based foot protection system? *J Diabetes Sci Technol* 2017; 11(4):702–713. <https://doi.org/10.1177/1932296816689105>
- 451 Razjouyan J, Grewal GS, Talal TK et al. Does physiological stress slow down wound healing in patients with diabetes? *J Diabetes Sci Technol* 2017; 11(4):685–692. <https://doi.org/10.1177/1932296817705397>
- 452 Najafi B, Armstrong DG, Mohler J. Novel wearable technology for assessing spontaneous daily physical activity and risk of falling in older adults with diabetes. *J Diabetes Sci Technol* 2013; 7(5):1147–1160. <https://doi.org/10.1177/193229681300700507>
- 453 Edmonds M, Lázaro-Martínez JL, Alfayate-García JM et al. Sucrose octasulfate dressing versus control dressing in patients with neuroischaemic diabetic foot ulcers (Explorer): an international multicentre, double-blind, randomised, controlled trial. *Lancet Diabetes Endocrinol* 2018; 6(3):186–196. [https://doi.org/10.1016/S2213-8587\(17\)30438-2](https://doi.org/10.1016/S2213-8587(17)30438-2)
- 454 Najafi B, Talal TK, Grewal GS et al. Using plantar electrical stimulation to improve postural balance and plantar sensation among patients with diabetic peripheral neuropathy: a randomized double blinded study. *J Diabetes Sci Technol* 2017; 11(4):693–701. <https://doi.org/10.1177/1932296817695338>
- 455 Niederauer MQ, Michalek JE, Armstrong DG. A prospective, randomized, double-blind multicenter study comparing continuous diffusion of oxygen therapy to sham therapy in the treatment of diabetic foot ulcers. *J Diabetes Sci Technol* 2017; 11(5):883–891. <https://doi.org/10.1177/1932296817695574>
- 456 Kadry AM, Nosseir AAEH, Mohamed Z, Ibrahim AA. The clinical efficacy of pulsed radio frequency energy on chronic wound healing. *International Journal of PharmTech Research* 2016; 9(5):23–29
- 457 Lewin PA, Bawiec C, Sunny Y et al. 2070151 20 Khz, ultrasound assisted treatment of chronic wounds with concurrent optic monitoring: a human study. *Ultrasound Med Biol* 2015; 41(4):S65–S66. <https://doi.org/10.1016/j.ultrasmedbio.2014.12.278>
- 458 Thakral G, LaFontaine J, Najafi B et al. Electrical stimulation to accelerate wound healing. *Diabet Foot Ankle* 2013; 4(1):22081. <https://doi.org/10.3402/dfa.v4i0.22081>
- 459 Rawe IM, Vlahovic TC. The use of a portable, wearable form of pulsed radio frequency electromagnetic energy device for the healing of recalcitrant ulcers: a case report. *Int Wound J* 2012; 9(3):253–258. <https://doi.org/10.1111/j.1742-481X.2011.00853.x>
- 460 Marston WA, Hanft J, Norwood et al. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. *Diabetes Care* 2003; 26(6):1701–1705. <https://doi.org/10.2337/diacare.26.6.1701>
- 461 Smiell JM, Wieman TJ, Steed DL et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. *Wound Repair Regen* 1999; 7(5):335–346
- 462 Driver VR, Lavery LA, Reyzelman AM et al. A clinical trial of Integra Template for diabetic foot ulcer treatment. *Wound Repair Regen* 2015; 23(6):891–900. <https://doi.org/10.1111/wrr.12357>
- 463 Fan K, Tang J, Escandon J, Kirsner RS. State of the art in topical wound-healing products. *Plast Reconstr Surg* 2011; 127 Suppl 1:44S–59S. <https://doi.org/10.1097/PRS.0b013e3181f8e275>
- 464 Farrow MJ, Hunter IS, Connolly P. Developing a real time sensing system to monitor bacteria in wound dressings. *Biosensors* 2012; 2(2):171–188. <https://doi.org/10.3390/bios2020171>
- 465 Mehmood N, Hariz A, Templeton S, Voelcker NH. A flexible and low power telemetric sensing and monitoring system for chronic wound diagnostics. *Biomed Eng Online* 2015; 14(1):17. <https://doi.org/10.1186/s12938-015-0011-y>
- 466 Sharp D. Printed composite electrodes for in-situ wound pH monitoring. *Biosens Bioelectron* 2013; 50:399–405. <https://doi.org/10.1016/j.bios.2013.06.042>
- 467 Sharp D, Gladstone P, Smith RB et al. Approaching intelligent infection diagnostics: carbon fibre sensor for electrochemical pyocyanin detection. *Bioelectrochemistry* 2010; 77(2):114–119. <https://doi.org/10.1016/j.bioelect.2009.07.008>
- 468 Sharp D, Forsythe S, Davis J. Carbon fibre composites: integrated electrochemical sensors for wound management. *J Biochem* 2008; 144(1):87–93. <https://doi.org/10.1093/jb/mvn045>
- 469 Parvaneh S, Grewal GS, Grewal E et al. Stressing the dressing: assessing

- stress during wound care in real-time using wearable sensors. *Wound Medicine* 2014; 4:21–26. <https://doi.org/10.1016/j.wndm.2014.01.003>
- 470 Mehmood N, Hariz A, Fitridge R, Voelcker NH. Applications of modern sensors and wireless technology in effective wound management. *J Biomed Mater Res B Appl Biomater* 2014; 102(4):885–895. <https://doi.org/10.1002/jbm.b.33063>
- 471 Milne SD, Seoudi I, Al Hamad H et al. A wearable wound moisture sensor as an indicator for wound dressing change: an observational study of wound moisture and status. *Int Wound J* 2016; 13(6):1309–1314. <https://doi.org/10.1111/iwj.12521>
- 472 Milne SD, Connolly P, Al Hamad H, Seoudi I. Development of wearable sensors for tailored patient wound care. *Conf Proc IEEE Eng Med Biol Soc* 2014; 2014:618–621
- 473 Aldaz G, Shluzas LA, Pickham D et al. Hands-free image capture, data tagging and transfer using Google Glass: a pilot study for improved wound care management. *PLoS One* 2015; 10(4):e0121179. <https://doi.org/10.1371/journal.pone.0121179>
- 474 Ge K, Wu M, Liu H et al. Wound documentation by using 3G mobile as acquisition terminal: an appropriate proposal for community wound care. *Int J Low Extrem Wounds* 2015; 14(2):200–203. <https://doi.org/10.1177/1534734614549925>
- 475 Parmanto B, Pramana G, Yu DX et al. Development of mHealth system for supporting self-management and remote consultation of skincare. *BMC Med Inform Decis Mak* 2015; 15(1):14. <https://doi.org/10.1186/s12911-015-0237-4>
- 476 Wang L, Pedersen PC, Strong DM et al. Smartphone-based wound assessment system for patients with diabetes. *IEEE Trans Biomed Eng* 2015; 62(2):477–488. <https://doi.org/10.1109/TBME.2014.2358632>
- 477 Mammas CS, Geropoulos S, Markou G et al. Mobile tele-medicine systems in the multidisciplinary approach of diabetes management : the remote prevention of diabetes complications. *Stud Health Technol Inform* 2014; 202:307–310
- 478 Foltynski P, Ladyzynski P, Wojcicki JM. A new smartphone-based method for wound area measurement. *Artif Organs* 2014; 38(4):346–352. <https://doi.org/10.1111/aor.12169>
- 479 Foltynski P, Ladyzynski P, Sabalinska S, Wojcicki JM. Accuracy and precision of selected wound area measurement methods in diabetic foot ulceration. *Diabetes Technol Ther* 2013; 15(8):711–720. <https://doi.org/10.1089/dia.2013.0026>
- 480 Sanger P, Hartzler A, Lober WB et al. Design Considerations for Post-Acute Care mHealth: Patient Perspectives. *AMIA Annu Symp Proc* 2014; 2014:1920–1929
- 481 Quinn EM, Corrigan MA, O'Mullane J et al. Clinical unity and community empowerment: the use of smartphone technology to empower community management of chronic venous ulcers through the support of a tertiary unit. *PLoS One* 2013; 8(11):e78786. <https://doi.org/10.1371/journal.pone.0078786>
- 482 Wootton R. Twenty years of telemedicine in chronic disease management – an evidence synthesis. *J Telemed Telecare* 2012; 18(4):211–220. <https://doi.org/10.1258/jtt.2012.120219>
- 483 Tchero H, Noubou L, Becsangele B et al. Telemedicine in Diabetic Foot Care: A Systematic Literature Review of Interventions and Meta-analysis of Controlled Trials. *Int J Low Extrem Wounds* 2017; 16(4):274–283. <https://doi.org/10.1177/1534734617739195>
- 484 Lazzarini PA, Clark D, Mann RD et al. Does the use of store-and-forward telehealth systems improve outcomes for clinicians managing diabetic foot ulcers?: A pilot study. *Wound Practice & Research. Journal of the Australian Wound Management Association*. 2010; 18(4):164.
- 485 Rasmussen BS, Jensen LK, Froekjaer J et al. A qualitative study of the key factors in implementing telemedical monitoring of diabetic foot ulcer patients. *Int J Med Inform* 2015; 84(10):799–807. <https://doi.org/10.1016/j.jmedinf.2015.05.012>
- 486 Kolltveit BC, Gjengedal E, Graue M et al. Conditions for success in introducing telemedicine in diabetes foot care: a qualitative inquiry. *BMC Nurs* 2017; 16(1):2. <https://doi.org/10.1186/s12912-017-0201-y>
- 487 Zarchi K, Haugaard VB, Dufour DN, Jemec GB. Expert advice provided through telemedicine improves healing of chronic wounds: prospective cluster controlled study. *J Invest Dermatol* 2015; 135(3):895–900. <https://doi.org/10.1038/jid.2014.441>
- 488 Vowden K, Vowden P. A pilot study on the potential of remote support to enhance wound care for nursing-home patients. *J Wound Care* 2013; 22(9):481–488. <https://doi.org/10.12968/jowc.2013.22.9.481>
- 489 Rasmussen BS, Froekjaer J, Bjerregaard MR et al. A randomized controlled trial comparing telemedical and standard outpatient monitoring of diabetic foot ulcers. *Diabetes Care* 2015; 38(9):1723–1729. <https://doi.org/10.2337/dc15-0332>
- 490 Muller M, David-Tchouda S, Margier J et al. Comment on rasmussen et al. a randomized controlled trial comparing telemedical and standard outpatient monitoring of diabetic foot ulcers. *diabetes care* 2015; 38:1723–1729. *Diabetes Care* 2016; 39(1):e9–e10. <https://doi.org/10.2337/dc15-1659>
- 491 Clarke JL, Bourn S, Skoufalos A et al. An innovative approach to health care delivery for patients with chronic conditions. *Popul Health Manag* 2017; 20(1):23–30. <https://doi.org/10.1089/pop.2016.0076>
- 492 Turnin MC, Schirr-Bonnans S, Chauchard MC et al. DIABSAT telemedicine itinerant screening of chronic complications of diabetes using a satellite. *Telemed J E Health* 2017; 23(5):397–403. <https://doi.org/10.1089/tmj.2016.0185>
- 493 Kolltveit BC, Gjengedal E, Graue M et al. Telemedicine in diabetes foot care delivery: health care professionals' experience. *BMC Health Serv Res* 2016; 16(1):134. <https://doi.org/10.1186/s12913-016-1377-7>
- 494 Sparsa A, Doffoel-Hantz V, Bonnetblanc JM. [Assessment of tele-expertise among elderly subjects in retirement homes]. [Article in French] *Ann Dermatol Venerol* 2013; 140(3):165–169. <https://doi.org/10.1016/j.annder.2012.11.008>
- 495 Dobke MK, Bhavsar D, Gosman A et al. Pilot trial of telemedicine as a decision aid for patients with chronic wounds. *Telemed J E Health* 2008; 14(3):245–249. <https://doi.org/10.1089/tmj.2007.0038>
- 496 FASTERHOLDT I, GERSTRØM M, RASMUSSEN BS et al. Cost-effectiveness of telemonitoring of diabetic foot ulcer patients. *Health Informatics J* 2016; 1460458216663026
- 497 Litzinger G, Rossman T, Demuth B, Roberts J. In-home wound care management utilizing information technology. *Home Healthcare Nurse: The Journal for the Home Care and Hospice Professional* 2007; 25(2):119–130. <https://doi.org/10.1097/00004045-200702000-00013>
498. Bowling FL, King L, Paterson JA et al. Remote assessment of diabetic foot ulcers using a novel wound imaging system. *Wound Repair Regen* 2011; 19(1):25–30. <https://doi.org/10.1111/j.1524-475X.2010.00645.x>
- 499 Binder B, Hofmann-Wellenhof R, Salmhofer W et al. Teledermatological monitoring of leg ulcers in cooperation with home care nurses. *Arch Dermatol* 2007; 143(12):1511–1514. <https://doi.org/10.1001/archderm.143.12.1511>

- 500 Narasimha Murthy D, Vijaya Kumar B. Internet of Things (IoT): Is IoT a disruptive technology or a disruptive business model? *Indian Journal of Marketing* 2015; 45(8):18–27. <https://doi.org/10.17010/ijom/2015/v45/i8/79915>
- 501 Gubbi J, Buyya R, Marusic S, Palaniswami M. Internet of Things (IoT): A vision, architectural elements, and future directions. *Future Gener Comput Syst* 2013; 29(7):1645–1660. <https://doi.org/10.1016/j.future.2013.01.010>
- 502 Haugom J. Is the Health Sensor Revolution About to Dramatically Change Healthcare? *HealthCatalyst* 2017. <https://tinyurl.com/yd7qc7ek> (accessed 21 May 2018)
- 503 Senior M. Novartis signs up for Google smart lens. *Nat Biotechnol* 2014; 32(9):856. <https://doi.org/10.1038/nbt0914-856>
- 504 Coombs B. How Alexa's best skill could be as a home health-care assistant [Internet]: CNBC; 2017 [cited 1/23/2018]. <https://tinyurl.com/ya9bqohu> (accessed 21 May 2018)
- 505 Järbrink K, Ni G, Sönnengren H, Schmidtchen A et al. The humanistic and economic burden of chronic wounds: a protocol for a systematic review. *Syst Rev* 2017; 6(1):15. <https://doi.org/10.1186/s13643-016-0400-8>
- 506 Posnett J, Gottrup F, Lundgren H, Saal G. The resource impact of wounds on health-care providers in Europe. *J Wound Care* 2009; 18(4):154–161. <https://doi.org/10.12968/jowc.2009.18.4.1607>
- 507 Phillips CJ, Humphreys I, Fletcher J et al. Estimating the costs associated with the management of patients with chronic wounds using linked routine data. *Int Wound J* 2016; 13(6):1193–1197. <https://doi.org/10.1111/iwj.12443>
- 508 Zhou K, Krug K, Brogan MS. Physical Therapy in Wound Care. *Medicine* 2015; 94(49):e2202. <https://doi.org/10.1097/MD.0000000000002202>
509. Sen CK, Gordillo GM, Roy S et al. Human skin wounds: a major and snowballing threat to public health and the economy. *Wound Repair Regen* 2009; 17(6):763–771. <https://doi.org/10.1111/j.1524-475X.2009.00543.x>
- 510 International consensus. Making the case for cost-effective wound management. *Wounds International*, 2013
- 511 Briggs et al. *Decision modelling for health economic evaluation*. Oxford University Press, 2006.
- 512 Drummond MF, Sculpher MJ, Claxton GL et al. *Methods for the economic evaluation of healthcare programs* (4th edn). Oxford University Press, 2015.
- 513 Carter MJ, Waycaster C, Schaum K, Gilligan AM. Cost-effectiveness of three adjunct cellular/tissue-derived products used in the management of chronic venous leg ulcers. *Value Health* 2014; 17(8):801–813. <https://doi.org/10.1016/j.jval.2014.08.001>
- 514 Gilligan AM, Waycaster CR, Landsman AL. Wound closure in patients with DFU: a cost-effectiveness analysis of two cellular/tissue-derived products. *J Wound Care* 2015; 24(3):149–156. <https://doi.org/10.12968/jowc.2015.24.3.149>
- 515 Marston WA, Sabolinski ML, Parsons NB, Kirsner RS. Comparative effectiveness of a bilayered living cellular construct and a porcine collagen wound dressing in the treatment of venous leg ulcers. *Wound Repair Regen* 2014; 22(3):334–340. <https://doi.org/10.1111/wrr.12156>
- 516 Rice JB, Desai U, Ristovski L et al. Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers. *J Med Econ* 2015; 18(8):586–595. <https://doi.org/10.3111/13696998.2015.1031793>
- 517 Augustin M, Herberger K, Kroeger K et al. Cost-effectiveness of treating vascular leg ulcers with UrgoStart® and UrgoCell® Contact. *Int Wound J* 2016; 13(1):82–87. <https://doi.org/10.1111/iwj.12238>
- 518 Meaume S, Truchetet F, Cambazard F, Lok C, Debure C, Dalac S, et al. A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. *Wound Repair Regen* 2012; 20(4):500–511. <https://doi.org/10.1111/j.1524-475X.2012.00797.x>
- 519 Guest JF, Weidlich D, Singh H et al. Cost-effectiveness of using adjunctive porcine small intestine submucosa tri-layer matrix compared with standard care in managing diabetic foot ulcers in the US. *J Wound Care* 2017; 26 Supl:S12–S24. <https://doi.org/10.12968/jowc.2017.26.Sup1.S12>
- 520 Nherera LM, Trueman P, Karlakki SL. Cost-effectiveness analysis of single-use negative pressure wound therapy dressings (sNPWT) to reduce surgical site complications (SSC) in routine primary hip and knee replacements. *Wound Repair Regen* 2017; 25(3):474–482. <https://doi.org/10.1111/wrr.12530>
- 521 Romanelli M, Gilligan AM, Waycaster CR, Dini V. Difficult-to-heal wounds of mixed arterial/venous and venous etiology: a cost-effectiveness analysis of extracellular matrix. *Clinicoecon Outcomes Res* 2016; 8:153–161
- 522 Arroyo AA, Casanova PL, Soriano JV et al. Open-label clinical trial comparing the clinical and economic effectiveness of using a polyurethane film surgical dressing with gauze surgical dressings in the care of post-operative surgical wounds. *Int Wound J* 2015; 12(3):285–292. <https://doi.org/10.1111/iwj.12099>
- 523 Guest JF, Gerrish A, Ayoub N et al. Clinical outcomes and cost-effectiveness of three alternative compression systems used in the management of venous leg ulcers. *J Wound Care* 2015; 24(7):300–310. <https://doi.org/10.12968/jowc.2015.24.7.300>
- 524 Panca M, Cutting K, Guest JF. Clinical and cost-effectiveness of absorbent dressings in the treatment of highly exuding VLU's. *J Wound Care* 2013; 22(3):109–118. <https://doi.org/10.12968/jowc.2013.22.3.109>
- 525 Guest JF, Taylor RR, Vowden K, Vowden P. Relative cost-effectiveness of a skin protectant in managing venous leg ulcers in the UK. *J Wound Care* 2012; 21(8):389–398. <https://doi.org/10.12968/jowc.2012.21.8.389>
- 526 Guest JF, Ayoub N, Greaves T. Clinical outcomes and cost-effectiveness of an externally applied electroceutical device in managing venous leg ulcers in clinical practice in the UK. *J Wound Care* 2015; 24(12):572–580. <https://doi.org/10.12968/jowc.2015.24.12.572>
- 527 Taylor RR, Sladkevicius E, Guest JF. Modelling the cost-effectiveness of electric stimulation therapy in non-healing venous leg ulcers. *J Wound Care* 2011; 20(10):464–472. <https://doi.org/10.12968/jowc.2011.20.10.464>
- 528 Hirsch T, Rothoefl T, Teig N et al. Regeneration of the entire human epidermis using transgenic stem cells. *Nature* 2017; 551(7680):327–332. <https://doi.org/10.1038/nature24487>
- 529 Gurtner GC, Chapman MA. Regenerative medicine: charting a new course in wound healing. *Adv Wound Care* 2016; 5(7):314–328. <https://doi.org/10.1089/wound.2015.0663>
- 530 Regranex, bedapemrin. EPAR summary for the public. EMA/163092/2010. 2010. <https://tinyurl.com/ydfvt37y> (accessed 21 May 2018)
- 531 Epivalan. birch bark extract. EPAR. EMA/833320/2015. 2015. <https://tinyurl.com/ybjdlh9q> (accessed 21 May 2018)
- 532 Council Directive 93/42/EEC concerning medical devices. 1993. <https://tinyurl.com/cm7lgmt> (accessed 21 May 2018)
- 533 French-Mowat E, Burnett J. How are medical devices regulated in the European Union? *J R Soc Med* 2012; 105(1_suppl 1):22–28. <https://doi.org/10.1258/jrsm.2012.120036>

- 534 Regulation 2017/745/EC on medical devices. 2017. Accessed November 2017. <https://tinyurl.com/y8hzwvdc>. (accessed 21 May 2018)
- 535 Emergo. EU MDR 2017/745 Gap Assessment and CE Transition Strategy for Medical Device Manufacturers. <https://tinyurl.com/yb2zybdb>. (accessed 21 May 2018)
- 536 Lang J. Regulatory Pathways of Drug-Device and Device-Drug Combination Products in the EU. Whitepaper NSF. <https://tinyurl.com/ycfdaqxn>. (accessed 21 May 2018)
- 537 Regulation (EC) No 1394/2007 on advanced therapy medicinal products. Accessed November 2017. <https://tinyurl.com/yaqwrvarE> (accessed 21 May 2018)
- 538 Regulation (EC) No. 726/2004. <https://tinyurl.com/y9ssdu3k> (accessed 21 May 2018)
- 539 Summaries of scientific recommendations on classification of advanced therapy medicinal products. <https://tinyurl.com/y93u8y3d> (accessed 21 May 2018)
- 540 Xconomy. StrataGraft Skin Treatment Gets New FDA Regenerative Med Status. 19 July 2017. <https://tinyurl.com/yasdygq5>. (accessed 21 May 2018)
- 541 Seimetz D. ATMPs: How to successfully master Challenges and foster the Regulatory Success rate? . *Pharmazeutische Medizin* 2016; 18(3):132–139. <https://tinyurl.com/yb3vgvbb>
- 542 Guidance for Industry- Chronic cutaneous Ulcer and Burn Wounds- Developing Products for Treatment. 2006. <https://www.fda.gov/downloads/drugs/guidances/ucm071324.pdf> (accessed 21 May 2018)
- 543 Maderal AD, Vivas AC, Eaglstein WH, Kirsner RS. The FDA and designing clinical trials for chronic cutaneous ulcers. *Semin Cell Dev Biol* 2012; 23(9):993–999. <https://doi.org/10.1016/j.semcdb.2012.09.014>
- 544 Seimetz D. The Key to Successful Drug Approval: An Effective Regulatory Strategy. In: Becker J, Villinger T (eds) *Life Science Venturing* Springer Gabler; 2017.
- 545 FDA Wound Healing Clinical Focus Group. Guidance for industry: chronic cutaneous ulcer and burn wounds-developing products for treatment. *Wound Repair Regen* 2001; 9(4):258–268.
- 546 European Medicines Agency. Supporting SMEs. <https://tinyurl.com/y826x5ug>. (accessed 21 May 2018)
- 547 European Medicines Agency. Advanced therapy classification. EMA. <https://tinyurl.com/y8lb6zu5>. (accessed 21 May 2018)
- 548 European Medicines Agency. Certification procedures for micro-, small- and medium-sized enterprises (SMEs). <https://tinyurl.com/y8r6k9sy> (accessed 21 May 2018)
- 549 European Medicines Agency. Innovation in medicines. <https://tinyurl.com/y9gxbauN>. (accessed 21 May 2018)
- 550 European Medicines Agency. PRIME- Priority Medicines. Paving the way for promising medicines for patients. <https://tinyurl.com/y9lk4zqyf>. (accessed 21 May 2018)
- 551 Dallmann G. Scientific Advice in the EU and US: Practical Experience and Rules of the Game on Both Sides of the Atlantic. *Pharmazeutische Medizin* 2017; 19(2). <https://tinyurl.com/yd5hodcf>
- 552 Aushev M, Koller U, Mussolino C et al. Traceless targeting and isolation of gene-edited immortalized keratinocytes from Epidermolysis bullosa simplex patients. *Mol Ther Methods Clin Dev* 2017; 6: 112–123. <https://doi.org/10.1016/j.omtm.2017.06.008>